{
  "filename": "ehab368.pdf",
  "title": null,
  "type": "heart_failure",
  "year": null,
  "chapters": [
    {
      "number": "1",
      "title": "1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3607 2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "introduction",
        "preamble"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "2.1 What is new . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3609 3 Definition, epidemiology and prognosis . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "prognosis",
        "what",
        "epidemiology",
        "definition"
      ],
      "tables": []
    },
    {
      "number": "3",
      "title": "3.1 Definition of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612 3.2 Terminology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 1,
      "end_page": 1,
      "content": "3.2.1 Heart failure with preserved, mildly reduced, and reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612\n3.2.2 Right ventricular dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613 3.2.3 Other common terminology used in heart failure . . . . . . . 3613 3.2.4 Terminology related to the symptomatic severity of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613 3.3 Epidemiology and natural history of heart failure . . . . . . . . . . . . 3613\n3.3.1 Incidence and prevalence. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613 3.3.2 Aetiology of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3614 3.3.3 Natural history and prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . 3614 4 Chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3614\n",
      "keywords": [
        "ejection fraction",
        "failure",
        "heart failure",
        "definition",
        "heart",
        "terminology"
      ],
      "tables": []
    },
    {
      "number": "4",
      "title": "4.1 Key steps in the diagnosis of chronic heart failure . . . . . . . . . . . 3614",
      "start_page": 1,
      "end_page": 2,
      "content": "3600 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.2 Natriuretic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3616\n4.2.1 Use in the non-acute setting . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617 4.3 Investigations to determine the underlying aetiology of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617 5 Heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . 3619\n",
      "keywords": [
        "chronic",
        "ejection fraction",
        "failure",
        "heart failure",
        "steps",
        "heart",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "5",
      "title": "5.1 The diagnosis of heart failure with reduced ejection fraction . 3619 5.2 Pharmacological treatments for patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . .",
      "start_page": 2,
      "end_page": 2,
      "content": "5.2.1 Goals of pharmacotherapy for patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3619 5.2.2 General principles of pharmacotherapy for heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3619 5.3 Drugs recommended in all patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3620\n5.3.1 Angiotensin-converting enzyme inhibitors . . . . . . . . . . . . . . 3621 5.3.2 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3621 5.3.3 Mineralocorticoid receptor antagonists . . . . . . . . . . . . . . . . 3621 5.3.4 Angiotensin receptor-neprilysin inhibitor . . . . . . . . . . . . . . . 3621 5.3.5 Sodium-glucose co-transporter 2 inhibitors . . . . . . . . . . . . 3622 5.4 Other drugs recommended or to be considered in selected patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3622\n5.4.1 Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623 5.4.2 Angiotensin II type 1 receptor blockers . . . . . . . . . . . . . . . . . 3623 5.4.3 I f -channel inhibitor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623 5.4.4 Combination of hydralazine and isosorbide dinitrate . . . . 3623 5.4.5 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623 5.4.6 Recently reported advances from trials in heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3624 5.5 Strategic phenotypic overview of the management of heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . 3624 6 Cardiac rhythm management for heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3624\n",
      "keywords": [
        "pharmacological",
        "ejection fraction",
        "glucose",
        "failure",
        "ejection",
        "heart failure",
        "patients",
        "heart",
        "treatments",
        "recommended",
        "fraction",
        "reduced",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "6",
      "title": "6.1 Implantable cardioverter-defibrillator . . . . . . . . . . . . . . . . . . . . . . . 3625",
      "start_page": 2,
      "end_page": 2,
      "content": "6.1.1 Secondary prevention of sudden cardiac death . . . . . . . . . 3626 6.1.2 Primary prevention of sudden cardiac death . . . . . . . . . . . . 3626 6.1.3 Patient selection for implantable cardioverter- defibrillator therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3626 6.1.4 Implantable cardioverter-defibrillator programming . . . . . 3626 6.1.5 Subcutaneous and wearable implantable cardioverter-defibrillators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3626 6.2 Cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . 3627 6.3 Devices under evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628 7 Heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . 3628\n",
      "keywords": [
        "secondary prevention",
        "implantable",
        "primary prevention",
        "ejection fraction",
        "heart failure",
        "defibrillator",
        "cardioverter",
        "sudden cardiac death"
      ],
      "tables": []
    },
    {
      "number": "7",
      "title": "7.1 The diagnosis of heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628 7.2 Clinical",
      "start_page": 2,
      "end_page": 2,
      "content": "7.3.1 Angiotensin-converting enzyme inhibitors . . . . . . . . . . . . . . 3629 7.3.2 Angiotensin receptor II type 1 receptor blockers . . . . . . . 3629 7.3.3 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629 7.3.4 Mineralocorticoid receptor antagonists . . . . . . . . . . . . . . . . 3629 7.3.5 Angiotensin receptor-neprilysin inhibitor . . . . . . . . . . . . . . . 3629 7.3.6 Other drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630 7.3.7 Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630\n",
      "keywords": [
        "failure",
        "clinical",
        "mildly",
        "ejection",
        "heart",
        "fraction",
        "reduced",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "8",
      "title": "8 Heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . 3630",
      "start_page": 2,
      "end_page": 2,
      "content": "",
      "keywords": [
        "preserved",
        "failure",
        "ejection",
        "heart",
        "fraction"
      ],
      "tables": []
    },
    {
      "number": "9",
      "title": "8.1 The background to heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630 8.2 Clinical cha",
      "start_page": 2,
      "end_page": 2,
      "content": "",
      "keywords": [
        "background",
        "preserved",
        "failure",
        "clinical",
        "ejection",
        "heart",
        "fraction"
      ],
      "tables": []
    },
    {
      "number": "10",
      "title": "9.1 Prevention of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633 9.2 Multidisciplinary management of chronic heart failure . . . . . . . 3633",
      "start_page": 2,
      "end_page": 2,
      "content": "9.2.1 Models of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633 9.2.2 Characteristics and components of a heart failure management programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633 9.3 Patient education, self-care and lifestyle advice . . . . . . . . . . . . . . 3633 9.4 Exercise rehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636 9.5 Follow-up of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . 3636\n9.5.1 General follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636 9.5.2 Monitoring with biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636 9.6 Telemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636 10 Advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3637\n",
      "keywords": [
        "chronic",
        "failure",
        "prevention",
        "heart failure",
        "heart",
        "management",
        "multidisciplinary",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "11",
      "title": "10.1 Epidemiology, diagnosis, and prognosis . . . . . . . . . . . . . . . . . . . . 3637 10.2 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3639",
      "start_page": 2,
      "end_page": 2,
      "content": "10.2.1 Pharmacological therapy and renal replacement . . . . . . . 3639 10.2.2 Mechanical circulatory support . . . . . . . . . . . . . . . . . . . . . . . 3639 10.2.3 Heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643 10.2.4 Symptom control and end-of-life care . . . . . . . . . . . . . . . . . 3644 11 Acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644\n",
      "keywords": [
        "prognosis",
        "heart failure",
        "management",
        "epidemiology",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "12",
      "title": "11.1 Epidemiology, diagnosis and prognosis . . . . . . . . . . . . . . . . . . . . 3644 11.2 Clinical presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3646",
      "start_page": 2,
      "end_page": 2,
      "content": "11.2.1 Acute decompensated heart failure . . . . . . . . . . . . . . . . . . . 3646 11.2.2 Acute pulmonary oedema . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3647 11.2.3 Isolated right ventricular failure . . . . . . . . . . . . . . . . . . . . . . . 3647 11.2.4 Cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3647 11.3 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649\n11.3.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649 11.3.2 Oxygen therapy and/or ventilatory support . . . . . . . . . . . 3650 11.3.3 Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3652 11.3.4 Vasodilators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3654 11.3.5 Inotropes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655 11.3.6 Vasopressors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655 11.3.7 Opiates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655 11.3.8 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3656 11.3.9 Thromboembolism prophylaxis . . . . . . . . . . . . . . . . . . . . . . 3656 11.3.10 Short-term mechanical circulatory support . . . . . . . . . . 3656 11.3.11 Pre-discharge assessment and post-discharge management planning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657 12 Cardiovascular comorbidities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657\n",
      "keywords": [
        "presentations",
        "clinical",
        "prognosis",
        "heart failure",
        "epidemiology",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "13",
      "title": "12.1 Arrhythmias and conduction disturbances . . . . . . . . . . . . . . . . . 3657",
      "start_page": 2,
      "end_page": 3,
      "content": "12.1.1 Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657 12.1.2 Ventricular arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660 12.1.3 Symptomatic bradycardia, pauses and atrio-ventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660 12.2 Chronic coronary syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660\n12.2.1 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3661 12.2.2 Myocardial revascularization . . . . . . . . . . . . . . . . . . . . . . . . . . 3662\nESC Guidelines 3601\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 12.3 Valvular heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3662\n12.3.1 Aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3662 12.3.2 Aortic regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3664 12.3.3 Mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3664 12.3.4 Tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666 12.4 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666 12.5 Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666 13 Non-cardiovascular comorbidities . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666\n",
      "keywords": [
        "arrhythmias",
        "atrial fibrillation",
        "aortic stenosis",
        "bradycardia",
        "hypertension",
        "conduction",
        "mitral regurgitation",
        "aortic",
        "disturbances",
        "tricuspid",
        "stenosis",
        "aortic regurgitation"
      ],
      "tables": []
    },
    {
      "number": "14",
      "title": "13.1 Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666 13.2 Thyroid disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 3,
      "end_page": 3,
      "content": "",
      "keywords": [
        "diabetes",
        "disorders",
        "thyroid"
      ],
      "tables": []
    },
    {
      "number": "15",
      "title": "14.1 Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675",
      "start_page": 3,
      "end_page": 8,
      "content": "14.1.1 Pregnancy in pre-existing heart failure . . . . . . . . . . . . . . . . . 3675 14.1.2 New heart failure presenting during pregnancy . . . . . . . . 3675 14.2 Cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677\n14.2.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677 14.2.2 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677 14.3 Left ventricular non-compaction . . . . . . . . . . . . . . . . . . . . . . . . . . 3681 14.4 Atrial disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682\n14.4.1 Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 14.4.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 14.4.3 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 14.5 Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682\n14.5.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 14.5.2 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 14.6 Amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682\n14.6.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 14.6.2 Therapy of amyloidosis and heart failure . . . . . . . . . . . . . . 3685 14.7 Iron overload cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3685 14.8 Adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686 15 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3688 16 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3689 17 ‘What to do’ and ‘what not to do’ messages from the guidelines . 3690 18 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3693 19 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694 20 Author information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694 21 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694 22 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3695\nList of recommendations\nRecommended diagnostic tests in all patients with suspected chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617\nRecommendations for specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3618 Pharmacological treatments indicated in patients with (NYHA class II \u0002 IV) heart failure with reduced ejection fraction (LVEF <_40%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3620 Other pharmacological treatments indicated in selected patients with NYHA class II \u0002 IV heart failure with reduced ejection fraction (LVEF <_40%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3622 Recommendations for an implantable cardioverter-defibrillator in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3625 Recommendations for cardiac resynchronization therapy implantation in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . 3627 Pharmacological treatments to be considered in patients with (NYHA class II \u0002 IV) heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629 Recommendations for the treatment of patients with heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632 Recommendations for the primary prevention of heart failure in patients with risk factors for its development . . . . . . . . . . . . . . . . . . . . . 3632 Multidisciplinary interventions recommended for the management of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633 Recommendations for exercise rehabilitation in patients with chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636 Recommendations for telemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3637 Recommendations for the treatment of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643 Recommendations for the initial treatment of acute heart failure . . . 3655 Recommendations for the use of short-term mechanical circulatory support in patients with cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . 3656 Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure . . . . . . . . . . . 3657 Recommendations for the treatment of atrial fibrillation in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660 Recommendations for myocardial revascularization in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . 3662 Recommendations for the management of valvular heart disease in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3665 Recommendations for the treatment of diabetes in heart failure . . . 3667 Recommendations for the management of anaemia and iron deficiency in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3669 Recommendations for the management of patients with cancer and heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675 Recommendations for the treatment of transthyretin amyloidosis-cardiac amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686\nList of tables\nTable 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3608 Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3608 Table 3 Definition of heart failure with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction . . . 3613 Table 4 New York Heart Association functional classification based on severity of symptoms and physical activity . . . . . . . . . . . . . . . 3614 Table 5 Causes of heart failure, common modes of presentation and specific investigations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3616 Table 6 Symptoms and signs typical of heart failure . . . . . . . . . . . . . . . . 3617\n3602 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Table 7 Causes of elevated concentrations of natriuretic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3618 Table 8 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3621 Table 9 Objective evidence of cardiac structural, functional and serological abnormalities consistent with the presence of left ventricular diastolic dysfunction/raised left ventricular filling pressures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3631 Table 10 Risk factors for the development of heart failure and potential corrective actions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632 Table 11 Important characteristics and components in a heart failure management programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3634 Table 12 Patient education and self-care . . . . . . . . . . . . . . . . . . . . . . . . . . 3634 Table 13 Criteria for definition of advanced heart failure . . . . . . . . . . . 3638 Table 14 Interagency Registry for Mechanically Assisted Circulatory Support profile descriptions of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3638 Table 15 Terms describing various indications for mechanical circulatory support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3642 Table 16 Patients potentially eligible for implantation of a left ventricular assist device . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3642 Table 17 Heart transplantation: indications and contraindications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643 Table 18 Patients with heart failure in whom end-of-life care should be considered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644 Table 19 Key components of palliative care service in patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644 Table 20 Diagnostic tests in patients with acute heart failure . . . . . . . 3646 Table 21 Clinical presentations of acute heart failure . . . . . . . . . . . . . . 3647 Table 22 Inotropes and/or vasopressors used to treat acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655 Table 23 Cancer drugs causing heart failure . . . . . . . . . . . . . . . . . . . . . . . 3673 Table 24 Infections in patients with heart failure . . . . . . . . . . . . . . . . . . . 3675 Table 25 Possible causes and disease modifiers of most frequent cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3678 Table 26 Initial diagnostic assessment in patients with suspected cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3678 Table 27 Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy: specific aspects of diagnosis and treatment . . . . . . . 3679 Table 28 Hypertrophic cardiomyopathy: specific aspects of diagnosis and treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3680 Table 29 Arrhythmogenic cardiomyopathy: specific aspects of diagnosis and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3681 Table 30 Aetiologies to be considered triggering acute myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682 Table 31 Diagnostic workup in suspected acute myocarditis . . . . . . . 3683 Table 32 Endomyocardial biopsy in patients with suspected myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3684 Table 33 Cardiac magnetic resonance in patients with suspected myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3685 Table 34 Treatment and follow-up of acute myocarditis . . . . . . . . . . . 3685 Table 35 “Red flags” for most common forms of cardiac amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686 Table 36 Treatment of adult congenital heart disease and heart failure in specialized centres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3688\nTable 37 Main European Society of Cardiology Quality Indicators for the evaluation of care and outcomes for patients with heart failure . 3693\nList of figures\nFigure 1 The diagnostic algorithm for heart failure . . . . . . . . . . . . . . . . . 3615 Figure 2 Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction . . . . . . . . . . . 3620 Figure 3 Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction . . . . . . . . 3624 Figure 4 Algorithm for the treatment of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3640 Figure 5 Triage of patients with advanced heart failure and appropriate timing of referral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641 Figure 6 Diagnostic workup of new onset acute heart failure . . . . . . . 3645 Figure 7 Management of acute decompensated heart failure . . . . . . . 3648 Figure 8 Management of pulmonary oedema . . . . . . . . . . . . . . . . . . . . . . 3649 Figure 9 Management of right ventricular failure . . . . . . . . . . . . . . . . . . . 3650 Figure 10 Management of cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . 3651 Figure 11 Stages of management of patients with acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3652 Figure 12 Initial management of acute heart failure . . . . . . . . . . . . . . . . 3653 Figure 13 Diuretic therapy (furosemide) in acute heart failure . . . . . . 3654 Figure 14 Management of atrial fibrillation in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3658 Figure 15 Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3661 Figure 16 Management of patients with severe low-flow low-gradient aortic stenosis and heart failure . . . . . . . . . . . . . . . . . . . . . 3663 Figure 17 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . 3664 Figure 18 Management of patients with cancer and heart failure . . . . 3674 Figure 19 Management of patients with heart failure before and during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3676 Figure 20 Management of patients with heart failure and acute myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3684 Figure 21 Diagnosis and treatment of cardiac amyloidosis in heart failure patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3687\nAbbreviations and acronyms\n6MWT 6-minute walk test 99m Tc-PYP Technetium-labelled pyrophosphate AATAC Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD (trial) AC Arrhythmogenic cardiomyopathy ACE Angiotensin-converting enzyme ACE-I Angiotensin-converting enzyme inhibitor ACHD Adult congenital heart disease ACS Acute coronary syndrome ADHF Acutely decompensated heart failure AF Atrial ﬁbrillation AF-CHF Atrial ﬁbrillation  \u0002  Congestive Heart Failure (trial)\nESC Guidelines 3603\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................................................................................................................................................... AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management (trial) AFFIRM-AHF A Randomized, Double-blind Placebo- controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalizations and Mortality in Iron- deﬁcient Subjects Admitted for Acute Heart Failure (trial) AHF Acute heart failure AL Light chain immunoglobulin AL-CA Light chain immunoglobulin cardiac amyloidosis AMICA Atrial Fibrillation Management in Congestive Heart Failure With Ablation (trial) ANCA Antineutrophil cytoplasmic antibody ARB Angiotensin-receptor blocker ARNI Angiotensin receptor-neprilysin inhibitor ARVC Arrhythmogenic right ventricular cardiomyopathy ATTR Transthyretin amyloidosis AV Atrio-ventricular b.i.d. Bis in die (twice daily) BAG3 Bcl2-associated athanogene 3 BiVAD Biventricular assist device BMI Body mass index BNP B-type natriuretic peptide BP Blood pressure b.p.m. Beats per minute BTB Bridge to bridge BTC Bridge to candidacy BTD Bridge to decision BTR Bridge to recovery BTT Bridge to transplantation CA Cardiac amyloidosis (or amyloid cardiomyopathy) CABANA Catheter ABlation vs. ANti-arrhythmic drug therapy for Atrial ﬁbrillation (trial) CABG Coronary artery bypass graft CAD Coronary artery disease CANVAS-R CANagliﬂozin cardioVascular Assessment Study - Renal CARE-HF CArdiac REsynchronization in Heart Failure CASTLE-AF Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular and Atrial Fibrillation (trial) CCB Calcium channel blocker CCS Chronic coronary syndrome CHA 2 DS 2 -VASc Congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)- Vascular disease, Age 65 \u0002 74, Sex category (female) (score) CHAMPIT Acute Coronary syndrome/Hypertension emergency/Arrhythmia/acute Mechanical cause/Pulmonary embolism/Infections/ Tamponade\nCHARM Candesartan in Heart Failure - Assessment of moRtality and Morbidity (trial) CHF Chronic heart failure CI Conﬁdence interval CKD Chronic kidney disease CMP Cardiomyopathy CMR Cardiac magnetic resonance CMV Cytomegalovirus COAPT Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for HF patients with functional mitral regurgitation (trial) COC Cardio-Oncology Council (part of the European Society of Cardiology) COMMANDER-HF A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (trial) COMPASS Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (trial) COPD Chronic obstructive pulmonary disease CORONA COntrolled ROsuvastatin multiNAtional (trial) COVID-19 Coronavirus disease 2019 CR Controlled release CREDENCE Canagliﬂozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (trial) CRT Cardiac resynchronization therapy CRT-D Cardiac resynchronization therapy with deﬁbrillator CRT-P Cardiac resynchronization therapy pacemaker CSA Central sleep apnoea CT Computed tomography CTCA Computed tomography coronary angiography CV Cardiovascular DAPA-HF Dapagliﬂozin And Prevention of Adverse- outcomes in Heart Failure (trial) DCM Dilated cardiomyopathy DECLARE- TIMI 58 Dapagliﬂozin Effect on CardiovascuLAR Events (Thrombolysis in Myocardial Infarction) (trial) DIAMOND Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (trial) DIG Digitalis Investigation Group (trial) DNA Deoxyribonucleic acid DOAC Direct-acting oral anticoagulant DPD 3,3-diphosphono-1,2-propanodicarboxylic acid\n3604 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................................................................................................................................................... DPP-4 Dipeptidyl peptidase-4 DSC2 Desmocollin 2 DSG2 Desmoglein 2 DSP Desmoplakin DT Destination therapy E/e 0   (ratio) E/e 0   (ratio) = early ﬁlling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler EACVI European Association of Cardiovascular Imaging (part of the European Society of Cardiology) EAST-AFNET 4 Early Treatment of Atrial Fibrillation for Stroke Prevention Trial 4 (trial) ECG Electrocardiogram EchoCRT Echocardiography Guided Cardiac Resynchronization Therapy (trial) ECLS Extracorporeal life support ECMO Extracorporeal membrane oxygenation EF Ejection fraction eGFR Estimated glomerular ﬁltration rate EHRA European Heart Rhythm Association EMA European Medicines Agency EMB Endomyocardial biopsy EMPA-REG OUTCOME Empagliﬂozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (trial) EMPEROR- Reduced EMPagliﬂozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (trial) EROA Effective regurgitant oriﬁce area ESC European Society of Cardiology EU European Union EuroSCORE II European System for Cardiac Operative Risk Evaluation II (score) FDA Food and Drug Administration FDG Fluorodeoxyglucose FiO 2 Fraction of inspired oxygen FLN Filamin FLNC Filamin C GGT Gamma-glutamyl transferase GISSI-HF Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico  \u0002 Heart Failure (trial) GLP-1 Glucagon-like peptide-1 GUIDE-HF Hemodynamic-GUIDEd Management of Heart Failure (trial) h Hour/hours H 2 FPEF Heavy (BMI >30 kg/m 2 ), Hypertensive (use of >_2 antihypertensive medications), atrial Fibrillation (paroxysmal or persistent), Pulmonary hypertension (Doppler Echocardiographic estimated Pulmonary Artery Systolic Pressure >35 mmHg), Elderly (age >60 years), Filling pressure (Doppler Echocardiographic E/e 0   >9) (score) HbA1c Glycated haemoglobin\nHCM Hypertrophic cardiomyopathy HEART Heart Failure Revascularisation Trial HER2 Human epidermal growth factor receptor 2 HF Heart failure HFA Heart Failure Association HFA-PEFF Heart Failure Association of ESC diagnostic algorithm, P  \u0002  Initial Workup (Step 1: Pretest Assessment), E - Diagnostic Workup (Step 2: Echocardiographic and Natriuretic Peptide score), F1  \u0002  Advanced Workup (Step 3: Functional testing in Case of Uncertainty), F2  \u0002  Aetiological Workup (Step 4: Final Aetiology) HF-MP Heart failure management programme HFmrEF Heart failure with mildly reduced ejection fraction HFpEF Heart failure with preserved ejection fraction HFrEF Heart failure with reduced ejection fraction HHV Human herpes virus HIV Human immunodeﬁciency virus HLA-DR Human leukocyte antigen-DR isotype HMDP Hydroxyl-methylene-diphosphonate HR Hazard ratio HT Heart transplantation HTM Home telemonitoring i.v. Intravenous IABP Intra-aortic balloon pump ICCU Intensive coronary care unit ICD Implantable cardioverter-deﬁbrillator ICU Intensive care unit IHD Ischaemic heart disease INR International normalized ratio INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support INTrEPID Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent (trial) IOCM Iron overload cardiomyopathy IPD Individual patient data I-PRESERVE Irbesartan in Patients with Heart Failure and PRESERVEd Ejection Fraction (trial) KCNH2 Potassium voltage-gated channel subfamily H member 2 KCNQ1 Potassium voltage-gated channel subfamily Q member 1 LA Left atrium/atrial LAE Left atrial enlargement LBBB Left bundle branch block LDB3 LIM domain binding 3 LFT Liver function test LGE Late gadolinium enhancement LMNA Lamin A/C LMWH Low-molecular-weight heparin LUS Lung ultrasound LV Left ventricular/ventricle LVAD Left ventricular assist device\nESC Guidelines 3605\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................................................................................................................................................... LVEDP Left ventricular end-diastolic pressure LVEF Left ventricular ejection fraction LVESD Left ventricular end-systolic diameter LVH Left ventricular hypertrophy LVNC Left ventricular non-compaction LVOT Left ventricular outﬂow tract LVOTO Left ventricular outﬂow tract obstruction MADIT-CRT Multicenter Automatic Deﬁbrillator Implantation Trial with Cardiac Resynchronization Therapy (trial) MADIT-II Multicenter Automatic Deﬁbrillator Implantation Trial II (trial) MADIT-RIT Multicenter Automatic Deﬁbrillator Implantation Trial  \u0002  Reduce Inappropriate Therapy (trial) MAGGIC Meta-Analysis Global Group in Chronic Heart Failure MCS Mechanical circulatory support MEK Mitogen-activated protein kinase MI Myocardial infarction MITRA-FR Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (trial) MMR Mismatch repair MR Mitral regurgitation MRA Mineralocorticoid receptor antagonist MRI Magnetic resonance imaging mRNA Messenger ribonucleic acid MR-proANP Mid-regional pro-atrial natriuretic peptide MT Medical therapy MV Mitral valve mWHO Modiﬁed World Health Organization MYPC Myosin-binding protein C NICM Non-ischaemic cardiomyopathy NKX2-5 NK2 transcription factor related, locus 5 NP Natriuretic peptide NSAID Non-steroidal anti-inﬂammatory drug NSVT Non-sustained ventricular tachycardia NT-proBNP N-terminal pro-B-type natriuretic peptide NYHA New York Heart Association o.d Omne in die (once daily) OMT Optimal medical therapy OSA Obstructive sleep apnoea PA Pulmonary artery PaO 2 Partial pressure of oxygen PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (trial) pCO 2 Partial pressure of carbon dioxide PCI Percutaneous coronary intervention PCR Polymerase chain reaction PCWP Pulmonary capillary wedge pressure PEP-CHF Perindopril in Elderly People with Chronic Heart Failure (trial) PET Positron emission tomography PKP2 Plakophilin 2\nPLN Phospholamban PPCM Peripartum cardiomyopathy PREVEND Prevention of REnal and Vascular ENd-stage Disease (trial) PV Pulmonary vein PVC Premature ventricular contraction PVI Pulmonary vein isolation pVO 2 Peak exercise oxygen consumption QI Quality indicator QOL Quality of life QRS Q, R, and S waves of an ECG RAAS Renin-angiotensin-aldosterone system RACE II Rate Control Efﬁcacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II (trial) RAFT Resynchronization/Deﬁbrillation for Ambulatory Heart Failure Trial (trial) RASi Renin-angiotensin system inhibitor RATE-AF Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (trial) RBM20 Ribonucleic acid binding motif 20 RCT Randomized controlled trial REMATCH Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (trial) REVERSE REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (trial) REVIVED REVascularization for Ischaemic VEntricular Dysfunction (trial) RNA Ribonucleic acid RRT Renal replacement therapy RV Right ventricular/ventricle RVAD Right ventricular assist device RVEDP Right ventricular end-diastolic pressure SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 SAVR Surgical aortic valve replacement SBP Systolic blood pressure SCN5a Sodium channel alpha subunit 5 SCORED Effect of Sotagliﬂozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (trial) SENIORS Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalizations in Seniors with Heart Failure (trial) SERVE-HF Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure (trial) SGLT2 Sodium-glucose co-transporter 2 S-ICD Subcutaneous implantable cardioverter- deﬁbrillator SMR Secondary mitral regurgitation SPECT Single-photon emission computed tomography\n3606 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ SpO 2 Transcutaneous oxygen saturation SR Sinus rhythm STEMI ST-elevation myocardial infarction STICH Surgical Treatment for Ischemic Heart Failure (trial) STICHES Extended follow-up of patients from the STICH trial STS-PROM Society of Thoracic Surgeons Predicted Risk of Mortality SZC Sodium zirconium cyclosilicate T2DM Type 2 diabetes mellitus TAVI Transcatheter aortic valve implantation TFT Thyroid function test t.i.d. Ter in die (three times a day) TKI Tyrosine kinase inhibitor TMEM43 Transmembrane protein 43 TNNT Troponin-T TR Tricuspid regurgitation TRPM4 Transient receptor potential cation channel subfamily M member 4 TSAT Transferrin saturation TSH Thyroid-stimulating hormone TTN Titin TTR Transthyretin UK United Kingdom US United States VAD Ventricular assist device Val-HeFT Valsartan Heart Failure Trial (trial) VEGF Vascular endothelial growth factor VERTIS-CV Cardiovascular Outcomes Following Ertugliﬂozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease (trial) VEST Vest Prevention of Early Sudden Death Trial (trial) VKA Vitamin K antagonist VO 2 Oxygen consumption VPB Ventricular premature beat vs. Versus VV interval Interventricular delay interval WARCEF Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (trial) wtTTR-CA Wild-type transthyretin cardiac amyloidosis XL Extended release\n",
      "keywords": [
        "diastolic dysfunction",
        "class i",
        "aortic stenosis",
        "cardiovascular risk",
        "antihypertensive",
        "anticoagulant",
        "elderly",
        "blood pressure",
        "sbp",
        "angiography",
        "heart failure",
        "mri",
        "recommended",
        "pulmonary hypertension",
        "glp-1",
        "ecg",
        "peripheral artery",
        "physical activity",
        "hfref",
        "hfpef",
        "female",
        "glucose",
        "echocardiography",
        "hypertension",
        "lvef",
        "bnp",
        "tachycardia",
        "crt",
        "should be considered",
        "class ii"
      ],
      "tables": []
    },
    {
      "number": "16",
      "title": "1 Preamble",
      "start_page": 8,
      "end_page": 9,
      "content": "Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strat- egies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health pro- fessionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professio- nal(s) in consultation with the patient and caregiver as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other\nsocieties and organizations. Because of their impact on clinical prac- tice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/ Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. In addition to the publication of Clinical Practice guidelines, the ESC carries out the EURObservational Research Programme of international registries of cardiovascular (CV) diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice. Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes. The Members of this Task Force were selected by the ESC, includ- ing representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines (CPG) Committee policy. A critical evaluation of diagnostic and ther- apeutic procedures was performed, including assessment of the risk \u0002 benefit ratio. The level of evidence and the strength of the rec- ommendation of particular management options were weighed and graded according to predefined scales, as outlined below. The experts of the writing and reviewing panels provided declara- tion of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/ guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines. This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry. The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task Force. The finalized document is signed-off by the CPG for publica- tion in the European Heart Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommen- dations including condensed pocket guideline versions, summary slides, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus,\nESC Guidelines 3607\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................. for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC web- site and hosted on the European Heart Journal website. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, trans- late and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical\njudgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatso- ever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.\nTable 2 Levels of evidence\n©ESC 2021\nLevel of  evidence A Data derived from multiple randomized clinical trials  or meta-analyses.\nLevel of  evidence B Data derived from a single randomized clinical trial or large non-randomized studies.\nLevel of  evidence C Consensus of opinion of the experts and/or small studies,  retrospective studies, registries.\nTable 1 Classes of recommendations\n©ESC 2021\nClasses of recommendations\nClass I  Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.\nConflicting evidence and/or a divergence of opinion about the usefulness/  efficacy of the given treatment or procedure.\nIs recommended or is indicated\nWording to use Definition\nClass III  Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.\nIs not recommended\nClass IIb Usefulness/efficacy is less well established by evidence/opinion. May be considered\nClass IIa Weight of evidence/opinion is in favour of usefulness/efficacy.  Should be considered\nClass II\n3608 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n",
      "keywords": [
        "guideline",
        "class i",
        "preamble",
        "may be considered",
        "should be considered",
        "recommended",
        "class ii",
        "weight",
        "class iii"
      ],
      "tables": [
        {
          "title": "3608 ESC Guidelines",
          "page_number": 9,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective. | Is recommended or is indicated",
          "bbox": [
            117.85979766845703,
            119.052001953125,
            489.6565410907452,
            172.7080078125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3608 ESC Guidelines",
          "page_number": 9,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\nefficacy of the given treatment or procedure. |  | \n |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/efficacy. | Should be considered\n |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered",
          "bbox": [
            117.85979766845703,
            178.89047241210938,
            489.6565410907452,
            281.22796630859375
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3608 ESC Guidelines",
          "page_number": 9,
          "content": "Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            117.85979766845703,
            286.833984375,
            489.6565410907452,
            340.3849792480469
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "17",
      "title": "2 Introduction",
      "start_page": 10,
      "end_page": 10,
      "content": "The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evi- dence. Fortunately, we now have a wealth of clinical trials to help us select the best management to improve the outcomes for people with HF; for many, it is now both preventable and treatable. This guideline provides practical, evidence-based recommendations. We have revised the format of the previous 2016 ESC HF Guidelines 1   to make each phenotype of HF stand-alone in terms of its diagnosis and management. The therapy recommendations men- tion the treatment effect supported by the class and level of evidence and are presented in tables. For HF with reduced ejection fraction (HFrEF), the tabular recommendations focus on mortality and mor- bidity outcomes. Where there are symptomatic benefits, these are highlighted in the text and/or in the web appendices. Detailed sum- maries of the trials underpinning the recommendations are available in the web appendices. For diagnostic indications, we have suggested investigations that all patients with HF should receive, and investiga- tions that can be targeted to specific circumstances. As diagnostic tests have rarely been subject to randomized controlled trials (RCTs), most of the evidence would be regarded as level C. However, that does not mean that there has not been appropriate rigorous evaluation of diagnostic tests. In this guideline, we have decided to focus on the diagnosis and treatment of HF, not on its prevention. Management of CV risk and many CV diseases [especially systemic hypertension, diabetes melli- tus, coronary artery disease, myocardial infarction (MI), atrial fibrilla- tion (AF), and asymptomatic left ventricular (LV) systolic dysfunction] will reduce the risk of developing HF, which is addressed by many other ESC Guidelines and in  section 9.1  of the current guideline. 2 \u0002 7\nThis guideline is the result of a collaboration between the Task Force (including two patient representatives), the reviewers, and the ESC CPG Committee. As such, it is a consensus/majority opinion of the experts consulted in its development.\n",
      "keywords": [
        "hfref",
        "guideline",
        "introduction",
        "ejection fraction",
        "systolic",
        "diabetes",
        "level c",
        "hypertension",
        "heart failure",
        "systolic dysfunction",
        "coronary artery"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3609",
          "page_number": 10,
          "content": " |  | \nRecommendations | Class | \n |  | \nRecommendations for the diagnosis of HF |  | \nRight heart catheterization should be considered in patients\nwhere HF is thought to be due to constrictive pericarditis,\nrestrictive cardiomyopathy, congenital heart disease, and high\noutput states. | IIa | \nRight heart catheterization may be considered in selected\npatients with HFpEF to confirm the diagnosis. | IIb | \nRecommendations for treatment of chronic HF |  | \nHFrEF |  | \nDapagliflozin or empagliflozin are recommended for patients\nwith HFrEF to reduce the risk of HF hospitalization and\ndeath. | I | \nVericiguat may be considered in patients in NYHA class II\u0002IV\nwho have had worsening HF despite treatment with an ACE-I\n(or ARNI), a beta-blocker and an MRA to reduce the risk of\nCV mortality or HF hospitalization. | IIb | \nHFmrEF |  | \nAn ACE-I may be considered for patients with HFmrEF to\nreduce the risk of HF hospitalization and death. | IIb | \nAn ARB may be considered for patients with HFmrEF to\nreduce the risk of HF hospitalization and death. | IIb | \nA beta-blocker may be considered for patients with HFmrEF\nto reduce the risk of HF hospitalization and death. | IIb | \nAn MRA may be considered for patients with HFmrEF to\nreduce the risk of HF hospitalization and death. | IIb | \nSacubitril/valsartan may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization and death. | IIb | \nHFpEF |  | \nScreening for, and treatment of, aetiologies, and CV and non-\nCV comorbidities are recommended in patients with HFpEF\n(see relevant sections of this document). | I | \nPrevention and monitoring |  | \nSelf-management strategies are recommended to reduce the\nrisk of HF hospitalization and mortality. | I | \nEither home-based and/or clinic-based programmes improve\noutcomes and are recommended to reduce the risk of HF\nhospitalization and mortality. | I | \nInfluenza and pneumococcal vaccinations should be consid-\nered in order to prevent HF hospitalizations. | IIa | \nA supervised, exercise-based, cardiac rehabilitation pro-\ngramme should be considered in patients with more severe\ndisease, frailty, or with comorbidities. | IIa | \nNon-invasive HTM may be considered for patients with HF in\norder to reduce the risk of recurrent CV and HF hospitaliza-\ntions and CV death. | IIb | \nRecommendations for management of patients with advanced\nHF |  | \nPatients being considered for long-term MCS must have good\ncompliance, appropriate capacity for device handling and psy-\nchosocial support. | I | ",
          "bbox": [
            311.3709875488281,
            76.47918701171875,
            556.4977213541666,
            727.0302856445312
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3609",
          "page_number": 10,
          "content": "A change of the term ‘heart failure with mid-range ejection fraction’ to\n‘heart failure with mildly reduced ejection fraction’ (HFmrEF). | ESC 2021\nA new simplified treatment algorithm for HFrEF. | \nThe addition of a treatment algorithm for HFrEF according to\nphenotypes. | \nModified classification for acute HF. | \nUpdated treatments for most non-cardiovascular comorbidities\nincluding diabetes, hyperkalaemia, iron deficiency, and cancer. | \nUpdates on cardiomyopathies including the role of genetic testing and\nnew treatments. | \nThe addition of key quality indicators. | ",
          "bbox": [
            48.04241907596588,
            564.5446815490723,
            293.2829895019531,
            703.3836242675782
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "18",
      "title": "2.1 What is new In addition to the recommendations listed below, the following table lists some new concepts compared with the 2016 version.",
      "start_page": 10,
      "end_page": 12,
      "content": "New concepts\nA change of the term ‘heart failure with mid-range ejection fraction’ to ‘heart failure with mildly reduced ejection fraction’ (HFmrEF).\nA new simpliﬁed treatment algorithm for HFrEF.\nThe addition of a treatment algorithm for HFrEF according to\nphenotypes.\nModiﬁed classiﬁcation for acute HF.\nUpdated treatments for most non-cardiovascular comorbidities\nincluding diabetes, hyperkalaemia, iron deﬁciency, and cancer.\nUpdates on cardiomyopathies including the role of genetic testing and\nnew treatments.\nThe addition of key quality indicators.\nHF = heart failure.\nNew recommendations\nRecommendations Class\nRecommendations for the diagnosis of HF\nRight heart catheterization should be considered in patients\nwhere HF is thought to be due to constrictive pericarditis,\nrestrictive cardiomyopathy, congenital heart disease, and high output states.\nIIa\nRight heart catheterization may be considered in selected\npatients with HFpEF to conﬁrm the diagnosis. IIb\nRecommendations for treatment of chronic HF\nHFrEF\nDapagliﬂozin or empagliﬂozin are recommended for patients\nwith HFrEF to reduce the risk of HF hospitalization and\ndeath.\nI\nVericiguat may be considered in patients in NYHA class II \u0002 IV who have had worsening HF despite treatment with an ACE-I\n(or ARNI), a beta-blocker and an MRA to reduce the risk of\nCV mortality or HF hospitalization.\nIIb\nHFmrEF\nAn ACE-I may be considered for patients with HFmrEF to\nreduce the risk of HF hospitalization and death. IIb\nAn ARB may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death. IIb\nA beta-blocker may be considered for patients with HFmrEF\nto reduce the risk of HF hospitalization and death. IIb\nAn MRA may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death. IIb\nSacubitril/valsartan may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization and death. IIb\nHFpEF\nScreening for, and treatment of, aetiologies, and CV and non- CV comorbidities are recommended in patients with HFpEF\n(see relevant sections of this document).\nI\nPrevention and monitoring\nSelf-management strategies are recommended to reduce the risk of HF hospitalization and mortality. I\nEither home-based and/or clinic-based programmes improve\noutcomes and are recommended to reduce the risk of HF hospitalization and mortality.\nI\nInﬂuenza and pneumococcal vaccinations should be consid-\nered in order to prevent HF hospitalizations. IIa\nA supervised, exercise-based, cardiac rehabilitation pro- gramme should be considered in patients with more severe\ndisease, frailty, or with comorbidities.\nIIa\nNon-invasive HTM may be considered for patients with HF in\norder to reduce the risk of recurrent CV and HF hospitaliza- tions and CV death.\nIIb\nRecommendations for management of patients with advanced\nHF\nPatients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psy-\nchosocial support.\nI\nContinued\nESC 2021\n. ...........................................................................................................................................................................\nESC Guidelines 3609\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nHeart transplantation is recommended for patients\nwith advanced HF, refractory to medical/device therapy and\nwho do not have absolute contraindications.\nI\nContinuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypo-\nperfusion as bridge to MCS or heart transplantation.\nIIb\nRecommendations for management of patients after HF hospitalization\nIt is recommended that patients hospitalized for HF be care- fully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment. I\nIt is recommended that evidence-based oral medical treat-\nment be administered before discharge. I\nAn early follow-up visit is recommended at 1 \u0002 2 weeks after\ndischarge to assess signs of congestion, drug tolerance, and start and/or uptitrate evidence-based therapy.\nI\nRecommendations for management of patients with HF and\natrial ﬁbrillation\nLong-term treatment with an oral anticoagulant should be considered for stroke prevention in AF patients with a\nCHA 2 DS 2 -VASc score of 1 in men or 2 in women.\nIIa\nRecommendations for management of patients with HF and CCS\nCABG should be considered as the ﬁrst-choice revasculariza- tion strategy, in patients suitable for surgery, especially if they have diabetes and for those with multivessel disease. IIa\nIn LVAD candidates needing coronary revascularization, CABG should be avoided, if possible. IIa\nCoronary revascularization may be considered to improve out- comes in patients with HFrEF, CCS, and coronary anatomy suit- able for revascularization, after careful evaluation of the individual risk to beneﬁt ratio, including coronary anatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal LAD), comorbidities, life expectancy, and patient’s perspectives.\nIIb\nPCI may be considered as alternative to CABG, based on\nHeart Team evaluation, considering coronary anatomy,\ncomorbidities, and surgical risk.\nIIb\nRecommendations for management of patients with HF and valvular heart disease\nAortic valve intervention, TAVI or SAVR is recommended in\npatients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms.\nI\nIt is recommended that the choice between TAVI and SAVR\nbe made by the Heart Team, according to individual patient\npreference and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and\nbeneﬁts of each approach.\nI\nPercutaneous edge-to-edge mitral valve repair should be consid- ered in carefully selected patients with secondary mitral regurgi-\ntation, not eligible for surgery and not needing coronary\nrevascularization, who are symptomatic despite OMT and who fulﬁl criteria to achieve a reduction in HF hospitalizations.\nIIa\nPercutaneous edge-to-edge mitral valve repair may be con- sidered to improve symptoms in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are highly symptomatic despite OMT and who do not fulﬁl criteria for reducing HF hospitalization.\nIIb\nContinued\nRecommendations for management of patients with HF and\ndiabetes\nSGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with T2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.\nI\nSGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂo-\nzin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.\nI\nThe DPP-4 inhibitor saxagliptin is not recommended in\npatients with HF. III\nRecommendations for management of patients with HF and iron deﬁciency\nIt is recommended that all patients with HF are periodically\nscreened for anaemia and iron deﬁciency with a full blood\ncount, serum ferritin concentration, and TSAT.\nI\nIntravenous iron supplementation with ferric carboxymaltose\nshould be considered in symptomatic HF patients recently hospi-\ntalized for HF and with LVEF <_50% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100 \u0002 299 ng/mL\nwith TSAT <20%, to reduce the risk of HF hospitalization.\nIIa\nTreatment of anaemia in HF with erythropoietin stimulating\nagents is not recommended in the absence of other indica- tions for this therapy.\nIII\nRecommendations for management of patients with HF and\ncancer\nIt is recommended that cancer patients at increased risk for cardi- otoxicity, deﬁned by a history or risk factors of CV disease, pre-\nvious cardiotoxicity or exposure to cardiotoxic agents, undergo\nCV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in Cardio-Oncology.\nI\nTreatment with an ACE-I and a beta-blocker (preferably carvedi-\nlol) should be considered in cancer patients developing LV systolic dysfunction, deﬁned as a 10% or more decrease in LVEF and to a\nvalue lower than 50%, during anthracycline chemotherapy.\nIIa\nA baseline CV risk assessment should be considered in all\ncancer patients scheduled to receive a cancer treatment with the potential to cause HF.\nIIa\nRecommendations for treatment of patients with HF and\namyloidosis\nTafamidis is recommended in patients with genetic testing pro- ven hTTR-CA and NYHA class I or II symptoms to reduce\nsymptoms, CV hospitalization and mortality.\nI\nTafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospi-\ntalization and mortality.\nI\nACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; CABG = coronary artery bypass graft; CCS = chronic coronary syndrome; CHA 2 DS 2 -VASc = con- gestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65 \u0002 74, Sex cate- gory (female) (score); CMP = cardiomyopathy; CV = cardiovascular; DPP-4 = dipeptidyl peptidase-4; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; HTM = home telemonitor- ing; hTTR = hereditary transthyretin; LAD = left anterior descending artery; LV = left ventricular; LVAD = left ventricular assist device; LVEF = left ventricular ejec- tion fraction; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus; TAVI = transcatheter aortic valve implantation; TSAT = transferrin saturation; wtTTR-CA = wild-type transthyretin cardiac amyloidosis.\nESC 2021\n. .................................................................................................................................................................................\n3610 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nChanges in recommendations\n",
      "keywords": [
        "aortic stenosis",
        "anticoagulant",
        "class i",
        "heart failure",
        "table",
        "recommended",
        "what",
        "systolic dysfunction",
        "hfref",
        "hfpef",
        "female",
        "glucose",
        "valve repair",
        "listed",
        "hypertension",
        "lvef",
        "hereditary",
        "recommendations",
        "should be considered",
        "lists",
        "class ii",
        "addition",
        "coronary artery",
        "concepts",
        "below",
        "mitral regurgitation",
        "arb",
        "nyha",
        "aortic",
        "may be considered"
      ],
      "tables": [
        {
          "title": "3610 ESC Guidelines",
          "page_number": 11,
          "content": "Heart transplantation is recommended for patients\nwith advanced HF, refractory to medical/device therapy and\nwho do not have absolute contraindications. | I | \nContinuous inotropes and/or vasopressors may be considered\nin patients with low cardiac output and evidence of organ hypo-\nperfusion as bridge to MCS or heart transplantation. | IIb | \nRecommendations for management of patients after HF\nhospitalization |  | \nIt is recommended that patients hospitalized for HF be care-\nfully evaluated to exclude persistent signs of congestion\nbefore discharge and to optimize oral treatment. | I | \nIt is recommended that evidence-based oral medical treat-\nment be administered before discharge. | I | \nAn early follow-up visit is recommended at 1\u00022 weeks after\ndischarge to assess signs of congestion, drug tolerance, and\nstart and/or uptitrate evidence-based therapy. | I | \nRecommendations for management of patients with HF and\natrial fibrillation |  | \nLong-term treatment with an oral anticoagulant should be\nconsidered for stroke prevention in AF patients with a\nCHADS-VASc score of 1 in men or 2 in women.\n2 2 | IIa | \nRecommendations for management of patients with HF and\nCCS |  | \nCABG should be considered as the first-choice revasculariza-\ntion strategy, in patients suitable for surgery, especially if they\nhave diabetes and for those with multivessel disease. | IIa | \nIn LVAD candidates needing coronary revascularization,\nCABG should be avoided, if possible. | IIa | \nCoronary revascularization may be considered to improve out-\ncomes in patients with HFrEF, CCS, and coronary anatomy suit-\nable for revascularization, after careful evaluation of the individual\nrisk to benefit ratio, including coronary anatomy (i.e. proximal\nstenosis >90% of large vessels, stenosis of left main or proximal\nLAD), comorbidities, life expectancy, and patient’s perspectives. | IIb | \nPCI may be considered as alternative to CABG, based on\nHeart Team evaluation, considering coronary anatomy,\ncomorbidities, and surgical risk. | IIb | \nRecommendations for management of patients with HF and\nvalvular heart disease |  | \nAortic valve intervention, TAVI or SAVR is recommended in\npatients with HF and severe high-gradient aortic stenosis to\nreduce mortality and improve symptoms. | I | \nIt is recommended that the choice between TAVI and SAVR\nbe made by the Heart Team, according to individual patient\npreference and features including age, surgical risk, clinical,\nanatomical and procedural aspects, weighing the risks and\nbenefits of each approach. | I | \nPercutaneous edge-to-edge mitral valve repair should be consid-\nered in carefully selected patients with secondary mitral regurgi-\ntation, not eligible for surgery and not needing coronary\nrevascularization, who are symptomatic despite OMT and who\nfulfil criteria to achieve a reduction in HF hospitalizations. | IIa | \nPercutaneous edge-to-edge mitral valve repair may be con-\nsidered to improve symptoms in carefully selected patients\nwith secondary mitral regurgitation, not eligible for surgery\nand not needing coronary revascularization, who are highly\nsymptomatic despite OMT and who do not fulfil criteria for\nreducing HF hospitalization. | IIb | ",
          "bbox": [
            42.45204398415306,
            50.7990460395813,
            287.6030124973606,
            750.2743041992187
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3610 ESC Guidelines",
          "page_number": 11,
          "content": "Recommendations for management of patients with HF and\ndiabetes |  | \nSGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin,\nertugliflozin, sotagliflozin) are recommended in patients with\nT2DM at risk of CV events to reduce hospitalizations for HF,\nmajor CV events, end-stage renal dysfunction, and CV death. | I | \nSGLT2 inhibitors (dapagliflozin, empagliflozin, and sotagliflo-\nzin) are recommended in patients with T2DM and HFrEF to\nreduce hospitalizations for HF and CV death. | I | \nThe DPP-4 inhibitor saxagliptin is not recommended in\npatients with HF. | III | \nRecommendations for management of patients with HF and\niron deficiency |  | \nIt is recommended that all patients with HF are periodically\nscreened for anaemia and iron deficiency with a full blood\ncount, serum ferritin concentration, and TSAT. | I | \nIntravenous iron supplementation with ferric carboxymaltose\nshould be considered in symptomatic HF patients recently hospi-\ntalized for HF and with LVEF <50% and iron deficiency, defined\n_\nas serum ferritin <100 ng/mL or serum ferritin 100\u0002299 ng/mL\nwith TSAT <20%, to reduce the risk of HF hospitalization. | IIa | \nTreatment of anaemia in HF with erythropoietin stimulating\nagents is not recommended in the absence of other indica-\ntions for this therapy. | III | \nRecommendations for management of patients with HF and\ncancer |  | \nIt is recommended that cancer patients at increased risk for cardi-\notoxicity, defined by a history or risk factors of CV disease, pre-\nvious cardiotoxicity or exposure to cardiotoxic agents, undergo\nCV evaluation before scheduled anticancer therapy, preferably by\na cardiologist with experience/interest in Cardio-Oncology. | I | \nTreatment with an ACE-I and a beta-blocker (preferably carvedi-\nlol) should be considered in cancer patients developing LV systolic\ndysfunction, defined as a 10% or more decrease in LVEF and to a\nvalue lower than 50%, during anthracycline chemotherapy. | IIa | \nA baseline CV risk assessment should be considered in all\ncancer patients scheduled to receive a cancer treatment with\nthe potential to cause HF. | IIa | \nRecommendations for treatment of patients with HF and\namyloidosis |  | \nTafamidis is recommended in patients with genetic testing pro-\nven hTTR-CA and NYHA class I or II symptoms to reduce\nsymptoms, CV hospitalization and mortality. | I | \nTafamidis is recommended in patients with wtTTR-CA and\nNYHA class I or II symptoms to reduce symptoms, CV hospi-\ntalization and mortality. | I | ESC 2021",
          "bbox": [
            306.64067973261297,
            50.7990460395813,
            551.833507907006,
            616.6996032714844
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3611",
          "page_number": 12,
          "content": " |  |  |  | \n2021 | Class | 2016 | Class | \n |  |  |  | \nRecommendations for diagnosis of HF |  |  |  | \nInvasive coronary angiography may be considered in\npatients with HFrEF with an intermediate to high pre-test\nprobability of CAD and the presence of ischaemia in non-\ninvasive stress tests. | IIb | Invasive coronary angiography should be considered in\npatients with HF and intermediate to high pre-test proba-\nbility of CAD and the presence of ischaemia in non-inva-\nsive stress tests (who are considered suitable for potential\ncoronary revascularization) in order to establish the diag-\nnosis of CAD and its severity. | IIa | \nCTCA should be considered in patients with a low to\nintermediate pre-test probability of CAD or those with\nequivocal non-invasive stress tests in order to rule out\ncoronary artery stenosis. | IIa | Cardiac CT may be considered in patients with HF and\nlow to intermediate pre-test probability of CAD or those\nwith equivocal non-invasive stress tests in order to rule\nout coronary artery stenosis. | IIb | \nRecommendations for device therapy in HFrEF |  |  |  | \nAn ICD should be considered to reduce the risk of sud-\nden death and all-cause mortality in patients with sympto-\nmatic HF (NYHA class II\u0002III) of a non-ischaemic\naetiology, and an LVEF <35% despite >3 months of OMT,\n_ _\nprovided they are expected to survive substantially longer\nthan 1 year with good functional status. | IIa | Primary prevention\nAn ICD is recommended to reduce the risk of sudden\ndeath and all-cause mortality in patients with symptomatic\nHF (NYHA class II\u0002III), and an LVEF <35% despite >3\n_ _\nmonths of OMT, provided they are expected to survive\nsubstantially longer than 1 year with good functional sta-\ntus, and they have DCM. | I | \nCRT should be considered for symptomatic patients with\nHF in sinus rhythm with a QRS duration of 130\u0002149 ms\nand LBBB QRS morphology and with LVEF <35% despite\n_\nOMT in order to improve symptoms and reduce morbid-\nity and mortality. | IIa | CRT is recommended for symptomatic patients with HF\nin sinus rhythm with a QRS duration of 130\u0002149 ms and\nLBBB QRS morphology and with LVEF <35% despite\n_\nOMT in order to improve symptoms and reduce morbid-\nity and mortality. | I | \nPatients with an LVEF <35% who have received a conven-\n_\ntional pacemaker or an ICD and subsequently develop\nworsening HF despite OMT and who have a significant\nproportion of RV pacing should be considered for\n‘upgrade’ to CRT. | IIa | Patients with HFrEF who have received a conventional\npacemaker or an ICD and subsequently develop\nworsening HF despite OMT and who have a high\nproportion of RV pacing may be considered for\nupgrade to CRT. This does not apply to patients with\nstable HF. | IIb | \nRecommendations for management of patients with acute HF |  |  |  | \nCombination of a loop diuretic with thiazide-type diuretic\nshould be considered in patients with resistant oedema\nwho do not respond to an increase in loop diuretic\ndoses. | IIa | Combination of loop diuretic with either thiazide-type diu-\nretic or spironolactone may be considered in patients with\nresistant oedema or insufficient symptomatic response. | IIb | \nIn patients with AHF and SBP >110 mmHg, i.v. vasodila-\ntors may be considered as initial therapy to improve\nsymptoms and reduce congestion. | IIb | In patients with hypertensive AHF, i.v. vasodilators should\nbe considered as initial therapy to improve symptoms and\nreduce congestion. | IIa | \nRoutine use of opiates is not recommended, unless in\nselected patients with severe/intractable pain or anxiety. | III | Opiates may be considered for cautious use to relieve\ndyspnoea and anxiety in patients with severe dyspnoea\nbut nausea and hypopnea may occur. | IIb | \nShort-term MCS should be considered in patients with\ncardiogenic shock as a BTR, BTD, BTB. Further indica-\ntions include treatment of the cause of cardiogenic shock\nor long-term MCS or transplantation. | IIa | Short-term MCS may be considered in refractory cardio-\ngenic shock depending on patient age, comorbidities, and\nneurological function. | IIb | ",
          "bbox": [
            47.04587333146916,
            76.50606496710526,
            556.497723614728,
            653.8330078125
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "19",
      "title": "2021 Class 2016 Class",
      "start_page": 12,
      "end_page": 13,
      "content": "Recommendations for diagnosis of HF\nInvasive coronary angiography may be considered in\npatients with HFrEF with an intermediate to high pre-test\nprobability of CAD and the presence of ischaemia in non- invasive stress tests. IIb\nInvasive coronary angiography should be considered in\npatients with HF and intermediate to high pre-test proba-\nbility of CAD and the presence of ischaemia in non-inva- sive stress tests (who are considered suitable for potential\ncoronary revascularization) in order to establish the diag-\nnosis of CAD and its severity.\nIIa\nCTCA should be considered in patients with a low to intermediate pre-test probability of CAD or those with\nequivocal non-invasive stress tests in order to rule out\ncoronary artery stenosis.\nIIa\nCardiac CT may be considered in patients with HF and low to intermediate pre-test probability of CAD or those\nwith equivocal non-invasive stress tests in order to rule\nout coronary artery stenosis.\nIIb\nRecommendations for device therapy in HFrEF\nAn ICD should be considered to reduce the risk of sud-\nden death and all-cause mortality in patients with sympto-\nmatic HF (NYHA class II \u0002 III) of a non-ischaemic aetiology, and an LVEF <_35% despite >_3 months of OMT,\nprovided they are expected to survive substantially longer\nthan 1 year with good functional status.\nIIa\nPrimary prevention\nAn ICD is recommended to reduce the risk of sudden\ndeath and all-cause mortality in patients with symptomatic HF (NYHA class II \u0002 III), and an LVEF <_35% despite >_3\nmonths of OMT, provided they are expected to survive\nsubstantially longer than 1 year with good functional sta- tus, and they have DCM.\nI\nCRT should be considered for symptomatic patients with\nHF in sinus rhythm with a QRS duration of 130 \u0002 149 ms and LBBB QRS morphology and with LVEF <_35% despite\nOMT in order to improve symptoms and reduce morbid-\nity and mortality.\nIIa\nCRT is recommended for symptomatic patients with HF\nin sinus rhythm with a QRS duration of 130 \u0002 149 ms and LBBB QRS morphology and with LVEF <_35% despite\nOMT in order to improve symptoms and reduce morbid-\nity and mortality.\nI\nPatients with an LVEF <_35% who have received a conven- tional pacemaker or an ICD and subsequently develop\nworsening HF despite OMT and who have a signiﬁcant\nproportion of RV pacing should be considered for ‘upgrade’ to CRT.\nIIa\nPatients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop\nworsening HF despite OMT and who have a high\nproportion of RV pacing may be considered for upgrade to CRT. This does not apply to patients with\nstable HF.\nIIb\nRecommendations for management of patients with acute HF\nCombination of a loop diuretic with thiazide-type diuretic should be considered in patients with resistant oedema\nwho do not respond to an increase in loop diuretic\ndoses.\nIIa\nCombination of loop diuretic with either thiazide-type diu- retic or spironolactone may be considered in patients with\nresistant oedema or insufﬁcient symptomatic response. IIb\nIn patients with AHF and SBP >110 mmHg, i.v. vasodila-\ntors may be considered as initial therapy to improve\nsymptoms and reduce congestion.\nIIb In patients with hypertensive AHF, i.v. vasodilators should\nbe considered as initial therapy to improve symptoms and\nreduce congestion.\nIIa\nRoutine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety. III Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea\nbut nausea and hypopnea may occur.\nIIb\nShort-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD, BTB. Further indica-\ntions include treatment of the cause of cardiogenic shock\nor long-term MCS or transplantation.\nIIa\nShort-term MCS may be considered in refractory cardio- genic shock depending on patient age, comorbidities, and\nneurological function. IIb\nContinued\nESC Guidelines 3611\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................................ 3 Definition, epidemiology and prognosis\n",
      "keywords": [
        "hfref",
        "class",
        "primary prevention",
        "angiography",
        "icd",
        "sbp",
        "diuretic",
        "lvef",
        "pacemaker",
        "crt",
        "age",
        "should be considered",
        "recommended",
        "nyha",
        "class ii",
        "coronary artery",
        "may be considered",
        "stenosis"
      ],
      "tables": [
        {
          "title": "3612 ESC Guidelines",
          "page_number": 13,
          "content": "Recommendations for management of patients with HF and AF |  |  |  | \nDOACs are recommended in preference to VKAs in\npatients with HF, except in those with moderate or\nsevere mitral stenosis or mechanical prosthetic heart\nvalves. | I | For patients with HF and non-valvular AF eligible for anti-\ncoagulation based on a CHADS-VASc score, NOACs\n2 2\nrather than warfarin should be considered for anticoagula-\ntion as NOACs are associated with a lower risk of stroke,\nintracranial haemorrhage, and mortality, which outweigh\nthe increased risk of gastrointestinal haemorrhage. | IIa | \nBeta-blockers should be considered for short- and long-\nterm rate control in patients with HF and AF. | IIa | For patients in NYHA class I\u0002III, a beta-blocker, usually\ngiven orally, is safe and therefore is recommended as first-\nline treatment to control ventricular rate, provided the\npatient is euvolaemic. | I | \nIn cases of a clear association between paroxysmal or\npersistent AF and worsening of HF symptoms, which\npersist despite medical therapy, catheter ablation should\nbe considered for the prevention or treatment of AF. | IIa | AV node catheter ablation may be considered to control\nheart rate and relieve symptoms in patients unresponsive\nor intolerant to intensive pharmacological rate and rhythm\ncontrol therapy, accepting that these patients will become\npacemaker-dependent. | IIb | \nRecommendations for management of patients with HF and CCS |  |  |  | \nCoronary revascularization should be considered to\nrelieve persistent symptoms of angina (or an angina-\nequivalent) in patients with HFrEF, CCS, and coronary\nanatomy suitable for revascularization, despite OMT\nincluding anti-anginal drugs. | IIa | Myocardial revascularization is recommended when angina\npersists despite treatment with anti-anginal drugs. | I | \nRecommendations for management of patients with HF and diabetes |  |  |  | \nSGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflo-\nzin, ertugliflozin, sotagliflozin) are recommended in\npatients with T2DM at risk of CV events to reduce hospi-\ntalizations for HF, major CV events, end-stage renal dys-\nfunction, and CV death. | I | Empagliflozin should be considered in patients with T2DM\nin order to prevent or delay the onset of HF and prolong\nlife. | IIa | ESC 2021",
          "bbox": [
            42.449776306152344,
            59.86335754394531,
            552.0275268554688,
            405.34168497721356
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "20",
      "title": "3.1 Definition of heart failure Heart failure is not a single pathological diagnosis, but a clinical syn- drome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that ",
      "start_page": 13,
      "end_page": 13,
      "content": "",
      "keywords": [
        "ankle",
        "symptoms",
        "consisting",
        "failure",
        "fatigue",
        "clinical",
        "breathlessness",
        "single",
        "definition",
        "heart",
        "swelling",
        "cardinal",
        "pathological",
        "drome",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "21",
      "title": "3.2 Terminology 3.2.1 Heart failure with preserved, mildly reduced, and reduced ejection fraction Traditionally, HF has been divided into distinct phenotypes based on the measurement of left ventricul",
      "start_page": 13,
      "end_page": 14,
      "content": "•   Reduced LVEF is defined as <_40%, i.e. those with a significant reduction in LV systolic function. This is designated as HFrEF. •   Patients with a LVEF between 41% and 49% have  mildly  reduced LV systolic function, i.e. HFmrEF. Retrospective analyses from RCTs in HFrEF or HF with preserved ejection fraction (HFpEF) that have included patients with ejection fractions in the 40 \u0002 50% range suggest that they may benefit from similar\nRecommendations for management of patients with HF and AF\nDOACs are recommended in preference to VKAs in\npatients with HF, except in those with moderate or\nsevere mitral stenosis or mechanical prosthetic heart valves. I\nFor patients with HF and non-valvular AF eligible for anti-\ncoagulation based on a CHA 2 DS 2 -VASc score, NOACs\nrather than warfarin should be considered for anticoagula- tion as NOACs are associated with a lower risk of stroke,\nintracranial haemorrhage, and mortality, which outweigh the increased risk of gastrointestinal haemorrhage.\nIIa\nBeta-blockers should be considered for short- and long-\nterm rate control in patients with HF and AF. IIa\nFor patients in NYHA class I \u0002 III, a beta-blocker, usually\ngiven orally, is safe and therefore is recommended as ﬁrst-\nline treatment to control ventricular rate, provided the patient is euvolaemic.\nI\nIn cases of a clear association between paroxysmal or\npersistent AF and worsening of HF symptoms, which persist despite medical therapy, catheter ablation should\nbe considered for the prevention or treatment of AF.\nIIa\nAV node catheter ablation may be considered to control\nheart rate and relieve symptoms in patients unresponsive or intolerant to intensive pharmacological rate and rhythm\ncontrol therapy, accepting that these patients will become\npacemaker-dependent.\nIIb\nRecommendations for management of patients with HF and CCS\nCoronary revascularization should be considered to\nrelieve persistent symptoms of angina (or an angina-\nequivalent) in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, despite OMT\nincluding anti-anginal drugs.\nIIa\nMyocardial revascularization is recommended when angina\npersists despite treatment with anti-anginal drugs. I\nRecommendations for management of patients with HF and diabetes\nSGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂo- zin, ertugliﬂozin, sotagliﬂozin) are recommended in\npatients with T2DM at risk of CV events to reduce hospi-\ntalizations for HF, major CV events, end-stage renal dys- function, and CV death.\nI\nEmpagliﬂozin should be considered in patients with T2DM in order to prevent or delay the onset of HF and prolong\nlife. IIa\nAF = atrial ﬁbrillation; AHF = acute heart failure; AV = atrio-ventricular; BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to cardiac recovery; CAD = coronary artery disease; CCS = chronic coronary syndrome; CHA 2 DS 2 -VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65 \u0002 74, Sex category (female) (score); CRT = cardiac resynchronization therapy; CT = computed tomography; CTCA = computed tomography coronary angiography; CV = cardiovascular; DCM = dilated cardiomyopathy; DOAC = direct oral anticoagulant; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; NOAC = non-vitamin K antagonist oral anticoagulant; NYHA = New York Heart Association; OMT = optimal medical therapy; QRS = Q, R, and S waves of an ECG; RV = right ventricular/ventricle; SBP = systolic blood pressure; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus; VKA = vitamin K antagonist.\nESC 2021\n3612 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................................................................................. therapies to those with LVEF <_40%. 8 \u0002 13   This supports the renaming of HFmrEF from ‘heart failure with mid-range ejection fraction’ to ‘heart failure with mildly reduced ejection fraction’. 14\n•   Those with symptoms and signs of HF, with evidence of structural and/or functional cardiac abnormalities and/or raised natriuretic peptides (NPs), and with an LVEF >_50%, have HFpEF.\nThe diagnosis of HFrEF, HFmrEF, and HFpEF is covered in more detail in their respective sections ( sections 5 ,  7 , and  8 , respectively). These definitions are consistent with a recent report on the Universal Definition of Heart Failure. 15\nPatients with non-CV disease, e.g. anaemia, pulmonary, renal, thy- roid, or hepatic disease may have symptoms and signs very similar to those of HF, but in the absence of cardiac dysfunction, they do not fulfil the criteria for HF. However, these pathologies can coexist with HF and exacerbate the HF syndrome.\n3.2.2 Right ventricular dysfunction Heart failure can also be a result of right ventricular (RV) dysfunc- tion. RV mechanics and function are altered in the setting of either pressure or volume overload. 16   Although the main aetiology of chronic RV failure is LV dysfunction-induced pulmonary hyperten- sion, there are a number of other causes of RV dysfunction [e.g. MI, arrhythmogenic right ventricular cardiomyopathy (ARVC), or valve disease]. 17   The diagnosis is determined by a quantitative assessment of global RV function, most commonly by echocar- diography, using at least one of the following measurements: frac- tional area change (FAC); tricuspid annular plane systolic excursion (TAPSE); and Doppler tissue imaging-derived systolic S 0\nvelocity of the tricuspid annulus. The diagnosis and management of RV dysfunction is covered comprehensively in a recent Heart Failure Association (HFA) position paper. 18\n3.2.3 Other common terminology used in heart failure Heart failure is usually divided into two presentations: chronic heart failure (CHF) and acute heart failure (AHF). CHF describes those who have had an established diagnosis of HF or who have a more gradual onset of symptoms. If CHF deteriorates, either suddenly or\nslowly, the episode may be described as ‘decompensated’ HF. This can result in a hospital admission or treatment with intravenous (i.v.) diuretic therapy in the outpatient setting. In addition, HF can present more acutely. Both of these are considered in the section on AHF ( section 11 ). Some individuals with HF may recover completely [e.g. those due to alcohol-induced cardiomyopathy (CMP), viral myocarditis, Takotsubo syndrome, peripartum cardiomyopathy (PPCM), or tachycardiomyopathy]. Other patients with LV systolic dysfunction may show a substantial or even complete recovery of LV systolic function after receiving drug and device therapy.\n3.2.4 Terminology related to the symptomatic severity of heart failure The simplest terminology used to describe the severity of HF is the New York Heart Association (NYHA) functional classification ( Table  4 ). However, this relies solely on symptoms and there are many other better prognostic indicators in HF. 19   Importantly, patients with mild symptoms may still have a high risk of hospitaliza- tion and death. 20   Predicting outcome is particularly important in advanced HF to guide selection of cardiac transplantation and device therapies. This will be covered in detail in the section on advanced HF ( section 10 ).\n",
      "keywords": [
        "class i",
        "anticoagulant",
        "angiography",
        "blood pressure",
        "sbp",
        "heart failure",
        "recommended",
        "terminology",
        "systolic dysfunction",
        "ecg",
        "hfref",
        "ventricul",
        "hfpef",
        "female",
        "glucose",
        "failure",
        "distinct",
        "hypertension",
        "lvef",
        "crt",
        "heart",
        "should be considered",
        "phenotypes",
        "mitral stenosis",
        "coronary artery",
        "left",
        "preserved",
        "alcohol",
        "icd",
        "mildly"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3613",
          "page_number": 14,
          "content": "Type of HF |  |  | HFrEF |  | HFmrEF |  | HFpEF | ESC 2021\nCRITERIA | 1 |  | Symptoms ± Signsa |  | Symptoms ± Signsa |  | Symptoms ± Signsa | \n | 2 |  | LVEF <40%\n_ |  | LVEF 41\u000249%b |  | LVEF >50%\n_ | \n | 3 |  | \u0002 |  | \u0002 |  | Objective evidence of cardiac structural and/or functional\nabnormalities consistent with the presence of LV diastolic\ndysfunction/raised LV filling pressures, including raised natriuretic peptidesc | ",
          "bbox": [
            48.00993792215983,
            91.33294677734375,
            557.6139526367188,
            165.40826416015625
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "22",
      "title": "3.3 Epidemiology and natural history of heart failure 3.3.1 Incidence and prevalence In developed countries, the age-adjusted incidence of HF may be fall- ing, presumably reflecting better management ",
      "start_page": 14,
      "end_page": 14,
      "content": "Table 3 Deﬁnition of heart failure with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction\nType of HF HFrEF HFmrEF HFpEF\nCRITERIA\n",
      "keywords": [
        "presumably",
        "history",
        "heart failure",
        "natural",
        "developed",
        "fall",
        "adjusted",
        "reflecting",
        "hfref",
        "hfpef",
        "failure",
        "heart",
        "better",
        "management",
        "countries",
        "ejection fraction",
        "hfmref",
        "prevalence",
        "epidemiology",
        "incidence"
      ],
      "tables": []
    },
    {
      "number": "23",
      "title": "1 Symptoms ± Signs a Symptoms ± Signs a Symptoms ± Signs a",
      "start_page": 14,
      "end_page": 15,
      "content": "2 LVEF <_40% LVEF 41 \u0002 49% b LVEF >_50%\n3 \u0002 \u0002 Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic\ndysfunction/raised LV ﬁlling pressures, including raised natriuretic peptides c\nHF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejec- tion fraction; LV = left ventricle; LVEF = left ventricular ejection fraction. a Signs may not be present in the early stages of HF (especially in HFpEF) and in optimally treated patients. b For the diagnosis of HFmrEF, the presence of other evidence of structural heart disease (e.g. increased left atrial size, LV hypertrophy or echocardiographic measures of impaired LV ﬁlling) makes the diagnosis more likely. c For the diagnosis of HFpEF, the greater the number of abnormalities present, the higher the likelihood of HFpEF.\nESC 2021\nESC Guidelines 3613\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................................................................................................................................\nis generally believed that, of those with HF, about 50% have HFrEF and 50% have HFpEF/HFmrEF, mainly based on studies in hospitalized patients. 32 , 35 , 37 , 38   The ESC Long-Term Registry, in the outpatient set- ting, reports that 60% have HFrEF, 24% have HFmrEF, and 16% have HFpEF. 39   Somewhat more than 50% of HF patients are female. 21 , 40 , 41\n3.3.2 Aetiology of heart failure The most common causes (as well as some key investigations) of HF are shown in  Table  5 . The aetiology of HF varies according to geography. In Western-type and developed countries, coronary artery disease (CAD) and hypertension are predomi- nant factors. 27\nWith regard to ischaemic aetiology, HFmrEF resembles HFrEF, with a higher frequency of underlying CAD compared to those with HFpEF. 38 , 42 , 43\n3.3.3 Natural history and prognosis The prognosis of patients with HF has improved considerably since the publication of the first treatment trials a few decades ago. However, it remains poor, and quality of life (QOL) is also markedly reduced. The improvement in prognosis has been confined to those with HFrEF. Mortality rates are higher in observational studies than in clinical trials. 44   In the Olmsted County cohort, 1-year and 5-year mortality rates after diagnosis, for all types of HF patients, were 20% and 53%, respectively, between 2000 and 2010. 45   A study combining the Framingham Heart Study (FHS) and Cardiovascular Health Study (CHS) cohorts reported a 67% mortality rate within 5 years following diagnosis. 46   Despite receiving less evidence-based treatment, women have a better survival than men. 47\nOverall prognosis is better in HFmrEF compared to HFrEF. 39   Of note, transition in ejection fraction over time is common, and patients who progress from HFmrEF to HFrEF have a worse prognosis than\nthose who remain stable or transition to a higher ejection fraction category. 48 \u0002 52\nHFpEF is generally considered to confer a better survival than HFrEF, but most observational studies show that this difference is negligible. 45 , 46   In contrast, the large MAGGIC meta-analysis con- cluded that the adjusted mortality risk for patients with HFpEF was considerably lower than in patients with HFrEF. 53\nStudies from several countries have shown that between 1980 and 2000 survival in HF patients has improved markedly. 41 , 54 \u0002 57\nHowever, this positive trend may have levelled off since then. 45\nAfter the initial diagnosis, HF patients are hospitalized once every year on average. 54   From 2000 to 2010, the mean rate of hospitaliza- tion in the Olmsted County cohort was 1.3 per person-year. Interestingly, the majority (63%) of hospitalizations were related to non-CV causes. 45   Studies from several European countries and the United States (US) have shown that HF hospitalization rates peaked in the 1990s, and then declined. 54 , 55 * , 58 \u0002 60   However, in a recent study of incident HF conducted between 1998 and 2017 in the United Kingdom (UK), age-adjusted rates of first hospitalizations increased by 28% for both all-cause and HF admissions, and by 42% for non-CV admissions. 61   These increases were higher in women, perhaps related to higher comorbidity rates. The risk of HF hospital- ization is 1.5 times higher in patients with diabetes compared to con- trols. AF, a higher body mass index (BMI), and higher glycated haemoglobin (HbA1c), as well as a low estimated glomerular filtra- tion rate (eGFR) are strong predictors of HF hospitalizations. 29\nDue to population growth, ageing, and the increasing prevalence of comorbidities, the absolute number of hospital admissions for HF is expected to increase considerably in the future, perhaps by as much as 50% in the next 25 years. 24 , 62\n",
      "keywords": [
        "hfref",
        "signs",
        "hfpef",
        "female",
        "diastolic",
        "ejection fraction",
        "diabetes",
        "hypertension",
        "lvef",
        "heart failure",
        "framingham",
        "hfmref",
        "age",
        "bmi",
        "egfr",
        "coronary artery",
        "hba1c",
        "symptoms"
      ],
      "tables": [
        {
          "title": "3614 ESC Guidelines",
          "page_number": 15,
          "content": "Class I | No limitation of physical activity. Ordinary physical activity\ndoes not cause undue breathlessness, fatigue, or\npalpitations. | ESC 2021\nClass II | Slight limitation of physical activity. Comfortable at rest,\nbut ordinary physical activity results in undue breathless-\nness, fatigue, or palpitations. | \nClass III | Marked limitation of physical activity. Comfortable at rest,\nbut less than ordinary activity results undue breathless-\nness, fatigue, or palpitations. | \nClass IV | Unable to carry on any physical activity without discom-\nfort. Symptoms at rest can be present. If any physical activ-\nity is undertaken, discomfort is increased. | ",
          "bbox": [
            43.46594208937425,
            101.75886119495739,
            288.7480163574219,
            250.63299560546875
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "24",
      "title": "4 Chronic heart failure",
      "start_page": 15,
      "end_page": 15,
      "content": "",
      "keywords": [
        "heart",
        "failure",
        "chronic"
      ],
      "tables": []
    },
    {
      "number": "25",
      "title": "4.1 Key steps in the diagnosis of chronic heart failure The diagnosis of CHF requires the presence of symptoms and/or signs of HF and objective evidence of cardiac dysfunction ( Figure  1 ). Typical s",
      "start_page": 15,
      "end_page": 18,
      "content": "The diagnosis of CHF is made more likely in patients with a history of MI, arterial hypertension, CAD, diabetes mellitus, alcohol misuse, chronic kidney disease (CKD), cardiotoxic chemotherapy, and in those with a family history of CMP or sudden death. The following diagnostic tests are recommended for the assess- ment of patients with suspected chronic HF:\n(1) Electrocardiogram (ECG). A normal ECG makes the diagnosis of HF unlikely. 63   The ECG may reveal abnormalities such as AF, Q waves, LV hypertrophy (LVH), and a widened QRS complex ( Table  7 ) that increase the likelihood of a diagnosis of HF and also may guide therapy.\nTable 4 New York Heart Association functional classiﬁcation based on severity of symptoms and physical activity\nClass I No limitation of physical activity. Ordinary physical activity\ndoes not cause undue breathlessness, fatigue, or palpitations.\nClass II Slight limitation of physical activity. Comfortable at rest,\nbut ordinary physical activity results in undue breathless- ness, fatigue, or palpitations.\nClass III Marked limitation of physical activity. Comfortable at rest,\nbut less than ordinary activity results undue breathless-\nness, fatigue, or palpitations.\nClass IV Unable to carry on any physical activity without discom-\nfort. Symptoms at rest can be present. If any physical activ-\nity is undertaken, discomfort is increased.\nESC 2021\n3614 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nY\nSuspected heart failure\nEchocardiography\nNT-proBNP  ≥  125 pg/mL or BNP  ≥  35 pg/mL N\nY\nDiagnostic algorithm for heart failure\nRisk factors Symptoms and/or signs Abnormal ECG\nor if HF strongly suspected or if NT-proBNP/BNP unavailable\nAbnormal findings\nY\nHeart failure confirmed Define heart failure phenotype based on LVEF measurement\n≤ 40% (HFrEF) 41–49% (HFmrEF) ≥50% (HFpEF)\nDetermine aetiology and commence treatment Heart failure unlikely\nConsider other diagnoses\nN\nFigure 1  The diagnostic algorithm for heart failure. BNP= B-type natriuretic peptide; ECG= electrocardiogram; HFmrEF= heart failure with mildly reduced ejection fraction; HFpEF= heart failure with preserved ejection fraction; HFrEF= heart failure with reduced ejection fraction; LVEF= left ventricu- lar ejection fraction; NT-proBNP= N-terminal pro-B type natriuretic peptide. The abnormal echocardiographic findings are described in more detail in the respective sections on HFrEF ( section 5 ), HFmrEF ( section 7 ), and HFpEF ( section 8 ).\nESC Guidelines 3615\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 5 Causes of heart failure, common modes of presentation and speciﬁc investigations\nCause Examples of presentations Specific investigations\nCAD Myocardial infarction Angina or “angina-equivalent”\nArrhythmias\nInvasive coronary angiography CT coronary angiography\nImaging stress tests (echo, nuclear, CMR)\nHypertension Heart failure with preserved systolic function Malignant hypertension/acute pulmonary oedema 24 h ambulatory BP Plasma metanephrines, renal artery imaging\nRenin and aldosterone\nValve disease Primary valve disease e.g., aortic stenosis\nSecondary valve disease, e.g. functional regurgitation Congenital valve disease\nEcho  \u0002  transoesophageal/stress\nArrhythmias Atrial tachyarrhythmias\nVentricular arrhythmias\nAmbulatory ECG recording\nElectrophysiology study, if indicated\nCMPs All Dilated\nHypertrophic\nRestrictive ARVC\nPeripartum\nTakotsubo syndrome Toxins: alcohol, cocaine, iron, copper\nCMR, genetic testing\nRight and left heart catheterization\nCMR, angiography Trace elements, toxicology, LFTs, GGT\nCongenital heart disease Congenitally corrected/repaired transposition of great arteries\nShunt lesions Repaired tetralogy of Fallot\nEbstein’s anomaly\nCMR\nInfective Viral myocarditis\nChagas disease HIV\nLyme disease\nCMR, EMB\nSerology\nDrug-induced Anthracyclines Trastuzumab\nVEGF inhibitors\nImmune checkpoint inhibitors Proteasome inhibitors\nRAF þ MEK inhibitors\nInﬁltrative Amyloid\nSarcoidosis\nNeoplastic\nSerum electrophoresis and serum free light chains, Bence\nJones protein, bone scintigraphy, CMR, CT-PET, EMB Serum ACE, CMR, FDG-PET, chest CT, EMB\nCMR, EMB\nStorage disorders Haemochromatosis Fabry disease\nGlycogen storage diseases\nIron studies, genetics, CMR (T2* imaging), EMB a -galactosidase A, genetics, CMR (T1 mapping)\nEndomyocardial disease Radiotherapy\nEndomyocardial ﬁbrosis/eosinophilia Carcinoid\nCMR\nEMB 24 h urine 5-HIAA\nPericardial disease Calciﬁcation\nInﬁltrative\nChest CT, CMR, right and left heart catheterization\nMetabolic Endocrine disease Nutritional disease (thiamine, vitamin B1 and selenium deﬁciencies)\nAutoimmune disease\nTFTs, plasma metanephrines, renin and aldosterone, cortisol Speciﬁc plasma nutrients\nANA, ANCA, rheumatology review\nNeuromuscular disease Friedreich’s ataxia Muscular dystrophy Nerve conduction studies, electromyogram, genetics CK, electromyogram, genetics\n5-HIAA = 5-hydroxyindoleacetic acid; ACE = angiotensin-converting enzyme; ANA = anti-nuclear antibody; ANCA = anti-nuclear cytoplasmic antibody; ARVC = arrhythmogenic right ventricular cardiomyopathy; BP = blood pressure; CAD = coronary artery disease; CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CK = creatinine kinase; CT = computed tomography; ECG = electrocardiogram; Echo = echocardiography; EMB = endomyocardial biopsy; FDG = ﬂuorodeoxyglucose; GGT = gamma-glutamyl transferase; HIV = human immunodeﬁciency virus; h = hour; LFT = liver function test; LGE = late gadolinium enhancement; MEK = mitogen-activated protein kinase; PET = positron emission tomography; TFT = thyroid function test; VEGF = vascular endothelial growth factor.\nESC 2021\n3616 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ..........................................................\n(2) Measurement of NPs are recommended, if available. A plasma concentration of B-type natriuretic peptide (BNP) <35 pg/mL, N-terminal pro-B-type natriuretic peptide (NT-proBNP) <125 pg/ mL, or mid-regional pro-atrial natriuretic peptide (MR-proANP) <40 pmol/L 68   make a diagnosis of HF unlikely. These will be dis- cussed in more detail in  section 4.2 . 69 , 70\n(3) Basic investigations such as serum urea and electrolytes, creatinine, full blood count, liver and thyroid function tests are recommended to differentiate HF from other conditions, to provide prognostic information, and to guide potential therapy. (4) Echocardiography is recommended as the key investigation for the assessment of cardiac function. As well as the determination of the LVEF, echocardiography also provides information on other param- eters such as chamber size, eccentric or concentric LVH, regional wall motion abnormalities (that may suggest underlying CAD, Takotsubo syndrome, or myocarditis), RV function, pulmonary hypertension, valvular function, and markers of diastolic function. 16 , 71\n(5) A chest X-ray is recommended to investigate other potential causes of breathlessness (e.g. pulmonary disease). It may also provide sup- portive evidence of HF (e.g. pulmonary congestion or cardiomegaly).\n",
      "keywords": [
        "aortic stenosis",
        "class i",
        "angiography",
        "objective",
        "presence",
        "blood pressure",
        "heart failure",
        "echo",
        "steps",
        "recommended",
        "pulmonary hypertension",
        "ecg",
        "requires",
        "physical activity",
        "class iii",
        "hfref",
        "evidence",
        "hfpef",
        "failure",
        "echocardiography",
        "hypertension",
        "lvef",
        "bnp",
        "heart",
        "class ii",
        "coronary artery",
        "signs",
        "diastolic",
        "alcohol",
        "electrocardiogram"
      ],
      "tables": [
        {
          "title": "3616 ESC Guidelines",
          "page_number": 17,
          "content": "Cause |  | Examples of presentations |  | Specific investigations | ESC 2021\nCAD |  | Myocardial infarction\nAngina or “angina-equivalent”\nArrhythmias |  | Invasive coronary angiography\nCT coronary angiography\nImaging stress tests (echo, nuclear, CMR) | \nHypertension |  | Heart failure with preserved systolic function\nMalignant hypertension/acute pulmonary oedema |  | 24 h ambulatory BP\nPlasma metanephrines, renal artery imaging\nRenin and aldosterone | \nValve disease |  | Primary valve disease e.g., aortic stenosis\nSecondary valve disease, e.g. functional regurgitation\nCongenital valve disease |  | Echo \u0002 transoesophageal/stress | \nArrhythmias |  | Atrial tachyarrhythmias\nVentricular arrhythmias |  | Ambulatory ECG recording\nElectrophysiology study, if indicated | \nCMPs |  | All\nDilated\nHypertrophic\nRestrictive\nARVC\nPeripartum\nTakotsubo syndrome\nToxins: alcohol, cocaine, iron, copper |  | CMR, genetic testing\nRight and left heart catheterization\nCMR, angiography\nTrace elements, toxicology, LFTs, GGT | \nCongenital heart disease |  | Congenitally corrected/repaired transposition of great arteries\nShunt lesions\nRepaired tetralogy of Fallot\nEbstein’s anomaly |  | CMR | \nInfective |  | Viral myocarditis\nChagas disease\nHIV\nLyme disease |  | CMR, EMB\nSerology | \nDrug-induced |  | Anthracyclines\nTrastuzumab\nVEGF inhibitors\nImmune checkpoint inhibitors\nProteasome inhibitors\nRAFþMEK inhibitors |  |  | \nInfiltrative |  | Amyloid\nSarcoidosis\nNeoplastic |  | Serum electrophoresis and serum free light chains, Bence\nJones protein, bone scintigraphy, CMR, CT-PET, EMB\nSerum ACE, CMR, FDG-PET, chest CT, EMB\nCMR, EMB | \nStorage disorders |  | Haemochromatosis\nFabry disease\nGlycogen storage diseases |  | Iron studies, genetics, CMR (T2* imaging), EMB\na-galactosidase A, genetics, CMR (T1 mapping) | \nEndomyocardial disease |  | Radiotherapy\nEndomyocardial fibrosis/eosinophilia\nCarcinoid |  | CMR\nEMB\n24 h urine 5-HIAA | \nPericardial disease |  | Calcification\nInfiltrative |  | Chest CT, CMR, right and left heart catheterization | \nMetabolic |  | Endocrine disease\nNutritional disease (thiamine, vitamin B1 and selenium deficiencies)\nAutoimmune disease |  | TFTs, plasma metanephrines, renin and aldosterone, cortisol\nSpecific plasma nutrients\nANA, ANCA, rheumatology review | \nNeuromuscular disease |  | Friedreich’s ataxia\nMuscular dystrophy |  | Nerve conduction studies, electromyogram, genetics\nCK, electromyogram, genetics | ",
          "bbox": [
            43.52087728438839,
            81.29803466796875,
            553.0789794921875,
            708.6244689941407
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3617",
          "page_number": 18,
          "content": "Symptoms | Signs | ESC 2021\nTypical | More specific | \nBreathlessness\nOrthopnoea\nParoxysmal nocturnal dyspnoea\nReduced exercise tolerance\nFatigue, tiredness, increased\ntime to recover after exercise\nAnkle swelling | Elevated jugular venous pressure\nHepatojugular reflux\nThird heart sound (gallop rhythm)\nLaterally displaced apical impulse | \nLess typical | Less specific | \nNocturnal cough\nWheezing\nBloated feeling\nLoss of appetite\nConfusion (especially in the elderly)\nDepression\nPalpitation\nDizziness\nSyncope\nBendopneaa | Weight gain (>2 kg/week)\nWeight loss (in advanced HF)\nTissue wasting (cachexia)\nCardiac murmur\nPeripheral oedema (ankle,\nsacral, scrotal)\nPulmonary crepitations\nPleural effusion\nTachycardia\nIrregular pulse\nTachypnoea\nCheyne-Stokes respiration\nHepatomegaly\nAscites\nCold extremities\nOliguria\nNarrow pulse pressure | ",
          "bbox": [
            312.3584950764974,
            81.29803466796875,
            559.0309448242188,
            423.04112333409927
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3617",
          "page_number": 18,
          "content": " |  |  | \n |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nBNP/NT-proBNPc | I | B | \n12-lead ECG | I | C | \nTransthoracic echocardiography | I | C | \nChest radiography (X-ray) | I | C | \nRoutine blood tests for comorbidities, including\nfull blood count, urea and electrolytes, thyroid\nfunction, fasting glucose and HbA1c, lipids, iron\nstatus (TSAT and ferritin) | I | C | ESC 2021",
          "bbox": [
            47.100224928422406,
            371.16900634765625,
            292.2265413724459,
            499.2902374267578
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "26",
      "title": "4.2 Natriuretic peptides Plasma concentrations of NPs are recommended as initial diagnostic tests in patients with symptoms suggestive of HF to rule out the diag- nosis. Elevated concentrations suppor",
      "start_page": 18,
      "end_page": 18,
      "content": "However, it should be noted that there are many causes of an ele- vated NP—both CV and non-CV—that might reduce their diagnostic accuracy ( Table  7 ). These causes include AF, increasing age, and acute or chronic kidney disease. 74   Conversely, NP concentrations may be disproportionately low in obese patients. 75\n4.2.1 Use in the non-acute setting The diagnostic value of NPs, in addition to signs and symptoms and other diagnostic tests, such as an ECG, has been assessed in several studies in the primary care setting. 68 , 76 \u0002 80   The aim of these studies was to either exclude or establish a diagnosis of HF. The Task Force considered studies of adequate quality that included NP cut-off points in their diagnostic algorithms, below which the probability of having HF was extremely low. The upper limits of normal in the non-acute setting are 35 pg/mL for BNP, and 125 pg/mL for NT-proBNP. In these stud- ies, the negative predictive values of NP concentrations below these thresholds range from 0.94 to 0.98. 76 \u0002 78   Fewer data are available for MR-proANP in CHF than in AHF. A concentration of <40 pmol/L can be used to rule out HF. 68\n",
      "keywords": [
        "suppor",
        "diagnostic",
        "recommended",
        "concentrations",
        "ecg",
        "elevated",
        "diag",
        "bnp",
        "tests",
        "plasma",
        "initial",
        "suggestive",
        "patients",
        "nt-probnp",
        "peptides",
        "rule",
        "natriuretic",
        "age",
        "nosis",
        "symptoms"
      ],
      "tables": []
    },
    {
      "number": "27",
      "title": "4.3 Investigations to determine the underlying aetiology of chronic heart failure Recommended tests to determine the underlying aetiology of CHF are summarized in  Table  5 .",
      "start_page": 18,
      "end_page": 20,
      "content": "Recommended diagnostic tests in all patients with suspected chronic heart failure\nRecommendations Class a Level b\nBNP/NT-proBNP c I B\n12-lead ECG I C\nTransthoracic echocardiography I C\nChest radiography (X-ray) I C\nRoutine blood tests for comorbidities, including\nfull blood count, urea and electrolytes, thyroid function, fasting glucose and HbA1c, lipids, iron\nstatus (TSAT and ferritin)\nI C\nBNP = B-type natriuretic peptide; ECG = electrocardiogram; HbA1c = glycated haemoglobin; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSAT = transferrin saturation. a Class of recommendation. b Level of evidence. c References are listed in section 4.2 for this item.\nTable 6 Symptoms and signs typical of heart failure\nSymptoms Signs\nTypical More speciﬁc\nBreathlessness\nOrthopnoea\nParoxysmal nocturnal dyspnoea Reduced exercise tolerance\nFatigue, tiredness, increased\ntime to recover after exercise Ankle swelling\nElevated jugular venous pressure\nHepatojugular reﬂux\nThird heart sound (gallop rhythm) Laterally displaced apical impulse\nLess typical Less speciﬁc\nNocturnal cough\nWheezing Bloated feeling\nLoss of appetite\nConfusion (especially in the elderly) Depression\nPalpitation\nDizziness Syncope\nBendopnea a\nWeight gain (>2 kg/week)\nWeight loss (in advanced HF) Tissue wasting (cachexia)\nCardiac murmur\nPeripheral oedema (ankle, sacral, scrotal)\nPulmonary crepitations\nPleural effusion Tachycardia\nIrregular pulse\nTachypnoea Cheyne-Stokes respiration\nHepatomegaly\nAscites Cold extremities\nOliguria\nNarrow pulse pressure\nHF = heart failure. a This symptom of advanced HF corresponds to shortness of breath when leaning forward. 67\nESC 2021\nESC 2021\n. .........................................................................................................\nESC Guidelines 3617\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nExercise or pharmacological stress echocardiography may be used for the assessment of inducible ischaemia in those who are consid- ered suitable for coronary revascularization. 81   In patients with HFpEF, valve disease, or unexplained dyspnoea, stress echocardiogra- phy might help clarify the diagnosis. 82\nCardiac magnetic resonance (CMR) imaging with late gadoli- nium enhancement (LGE), T1 mapping and extracellular volume will identify myocardial fibrosis/scar, which are typically subendo- cardial for patients with ischaemic heart disease (IHD) in contrast to the mid-wall scar typical of dilated cardiomyopathy (DCM). In addition, CMR allows myocardial characterization in, e.g. myocar- ditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease, LV non-compaction CMP, haemochromatosis, and arrhythmogenic cardiomyopathy (AC). 83 , 84\nComputed tomography coronary angiography (CTCA) may be considered in patients with a low to intermediate pre-test probability of CAD, or those with equivocal non-invasive stress tests in order to exclude the diagnosis of CAD. 5\nSingle-photon emission CT (SPECT) can also be used to assess myocardial ischaemia and viability, myocardial inflammation or infil- tration. Scintigraphy with technetium (Tc)-labelled bisphosphonate has shown high sensitivity and specificity for imaging cardiac trans- thyretin amyloid. 85\nESC 2021\nRecommendations for specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure\nRecommendations Class a Level b\nCMR\nCMR is recommended for the assessment of\nmyocardial structure and function in those with\npoor echocardiogram acoustic windows.\nI C\nCMR is recommended for the characterization\nof myocardial tissue in suspected inﬁltrative dis-\nease, Fabry disease, inﬂammatory disease (myo- carditis), LV non-compaction, amyloid,\nsarcoidosis, iron overload/haemochromatosis.\nI C\nCMR with LGE should be considered in DCM to\ndistinguish between ischaemic and non-ischae- mic myocardial damage.\nIIa C\nInvasive coronary angiography (in those who are considered\neligible for potential coronary revascularization)\nInvasive coronary angiography is recommended in patients with angina despite pharmacological ther-\napy or symptomatic ventricular arrhythmias. 5\nI B\nInvasive coronary angiography may be considered in patients with HFrEF with an intermediate to high\npre-test probability of CAD and the presence of\nischaemia in non-invasive stress tests. 89\nIIb B\nNon-invasive testing\nCTCA should be considered in patients with a\nlow to intermediate pre-test probability of CAD\nor those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.\nIIa C\nNon-invasive stress imaging (CMR, stress echocar-\ndiography, SPECT, PET) may be considered for the\nassessment of myocardial ischaemia and viability in patients with CAD who are considered suitable for\ncoronary revascularization. 90 \u0002 93\nIIb B\nExercise testing may be considered to detect reversible myocardial ischaemia and investigate\nthe cause of dyspnoea. 94 \u0002 96\nIIb C\nCardiopulmonary exercise testing\nCardiopulmonary exercise testing is recom- mended as a part of the evaluation for heart\ntransplantation and/or MCS. 94 \u0002 96\nI C\nCardiopulmonary exercise testing should be\nconsidered to optimize prescription of exercise training. 94 \u0002 96\nIIa C\nCardiopulmonary exercise testing should be\nconsidered to identify the cause of unexplained dyspnoea and/or exercise intolerance. 94 \u0002 96\nIIa C\nRight heart catheterization\nRight heart catheterization is recommended in\npatients with severe HF being evaluated for heart transplantation or MCS.\nI C\nContinued\nTable 7 Causes of elevated concentrations of natriuretic peptides 86-88\nCardiac\nHeart failure ACS\nPulmonary embolism\nMyocarditis Left ventricular hypertrophy\nHypertrophic or restrictive cardiomyopathy\nValvular heart disease Congenital heart disease\nAtrial and ventricular tachyarrhythmias\nHeart contusion Cardioversion, ICD shock\nSurgical procedures involving the heart\nPulmonary hypertension\nNon-cardiac\nAdvanced age\nIschaemic stroke\nSubarachnoid haemorrhage Renal dysfunction\nLiver dysfunction (mainly liver cirrhosis with ascites)\nParaneoplastic syndrome COPD\nSevere infections (including pneumonia and sepsis)\nSevere burns Anaemia\nSevere metabolic and hormone abnormalities\n(e.g. thyrotoxicosis, diabetic ketosis)\nACS = acute coronary syndrome; COPD = chronic obstructive pulmonary dis- ease; ICD = implantable cardioverter-deﬁbrillator.\n. ...........................................................................................................................................................................\n3618 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...............................................................................................................................................................\nCoronary angiography is recommended in patients with HF, who have angina pectoris or an ‘angina equivalent’ despite pharmacological therapy, in order to establish the diagnosis of CAD and its severity. Coronary angiography may also be considered in patients with HFrEF who have an intermediate to high pre-test probability of CAD and who are considered potentially suitable for coronary revascularization. 5\n",
      "keywords": [
        "determine",
        "investigations",
        "elderly",
        "angiography",
        "heart failure",
        "table",
        "recommended",
        "summarized",
        "pulmonary hypertension",
        "aetiology",
        "ecg",
        "level b",
        "hfref",
        "hfpef",
        "glucose",
        "failure",
        "echocardiography",
        "hypertension",
        "bnp",
        "tachycardia",
        "syncope",
        "diabetic",
        "should be considered",
        "heart",
        "tests",
        "coronary artery",
        "electrocardiogram",
        "icd",
        "nt-probnp",
        "weight"
      ],
      "tables": [
        {
          "title": "3618 ESC Guidelines",
          "page_number": 19,
          "content": "Cardiac | Heart failure\nACS\nPulmonary embolism\nMyocarditis\nLeft ventricular hypertrophy\nHypertrophic or restrictive cardiomyopathy\nValvular heart disease\nCongenital heart disease\nAtrial and ventricular tachyarrhythmias\nHeart contusion\nCardioversion, ICD shock\nSurgical procedures involving the heart\nPulmonary hypertension | ESC 2021\nNon-cardiac | Advanced age\nIschaemic stroke\nSubarachnoid haemorrhage\nRenal dysfunction\nLiver dysfunction (mainly liver cirrhosis with ascites)\nParaneoplastic syndrome\nCOPD\nSevere infections (including pneumonia and sepsis)\nSevere burns\nAnaemia\nSevere metabolic and hormone abnormalities\n(e.g. thyrotoxicosis, diabetic ketosis) | ",
          "bbox": [
            43.45908900669643,
            91.75038840553977,
            288.7480163574219,
            406.2486979166667
          ],
          "function_potential": "raw"
        },
        {
          "title": "3618 ESC Guidelines",
          "page_number": 19,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nCMR |  |  | \nCMR is recommended for the assessment of\nmyocardial structure and function in those with\npoor echocardiogram acoustic windows. | I | C | \nCMR is recommended for the characterization\nof myocardial tissue in suspected infiltrative dis-\nease, Fabry disease, inflammatory disease (myo-\ncarditis), LV non-compaction, amyloid,\nsarcoidosis, iron overload/haemochromatosis. | I | C | \nCMR with LGE should be considered in DCM to\ndistinguish between ischaemic and non-ischae-\nmic myocardial damage. | IIa | C | \nInvasive coronary angiography (in those who are considered\neligible for potential coronary revascularization) |  |  | \nInvasive coronary angiography is recommended in\npatients with angina despite pharmacological ther-\napy or symptomatic ventricular arrhythmias.5 | I | B | \nInvasive coronary angiography may be considered\nin patients with HFrEF with an intermediate to high\npre-test probability of CAD and the presence of\nischaemia in non-invasive stress tests.89 | IIb | B | \nNon-invasive testing |  |  | \nCTCA should be considered in patients with a\nlow to intermediate pre-test probability of CAD\nor those with equivocal non-invasive stress tests\nin order to rule out coronary artery stenosis. | IIa | C | \nNon-invasive stress imaging (CMR, stress echocar-\ndiography, SPECT, PET) may be considered for the\nassessment of myocardial ischaemia and viability in\npatients with CAD who are considered suitable for\ncoronary revascularization.90\u000293 | IIb | B | \nExercise testing may be considered to detect\nreversible myocardial ischaemia and investigate\nthe cause of dyspnoea.94\u000296 | IIb | C | \nCardiopulmonary exercise testing |  |  | \nCardiopulmonary exercise testing is recom-\nmended as a part of the evaluation for heart\ntransplantation and/or MCS.94\u000296 | I | C | \nCardiopulmonary exercise testing should be\nconsidered to optimize prescription of exercise\ntraining.94\u000296 | IIa | C | \nCardiopulmonary exercise testing should be\nconsidered to identify the cause of unexplained\ndyspnoea and/or exercise intolerance.94\u000296 | IIa | C | \nRight heart catheterization |  |  | \nRight heart catheterization is recommended in\npatients with severe HF being evaluated for\nheart transplantation or MCS. | I | C | ",
          "bbox": [
            306.84390758645947,
            96.49192504882812,
            551.9618282833615,
            715.8511548723493
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3619",
          "page_number": 20,
          "content": "Right heart catheterization should be considered\nin patients where HF is thought to be due to\nconstrictive pericarditis, restrictive cardiomyop-\nathy, congenital heart disease, and high output\nstates. | IIa | C | \nRight heart catheterization should be considered\nin patients with probable pulmonary hyperten-\nsion, assessed by echo in order to confirm the\ndiagnosis and assess its reversibility before the\ncorrection of valve/structural heart disease. | IIa | C | \nRight heart catheterization may be considered in\nselected patients with HFpEF to confirm the\ndiagnosis. | IIb | C | \nEMB |  |  | \nEMB should be considered in patients with rap-\nidly progressive HF despite standard therapy\nwhen there is a probability of a specific diagnosis,\nwhich can be confirmed only in myocardial\nsamples.97,98 | IIa | C | ESC 2021",
          "bbox": [
            46.98243761062622,
            59.87787927900042,
            292.24254816228694,
            293.7222475324358
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "28",
      "title": "5 Heart failure with reduced ejection fraction",
      "start_page": 20,
      "end_page": 20,
      "content": "",
      "keywords": [
        "failure",
        "ejection",
        "heart",
        "fraction",
        "reduced"
      ],
      "tables": []
    },
    {
      "number": "29",
      "title": "5.1 The diagnosis of heart failure with reduced ejection fraction The diagnosis of HFrEF requires the presence of symptoms and/or signs of HF and a reduced ejection fraction (LVEF <_40%). This is most",
      "start_page": 20,
      "end_page": 20,
      "content": "An algorithm for the diagnosis of HFrEF is depicted in  Figure  1 . For the investigation of the underlying aetiology, please refer to  Table  5 .\n",
      "keywords": [
        "hfref",
        "symptoms",
        "failure",
        "presence",
        "most",
        "ejection",
        "lvef",
        "heart",
        "fraction",
        "signs",
        "reduced",
        "requires",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "30",
      "title": "5.2 Pharmacological treatments for patients with heart failure with reduced ejection fraction 5.2.1 Goals of pharmacotherapy for patients with heart failure with reduced ejection fraction Pharmacother",
      "start_page": 20,
      "end_page": 21,
      "content": "The key evidence supporting the recommendations in this section for patients with symptomatic HFrEF is given in  Supplementary Table 1 . Figure  2  depicts the algorithm for the treatment strategy, including drugs and devices in patients with HFrEF, for Class I indications for the reduction of mortality (either all-cause or CV). The recommen- dations for each treatment are summarized below.\n5.2.2 General principles of pharmacotherapy for heart failure with reduced ejection fraction Modulation of the renin-angiotensin-aldosterone (RAAS) and sympa- thetic nervous systems with angiotensin-converting enzyme inhibi- tors (ACE-I) or an angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, and mineralocorticoid receptor antagonists (MRA) has been shown to improve survival, reduce the risk of HF hospital- izations, and reduce symptoms in patients with HFrEF. These drugs serve as the foundations of pharmacotherapy for patients with HFrEF. The triad of an ACE-I/ARNI, a beta-blocker, and an MRA is recommended as cornerstone therapies for these patients, unless the drugs are contraindicated or not tolerated. 103 \u0002 105   They should be uptitrated to the doses used in the clinical trials (or to maximally tolerated doses if that is not possible). This guideline still recom- mends the use of ARNI as a replacement for ACE-I in suitable patients who remain symptomatic on ACE-I, beta-blocker, and MRA therapies; however, an ARNI may be considered as a first-line ther- apy instead of an ACE-I. 106 , 107   The recommended doses of these drugs are given in  Table  8 . Angiotensin-receptor blockers (ARBs) still have a role in those who are intolerant to ACE-I or ARNI. The sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagli- flozin and empagliflozin added to therapy with ACE-I/ARNI/beta- blocker/MRA reduced the risk of CV death and worsening HF in patients with HFrEF. 108 , 109   Unless contraindicated or not tolerated, dapagliflozin or empagliflozin are recommended for all patients with HFrEF already treated with an ACE-I/ARNI, a beta-blocker, and an MRA, regardless of whether they have diabetes or not. Other drugs may be used for selected patients with HFrEF. These are discussed in  section 5.4 .\nRight heart catheterization should be considered\nin patients where HF is thought to be due to\nconstrictive pericarditis, restrictive cardiomyop- athy, congenital heart disease, and high output\nstates.\nIIa C\nRight heart catheterization should be considered in patients with probable pulmonary hyperten-\nsion, assessed by echo in order to conﬁrm the\ndiagnosis and assess its reversibility before the correction of valve/structural heart disease.\nIIa C\nRight heart catheterization may be considered in\nselected patients with HFpEF to conﬁrm the\ndiagnosis.\nIIb C\nEMB\nEMB should be considered in patients with rap-\nidly progressive HF despite standard therapy\nwhen there is a probability of a speciﬁc diagnosis, which can be conﬁrmed only in myocardial\nsamples. 97 , 98\nIIa C\nCAD = coronary artery disease; CMR = cardiac magnetic resonance; CTCA = computed tomography coronary angiography; DCM = dilated cardiomyopathy; EMB = endomyocardial biopsy; HF = heart failure; HFpEF = heart failure with pre- served ejection fraction; HFrEF = heart failure with reduced ejection fraction; LGE = late gadolinium enhancement; LV = left ventricular; MCS = mechanical cir- culatory support; PET = positron emission tomography; SPECT = single-photon emission computed tomography. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 3619\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nManagement of patients with HFrEF\nLVEF  ≤ 35% and QRS <130 ms and where appropriate\n(Class I)\nSR and LVEF  ≤ 35% and QRS  ≥ 130 ms\nIf symptoms persist, consider therapies with Class II recommendations\nLVEF >35% or device therapy not indicated or inappropriate\nACE-I/ARNI a\nBeta-blocker MRA Dapagliflozin/Empagliflozin Loop diuretic for fluid retention\nIschaemic (Class I) Non-ischaemic (Class IIa)\nICD\nQRS  ≥ 150 ms (Class I) QRS 130–149 ms (Class IIa)\nCRT-D b /-P\nFigure 2  Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction. ACE-I =angiotensin-con- verting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; CRT-D=cardiac resynchronization therapy with defibrillator; CRT-P= cardiac resynchronization therapy pacemaker; ICD= implantable cardioverter-defibrillator; HFrEF= heart failure with reduced ejection fraction; MRA= mineralo- corticoid receptor antagonist; QRS= Q, R, and S waves of an ECG; SR = sinus rhythm.   a As a replacement for ACE-I.   b Where appropriate. Class I = green. Class IIa= Yellow.\nPharmacological treatments indicated in patients with (NYHA class II–IV) heart failure with reduced ejection fraction (LVEF <_40 % )\nRecommendations Class a Level b\nAn ACE-I is recommended for patients with HFrEF to reduce the risk of HF\nhospitalization and death. 110 \u0002 113 I A\nA beta-blocker is recommended for patients with stable HFrEF to reduce the risk of\nHF hospitalization and death. 114 \u0002 120 I A\nAn MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. 121 , 122 I A\nDapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. 108 , 109 I A\nSacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF\nhospitalization and death. 105 I B\nACE-I = angiotensin-converting enzyme inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = miner- alocorticoid receptor antagonist; NYHA = New York Heart Association. a Class of recommendation. b Level of evidence.\nESC 2021\n",
      "keywords": [
        "class i",
        "goals",
        "angiography",
        "heart failure",
        "echo",
        "treatments",
        "recommended",
        "ecg",
        "level b",
        "hfref",
        "hfpef",
        "glucose",
        "failure",
        "lvef",
        "crt",
        "heart",
        "should be considered",
        "class ii",
        "coronary artery",
        "icd",
        "pharmacotherapy",
        "patients",
        "nyha",
        "may be considered",
        "catheterization",
        "pharmacological",
        "guideline",
        "pharmacother",
        "reduced",
        "ejection fraction"
      ],
      "tables": [
        {
          "title": "3620 ESC Guidelines",
          "page_number": 21,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAn ACE-I is recommended for patients with HFrEF to reduce the risk of HF\nhospitalization and death.110\u0002113 | I | A | \nA beta-blocker is recommended for patients with stable HFrEF to reduce the risk of\nHF hospitalization and death.114\u0002120 | I | A | \nAn MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.121,122 | I | A | \nDapagliflozin or empagliflozin are recommended for patients with HFrEF to reduce the risk\nof HF hospitalization and death.108,109 | I | A | 21\nSacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF\nhospitalization and death.105 | I | B | ESC 20",
          "bbox": [
            42.6616780090332,
            562.4110290527344,
            552.0477529672476,
            699.3602687290737
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "31",
      "title": "5.3 Drugs recommended in all patients with heart failure with reduced ejection fraction",
      "start_page": 21,
      "end_page": 23,
      "content": "3620 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................\n5.3.1 Angiotensin-converting enzyme inhibitors ACE-Is were the first class of drugs shown to reduce mortality and morbidity in patients with HFrEF. 110 \u0002 113   They have also been shown to improve symptoms. 111   They are recommended in all patients unless contraindicated or not tolerated. They should be uptitrated to the maximum tolerated recommended doses.\nPractical guidance on how to use ACE-Is is given in  Supplementary Table 2 .\n5.3.2 Beta-blockers Beta-blockers have been shown to reduce mortality and morbidity in patients with HFrEF, in addition to treatment with an ACE-I and diu- retic. 114 \u0002 120   They also improve symptoms. 123   There is consensus that ACE-I and beta-blockers can be commenced together as soon as the diagnosis of symptomatic HFrEF is established. There is no evi- dence favouring the initiation of a beta-blocker before an ACE-I and vice versa. 124   Beta-blockers should be initiated in clinically stable, euvolaemic, patients at a low dose and gradually uptitrated to the maximum tolerated dose. In patients admitted with AHF, beta- blockers should be cautiously initiated in hospital, once the patient is haemodynamically stabilized. An individual patient data (IPD) meta-analysis of all major beta- blocker trials in HFrEF has shown no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF with AF. 125\nHowever, since this is a retrospective subgroup analysis, and because beta-blockers did not increase risk, the guideline committee decided not to make a separate recommendation according to heart rhythm. Practical guidance on how to use beta-blockers is given in Supplementary Table 3 .\n5.3.3 Mineralocorticoid receptor antagonists MRAs (spironolactone or eplerenone) are recommended, in addition to an ACE-I and a beta-blocker, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization. 121 , 122   They also improve symptoms. 121   MRAs block receptors that bind aldosterone and, with different degrees of affinity, other steroid hormones (e.g. corticoste- roid and androgen) receptors. Eplerenone is more specific for aldos- terone blockade and, therefore, causes less gynaecomastia. Caution should be exercised when MRAs are used in patients with impaired renal function and in those with serum potassium concen- trations >5.0 mmol/L. Practical guidance on how to use MRAs is given in  Supplementary Table 4 .\n5.3.4 Angiotensin receptor-neprilysin inhibitor In the PARADIGM-HF trial, sacubitril/valsartan, an ARNI, was shown to be superior to enalapril in reducing hospitalizations for worsening HF, CV mortality, and all-cause mortality in patients with ambulatory HFrEF with LVEF <_40% (changed to <_35% during the study). Patients in the trial had elevated plasma NP concentrations, an eGFR >_30 mL/ min/1.73 m 2   and were able to tolerate enalapril and then sacubitril/ valsartan during the run-in period. 105   Additional benefits of sacubitril/ valsartan included an improvement in symptoms and QOL, 105   a reduction in the incidence of diabetes requiring insulin treatment, 126\nand a reduction in the decline in eGFR, 127   as well as a reduced rate of hyperkalaemia. 128   Additionally, the use of sacubitril/valsartan may allow a reduction in loop diuretic requirement. 129   Symptomatic hypotension was reported more commonly in patients treated with sacubitril/valsartan as compared to enalapril, but despite developing hypotension, these patients also gained clinical benefits from sacubi- tril/valsartan therapy. 128 , 130\nTable 8 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction\nStarting dose Target dose\nACE-I\nCaptopril a 6.25 mg  t.i.d. 50 mg  t.i.d.\nEnalapril 2.5 mg  b.i.d. 10 \u0002 20 mg  b.i.d.\nLisinopril b 2.5 \u0002 5 mg  o.d. 20 \u0002 35 mg  o.d.\nRamipril 2.5 mg  b.i.d. 5 mg  b.i.d.\nTrandolapril a 0.5 mg  o.d. 4 mg  o.d.\nARNI\nSacubitril/valsartan 49/51 mg  b.i.d. c 97/103 mg  b.i.d.\nBeta-blockers\nBisoprolol 1.25 mg  o.d. 10 mg  o.d.\nCarvedilol 3.125 mg  b.i.d. 25 mg  b.i.d. e\nMetoprolol succinate (CR/XL) 12.5 \u0002 25 mg  o.d. 200 mg  o.d.\nNebivolol d 1.25 mg  o.d. 10 mg  o.d.\nMRA\nEplerenone 25 mg  o.d. 50 mg  o.d.\nSpironolactone 25 mg  o.d. f 50 mg  o.d.\nSGLT2 inhibitor\nDapagliﬂozin 10 mg  o.d. 10 mg  o.d.\nEmpagliﬂozin 10 mg  o.d. 10 mg  o.d.\nOther agents\nCandesartan 4 mg  o.d. 32 mg  o.d.\nLosartan 50 mg  o.d. 150 mg  o.d.\nValsartan 40 mg  b.i.d. 160 mg  b.i.d.\nIvabradine 5 mg  b.i.d. 7.5 mg  b.i.d.\nVericiguat 2.5 mg  o.d. 10 mg  o.d.\nDigoxin 62.5  m g  o.d. 250  m g  o.d.\nHydralazine/ Isosorbide dinitrate 37.5 mg  t.i.d. /20 mg  t.i.d. 75 mg  t.i.d. /40 mg  t.i.d.\nACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor- neprilysin inhibitor;  b.i.d.  = bis in die (twice daily); CR = controlled release; CV = cardiovascular; MRA = mineralocorticoid receptor antagonist;  o.d.  = omne in die (once daily); SGLT2 = sodium-glucose co-transporter 2;  t.i.d.  = ter in die (three times a day); XL = extended release. a Indicates an ACE-I where the dosing target is derived from post-myocardial infarction trials. b Indicates drugs where a higher dose has been shown to reduce morbidity/mor- tality compared with a lower dose of the same drug, but there is no substantive randomized, placebo-controlled trial and the optimum dose is uncertain. c Sacubitril/valsartan may have an optional lower starting dose of 24/26 mg  b.i.d. for those with a history of symptomatic hypotension. d Indicates a treatment not shown to reduce CV or all-cause mortality in patients with heart failure (or shown to be non-inferior to a treatment that does). e A maximum dose of 50 mg twice daily can be administered to patients weighing over 85 kg. f Spironolactone has an optional starting dose of 12.5 mg in patients where renal status or hyperkalaemia warrant caution.\nESC 2021\nESC Guidelines 3621\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................ Therefore, it is recommended that an ACE-I or ARB is replaced by sacubitril/valsartan in ambulatory patients with HFrEF, who remain symptomatic despite optimal treatment outlined above. Two studies have examined the use of ARNI in hospitalized patients, some of whom had not been previously treated with ACE-I. Initiation in this setting appears safe and reduces subsequent CV death or HF hospi- talizations by 42% compared to enalapril. 106 , 107 , 131   As such, initiation of sacubitril/valsartan in ACE-I naive (i.e.  de novo ) patients with HFrEF may be considered (class of recommendation IIb, level of evidence B). Patients being commenced on sacubitril/valsartan should have an adequate blood pressure (BP), and an eGFR >_30 mL/min/1.73 m 2 . A washout period of at least 36 h after ACE-I therapy is required in order to minimize the risk of angioedema. Practical guidance on how to use ARNI is given in  Supplementary Table 5 .\n5.3.5 Sodium-glucose co-transporter 2 inhibitors The DAPA-HF trial investigated the long-term effects of dapagliflozin (SGLT2 inhibitor) compared to placebo in addition to optimal medi- cal therapy (OMT), on morbidity and mortality in patients with ambu- latory HFrEF. 108   Patients participated in the trial if they were in NYHA class II \u0002 IV, and had an LVEF <_40% despite OMT. Patients were also required to have an elevated plasma NT-proBNP and an eGFR >_30 mL/min/1.73 m 2 . 108\nTherapy with dapagliflozin resulted in a 26% reduction in the pri- mary endpoint: a composite of worsening HF (hospitalization or an urgent visit resulting in i.v. therapy for HF) or CV death. Both of these components were significantly reduced. Moreover, dapagliflozin reduced all-cause mortality, 108   alleviated HF symptoms, improved physical function and QOL in patients with symptomatic HFrEF. 132\nBenefits were seen early after the initiation of dapagliflozin, and the absolute risk reduction was large. Survival benefits were seen to the same extent in patients with HFrEF with and without diabetes, and across the whole spectrum of HbA1c values. 108\nSubsequently, the EMPEROR-Reduced trial found that empagliflo- zin reduced the combined primary endpoint of CV death or HF hos- pitalization by 25% in patients with NYHA class II \u0002 IV symptoms, and an LVEF <_40% despite OMT. 109   This trial included patients with an eGFR >20 mL/min/1.73 m 2   and there was also a reduction in the decline in eGFR in individuals receiving empagliflozin. It was also asso- ciated with an improvement in QOL. 133   Although there was not a significant reduction in CV mortality in the EMPEROR-Reduced trial, a recent meta-analysis of the DAPA-HF and EMPEROR-Reduced tri- als found no heterogeneity in CV mortality. 134\nTherefore, dapagliflozin or empagliflozin are recommended, in addition to OMT with an ACE-I/ARNI, a beta-blocker and an MRA, for patients with HFrEF regardless of diabetes status. The diuretic/ natriuretic properties of SGLT2 inhibitors may offer additional bene- fits in reducing congestion and may allow a reduction in loop diuretic requirement. 135\nThe combined SGLT-1 and 2 inhibitor, sotagliflozin, has also been studied in patients with diabetes who were hospitalized with HF. The drug reduced CV death and hospitalization for HF. 136   It is discussed further in the AHF and comorbidity sections. Therapy with SGLT2 inhibitors may increase the risk of recurrent genital fungal infections. A small reduction in eGFR following initiation\nis expected and is reversible and should not lead to premature dis- continuation of the drug. Practical guidance on how to use the SGLT2 inhibitors dapagliflo- zin and empagliflozin are given in  Supplementary Table 6 .\n",
      "keywords": [
        "blood pressure",
        "heart failure",
        "recommended",
        "insulin",
        "hfref",
        "glucose",
        "failure",
        "lvef",
        "heart",
        "class ii",
        "drugs",
        "patients",
        "nt-probnp",
        "arb",
        "nyha",
        "egfr",
        "may be considered",
        "guideline",
        "ejection fraction",
        "diabetes",
        "diuretic",
        "ejection",
        "sglt2",
        "fraction",
        "hba1c",
        "reduced"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3621",
          "page_number": 22,
          "content": " |  | Starting dose |  | Target dose | ESC 2021\nACE-I |  |  |  |  | \nCaptoprila |  | 6.25 mg t.i.d. |  | 50 mg t.i.d. | \nEnalapril |  | 2.5 mg b.i.d. |  | 10\u000220 mg b.i.d. | \nLisinoprilb |  | 2.5\u00025 mg o.d. |  | 20\u000235 mg o.d. | \nRamipril |  | 2.5 mg b.i.d. |  | 5 mg b.i.d. | \nTrandolaprila |  | 0.5 mg o.d. |  | 4 mg o.d. | \nARNI |  |  |  |  | \nSacubitril/valsartan |  | 49/51 mg b.i.d.c |  | 97/103 mg b.i.d. | \nBeta-blockers |  |  |  |  | \nBisoprolol |  | 1.25 mg o.d. |  | 10 mg o.d. | \nCarvedilol |  | 3.125 mg b.i.d. |  | 25 mg b.i.d.e | \nMetoprolol succinate\n(CR/XL) |  | 12.5\u000225 mg o.d. |  | 200 mg o.d. | \nNebivolold |  | 1.25 mg o.d. |  | 10 mg o.d. | \nMRA |  |  |  |  | \nEplerenone |  | 25 mg o.d. |  | 50 mg o.d. | \nSpironolactone |  | 25 mg o.d.f |  | 50 mg o.d. | \nSGLT2 inhibitor |  |  |  |  | \nDapagliflozin |  | 10 mg o.d. |  | 10 mg o.d. | \nEmpagliflozin |  | 10 mg o.d. |  | 10 mg o.d. | \nOther agents |  |  |  |  | \nCandesartan |  | 4 mg o.d. |  | 32 mg o.d. | \nLosartan |  | 50 mg o.d. |  | 150 mg o.d. | \nValsartan |  | 40 mg b.i.d. |  | 160 mg b.i.d. | \nIvabradine |  | 5 mg b.i.d. |  | 7.5 mg b.i.d. | \nVericiguat |  | 2.5 mg o.d. |  | 10 mg o.d. | \nDigoxin |  | 62.5 mg o.d. |  | 250 mg o.d. | \nHydralazine/\nIsosorbide dinitrate |  | 37.5 mg t.i.d./20 mg t.i.d. |  | 75 mg t.i.d./40 mg t.i.d. | ",
          "bbox": [
            48.04912829789959,
            101.31108093261719,
            293.2829895019531,
            492.2284469604492
          ],
          "function_potential": "raw"
        },
        {
          "title": "3622 ESC Guidelines",
          "page_number": 23,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nLoop diuretics |  |  | \nDiuretics are recommended in patients with\nHFrEF with signs and/or symptoms of congestion\nto alleviate HF symptoms, improve exercise\ncapacity, and reduce HF hospitalizations.137 | I | C | \nARB |  |  | \nAn ARBc is recommended to reduce the risk of\nHF hospitalization and CV death in symptomatic\npatients unable to tolerate an ACE-I or ARNI\n(patients should also receive a beta-blocker and\nan MRA).138 | I | B | \nI-channel inhibitor\nf |  |  | \nIvabradine should be considered in symptomatic\npatients with LVEF <35%, in SR and a resting\n_\nheart rate >70 b.p.m. despite treatment with an\n_\nevidence-based dose of beta-blocker (or maxi-\nmum tolerated dose below that), ACE-I/(or\nARNI), and an MRA, to reduce the risk of HF\nhospitalization and CV death.139 | IIa | B | \nIvabradine should be considered in symptomatic\npatients with LVEF <35%, in SR and a resting\n_\nheart rate >70 b.p.m. who are unable to tolerate\n_\nor have contraindications for a beta-blocker to\nreduce the risk of HF hospitalization and CV\ndeath. Patients should also receive an ACE-I (or\nARNI) and an MRA.140 | IIa | C | \nSoluble guanylate cyclase stimulator |  |  | \nVericiguat may be considered in patients in\nNYHA class II\u0002IV who have had worsening HF\ndespite treatment with an ACE-I (or ARNI), a\nbeta-blocker and an MRA to reduce the risk of\nCV mortality or HF hospitalization.141 | IIb | B | \nHydralazine and isosorbide dinitrate |  |  | \nHydralazine and isosorbide dinitrate should be\nconsidered in self-identified black patients with\nLVEF <35% or with an LVEF <45% combined\n_\nwith a dilated left ventricle in NYHA class III\u0002IV\ndespite treatment with an ACE-I (or ARNI), a\nbeta-blocker and an MRA to reduce the risk of\nHF hospitalization and death.142 | IIa | B | ",
          "bbox": [
            306.86208992004396,
            215.90401611328124,
            551.9618310546875,
            732.0651441301618
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "32",
      "title": "5.4 Other drugs recommended or to be considered in selected patients with heart failure with reduced ejection fraction",
      "start_page": 23,
      "end_page": 26,
      "content": "Other pharmacological treatments indicated in selected patients with NYHA class II–IV heart failure with reduced ejection fraction (LVEF  \u0003 40 % )\nRecommendations Class a Level b\nLoop diuretics\nDiuretics are recommended in patients with\nHFrEF with signs and/or symptoms of congestion\nto alleviate HF symptoms, improve exercise capacity, and reduce HF hospitalizations. 137\nI C\nARB\nAn ARB c   is recommended to reduce the risk of\nHF hospitalization and CV death in symptomatic patients unable to tolerate an ACE-I or ARNI\n(patients should also receive a beta-blocker and\nan MRA). 138\nI B\nI f -channel inhibitor\nIvabradine should be considered in symptomatic\npatients with LVEF <_35%, in SR and a resting\nheart rate >_70 b.p.m. despite treatment with an evidence-based dose of beta-blocker (or maxi-\nmum tolerated dose below that), ACE-I/(or\nARNI), and an MRA, to reduce the risk of HF hospitalization and CV death. 139\nIIa B\nIvabradine should be considered in symptomatic\npatients with LVEF <_35%, in SR and a resting\nheart rate >_70 b.p.m. who are unable to tolerate or have contraindications for a beta-blocker to\nreduce the risk of HF hospitalization and CV\ndeath. Patients should also receive an ACE-I (or ARNI) and an MRA. 140\nIIa C\nSoluble guanylate cyclase stimulator\nVericiguat may be considered in patients in\nNYHA class II \u0002 IV who have had worsening HF despite treatment with an ACE-I (or ARNI), a\nbeta-blocker and an MRA to reduce the risk of\nCV mortality or HF hospitalization. 141\nIIb B\nHydralazine and isosorbide dinitrate\nHydralazine and isosorbide dinitrate should be\nconsidered in self-identiﬁed black patients with\nLVEF <_35% or with an LVEF <45% combined with a dilated left ventricle in NYHA class III \u0002 IV\ndespite treatment with an ACE-I (or ARNI), a\nbeta-blocker and an MRA to reduce the risk of HF hospitalization and death. 142\nIIa B\nContinued . ...............................................................................................................................................\n3622 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................\n5.4.1 Diuretics Loop diuretics are recommended to reduce the signs and/or symp- toms of congestion in patients with HFrEF. The quality of the evi- dence regarding diuretics is poor and their effects on morbidity and mortality have not been studied in RCTs. However, it should also be remembered that the major disease-modifying treatment trials for HFrEF were conducted with a high background use of loop diuretic therapy. One meta-analysis has shown that in patients with HFrEF, loop and thiazide diuretics appear to reduce the risk of death and worsening HF compared with a placebo, and compared with an active control, diuretics improve exercise capacity. 137\nLoop diuretics produce a more intense and shorter diuresis than thiazides, although they act synergistically (sequential nephron block- ade) and the combination may be used to treat diuretic resistance. However, adverse effects are more likely, and these combinations should only be used with care. Of note, ARNI, MRAs, and SGLT2 inhibitors may also possess diuretic properties. 129 , 145\nThe aim of diuretic therapy is to achieve and maintain euvolaemia with the lowest diuretic dose. In some euvolaemic/hypovolaemic patients, the use of a diuretic drug might be reduced or discontin- ued. 146   Patients should be trained to self-adjust their diuretic dose based on monitoring of symptoms/signs of congestion and daily weight measurements. Practical guidance on how to use diuretics is given in Supplementary Table 7 .\n5.4.2 Angiotensin II type 1 receptor blockers The place of ARBs in the management of HFrEF has changed over the last few years. They are now recommended for patients who can- not tolerate ACE-I or ARNI because of serious side effects. Candesartan in the CHARM-Alternative study reduced CV deaths and HF hospitalizations in patients who were not receiving an ACE-I due to previous intolerance. 138   Valsartan, in addition to usual therapy, including ACE-I, reduced HF hospitalizations in the Val-HeFT trial. 147\nHowever, no ARB has reduced all-cause mortality in any trial.\n5.4.3 I f  -channel inhibitor Ivabradine slows heart rate by inhibition of the I f  channel in the sinus node and is therefore only effective in patients in SR. Ivabradine reduced the combined endpoint of CV mortality and HF hospitaliza- tion in patients with symptomatic HFrEF with an LVEF <_35%, with HF hospitalization in recent 12 months, in sinus rhythm (SR) and with a heart rate >_70 b.p.m. who were on evidence-based therapy including an ACE-I (or ARB), a beta-blocker, and an MRA. 139 , 140   Our recom- mendation is based on the heart rate of >_70 b.p.m. used in the SHIFT trial. However, the European Medicines Agency (EMA) approved ivabradine for use in Europe in patients with HFrEF with LVEF <_35% and in SR with a resting heart rate >_75 b.p.m., because in this group ivabradine conferred a survival benefit 148   based on a retrospective subgroup analysis. Every effort should be made to commence and uptitrate beta-blocker therapy to guideline recommended/maximally tolerated doses prior to considering ivabradine. Practical guidance on how to use ivabradine is given in Supplementary Table 8 .\n5.4.4 Combination of hydralazine and isosorbide dinitrate There is no clear evidence to suggest the use of this fixed-dose com- bination therapy in all patients with HFrEF. A small RCT conducted in self-identified black patients showed that an addition of the combina- tion of hydralazine and isosorbide dinitrate to conventional therapy (an ACE-I, a beta-blocker, and an MRA) reduced mortality and HF hospitalizations in patients with HFrEF and NYHA classes III \u0002 IV. 142\nThese results are difficult to translate to patients of other racial or ethnic origins. Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who cannot tolerate any of an ACE-I, ARNI, or an ARB (or if they are contraindi- cated) to reduce mortality. However, this recommendation is based on the results of the relatively small Veterans Administration Cooperative Study, which included only male patients with sympto- matic HFrEF who were treated with digoxin and diuretics. 143\n5.4.5 Digoxin Digoxin may be considered in patients with HFrEF in SR to reduce the risk of hospitalization, 144   although its effect on those routinely treated with beta-blockers has not been tested. In the DIG trial, the overall effect on mortality with digoxin was neutral. The effects of digoxin in patients with HFrEF and AF have not been studied in RCTs. Some studies have suggested a potentially higher risk of events in patients with AF receiving digoxin, 149 , 150   whereas another meta-analysis concluded, on the basis of non-RCTs, that digoxin has no deleterious effect on mortality in patients with AF and HF, most of whom had HFrEF. 151   Therefore, in patients with sympto- matic HF and AF, digoxin may be useful for the treatment of patients with HFrEF and AF with rapid ventricular rate, when other therapeu- tic options cannot be pursued. 150 , 152 \u0002 155\nDigoxin has a narrow therapeutic window and so levels should be checked aiming for a serum digoxin concentration <1.2 ng/mL. 156 , 157\nCaution should also be exercised when using it in females, the elderly, frail, hypokalaemic, and malnourished subjects. In patients with reduced renal function, digitoxin could be considered. Digitoxin use in HF and SR is currently being investigated. 158\nHydralazine and isosorbide dinitrate may be con-\nsidered in patients with symptomatic HFrEF who\ncannot tolerate any of an ACE-I, an ARB, or ARNI (or they are contraindicated) to reduce\nthe risk of death. 143\nIIb B\nDigoxin\nDigoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite\ntreatment with an ACE-I (or ARNI), a beta-\nblocker and an MRA, to reduce the risk of hospi- talization (both all-cause and HF\nhospitalizations). 144\nIIb B\nACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; b.p.m. = beats per minute; CV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = minera- locorticoid receptor antagonist; NYHA = New York Heart Association; SR = sinus rhythm. a Class of recommendation. b Level of evidence. c The ARBs with evidence in HFrEF are candesartan, losartan, and valsartan.\nESC 2021\nESC Guidelines 3623\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nDiuretics\nSR with LBBB  ≥  150 ms\nTo reduce mortality - for all patients\nTo reduce HF hospitalization/mortality - for selected patients\nVolume overload\nACE-I/ARNI\nBB\nMRA\nSGLT2i\nExercise rehabilitation\nTo reduce HF hospitalization and improve QOL - for all patients\nFor selected advanced HF patients\nCRT-P/D\nAtrial fibrillation\nAnticoagulation\nMCS as BTT/BTC\nAortic stenosis\nSAVR/TAVI\nMitral regurgitation\nTEE MV Repair\nHeart rate SR>70 bpm\nIvabradine\nBlack Race\nHydralazine/ISDN\nACE-I/ARNI intolerance\nARB\nAtrial fibrillation\nDigoxin\nCoronary artery disease\nCABG\nIron deficiency\nFerric carboxymaltose\nICD\nIschaemic aetiology\nHeart transplantation\nLong-term MCS as DT\nMulti-professional disease management\nNon-ischaemic aetiology\nSR with LBBB 130–149 ms or non LBBB  ≥  150 ms\nCRT-P/D\nManagement of HFrEF\nICD\nPVI\nFigure 3  Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction. ACE-I=angiotensin-convert- ing enzyme inhibitor; ARB=angiotensin receptor blocker; ARNI=angiotensin receptor-neprilysin inhibitor; BB=beta-blocker; b.p.m.=beats per minute; BTC =bridge to candidacy; BTT=bridge to transplantation; CABG=coronary artery bypass graft; CRT-D= cardiac resynchronization therapy with defibrillator; CRT-P=cardiac resynchronization therapy pacemaker; DT=destination therapy; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; ICD= implantable cardioverter-defibrillator; ISDN=isosorbide dinitrate; LBBB=left bundle branch block; MCS=mechanical circulatory support; MRA=mineralocor- ticoid receptor antagonist; MV=mitral valve; PVI=pulmonary vein isolation; QOL=quality of life; SAVR=surgical aortic valve replacement; SGLT2i=sodium- glucose co-transporter 2 inhibitor; SR=sinus rhythm; TAVI=transcatheter aortic valve replacement; TEE=transcatheter edge to edge. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see  Table  1  for further details on classes of recommenda- tion). The Figure shows management options with Class I and IIa recommendations. See the specific Tables for those with Class IIb recommendations.\n3624 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ......... 5.4.6 Recently reported advances from trials in heart failure with reduced ejection fraction\nSoluble guanylate cyclase stimulator The VICTORIA study assessed the efficacy and safety of the oral soluble guanylate cyclase stimulator, vericiguat, in patients with a reduced EF and recently decompensated CHF. The incidence of the primary endpoint of death from CV causes or hospitalization for HF was lower among those who received vericiguat than among those who received placebo. 141   There was no reduction in either all-cause or CV mortality. Thus, vericiguat may be consid- ered, in addition to standard therapy for HFrEF, to reduce the risk of CV mortality and hospitalizations for HF.\nCardiac myosin activator The GALACTIC-HF study assessed the efficacy and safety of the car- diac myosin activator, omecamtiv mecarbil, in HFrEF patients, enroll- ing patients in both the inpatient and outpatient settings. The primary endpoint of a first HF event or CV death was reduced by 8%. There was no significant reduction in CV mortality. Currently, this drug is not licensed for use in HF. However, in the future it may be able to be considered, in addition to standard therapy for HFrEF to reduce the risk of CV mortality and hospitalization for HF. 159\n",
      "keywords": [
        "aortic stenosis",
        "elderly",
        "class i",
        "heart failure",
        "other",
        "recommended",
        "ethnic",
        "level b",
        "class iii",
        "hfref",
        "selected",
        "glucose",
        "failure",
        "anticoagulation",
        "lvef",
        "crt",
        "heart",
        "should be considered",
        "class ii",
        "coronary artery",
        "drugs",
        "considered",
        "icd",
        "patients",
        "mitral regurgitation",
        "arb",
        "nyha",
        "aortic",
        "weight",
        "may be considered"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3623",
          "page_number": 24,
          "content": "Hydralazine and isosorbide dinitrate may be con-\nsidered in patients with symptomatic HFrEF who\ncannot tolerate any of an ACE-I, an ARB, or\nARNI (or they are contraindicated) to reduce\nthe risk of death.143 | IIb | B | \nDigoxin |  |  | \nDigoxin may be considered in patients with\nsymptomatic HFrEF in sinus rhythm despite\ntreatment with an ACE-I (or ARNI), a beta-\nblocker and an MRA, to reduce the risk of hospi-\ntalization (both all-cause and HF\nhospitalizations).144 | IIb | B | ESC 2021",
          "bbox": [
            46.9785400390625,
            59.87787927900042,
            292.302001953125,
            207.32225690569197
          ],
          "function_potential": "raw"
        },
        {
          "title": "3624 ESC Guidelines",
          "page_number": 25,
          "content": "ACE-I/ARNI | BB | MRA | SGLT2i",
          "bbox": [
            109.1900867280506,
            118.9273173014323,
            481.63769140908886,
            183.2509765625
          ],
          "function_potential": "raw"
        },
        {
          "title": "3624 ESC Guidelines",
          "page_number": 25,
          "content": "To reduce HF hospitalization/mortality - for selected patients |  |  |  |  |  |  | \nVolume overload\nDiuretics |  |  |  |  |  |  | \nSR with LBBB ≥ 150 ms\nCRT-P/D |  |  |  | SR with LBBB 130–149 ms or non LBBB ≥ 150 ms\nCRT-P/D |  |  | \nIschaemic aetiology\nICD |  |  |  | Non-ischaemic aetiology\nICD |  |  | \nAtrial fibrillation\nAnticoagulation |  | Atrial fibrillation\nDigoxin PVI |  | Coronary artery disease\nCABG |  | Iron deficiency\nFerric carboxymaltose | \nAortic stenosis\nSAVR/TAVI | Mitral regurgitation\nTEE MV Repair |  | Heart rate SR>70 bpm\nIvabradine |  | Black Race\nHydralazine/ISDN |  | ACE-I/ARNI intolerance\nARB",
          "bbox": [
            109.1900867280506,
            195.13379414876303,
            481.63769140908886,
            431.56182352701825
          ],
          "function_potential": "raw"
        },
        {
          "title": "3624 ESC Guidelines",
          "page_number": 25,
          "content": "For selected advanced HF patients |  | \nHeart transplantation | MCS as BTT/BTC | Long-term MCS as DT",
          "bbox": [
            109.1900867280506,
            443.53685869489397,
            481.63769140908886,
            504.21600341796875
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3625",
          "page_number": 26,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nSecondary prevention |  |  | \nAn ICD is recommended to reduce the risk of\nsudden death and all-cause mortality in patients\nwho have recovered from a ventricular arrhyth-\nmia causing haemodynamic instability, and who\nare expected to survive for >1 year with good\nfunctional status, in the absence of reversible\ncauses or unless the ventricular arrhythmia has\noccurred <48 h after a MI.162\u0002164 | I | A | \nPrimary prevention |  |  | \nAn ICD is recommended to reduce the risk of\nsudden death and all-cause mortality in patients\nwith symptomatic HF (NYHA class II\u0002III) of an\nischaemic aetiology (unless they have had a MI in\nthe prior 40 days—see below), and an LVEF\n<35% despite >3 months of OMT, provided\n_ _\nthey are expected to survive substantially longer\nthan 1 year with good functional status.161,165 | I | A | \nAn ICD should be considered to reduce the risk\nof sudden death and all-cause mortality in\npatients with symptomatic HF (NYHA class\nII\u0002III) of a non-ischaemic aetiology, and an LVEF\n<35% despite >3 months of OMT, provided\n_ _\nthey are expected to survive substantially longer\nthan 1 year with good functional status.161,166,167 | IIa | A | \nPatients should be carefully evaluated by an\nexperienced cardiologist before generator\nreplacement, because management goals, the\npatient’s needs and clinical status may have\nchanged.168\u0002172 | IIa | B | \nA wearable ICD may be considered for patients\nwith HF who are at risk of sudden cardiac death\nfor a limited period or as a bridge to an\nimplanted device.173\u0002176 | IIb | B | \nICD implantation is not recommended within 40\ndays of a MI as implantation at this time does not\nimprove prognosis.177,178 | III | A | \nICD therapy is not recommended in patients in\nNYHA class IV with severe symptoms refractory\nto pharmacological therapy unless they are can-\ndidates for CRT, a VAD, or cardiac\ntransplantation.179\u0002183 | III | C | ESC 2021",
          "bbox": [
            311.4074078728171,
            135.22978922526042,
            556.5508713495163,
            672.9982147216797
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "33",
      "title": "5.5 Strategic phenotypic overview of the management of heart failure with reduced ejection fraction In addition to the general therapies considered in  section 5 , other therapies are appropriate to c",
      "start_page": 26,
      "end_page": 26,
      "content": "",
      "keywords": [
        "considered",
        "general",
        "phenotypic",
        "failure",
        "section",
        "overview",
        "ejection",
        "heart",
        "other",
        "management",
        "fraction",
        "therapies",
        "appropriate",
        "strategic",
        "addition",
        "reduced"
      ],
      "tables": []
    },
    {
      "number": "34",
      "title": "6 Cardiac rhythm management for heart failure with reduced ejection fraction",
      "start_page": 26,
      "end_page": 26,
      "content": "This section provides recommendations on the use of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization ther- apy (CRT). Other implantable devices will be discussed at the end of this section.\n",
      "keywords": [
        "rhythm",
        "failure",
        "icd",
        "ejection",
        "crt",
        "heart",
        "management",
        "cardiac",
        "fraction",
        "reduced"
      ],
      "tables": []
    },
    {
      "number": "35",
      "title": "6.1 Implantable cardioverter- defibrillator A high proportion of deaths among patients with HF, especially in those with milder symptoms, occur suddenly and unexpectedly. Many of these may be due to e",
      "start_page": 26,
      "end_page": 28,
      "content": "prevent bradycardia. Some antiarrhythmic drugs might reduce the rate of tachyarrhythmias and sudden death, but they do not reduce overall mortality, 161   and may increase it.\nRecommendations for an implantable cardioverter- deﬁbrillator in patients with heart failure\nRecommendations Class a Level b\nSecondary prevention\nAn ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients\nwho have recovered from a ventricular arrhyth-\nmia causing haemodynamic instability, and who are expected to survive for >1 year with good\nfunctional status, in the absence of reversible\ncauses or unless the ventricular arrhythmia has occurred <48 h after a MI. 162 \u0002 164\nI A\nPrimary prevention\nAn ICD is recommended to reduce the risk of\nsudden death and all-cause mortality in patients with symptomatic HF (NYHA class II \u0002 III) of an\nischaemic aetiology (unless they have had a MI in\nthe prior 40 days—see below), and an LVEF <_35% despite >_3 months of OMT, provided\nthey are expected to survive substantially longer\nthan 1 year with good functional status. 161 , 165\nI A\nAn ICD should be considered to reduce the risk of sudden death and all-cause mortality in\npatients with symptomatic HF (NYHA class\nII \u0002 III) of a non-ischaemic aetiology, and an LVEF <_35% despite >_3 months of OMT, provided\nthey are expected to survive substantially longer\nthan 1 year with good functional status. 161 , 166 , 167\nIIa A\nPatients should be carefully evaluated by an\nexperienced cardiologist before generator\nreplacement, because management goals, the patient’s needs and clinical status may have\nchanged. 168 \u0002 172\nIIa B\nA wearable ICD may be considered for patients\nwith HF who are at risk of sudden cardiac death for a limited period or as a bridge to an\nimplanted device. 173 \u0002 176\nIIb B\nICD implantation is not recommended within 40 days of a MI as implantation at this time does not\nimprove prognosis. 177 , 178\nIII A\nICD therapy is not recommended in patients in\nNYHA class IV with severe symptoms refractory to pharmacological therapy unless they are can-\ndidates for CRT, a VAD, or cardiac\ntransplantation. 179 \u0002 183\nIII C\nCRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction; MI = myocar- dial infarction; NYHA = New York Heart Association; OMT = optimal medical therapy; VAD = ventricular assist device. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................................................................................\nESC Guidelines 3625\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 6.1.1 Secondary prevention of sudden cardiac death Compared with amiodarone treatment, ICDs reduce mortality in survivors of cardiac arrest and in patients who have experienced sus- tained symptomatic ventricular arrhythmias. An ICD is recom- mended in such patients when the intent is to increase survival; the decision to implant should take into account the patient’s view and their QOL, the LVEF (survival benefit is uncertain when LVEF >35%) and the absence of other diseases likely to cause death within the fol- lowing year. 162 \u0002 164 , 184\n6.1.2 Primary prevention of sudden cardiac death In an analysis of over 40 000 patients from 12 pivotal HF trials, rates of sudden cardiac death decreased by 44% over the 20-year period (from the mid-1990s to 2015). 160   This is almost certainly due to advances in HF treatment, as many key guideline-recommended therapies, including beta-blockers, MRAs, sacubitril/valsartan, and CRT pacemakers (CRT-P), reduce the risk of sudden death. While the afore-mentioned HF therapies have been shown to reduce mor- tality in patients with HFrEF, amiodarone has not. 161   However, if it is to be used, it should be with caution due to its significant side-effect profile. Conversely, dronedarone 185   and the class I antiarrhythmic agents disopyramide, encainide, and flecainide 186   should not be used for prevention of arrhythmias due to the increase in mortality seen in clinical studies. Although an ICD reduces the rate of sudden arrhythmic death in patients with HFrEF, 187   it would be expected that, in well-managed patients, the additional benefit afforded by an ICD would be lower. In the DANISH trial, rates of sudden death were low in patients with non- ischaemic cardiomyopathy (NICM); only 70 patients out of 1116 fol- lowed up over 5 years had sudden death. 166   Whilst there was a modest absolute reduction in sudden death with a defibrillator-containing device, this did not significantly improve the overall risk of mortality. However, subgroup analysis suggested there was a benefit in those <_70 years. 188   In a recent meta-analysis of studies that examined the effect of ICDs in NICM a survival benefit was still seen, although the effect was significantly weakened by the inclusion of the DANISH trial. 167\nOn average, patients with IHD are at greater risk of sudden death than patients with NICM and therefore, although the relative benefits are similar, the absolute benefit is greater in patients with IHD. 187   Two RCTs showed no benefit in patients who had an ICD implanted within 40 days after a MI. 177 , 178   Although sudden arrhythmic deaths were reduced, this was balanced by an increase in non-arrhythmic deaths. Accordingly, an ICD for primary prevention is contraindicated in this time period. Furthermore, ICD implantation is recommended only if a minimum of 3 months of OMT has failed to increase the LVEF to >35%. OMT ideally includes the use of Class I recommended drugs for HFrEF. However, the ICD trials we cite predate the use of ARNI and SGLT2 inhibitors. Whether implantation of ICDs reduces mortality in those with an LVEF >35% is unknown. There is an ongoing trial of ICD therapy in such patients with the presence of scar on CMR imaging. 189\n6.1.3 Patient selection for implantable cardioverter- defibrillator therapy Patients with HFrEF and a QRS duration >_130 ms can be considered for CRT with a defibrillator (CRT-D) rather than ICD. See the sec- tion on CRT for further details ( section 6.2 ).\nIn patients with moderate or severe HF, a reduction in sudden death may be partially or wholly offset by an increase in death due to worsening HF. 161   As such, ICD therapy is not recommended in patients in NYHA class IV, with severe symptoms refractory to phar- macological therapy, who are not candidates for a ventricular assist device (VAD) or cardiac transplantation. Such patients have a very limited life expectancy and are likely to die from pump failure. Similarly, patients with serious comorbidities who are unlikely to sur- vive substantially more than 1 year with good QOL are unlikely to obtain substantial benefit from an ICD. 179 \u0002 183\nAlthough the DANISH trial did not show a significant benefit from ICD therapy in patients with NICM, it should be remembered that NICM is a heterogeneous condition, and certain subgroups (e.g. lami- nopathies, sarcoidosis) are at higher risk of sudden death and there- fore merit careful consideration of ICD implantation. Tools to help risk stratification (e.g. scar burden on magnetic resonance imaging) can be helpful in that regard. 190 \u0002 192\nPatients should be counselled as to the purpose of an ICD and involved in the decision-making process. They should also be aware of the potential complications related to implantation, any additional impli- cations for driving, and the risk of inappropriate shocks. Furthermore, patients should be informed about the circumstances where the defib- rillator (or defibrillator component of a CRT-D) might be deactivated (e.g. terminal disease) or explanted (e.g. infection or recovery of LV function). 193   Subsequent timely conversations regarding defibrillator deactivation should be held with the patient and caregiver(s). When an ICD generator reaches its end of life or requires explan- tation, it should not be replaced automatically. Rather, shared deci- sion making should be undertaken. 168 \u0002 172   Patients should be carefully evaluated by an experienced cardiologist as treatment goals may have changed since implantation (the risk of fatal arrhythmia may be lower, or the risk of non-arrhythmic death may be higher). It is a matter of some controversy whether patients whose LVEF has greatly improved and who have not required device ther- apy during the lifetime of the ICD should have another device implanted. 168 \u0002 172\n6.1.4 Implantable cardioverter-defibrillator programming Routine defibrillation threshold testing is no longer performed fol- lowing implantation of an ICD or CRT-D as it does not improve shock efficacy or reduce arrhythmic death. 194   Conservative program- ming with long delays 195   between detection and the ICD delivering therapy dramatically reduces the risk of both inappropriate and appropriate but unnecessary shocks. 194 , 196 , 197   Generally, for primary prevention, defibrillators are programmed to minimize pacing (e.g. ventricular demand pacing VVI at 40/min), and with a tachycardia treatment zone >200/min. 194 , 198   Ultimately—and particularly for secondary prevention—programming should be adapted according to the patient’s specific needs.\n6.1.5 Subcutaneous and wearable implantable cardioverter-defibrillators Subcutaneous ICDs (S-ICDs) appear to be as effective as conven- tional transvenous ICDs with a similar complication rate. Although the risk of inappropriate shocks appeared to be higher initially,\n3626 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nimproved patient selection has shown S-ICDs are non-inferior to transvenous ICDs in this regard. 199 \u0002 202   They may be the preferred option for patients with difficult venous access or those who require ICD explantation due to infection. Patients must be carefully selected, as S-ICDs cannot treat bradyarrhythmia (except post-shock pacing) and cannot deliver either anti-tachycardia pacing or CRT. Substantial RCTs with these devices and more long-term data on safety and efficacy are awaited. A wearable cardioverter-defibrillator that is able to recognize and treat ventricular arrhythmias may be considered for a limited period of time in selected patients with HF who are at high risk for sudden death but otherwise are not suitable for ICD implantation. 162,175,176 , 203   However, the large VEST trial failed to show that the wearable cardioverter-defibrillator reduced arrhyth- mic death in patients with an LVEF <_35% following a recent acute MI. 204\nFor more detailed recommendations on the use/indications of ICD we refer the reader to the ESC/European Heart Rhythm Association (EHRA) Guidelines on ventricular tachyarrhythmias and sudden cardiac death. 201\n",
      "keywords": [
        "implantable",
        "class i",
        "unexpectedly",
        "heart failure",
        "recommended",
        "level b",
        "hfref",
        "proportion",
        "lvef",
        "tachycardia",
        "crt",
        "should be considered",
        "class ii",
        "high",
        "especially",
        "cardioverter",
        "those",
        "suddenly",
        "icd",
        "bradycardia",
        "milder",
        "patients",
        "nyha",
        "may be considered",
        "defibrillator",
        "deaths",
        "secondary prevention",
        "arrhythmia",
        "guideline",
        "among"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3627",
          "page_number": 28,
          "content": "CRT may be considered for symptomatic\npatients with HF in SR with a QRS duration of\n130\u0002149 ms and non-LBBB QRS morphology\nand with LVEF <35% despite OMT in order to\n_\nimprove symptoms and reduce morbidity and\nmortality.208,213 | IIb | B | \nCRT is not recommended in patients with a\nQRS duration <130 ms who do not have an indi-\ncation for pacing due to high degree AV\nblock.222\u0002224 | III | A | ESC 2021",
          "bbox": [
            311.3249816894531,
            59.87817600795201,
            556.7210815429687,
            182.1916765485491
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3627",
          "page_number": 28,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nCRT is recommended for symptomatic patients\nwith HF in SR with a QRS duration >150 ms and\n_\nLBBB QRS morphology and with LVEF <35%\n_\ndespite OMT in order to improve symptoms\nand reduce morbidity and mortality.205\u0002215 | I | A | \nCRT rather than RV pacing is recommended for\npatients with HFrEF regardless of NYHA class or\nQRS width who have an indication for ventricu-\nlar pacing for high degree AV block in order to\nreduce morbidity. This includes patients with\nAF.216\u0002219 | I | A | \nCRT should be considered for symptomatic\npatients with HF in SR with a QRS duration\n>150 ms and non-LBBB QRS morphology and\n_\nwith LVEF <35% despite OMT in order to\n_\nimprove symptoms and reduce morbidity and\nmortality.205\u0002215 | IIa | B | \nCRT should be considered for symptomatic\npatients with HF in SR with a QRS duration of\n130\u0002149 ms and LBBB QRS morphology and\nwith LVEF <35% despite OMT in order to\n_\nimprove symptoms and reduce morbidity and\nmortality.211,220 | IIa | B | \nPatients with an LVEF <35% who have received\n_\na conventional pacemaker or an ICD and subse-\nquently develop worsening HF despite OMT and\nwho have a significant proportion of RV pacing\nshould be considered for ‘upgrade’ to CRT.221 | IIa | B | ",
          "bbox": [
            46.97301032326438,
            363.85528462727865,
            292.02486713115985,
            728.7832489013672
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "36",
      "title": "6.2 Cardiac resynchronization therapy",
      "start_page": 28,
      "end_page": 29,
      "content": "In appropriately selected individuals, CRT reduces morbidity and mortality. 211   Furthermore, CRT improves cardiac function, and enhances QOL. 209 , 225\nWhilst the CARE-HF 206 , 208   and COMPANION 210   trials compared the effect of CRT with medical therapy (MT), the majority of CRT studies have compared CRT-D with ICD, and a few have compared CRT-P with backup pacing. The prevention of fatal bradycardia might be an important mechanism of benefit shared by all pacing devices. In CARE-HF, at baseline, 25% of patients had a resting heart rate of <_60 b.p.m. 206 , 208 , 209   If prevention of bradycardia is important, the effect of CRT will appear greater in trials where there is no device in the con- trol group. However, in MADIT-II, 35% of those who died with an ICD did so suddenly even though they were protected from both brady- and tachyarrhythmia. 226\nMost studies of CRT have specified that the LVEF should be <_35%, but RAFT 212   and MADIT-CRT 213 , 214   specified an LVEF <_30%, while REVERSE 207 , 215 , 227 specified <_40% and BLOCK-HF 216 <_50%. Relatively few patients with an LVEF of 35 \u0002 40% have been random- ized, but an IPD meta-analysis suggests no diminution of the effect of CRT in this group. 211\nAssessing the ‘response’ to CRT is challenging. Indeed, many who do not appear to ‘respond’ favourably in terms of their symptoms or LV function may well have experienced the mortality benefit. Several characteristics predict improvement in morbidity and mortality. The extent of reverse remodelling is one of the most important mecha- nisms of action of CRT. Patients with HFrEF of an ischaemic aetiology have less improvement in LV function due to myocardial scar tissue, which is less likely to undergo favourable remodelling. 228   Conversely, women may be more likely to respond than men, possibly due to smaller body and heart size. 220 , 224 , 229   QRS width predicts CRT response and was the inclusion criterion in all randomized trials, 211\nbut QRS morphology has also been related to a beneficial response to CRT. Several studies have shown that patients with left bundle branch block (LBBB) morphology are more likely to respond favour- ably to CRT, whereas there is less certainty about patients with non- LBBB morphology. 230   This latter group is also underrepresented in the large CRT trials. 206 , 210 , 213   However, patients with LBBB\nRecommendations for cardiac resynchronization therapy implantation in patients with heart failure\nRecommendations Class a Level b\nCRT is recommended for symptomatic patients\nwith HF in SR with a QRS duration >_150 ms and\nLBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms\nand reduce morbidity and mortality. 205 \u0002 215\nI A\nCRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or\nQRS width who have an indication for ventricu-\nlar pacing for high degree AV block in order to reduce morbidity. This includes patients with\nAF. 216 \u0002 219\nI A\nCRT should be considered for symptomatic\npatients with HF in SR with a QRS duration >_150 ms and non-LBBB QRS morphology and\nwith LVEF <_35% despite OMT in order to\nimprove symptoms and reduce morbidity and mortality. 205 \u0002 215\nIIa B\nCRT should be considered for symptomatic\npatients with HF in SR with a QRS duration of 130 \u0002 149 ms and LBBB QRS morphology and\nwith LVEF <_35% despite OMT in order to\nimprove symptoms and reduce morbidity and mortality. 211 , 220\nIIa B\nPatients with an LVEF <_35% who have received\na conventional pacemaker or an ICD and subse-\nquently develop worsening HF despite OMT and who have a signiﬁcant proportion of RV pacing\nshould be considered for ‘upgrade’ to CRT. 221\nIIa B\nContinued\nCRT may be considered for symptomatic\npatients with HF in SR with a QRS duration of\n130 \u0002 149 ms and non-LBBB QRS morphology and with LVEF <_35% despite OMT in order to\nimprove symptoms and reduce morbidity and\nmortality. 208 , 213\nIIb B\nCRT is not recommended in patients with a\nQRS duration <130 ms who do not have an indi-\ncation for pacing due to high degree AV block. 222 \u0002 224\nIII A\nAF = atrial ﬁbrillation; AV = atrio-ventricular; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OMT = optimal medical therapy (class I recommended medical therapies for at least 3 months); QRS = Q, R, and S waves of an ECG; RV = right ventricular; SR = sinus rhythm. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................................................................................\nESC Guidelines 3627\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ morphology often have wider QRS durations, and there is a current debate about whether QRS durations or QRS morphology is the main predictor of a beneficial response to CRT. Evidence from two IPD meta-analyses indicates that after accounting for QRS duration, there is little evidence to suggest that QRS morphology or aetiology of disease influence the effect of CRT on morbidity or mortal- ity. 211 , 220   In addition, none of the landmark trials selected patients for inclusion according to QRS morphology, sex, or ischaemic aetiology, nor were they powered for subgroup analyses. The Echo-CRT trial 222 , 223   and an IPD meta-analysis 213   suggest pos- sible harm from CRT when QRS duration is <130 ms, thus implanta- tion of CRT is not recommended if QRS duration is <130 ms. If a patient is scheduled to receive an ICD and is in SR, with a LBBB, CRT-D should be considered if the QRS is between 130 and 149 ms and is recommended if QRS is >_150 ms. However, clinical practice varies widely among countries and if the primary reason for implanting CRT is for the relief of symptoms, then the clinician should choose CRT-P or CRT-D, whichever they con- sider appropriate. The only randomized trial to compare CRT-P and CRT-D 210   did not demonstrate a difference in morbidity or mortality between these technologies (although the trial was not powered to show such a difference). Furthermore, in the DANISH study in patients with NICM where 58% of patients received CRT there was no suggestion from subgroup analysis that CRT-P was inferior to CRT-D. 166 , 167\nWhen LVEF is reduced, RV pacing may exacerbate cardiac dyssyn- chrony. This can be prevented by CRT, which might improve patient outcomes. 216 \u0002 218 , 231   However, a difference in outcome was not observed between CRT and RV pacing in a subgroup analysis of RAFT. 212   On balance, CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indi- cation for ventricular pacing in order to reduce morbidity, although no clear effect on mortality was observed. Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF with a high proportion of RV pacing, despite OMT, should be considered for ‘upgrading’ to CRT. Only two small trials have compared pharmacological therapy alone vs. CRT in patients with AF, with conflicting results. Several studies have indicated that CRT is superior to RV pacing in patients undergoing atrio-ventricular (AV) node ablation. 217 , 218 , 231\nHowever, AF is not an indication to carry out AV node ablation in patients with CRT except in a few cases when ventricular rate remains persistently high despite attempts at pharmacological rate control. A subgroup analysis of patients with AF from the RAFT study found no benefit from CRT-D compared with ICD, although less than half of patients had >90% biventricular capture. 219   In view of the paucity of evidence for the efficacy of CRT in patients with AF, it may be an option in selected patients—particularly those with a QRS >_150 ms—ensuring a proportion of biventricular pac- ing as high as possible. Observational studies report that when biventricular capture is <98%, the prognosis of patients with CRT declines. 218 , 232   Whether this association reflects a loss of resynchronization (which might be remedied by device programming), poor placement of the LV lead, or greater difficulty in pacing severely diseased myocardium is uncer- tain. This observation has not been confirmed in any randomized trial.\nEarly studies suggested that imaging tests for dyssynchrony were not of value in selecting patients for CRT. 233   However, a recent study has suggested that two novel markers of dyssynchrony (apical rock- ing and septal flash) are associated with a response to CRT, but these have not been tested as selection criteria or as prespecified sub- groups in a randomized trial. 234   Patients with extensive myocardial scar will have less improvement in LV function with CRT, but this is true of any treatment for HFrEF and does not reliably predict less clinical benefit. Pacing thresholds are higher in scarred myocardium and, if possible, lead placement should avoid such regions. 235 , 236\nAlthough patients with extensive scarring have an intrinsically worse prognosis, there is little evidence that they obtain less prognostic benefit from CRT. 211\nThe value of trying to optimize AV intervals or interventricular delay intervals (VV intervals) after implantation using echo- or elec- trocardiographic criteria or BP response is uncertain but may be con- sidered for patients who have had a disappointing response to CRT. 237 , 238   Other options to consider to optimize response to CRT are covered in a recently published practical article. 239\nFollowing CRT implantation, a review of diuretic therapy is advised as a reduction in dose or its discontinuation may be required. In addi- tion, CRT implantation may afford an opportunity to further optimize MT for HFrEF. 240\nThe reader is directed to guidelines on pacing and CRT for recom- mendations on device implantation procedures. 240a\n",
      "keywords": [
        "therapy",
        "class i",
        "heart failure",
        "echo",
        "recommended",
        "indication",
        "resynchronization",
        "level b",
        "ecg",
        "hfref",
        "lvef",
        "crt",
        "should be considered",
        "icd",
        "bradycardia",
        "nyha",
        "may be considered",
        "sex",
        "ejection fraction",
        "ablation",
        "diuretic",
        "pacemaker",
        "cardiac"
      ],
      "tables": []
    },
    {
      "number": "37",
      "title": "6.3 Devices under evaluation Cardiac contractility modulation (CCM) has been evaluated in patients with NYHA class III \u0002 IV HF, with an LVEF >_25% to <_45% and QRS duration <130 ms, and was associated",
      "start_page": 29,
      "end_page": 29,
      "content": "Technologies that involve modification of the activity of the auto- nomic nervous system, e.g. baroreflex activation therapy, 243 , 244   have also been shown to offer a modest improvement in effort capacity and QOL. However, currently, the evidence is considered insufficient to support specific guideline recommendations for a reduction in mortality or hospitalization for these and a variety of other implant- able electrical therapeutic technologies (see also Gaps in Evidence in section 16 ).\n",
      "keywords": [
        "guideline",
        "associated",
        "evaluated",
        "under",
        "modulation",
        "evaluation",
        "lvef",
        "contractility",
        "patients",
        "cardiac",
        "nyha",
        "devices",
        "class",
        "duration"
      ],
      "tables": []
    },
    {
      "number": "38",
      "title": "7 Heart failure with mildly reduced ejection fraction",
      "start_page": 29,
      "end_page": 29,
      "content": "",
      "keywords": [
        "failure",
        "ejection",
        "mildly",
        "heart",
        "fraction",
        "reduced"
      ],
      "tables": []
    },
    {
      "number": "39",
      "title": "7.1 The diagnosis of heart failure with mildly reduced ejection fraction The diagnosis of HFmrEF requires the presence of symptoms and/or signs of HF, and a mildly reduced EF (41 \u0002 49%) The presence o",
      "start_page": 29,
      "end_page": 30,
      "content": "3628 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................................................................................................................................................... 7.2 Clinical characteristics of patients with heart failure with mildly reduced ejection fraction There is a substantial overlap of clinical characteristics, risk factors, patterns of cardiac remodelling, and outcomes among the LVEF cate- gories in HF. Patients with HFmrEF have, on average, features that are more similar to HFrEF than HFpEF, in that they are more com- monly men, younger, and are more likely to have CAD (50 \u0002 60%), 38 , 42 , 43   and less likely to have AF and non-cardiac comor- bidities ( Supplementary Table 10 ). However, ambulatory patients with HFmrEF have a lower mortality than those with HFrEF, more akin to those with HFpEF. Patients with HFmrEF may include patients whose LVEF has improved from <_40% or declined from >_50%. 50\n",
      "keywords": [
        "hfref",
        "hfpef",
        "ejection fraction",
        "symptoms",
        "failure",
        "presence",
        "lvef",
        "hfmref",
        "heart failure",
        "heart",
        "mildly",
        "ejection",
        "fraction",
        "signs",
        "reduced",
        "requires",
        "diagnosis"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3629",
          "page_number": 30,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nDiuretics are recommended in patients with\ncongestion and HFmrEF in order to alleviate\nsymptoms and signs.137 | I | C | \nAn ACE-I may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization\nand death.11 | IIb | C | \nAn ARB may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization\nand death.245 | IIb | C | \nA beta-blocker may be considered for patients\nwith HFmrEF to reduce the risk of HF hospital-\nization and death.12,119 | IIb | C | \nAn MRA may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization\nand death.246 | IIb | C | \nSacubitril/valsartan may be considered for\npatients with HFmrEF to reduce the risk of HF\nhospitalization and death.13,247 | IIb | C | ESC 2021",
          "bbox": [
            47.08686996459961,
            433.66136067708334,
            292.2148030598958,
            679.8012542724609
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "40",
      "title": "7.3 Treatments for patients with heart failure with mildly reduced ejection fraction As in other forms of HF, diuretics should be used to control conges- tion. No substantial prospective RCT has been ",
      "start_page": 30,
      "end_page": 31,
      "content": "7.3.1 Angiotensin-converting enzyme inhibitors There are no specific trials of ACE-I in patients with HFmrEF. Although, the PEP-CHF trial was conducted in patients with HFpEF and included patients with an LVEF >40%, it did not report outcomes according to LVEF. 11\nHowever, in patients with HFmrEF, many will also have CAD, hypertension, or post-MI LV systolic dysfunction and will, therefore, already be treated with ACE-I. Therefore, ACE-I use may be considered in patients with HFmrEF.\n7.3.2 Angiotensin receptor II type 1 receptor blockers There are no specific trials of ARBs in HFmrEF. The CHARM- Preserved trial missed its primary endpoint of CV death or HF hospi- talizations. 245   However, a retrospective analysis showed that cande- sartan reduced the number of patients hospitalized for HF among those with HFmrEF (with similar trends for CV and all-cause mortal- ity). 8   Moreover, a recurrent-event analysis suggested a reduction in hospitalizations for HF among the entire CHARM-Preserved cohort, including those with HFmrEF. 248\nAs for ACE-I, many with HFmrEF will already be on an ARB for other CV indications. Therefore, treatment with ARBs may be con- sidered in patients with HFmrEF.\n7.3.3 Beta-blockers There is no specific trial of beta-blockade in HFmrEF. An IPD meta- analysis of landmark trials of beta-blockers suggested similar reduc- tions in CV and all-cause mortality (of 50%) for patients in SR with HFrEF and HFmrEF. 12   This IPD meta-analysis included the SENIORS trial where nebivolol reduced the composite primary endpoint of all- cause mortality or CV hospital admissions in the overall population. No interaction between LVEF (35% of patients had an LVEF of 35 \u0002 50%) and the effect of nebivolol on the primary outcome was observed. 119 , 249   Many patients with HFmrEF may have another CV indication, such as AF or angina, for a beta-blocker. Therefore, treat- ment with beta-blockers may be considered in patients with HFmrEF.\n7.3.4 Mineralocorticoid receptor antagonists There is no specific trial of MRAs in HFmrEF. In a retrospective analy- sis of the TOPCAT trial in patients with an LVEF >_45%, 9   spironolac- tone reduced hospitalizations for HF in those with an LVEF <55%. There was a similar trend for CV but not all-cause mortality. Treatment with an MRA may be considered in patients with HFmrEF.\n7.3.5 Angiotensin receptor-neprilysin inhibitor There is no specific trial of ARNI in HFmrEF. In the PARAGON-HF trial, which included patients with EF >_45%, although the trial missed its primary endpoint overall, a significant EF-by-treatment interaction was observed. Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalizations by 22% in those with an EF below or equal to the median of 57%. 13   Further data are available from a combined analysis of the PARADIGM-HF and PARAGON-HF trials showing that sacubitril/valsartan, compared to other forms of RAAS blockade, has a beneficial effect, especially on hospitalizations for HF in those with HFmrEF. 247\nPharmacological treatments to be considered in patients with (NYHA class II–IV) heart failure with mildly reduced ejection fraction\nRecommendations Class a Level b\nDiuretics are recommended in patients with congestion and HFmrEF in order to alleviate\nsymptoms and signs. 137\nI C\nAn ACE-I may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization and death. 11\nIIb C\nAn ARB may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization and death. 245\nIIb C\nA beta-blocker may be considered for patients\nwith HFmrEF to reduce the risk of HF hospital-\nization and death. 12 , 119\nIIb C\nAn MRA may be considered for patients with\nHFmrEF to reduce the risk of HF hospitalization\nand death. 246\nIIb C\nSacubitril/valsartan may be considered for patients with HFmrEF to reduce the risk of HF\nhospitalization and death. 13 , 247\nIIb C\nACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 3629\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Treatment with an ARNI may be considered in patients with HFmrEF.\n7.3.6 Other drugs In the DIG trial, 10   for those with HFmrEF in SR, there was a trend to fewer hospitalizations for HF in those assigned to digoxin, but no reduction in mortality and a trend to an excess of CV deaths. Therefore, there are insufficient data to recommend its use. There are also insufficient data on ivabradine in HFmrEF to draw any conclusions.\n7.3.7 Devices While post hoc analyses of landmark CRT trials suggest that CRT may benefit patients with LVEF >35%, trials of CRT for HFmrEF were abandoned due to poor recruitment. 250   There are no substantial tri- als of ICDs for primary prevention of ventricular arrhythmias for HFmrEF; trials conducted more than 20 years ago suggested no bene- fit from ICD implantation for secondary prevention of ventricular arrhythmias for HFmrEF. Therefore, there is insufficient evidence to advise CRT or ICD therapy in patients with HFmrEF. In HF patients with an LVEF >_40%, the implantation of an intera- trial shunt device was found to be safe, and this device is subject to investigation in a larger study before any recommendation on their use in HFpEF or HFmrEF can be given. 251\n",
      "keywords": [
        "heart failure",
        "should",
        "treatments",
        "other",
        "control",
        "recommended",
        "substantial",
        "systolic dysfunction",
        "indication",
        "level b",
        "hfref",
        "hfpef",
        "conges",
        "failure",
        "used",
        "hypertension",
        "lvef",
        "crt",
        "heart",
        "tion",
        "class ii",
        "forms",
        "icd",
        "mildly",
        "patients",
        "arb",
        "nyha",
        "may be considered",
        "prospective",
        "secondary prevention"
      ],
      "tables": []
    },
    {
      "number": "41",
      "title": "8 Heart failure with preserved ejection fraction",
      "start_page": 31,
      "end_page": 31,
      "content": "",
      "keywords": [
        "preserved",
        "failure",
        "ejection",
        "heart",
        "fraction"
      ],
      "tables": []
    },
    {
      "number": "42",
      "title": "8.1 The background to heart failure with preserved ejection fraction This guideline acknowledges the historical changes in nomenclature and the lack of consensus on the optimal LVEF cut-off to define ",
      "start_page": 31,
      "end_page": 31,
      "content": "Whether patients with higher EFs and HF should be named HF with ‘normal’ EF has also been considered. 14 , 254   However, given the known variability of echocardiographic measurements of LVEF, the difficulties in interpreting LVEF measured using different imaging modalities, and remaining controversies regarding the precise LVEF cut-off to define ‘normal’ , which may vary not only with sex but also with other factors such as age and ethnicity, 255   this guideline has kept the nomenclature of HFpEF using an EF cut-off of 50%. Importantly, clinicians should be aware that LVEF is a continuous variable with a normal distribution in the general population, and the EF cut-offs used in definitions are therefore arbitrary. Moreover, while the LVEF cut-off to define ‘normal’ will likely be higher than 50%, the presence\nof a very high EF (e.g. above 65 \u0002 70%) should also prompt a search for pathology, such as cardiac amyloidosis (CA) or hypertrophic car- diomyopathy (HCM), where a ‘supra-normal’ EF may result from shrinkage of the LV end-diastolic volume (denominator of EF). 256 , 257\n",
      "keywords": [
        "acknowledges",
        "changes",
        "nomenclature",
        "historical",
        "hfpef",
        "optimal",
        "failure",
        "lvef",
        "heart",
        "ethnicity",
        "background",
        "preserved",
        "diastolic",
        "consensus",
        "lack",
        "sex",
        "guideline",
        "define",
        "ejection",
        "age",
        "fraction"
      ],
      "tables": []
    },
    {
      "number": "43",
      "title": "8.2 Clinical characteristics of patients with heart failure with preserved ejection fraction HFpEF differs from HFrEF and HFmrEF in that HFpEF patients are older and more often female. AF, CKD, and no",
      "start_page": 31,
      "end_page": 31,
      "content": "There are numerous potential causes of HFpEF ( Table  5 ). The pathophysiology of various HFpEF syndromes differs, and thus they require distinct therapies. Red flags for the potential presence of CA include low normal BP in patients with a history of hypertension, intolerance to beta-blockers or ACE-I, history of bilateral carpal tun- nel syndrome, low voltage on ECG and echocardiographic features such as thickening of the septum, posterior wall, or RV wall, enlarged atria, a small pericardial effusion, or valve thickening [for more details see the section on CMP ( section 14.2 )]. Furthermore, it is important to exclude other conditions that might mimic the HFpEF syndrome (e.g. lung disease, anaemia, obesity, and deconditioning). For a more comprehensive overview on HFpEF, see the ESC/HFA position statement. 259\n",
      "keywords": [
        "differs",
        "ecg",
        "hfref",
        "hfpef",
        "female",
        "failure",
        "clinical",
        "hypertension",
        "heart",
        "often",
        "characteristics",
        "preserved",
        "obesity",
        "patients",
        "older",
        "ejection",
        "hfmref",
        "fraction",
        "more"
      ],
      "tables": []
    },
    {
      "number": "44",
      "title": "8.3 The diagnosis of heart failure with preserved ejection fraction The diagnosis of HFpEF remains challenging. Several diagnostic criteria have been proposed by societies and in clinical trials. 260 ",
      "start_page": 31,
      "end_page": 32,
      "content": "Both scores assign a substantial proportion of suspected HFpEF patients as intermediate likelihood, wherein additional diagnostics are proposed. Thus, depending on which score is used, different patients will be referred for additional testing or allocated as having HFpEF. Furthermore, physicians may not have access to all the specialized tests recommended by the specific diagnostic algorithms. This limits the broad clinical applicability of the scores and demonstrates the ongoing diagnostic uncertainty in HFpEF. 267\nTo facilitate broad clinical application, this guideline recom- mends a simplified pragmatic approach that distils the common major elements in prior diagnostic criteria and emphasizes the most frequently used variables widely available to clinicians. Some of these variables, in particular, LA size (LA volume index >32 mL/m 2 ), mitral E velocity >90 cm/s, septal e 0   velocity <9 cm/s, E/e 0   ratio >9 have been shown to be pivot points beyond which the risk of CV mortality is increased, underscoring their value. 270\nThis recommendation is therefore consistent with the consensus document of the HFA, and does not represent a new algorithm or diagnostic score but rather a simplified approach. Physicians with access to expertise may refer to the full diagnostic approach recommended by the HFA. 259\n3630 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .................................................................................................... This simplified diagnostic approach starts with assessment of pre- test probability (see clinical characteristics above). The diagnosis should include the following:\n(1) Symptoms and signs of HF. (2) An LVEF >_50%.* (3) Objective evidence of cardiac structural and/or functional abnor- malities consistent with the presence of LV diastolic dysfunction/ raised LV filling pressures, including raised NPs ( Table  9 ).\n*Of note, patients with a history of overtly reduced LVEF (<_40%), who later present with LVEF >_50%, should be considered to have recovered HFrEF or ‘HF with improved LVEF’ (rather than HFpEF). Continued treatment for HFrEF is recommended in these patients. 271\nIt is not known whether starting HF therapy in patients with recov- ered LVEF is beneficial. Patients with HFpEF tend to have stable tra- jectory of LVEF over time. 272   However, in those who develop a clinical indication for a repeat echo during follow-up, around one third have a decline in LVEF. 273\nIn the presence of AF, the threshold for LA volume index is >40 mL/m 2 . Exercise stress thresholds include E/e 0   ratio at peak stress >_15 or tricuspid regurgitation (TR) velocity at peak stress >3.4 m/s. 275   LV global longitudinal strain <16% has a sensitivity of 62% and a specificity of 56% for the diagnosis of HFpEF by invasive testing. 261\nThe approach to the diagnosis should involve additional confirma- tory tests in cases of diagnostic uncertainty, such as cardiopulmonary exercise testing (to confirm a reduction in exercise capacity and to help differentiate the cause of dyspnoea), exercise stress testing, and invasive haemodynamic testing. 259\nIf resting echocardiographic and laboratory markers are equivocal, a diastolic stress test is recommended. 259 , 274   The confirmatory test for the diagnosis of HFpEF is invasive haemodynamic exercise testing. An invasively measured pulmonary capillary wedge pressure (PCWP) of >_15 mmHg (at rest) or >_25 mmHg (with exercise) or LV\nend-diastolic pressure >_16 mmHg (at rest) is generally considered diagnostic. 266   However, instead of an exercise PCWP cut-off, some have used an index of PCWP to cardiac output for the invasive diag- nosis of HFpEF 260 , 276 . Recognizing that invasive haemodynamic exer- cise testing is not available in many centres worldwide, and is associated with risks, its main use is limited to the research setting. In the absence of any disease-modifying treatments, the current guide- lines do not mandate gold standard testing in every patient to make the diagnosis, but emphasize that the greater the number of objective non-invasive markers of raised LV filling pressures ( Table  9 ), the higher the probability of a diagnosis of HFpEF.\n",
      "keywords": [
        "diastolic dysfunction",
        "echo",
        "diagnostic",
        "recommended",
        "indication",
        "trials",
        "hfref",
        "hfpef",
        "failure",
        "stress test",
        "exercise",
        "clinical",
        "lvef",
        "heart",
        "should be considered",
        "societies",
        "preserved",
        "diastolic",
        "remains",
        "several",
        "tricuspid",
        "guideline",
        "criteria",
        "proposed",
        "ejection",
        "fraction",
        "challenging",
        "diagnosis"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3631",
          "page_number": 32,
          "content": "Parametera |  | Threshold |  | Comments | ESC 2021\nLV mass index\nRelative wall thickness |  | >95 g/m2 (Female), >115 g/m2 (Male)\n_ _\n>0.42 |  | Although the presence of concentric LV remodelling or hypertrophy is\nsupportive, the absence of LV hypertrophy does not exclude the diagno-\nsis of HFpEF | \nLA volume indexa |  | >34 mL/m2 (SR) |  | In the absence of AF or valve disease, LA enlargement reflects chronically\nelevated LV filling pressure (in the presence of AF, the threshold is\n>40 mL/m2) | \nE/e’ ratio at resta |  | >9 |  | Sensitivity 78%, specificity 59% for the presence of HFpEF by invasive\nexercise testing, although reported accuracy has varied. A higher cut-off\nof 13 had lower sensitivity (46%) but higher specificity (86%).71,259,274 | \nNT-proBNP\nBNP |  | >125 (SR) or\n>365 (AF) pg/mL\n>35 (SR) or\n>105 (AF) pg/mL |  | Up to 20% of patients with invasively proven HFpEF have NPs below\ndiagnostic thresholds, particularly in the presence of obesity | \nPA systolic pressure\nTR velocity at resta |  | >35 mmHg\n>2.8 m/s |  | Sensitivity 54%, specificity 85% for the presence of HFpEF by invasive\nexercise testing259,261 | ",
          "bbox": [
            48.00993792215983,
            506.3249816894531,
            557.6139526367188,
            702.8080978393555
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "45",
      "title": "8.4 Treatment of heart failure with preserved ejection fraction To date, no treatment has been shown to convincingly reduce mortality and morbidity in patients with HFpEF, although improve- ments have",
      "start_page": 32,
      "end_page": 34,
      "content": "Table 9 Objective evidence of cardiac structural, functional and serological abnormalities consistent with the presence of left ventricular diastolic dysfunction/raised left ventricular ﬁlling pressures 259,261\nParameter a Threshold Comments\nLV mass index\nRelative wall thickness\n>_ 95  g/m 2   (Female), >_ 115  g/m 2   (Male)\n> 0.42\nAlthough the presence of concentric LV remodelling or hypertrophy is\nsupportive, the absence of LV hypertrophy does not exclude the diagno- sis of HFpEF\nLA volume index a > 34  mL/m 2   (SR) In the absence of AF or valve disease, LA enlargement reﬂects chronically\nelevated LV ﬁlling pressure (in the presence of AF, the threshold is >40 mL/m 2 )\nE/e’ ratio at rest a > 9 Sensitivity 78%, speciﬁcity 59% for the presence of HFpEF by invasive\nexercise testing, although reported accuracy has varied. A higher cut-off\nof 13 had lower sensitivity (46%) but higher speciﬁcity (86%). 71 , 259 , 274\nNT-proBNP\nBNP\n> 125  (SR) or\n> 365  (AF) pg/mL\n> 35  (SR) or > 105  (AF) pg/mL\nUp to 20% of patients with invasively proven HFpEF have NPs below\ndiagnostic thresholds, particularly in the presence of obesity\nPA systolic pressure\nTR velocity at rest a > 35  mmHg\n> 2.8  m/s\nSensitivity 54%, speciﬁcity 85% for the presence of HFpEF by invasive\nexercise testing 259 , 261\nAF = atrial ﬁbrillation; BNP = B-type natriuretic peptide; E/e’ratio = early ﬁlling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler; HFpEF = heart failure with preserved ejection fraction; LA = left atrial; LV = left ventricular; NP = natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PA = pulmonary artery; SR = sinus rhythm; TR = tricuspid regurgitation. Note: The greater the number of abnormalities present, the higher the likelihood of HFpEF. a Only commonly used indices are listed in the table; for less commonly used indices refer to the consensus document of the ESC/HFA. 259\nESC 2021\nESC Guidelines 3631\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\ncapacity or QOL in HFpEF, e.g. NEAT-HFpEF, 280   INDIE-HFpEF, 281\nVITALITY-HFpEF, 282   and CAPACITY-HFpEF (praliciguat). 283\nDespite the lack of evidence for specific disease-modifying thera- pies in HFpEF, as the vast majority of HFpEF patients have underlying hypertension and/or CAD, many are already treated with ACE-I/ ARB, beta-blockers, or MRAs. In the PARAGON-HF study at base- line, more than 86% of patients were on ACE-I/ARBs, 80% were on beta-blockers, and more than 24% were on MRAs. 13\nThe Task Force acknowledge that the treatment options for HFpEF are being revised as this guideline is being published. We note that the Food and Drug Administration (FDA) has endorsed the use of sacubitril/valsartan and spironolactone in those with an LVEF ‘less than normal’. These statements relate to patients within both the HFmrEF and HFpEF categories. For sacubitril/valsartan, this decision was based on the subgroup analysis from the PARAGON-HF study, which showed a reduction in HF hospitalizations in those with an LVEF <57%, and a meta-analysis of the PARADIGM-HF and PARAGON-HF studies, showing a reduction in CV death and HF hospitalization in those with an LVEF below the normal range. 247\nRegarding spironolactone, the subgroup of individuals in the TOPCAT study recruited in the Americas had a significant reduc- tion in the primary endpoint of CV death and HF hospitalization, and a subsequent post hoc analysis by EF showed a significant reduction in outcomes for those with an LVEF <55%. 9 , 247   There are also ongoing trials with SGLT2 inhibitors. These developments may well accelerate a redefinition of HFpEF in the future and have thera- peutic implications. In the absence of recommendations regarding disease-modifying therapies, treatment should be aimed at reducing symptoms of con- gestion with diuretics. Loop diuretics are preferred, although thiazide diuretics may be useful for managing hypertension. Reducing body weight in obese patients and increasing exercise may further improve symptoms and exercise capacity and should therefore be considered in appropriate patients. 284 , 285\nIt is important to identify and treat the underlying risk factors, aeti- ology, and coexisting comorbidities in HFpEF (e.g. hypertension in section 12.4 , CAD in  section 12.2 , amyloidosis in  section 14.6 , AF in section 12.1.1 , and valvular heart disease in section 12.3 ). Undoubtably, treatment of some of the underlying phenotypes of the the HFpEF syndrome leads to improved outcomes.\nRecommendations for the treatment of patients with heart failure with preserved ejection fraction\nRecommendations Class a Level b\nScreening for, and treatment of, aetiologies, and cardiovascular and non-cardiovascular comor-\nbidities is recommended in patients with HFpEF\n(see relevant sections of this document).\nI C\nDiuretics are recommended in congested patients with HFpEF in order to alleviate symp-\ntoms and signs. 137\nI C\nHFpEF = heart failure with preserved ejection fraction. a Class of recommendation. b Level of evidence.\nESC 2021\nESC 2021\nTable 10 Risk factors for the development of heart failure and potential corrective actions\nRisk factors for heart failure Preventive strategies\nSedentary habit Regular physical activity\nCigarette smoking Cigarette smoking cessation\nObesity Physical activity and healthy diet\nExcessive alcohol intake 286 General population: no/light alcohol intake is beneﬁcial\nPatients with alcohol-induced CMP\nshould abstain from alcohol\nInﬂuenza Inﬂuenza vaccination\nMicrobes (e.g.  Trypanosoma\ncruzi , Streptococci)\nEarly diagnosis, speciﬁc antimicrobial\ntherapy for either prevention and/or\ntreatment\nCardiotoxic drugs (e.g., anthracyclines) Cardiac function and side effect moni- toring, dose adaptation, change of\nchemotherapy\nChest radiation Cardiac function and side effect moni- toring, dose adaptation\nHypertension Lifestyle changes, antihypertensive\ntherapy\nDyslipidaemia Healthy diet, statins\nDiabetes mellitus Physical activity and healthy diet, SGLT2 inhibitors\nCAD Lifestyle changes, statin therapy\nCAD = coronary artery disease; CMP = cardiomyopathy; SGLT2 = sodium-glu- cose co-transporter 2.\nESC 2021\nRecommendations for the primary prevention of heart failure in patients with risk factors for its development\nRecommendations Class a Level b\nTreatment of hypertension is recommended to\nprevent or delay the onset of HF, and to prevent HF hospitalizations. 287 \u0002 290\nI A\nTreatment with statins is recommended in\npatients at high risk of CV disease or with CV disease in order to prevent or delay the onset of\nHF, and to prevent HF hospitalizations. 291 , 292\nI A\nSGLT2 inhibitors (canagliﬂozin, dapagliﬂozin,\nempagliﬂozin, ertugliﬂozin, sotagliﬂozin) are rec- ommended in patients with diabetes at high risk\nof CV disease or with CV disease in order to\nprevent HF hospitalizations. 293 \u0002 297\nI A\nCounselling against sedentary habit, obesity, ciga-\nrette smoking, and alcohol abuse is recom-\nmended to prevent or delay the onset of HF. 298 \u0002 302\nI C\nCV=cardiovascular; HF= heart failure; SGLT2= sodium-glucose co-transporter 2. a Class of recommendation. b Level of evidence. . ...........................................................................................................................................................................\n3632 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................................... 9 Multidisciplinary team management for the prevention and treatment of chronic heart failure\n",
      "keywords": [
        "date",
        "diastolic dysfunction",
        "antihypertensive",
        "heart failure",
        "recommended",
        "level b",
        "although",
        "physical activity",
        "reduce",
        "ments",
        "hfpef",
        "female",
        "glucose",
        "failure",
        "hypertension",
        "lvef",
        "bnp",
        "heart",
        "coronary artery",
        "morbidity",
        "treatment",
        "preserved",
        "diastolic",
        "obesity",
        "alcohol",
        "statin",
        "convincingly",
        "improve",
        "patients",
        "nt-probnp"
      ],
      "tables": [
        {
          "title": "3632 ESC Guidelines",
          "page_number": 33,
          "content": "Risk factors for heart\nfailure | Preventive strategies | ESC 2021\nSedentary habit | Regular physical activity | \nCigarette smoking | Cigarette smoking cessation | \nObesity | Physical activity and healthy diet | \nExcessive alcohol intake286 | General population: no/light alcohol\nintake is beneficial\nPatients with alcohol-induced CMP\nshould abstain from alcohol | \nInfluenza | Influenza vaccination | \nMicrobes (e.g. Trypanosoma\ncruzi, Streptococci) | Early diagnosis, specific antimicrobial\ntherapy for either prevention and/or\ntreatment | \nCardiotoxic drugs (e.g.,\nanthracyclines) | Cardiac function and side effect moni-\ntoring, dose adaptation, change of\nchemotherapy | \nChest radiation | Cardiac function and side effect moni-\ntoring, dose adaptation | \nHypertension | Lifestyle changes, antihypertensive\ntherapy | \nDyslipidaemia | Healthy diet, statins | \nDiabetes mellitus | Physical activity and healthy diet,\nSGLT2 inhibitors | \nCAD | Lifestyle changes, statin therapy | ",
          "bbox": [
            307.4777861885403,
            91.3330078125,
            552.0633822354404,
            390.24190412248885
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3632 ESC Guidelines",
          "page_number": 33,
          "content": " |  |  |  | ESC 2021\nRecommendations | Classa | Levelb |  | \n |  |  |  | \nTreatment of hypertension is recommended to\nprevent or delay the onset of HF, and to prevent\nHF hospitalizations.287\u0002290 | I | A |  | \nTreatment with statins is recommended in\npatients at high risk of CV disease or with CV\ndisease in order to prevent or delay the onset of\nHF, and to prevent HF hospitalizations.291,292 | I | A |  | \nSGLT2 inhibitors (canagliflozin, dapagliflozin,\nempagliflozin, ertugliflozin, sotagliflozin) are rec-\nommended in patients with diabetes at high risk\nof CV disease or with CV disease in order to\nprevent HF hospitalizations.293\u0002297 | I | A |  | \nCounselling against sedentary habit, obesity, ciga-\nrette smoking, and alcohol abuse is recom-\nmended to prevent or delay the onset of\nHF.298\u0002302 | I | C |  | ",
          "bbox": [
            307.4777861885403,
            477.3717864990234,
            557.6139526367188,
            698.6201836722238
          ],
          "function_potential": "raw"
        },
        {
          "title": "3632 ESC Guidelines",
          "page_number": 33,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nScreening for, and treatment of, aetiologies, and\ncardiovascular and non-cardiovascular comor-\nbidities is recommended in patients with HFpEF\n(see relevant sections of this document). | I | C | \nDiuretics are recommended in congested\npatients with HFpEF in order to alleviate symp-\ntoms and signs.137 | I | C | ESC 2021",
          "bbox": [
            42.642042306753304,
            590.7573628743489,
            287.76658412388394,
            698.6201836722238
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3633",
          "page_number": 34,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that HF patients are enrolled\nin a multidisciplinary HF management pro-\ngramme to reduce the risk of HF hospitalization\nand mortality.309,314,315,316 | I | A | \nSelf-management strategies are recommended\nto reduce the risk of HF hospitalization and\nmortality.309 | I | A | \nEither home-based and/or clinic-based pro-\ngrammes improve outcomes and are recom-\nmended to reduce the risk of HF hospitalization\nand mortality.310,317 | I | A | \nInfluenza and pneumococcal vaccinations should\nbe considered in order to prevent HF\nhospitalizations.315,316 | IIa | B | ESC 2021",
          "bbox": [
            311.46182411595396,
            307.23622233072916,
            556.5992376154119,
            503.02616337367465
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "46",
      "title": "9.1 Prevention of heart failure General advice about risk factors for the development of HF (see Supplementary Figure 1 ) and strategies to prevent HF early in the CV continuum are summarized in  Tabl",
      "start_page": 34,
      "end_page": 34,
      "content": "This section focuses on areas where recommendations with an evi- dence level can be given: multidisciplinary team management, lifestyle advice, exercise training, follow-up, and monitoring.\n",
      "keywords": [
        "strategies",
        "early",
        "about",
        "risk",
        "general",
        "failure",
        "figure",
        "prevention",
        "advice",
        "heart",
        "tabl",
        "factors",
        "summarized",
        "continuum",
        "development",
        "prevent",
        "supplementary",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "47",
      "title": "9.2 Multidisciplinary management of chronic heart failure 9.2.1 Models of care In order to reduce hospitalizations and mortality, earlier guidelines 1",
      "start_page": 34,
      "end_page": 34,
      "content": "recommended the use of multidisciplinary HF management programmes (HF-MPs), which enable patients to have the correct investigations, an accurate diagnosis, appropriate evidence-based therapy, education, and suitable follow-up. The optimal implementa- tion of a HF-MP requires a multidisciplinary team that is active along the whole HF trajectory; from onset, through critical events, periods of apparent stability, and its terminal stages. 303   Since the 2016 guide- lines, new studies have been published that underscore the need for HF-MPs and reveal more insights into how care can be delivered. A network meta-analysis including 53 randomized trials published in 2017, concluded that both disease-management clinics and home visits by nurses reduced all-cause mortality compared to usual care; home visits being most effective. 308   An IPD meta-analysis of 20 stud- ies, including 5624 patients, concluded that self-management interven- tions in HF patients improve outcomes despite heterogeneity in the intensity, content, and the personnel who deliver the interventions. 309\nHF-MPs vary in their components and can apply different service models, such as clinic-based approaches (in primary, secondary, or tertiary care), home-based programmes, case management, or hybrids of these. Components used in the services vary, e.g. some HF-MPs use telemonitoring that may be applied at a local, regional, or national level. No service model has been shown to be consis- tently superior to others. 310   While home visits and HF clinics do reduce all-cause admissions and mortality, educational programmes, used alone, do not. 308 , 309   HF-MPs should be patient-centred and take a holistic approach to the patient rather than focussing solely on HF; management of comorbid conditions, such as arrhythmias, hyperten- sion, diabetes, renal dysfunction, and depression, improve patient well-being and self-management, leading to better outcomes. 309 , 311\nThe organization of a HF-MP should be adapted to the healthcare\nsystem, available resources (infrastructure, facilities, staff, and finan- ces), administrative policies, and tailored to the patient’s needs. Many patients with HF would derive benefit from the early integra- tion of a palliative and supportive approach within the care provided by all members of the HF multidisciplinary team. 312 , 313   Palliative and supportive care should be thought about for all patients with HF, regardless of stage of their illness. Patients in the advanced stages and those considered for mechanical circulatory support (MCS) or heart transplantation should receive a palliative care consultation before such interventions as a matter of protocol (see  section 10.2.4 ).\n9.2.2 Characteristics and components of a heart failure management programme Clinical trials have included complex, bundled interventions, making it difficult to determine the efficiency and effectiveness of each spe- cific component.  Table  11  presents an overview of characteristics and components that are important to consider in a HF-MP.\n",
      "keywords": [
        "chronic",
        "guidelines",
        "diabetes",
        "failure",
        "care",
        "heart failure",
        "heart",
        "hospitalizations",
        "management",
        "recommended",
        "order",
        "earlier",
        "mortality",
        "multidisciplinary",
        "reduce",
        "models"
      ],
      "tables": []
    },
    {
      "number": "48",
      "title": "9.3 Patient education, self-care and lifestyle advice Adequate patient self-care is essential in the effective management of HF and allows patients to understand what is beneficial, and to agree to se",
      "start_page": 34,
      "end_page": 35,
      "content": "Misunderstandings, misconceptions, and lack of knowledge all con- tribute to insufficient self-care and therefore patient education is vital. Improving patients’ knowledge of their condition is fundamental for the development of self-care skills. 304\nEducation to improve self-care should be tailored to the individual patient and based on, where available, scientific evidence or expert opinion. There is little evidence that specific lifestyle advice improves\nMultidisciplinary interventions recommended for the management of chronic heart failure\nRecommendations Class a Level b\nIt is recommended that HF patients are enrolled\nin a multidisciplinary HF management pro- gramme to reduce the risk of HF hospitalization\nand mortality. 309 , 314 , 315 , 316\nI A\nSelf-management strategies are recommended to reduce the risk of HF hospitalization and\nmortality. 309\nI A\nEither home-based and/or clinic-based pro-\ngrammes improve outcomes and are recom- mended to reduce the risk of HF hospitalization\nand mortality. 310 , 317\nI A\nInﬂuenza and pneumococcal vaccinations should be considered in order to prevent HF\nhospitalizations. 315 , 316\nIIa B\nHF = heart failure. a Class of recommendation. b Level of evidence.\nESC 2021\n. .....................................................................................................................\nESC Guidelines 3633\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 11 Important characteristics and components in a heart failure management programme\nCharacteristics\n",
      "keywords": [
        "lifestyle",
        "care",
        "advice",
        "heart failure",
        "recommended",
        "adequate",
        "what",
        "level b",
        "patient",
        "effective",
        "agree",
        "should be considered",
        "education",
        "management",
        "allows",
        "essential",
        "patients",
        "beneficial",
        "self",
        "understand"
      ],
      "tables": [
        {
          "title": "3634 ESC Guidelines",
          "page_number": 35,
          "content": "Characteristics\n1. Patient/person-centred318\n2. Multidisciplinary\n3. The focus of the programme should be flexible and include:\n• prevention of disease progression\n• symptom control\n• maintaining patients in their preferred place of care for end-stage heart failure\n4. Competent and professionally educated staff\n5. Encourage patient/carer engagement in the understanding and management of their condition | ESC 2021\nComponents\n1. Optimized management; lifestyle choices, pharmacological, and devices\n2. Patient education, with special emphasis on self-care and symptom management\n3. Provision of psychosocial support to patients and family caregivers\n4. Follow-up after discharge (clinic; home visits; telephone support or telemonitoring)\n5. Easy access to healthcare, especially to prevent and manage decompensation\n6. Assessment of (and appropriate intervention in response to) an unexplained change in weight, nutritional and functional status, quality of life, sleep\nproblems, psychosocial problems or other findings (e.g., laboratory values)\n7. Access to advanced treatment options; supportive and palliative care | ",
          "bbox": [
            43.48064305705409,
            81.70927429199219,
            553.0789794921875,
            312.25962829589844
          ],
          "function_potential": "raw"
        },
        {
          "title": "3634 ESC Guidelines",
          "page_number": 35,
          "content": "Education topic | Goal for the patient and caregiver | Professional behaviour and educational tools\nExplanation about HF | To understand the cause of their HF, symptoms and treat-\nment choice. | Provide tailored information.\nThe HF trajectory | To understand prognosis and the different possible phases\nin the HF trajectory.\nTo make joint treatment decisions that recognise the\npatient’s position on the HF trajectory. | Sensitively communicate information on prognosis at time of diag-\nnosis, during decision making about treatment options, when\nthere is a change in the clinical condition and whenever the\npatient requests.\nMedical treatment |  | \nMedication | To be able to make joint decisions about medication.\nTo understand the indications, benefits, the need for long-\nterm adherence to certain drugs, and the dosing and\nside effects of medication.\nTo be able to recognize the common side effects of medi-\ncation and know what actions to take. | Provide written and oral information on indication, benefits, dos-\ning, effects and side effects.\nDiscuss practical issues such as optimal time-schedule, what to do\nin case of a missed dose etc.\nDiscuss possible barriers for medication taking.\nAdvise on support aids such as dosette box, electronic reminders\netc. when appropriate.320\nImplanted devices | To be able to make joint decisions on device implantation.\nTo understand the indications, importance, expectations\nand check-up routine for implanted devices, and any\nexception management.\nTo be able to recognize the common complications\n(including the risk of inappropriate defibrillator shocks),\nand know what actions to take. | Provide written and oral information about the importance and\nexpectations of implanted devices, and possible ways of follow-\nup (remote monitoring).\nDiscuss expectations and any possible impact on driving.\nClearly identify situations where the device might be deactivated\nor explanted.\nInvolve patient and caregiver in decision making.\nSelf-care aspects |  | \nActivity and exercise | To undertake regular exercise and be physically active.\nTo be able to adapt physical activity to symptom status\nand personal circumstances. | Advise on exercise that recognizes physical and functional limita-\ntions, such as frailty, comorbidities.\nRefer to exercise programme or other activity modes.\nDiscuss possible barriers, side-effects and opportunities.\nSleep and breathing | To recognize the importance of sleep and rest for (CV)\nhealth.\nTo be able to recognize problems with sleeping and how\nto optimize sleep. | Review sleep history.\nAdvise and discuss the importance of good sleep and provide\nadvice on ‘sleep health’ (including timing of diuretics).",
          "bbox": [
            43.48064305705409,
            350.8719787597656,
            547.73537336077,
            731.0269636674361
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "49",
      "title": "1. Patient/person-centred 318",
      "start_page": 35,
      "end_page": 35,
      "content": "",
      "keywords": [
        "patient",
        "centred",
        "person"
      ],
      "tables": []
    },
    {
      "number": "50",
      "title": "2. Multidisciplinary",
      "start_page": 35,
      "end_page": 35,
      "content": "",
      "keywords": [
        "multidisciplinary"
      ],
      "tables": []
    },
    {
      "number": "51",
      "title": "3. The focus of the programme should be ﬂexible and include: •   prevention of disease progression •   symptom control •   maintaining patients in their preferred place of care for end-stage heart fai",
      "start_page": 35,
      "end_page": 35,
      "content": "",
      "keywords": [
        "progression",
        "programme",
        "disease",
        "symptom",
        "prevention",
        "care",
        "should",
        "patients",
        "include",
        "control",
        "heart",
        "their",
        "stage",
        "maintaining",
        "preferred",
        "place",
        "focus"
      ],
      "tables": []
    },
    {
      "number": "52",
      "title": "4. Competent and professionally educated staff 5. Encourage patient/carer engagement in the understanding and management of their condition",
      "start_page": 35,
      "end_page": 35,
      "content": "Components\n",
      "keywords": [
        "patient",
        "educated",
        "carer",
        "professionally",
        "condition",
        "understanding",
        "engagement",
        "competent",
        "encourage",
        "management",
        "their",
        "staff"
      ],
      "tables": []
    },
    {
      "number": "53",
      "title": "1. Optimized management; lifestyle choices, pharmacological, and devices",
      "start_page": 35,
      "end_page": 35,
      "content": "",
      "keywords": [
        "pharmacological",
        "choices",
        "optimized",
        "lifestyle",
        "management",
        "devices"
      ],
      "tables": []
    },
    {
      "number": "54",
      "title": "2. Patient education, with special emphasis on self-care and symptom management 3. Provision of psychosocial support to patients and family caregivers",
      "start_page": 35,
      "end_page": 35,
      "content": "",
      "keywords": [
        "patient",
        "support",
        "psychosocial",
        "self",
        "emphasis",
        "symptom",
        "special",
        "care",
        "family",
        "patients",
        "management",
        "education",
        "caregivers",
        "provision"
      ],
      "tables": []
    },
    {
      "number": "55",
      "title": "4. Follow-up after discharge (clinic; home visits; telephone support or telemonitoring)",
      "start_page": 35,
      "end_page": 35,
      "content": "",
      "keywords": [
        "clinic",
        "support",
        "after",
        "telemonitoring",
        "home",
        "follow",
        "discharge",
        "telephone",
        "visits"
      ],
      "tables": []
    },
    {
      "number": "56",
      "title": "5. Easy access to healthcare, especially to prevent and manage decompensation 6. Assessment of (and appropriate intervention in response to) an unexplained change in weight, nutritional and functional",
      "start_page": 35,
      "end_page": 35,
      "content": "problems, psychosocial problems or other ﬁndings (e.g., laboratory values)\n",
      "keywords": [
        "access",
        "nutritional",
        "change",
        "decompensation",
        "unexplained",
        "weight",
        "manage",
        "intervention",
        "appropriate",
        "assessment",
        "functional",
        "response",
        "easy",
        "especially",
        "prevent",
        "healthcare"
      ],
      "tables": []
    },
    {
      "number": "57",
      "title": "7. Access to advanced treatment options; supportive and palliative care",
      "start_page": 35,
      "end_page": 37,
      "content": "Table 12 Patient education and self-care\nEducation topic Goal for the patient and caregiver Professional behaviour and educational tools\nExplanation about HF To understand the cause of their HF, symptoms and treat- ment choice. Provide tailored information.\nThe HF trajectory To understand prognosis and the different possible phases\nin the HF trajectory. To make joint treatment decisions that recognise the\npatient’s position on the HF trajectory.\nSensitively communicate information on prognosis at time of diag-\nnosis, during decision making about treatment options, when there is a change in the clinical condition and whenever the\npatient requests.\nMedical treatment\nMedication To be able to make joint decisions about medication. To understand the indications, beneﬁts, the need for long-\nterm adherence to certain drugs, and the dosing and\nside effects of medication. To be able to recognize the common side effects of medi-\ncation and know what actions to take.\nProvide written and oral information on indication, beneﬁts, dos- ing, effects and side effects.\nDiscuss practical issues such as optimal time-schedule, what to do\nin case of a missed dose etc. Discuss possible barriers for medication taking.\nAdvise on support aids such as dosette box, electronic reminders\netc. when appropriate. 320\nImplanted devices To be able to make joint decisions on device implantation. To understand the indications, importance, expectations\nand check-up routine for implanted devices, and any\nexception management. To be able to recognize the common complications\n(including the risk of inappropriate deﬁbrillator shocks),\nand know what actions to take.\nProvide written and oral information about the importance and expectations of implanted devices, and possible ways of follow-\nup (remote monitoring).\nDiscuss expectations and any possible impact on driving. Clearly identify situations where the device might be deactivated\nor explanted.\nInvolve patient and caregiver in decision making.\nSelf-care aspects\nActivity and exercise To undertake regular exercise and be physically active.\nTo be able to adapt physical activity to symptom status\nand personal circumstances.\nAdvise on exercise that recognizes physical and functional limita-\ntions, such as frailty, comorbidities.\nRefer to exercise programme or other activity modes. Discuss possible barriers, side-effects and opportunities.\nSleep and breathing To recognize the importance of sleep and rest for (CV)\nhealth. To be able to recognize problems with sleeping and how\nto optimize sleep.\nReview sleep history.\nAdvise and discuss the importance of good sleep and provide advice on ‘sleep health’ (including timing of diuretics).\nContinued\nESC 2021\n3634 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 12 Continued\nEducation topic Goal for the patient and caregiver Professional behaviour and educational tools\nConsider and carefully discuss the beneﬁts and deleterious effects of sleep medication.\nFluids To avoid large volumes of ﬂuid intake. A ﬂuid restriction\nof 1.5 \u0002 2 L/day may be considered in patients with severe HF/hyponatraemia to relieve symptoms and\ncongestion.\nTo avoid dehydration: where ﬂuids are restricted, increase intake during periods of high heat/humidity and/or nau-\nsea/vomiting.\nProvide information and discuss the advantages and disadvantages\nof ﬂuid restriction. Advise to adapt ﬂuid intake to weight, and in times of high heat\nand humidity, nausea/vomiting.\nAdjust advice during periods of acute decompensation and con- sider altering this advice towards end-of-life.\nHealthy diet To be able to prevent malnutrition and know how to eat\nhealthily, avoiding excessive salt intake (>5 g/day) and maintaining a healthy body weight.\nDiscuss current food intake, role of salt, role of micronutrients.\nDiscuss the need for supplementing in case of nutrient deﬁcien- cies but there is no clear role for routine micronutrient\nsupplementation. 321\nDiscuss maintaining a healthy body weight.\nAlcohol To be able to abstain from or avoid excessive alcohol\nintake, especially for alcohol-induced CMP.\nTo restrict alcohol according to CV prevention guidelines.\nTailor alcohol advice to aetiology of HF; e.g. abstinence in alco-\nholic CMP.\nInform and discuss alcohol intake according to CV prevention guidelines (2 units per day in men or 1 unit per day in women) a .\nImmunization To be aware of the need for immunization for inﬂuenza\nand pneumococcal disease.\nDiscuss beneﬁts and possible barriers.\nAdvise on local immunization practice.\nSmoking and recrea- tional drugs To be aware of the consequences for health of smoking and use of recreational drugs.\nStop smoking (including e-cigarettes) and taking recrea-\ntional drugs.\nInform, discuss and help in decision making. Refer for specialist advice for smoking cessation and drug with-\ndrawal and replacement therapy.\nConsider referral for cognitive behavioural theory and psychological support if patient wishes to stop smoking or\ntaking drugs.\nTravel, leisure, driving To be able to prepare travel and leisure activities accord-\ning to physical capacity. To be able to take an informed decision about driving.\nInform and discuss practical issues related to long haul travel, stay-\ning abroad, exposure to sun (amiodarone effects), high humidity or heat (dehydration), and high altitude (oxygenation).\nProvide practical advice related to travel with medication/devices\n(keep medicines in hand luggage, have a list with medication, device name/card and treating centres).\nInform about local/national/international regulation related to\ndriving.\nSexual activity To be able to resume or adapt sexual activity according to\nphysical capacity.\nTo recognize possible problems with sexual activity and their relationship with HF or its treatment.\nInform and discuss that sexual activity is safe for stable HF\npatients.\nProvide advice on eliminating factors predisposing to sexual problems.\nDiscuss and provide available pharmacological treatment for sex-\nual problems. Refer to specialist for sexual counselling when necessary.\nSymptom monitoring\nand symptom self-\nmanagement\nMonitor and recognize change in signs and symptoms.\nBeing able to react adequately to change in signs and\nsymptoms. Know how and when to contact a healthcare professional.\nProvide individualized information to support self-management\nsuch as:\nIn the case of increasing dyspnoea or oedema or a sudden unex- pected weight gain of >2 kg in 3 days, patients may increase\ntheir diuretic dose and/or alert their healthcare team.\nLiving with HF\nPsychological issues To be able to live a good life with HF. To be able to seek help in case of psychological problems\nsuch as depressive symptoms, anxiety or low mood\nwhich may occur in the course of the HF trajectory.\nRegularly communicate information on disease, treatment options and self-care.\nRegularly discuss the need for support.\nTreat or referral to specialist for psychological support when necessary.\nContinued\nESC Guidelines 3635\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ......................................................................................................................................... QOL or prognosis; however, providing this information has become a key component of education for self-care. General educational approaches include:\n•   Providing information in a variety of formats that take into account educational grade and health literacy. Consider approaches with active roles for patients and caregivers such as ‘ask-tell-ask’, ‘teach back’, or motivational interviewing. Reinforce messages at regular time intervals. •   Recognizing barriers to communication (language, social skills, cognition, anxiety/depression, hearing or visual challenges). •   Recommending ‘HFmatters.org’. Offer help and guidance to use it and offer discussion of questions arising. •   Inviting patients to be accompanied by a family member or friend.\nKey topics to include are recommended in  Table  12 .\n",
      "keywords": [
        "access",
        "treatment",
        "diet",
        "weight",
        "palliative",
        "advanced",
        "options",
        "alcohol",
        "supportive",
        "may be considered",
        "diuretic",
        "care",
        "recommended",
        "smoking",
        "indication",
        "sex",
        "physical activity",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3635",
          "page_number": 36,
          "content": "Education topic | Goal for the patient and caregiver | Professional behaviour and educational tools\n |  | Consider and carefully discuss the benefits and deleterious effects\nof sleep medication.\nFluids | To avoid large volumes of fluid intake. A fluid restriction\nof 1.5\u00022 L/day may be considered in patients with\nsevere HF/hyponatraemia to relieve symptoms and\ncongestion.\nTo avoid dehydration: where fluids are restricted, increase\nintake during periods of high heat/humidity and/or nau-\nsea/vomiting. | Provide information and discuss the advantages and disadvantages\nof fluid restriction.\nAdvise to adapt fluid intake to weight, and in times of high heat\nand humidity, nausea/vomiting.\nAdjust advice during periods of acute decompensation and con-\nsider altering this advice towards end-of-life.\nHealthy diet | To be able to prevent malnutrition and know how to eat\nhealthily, avoiding excessive salt intake (>5 g/day) and\nmaintaining a healthy body weight. | Discuss current food intake, role of salt, role of micronutrients.\nDiscuss the need for supplementing in case of nutrient deficien-\ncies but there is no clear role for routine micronutrient\nsupplementation.321\nDiscuss maintaining a healthy body weight.\nAlcohol | To be able to abstain from or avoid excessive alcohol\nintake, especially for alcohol-induced CMP.\nTo restrict alcohol according to CV prevention guidelines. | Tailor alcohol advice to aetiology of HF; e.g. abstinence in alco-\nholic CMP.\nInform and discuss alcohol intake according to CV prevention\nguidelines (2 units per day in men or 1 unit per day in women)a.\nImmunization | To be aware of the need for immunization for influenza\nand pneumococcal disease. | Discuss benefits and possible barriers.\nAdvise on local immunization practice.\nSmoking and recrea-\ntional drugs | To be aware of the consequences for health of smoking\nand use of recreational drugs.\nStop smoking (including e-cigarettes) and taking recrea-\ntional drugs. | Inform, discuss and help in decision making.\nRefer for specialist advice for smoking cessation and drug with-\ndrawal and replacement therapy.\nConsider referral for cognitive behavioural theory and\npsychological support if patient wishes to stop smoking or\ntaking drugs.\nTravel, leisure, driving | To be able to prepare travel and leisure activities accord-\ning to physical capacity.\nTo be able to take an informed decision about driving. | Inform and discuss practical issues related to long haul travel, stay-\ning abroad, exposure to sun (amiodarone effects), high humidity\nor heat (dehydration), and high altitude (oxygenation).\nProvide practical advice related to travel with medication/devices\n(keep medicines in hand luggage, have a list with medication,\ndevice name/card and treating centres).\nInform about local/national/international regulation related to\ndriving.\nSexual activity | To be able to resume or adapt sexual activity according to\nphysical capacity.\nTo recognize possible problems with sexual activity and\ntheir relationship with HF or its treatment. | Inform and discuss that sexual activity is safe for stable HF\npatients.\nProvide advice on eliminating factors predisposing to sexual\nproblems.\nDiscuss and provide available pharmacological treatment for sex-\nual problems.\nRefer to specialist for sexual counselling when necessary.\nSymptom monitoring\nand symptom self-\nmanagement | Monitor and recognize change in signs and symptoms.\nBeing able to react adequately to change in signs and\nsymptoms.\nKnow how and when to contact a healthcare professional. | Provide individualized information to support self-management\nsuch as:\nIn the case of increasing dyspnoea or oedema or a sudden unex-\npected weight gain of >2 kg in 3 days, patients may increase\ntheir diuretic dose and/or alert their healthcare team.\nLiving with HF |  | \nPsychological issues | To be able to live a good life with HF.\nTo be able to seek help in case of psychological problems\nsuch as depressive symptoms, anxiety or low mood\nwhich may occur in the course of the HF trajectory. | Regularly communicate information on disease, treatment options\nand self-care.\nRegularly discuss the need for support.\nTreat or referral to specialist for psychological support when\nnecessary.",
          "bbox": [
            48.0499147268442,
            71.3199462890625,
            552.3351794433594,
            718.4409651322799
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3636 ESC Guidelines",
          "page_number": 37,
          "content": "Education topic | Goal for the patient and caregiver | Professional behaviour and educational tools | ESC 2021\n | To recognise that the carer or family members may be\ngreatly affected and need to seek help. |  | \nFamily and informal\ncaregivers | To be able to ask for support. | Discuss the preference of caregiver/family involvement.\nInvolve patients and caregivers in a respectful way. | ",
          "bbox": [
            42.963904153733026,
            71.3199462890625,
            553.0789794921875,
            143.63193581321022
          ],
          "function_potential": "raw"
        },
        {
          "title": "3636 ESC Guidelines",
          "page_number": 37,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nExercise is recommended for all patients who are\nable in order to improve exercise capacity, QOL,\nand reduce HF hospitalization.c 324\u0002328,335\u0002337 | I | A | \nA supervised, exercise-based, cardiac rehabilita-\ntion programme should be considered in\npatients with more severe disease, frailty, or\nwith comorbidities.95,324\u0002327,338 | IIa | C | ESC 2021",
          "bbox": [
            42.963904153733026,
            569.0840901692708,
            287.76658412388394,
            678.4341626848493
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "58",
      "title": "9.4 Exercise rehabilitation There is consistent evidence that physical conditioning by exercise training improves exercise tolerance, and health-related QOL in patients with HF. Clinical trials and me",
      "start_page": 37,
      "end_page": 37,
      "content": "exercise-based rehabilitation should be considered in those who are frail, who have more severe disease or comorbidities. 95\nPhysical conditioning also improves exercise capacity and QOL. 332 \u0002 335   No data on HFmrEF are available, but benefits observed in the other groups of HF should also apply to this group.\n",
      "keywords": [
        "tolerance",
        "there",
        "conditioning",
        "physical",
        "clinical",
        "hfmref",
        "improves",
        "health",
        "patients",
        "should be considered",
        "related",
        "training",
        "trials",
        "rehabilitation",
        "consistent",
        "evidence",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "59",
      "title": "9.5 Follow-up of chronic heart failure 9.5.1 General follow-up This is a relatively understudied area. Patients with HF, even if symp- toms are well controlled and stable, require follow-up to ensure ",
      "start_page": 37,
      "end_page": 37,
      "content": "and several studies suggest that care and follow-up provided by HF specialists, and use of quality improvement registries can lead to higher rates of optimal therapy and improved outcomes. 341 \u0002 343\nAn ECG should be done annually to detect QRS prolongation 344\nas such patients may become candidates for CRT. Furthermore, it may identify conduction disturbances and AF. Serial echocardiography is generally not necessary, although an echocardiogram should be repeated if there has been a deterioration in clinical status. An echocardiogram is also advised 3 \u0002 6 months after optimization of standard therapies for HFrEF to determine the need for addition of newer pharmacological agents and implanted devices.\n9.5.2 Monitoring with biomarkers Trials investigating the use of biomarkers (particularly BNP and/or NT-proBNP) to guide pharmacotherapy for HFrEF have produced conflicting results. 345 \u0002 352   They are undoubtedly good prognostic markers. 72 , 353 , 354   Conceptually, it is not clear what a biomarker- supported strategy might offer in addition to assiduous application of guideline-recommended therapy. Current evidence, therefore, does not support the routine measurement of BNP or NT-proBNP to guide titration of therapy.\n",
      "keywords": [
        "even",
        "recommended",
        "ecg",
        "hfref",
        "well",
        "area",
        "symp",
        "failure",
        "echocardiography",
        "bnp",
        "crt",
        "heart",
        "toms",
        "general",
        "patients",
        "understudied",
        "nt-probnp",
        "relatively",
        "controlled",
        "guideline",
        "chronic",
        "biomarker",
        "ensure",
        "follow",
        "require",
        "stable"
      ],
      "tables": []
    },
    {
      "number": "60",
      "title": "9.6 Telemonitoring Telemonitoring enables patients to provide, remotely, digital health information to support and optimize their care. Data such as",
      "start_page": 37,
      "end_page": 38,
      "content": "Table 12 Continued\nEducation topic Goal for the patient and caregiver Professional behaviour and educational tools\nTo recognise that the carer or family members may be greatly affected and need to seek help.\nFamily and informal\ncaregivers\nTo be able to ask for support. Discuss the preference of caregiver/family involvement.\nInvolve patients and caregivers in a respectful way.\nCMP = cardiomyopathy; CV = cardiovascular; HF = heart failure. a 1 unit is 10 mL of pure alcohol (e.g., 1 glass of wine,  1 = 2  pint of beer, 1 measure of spirit).\nRecommendations for exercise rehabilitation in patients with chronic heart failure\nRecommendations Class a Level b\nExercise is recommended for all patients who are\nable in order to improve exercise capacity, QOL,\nand reduce HF hospitalization. c  324 \u0002 328 , 335 \u0002 337\nI A\nA supervised, exercise-based, cardiac rehabilita-\ntion programme should be considered in\npatients with more severe disease, frailty, or with comorbidities. 95 , 324 \u0002 327 , 338\nIIa C\nHF = heart failure; QOL = quality of life. a Class of recommendation. b Level of evidence. c In those who are able to adhere to the exercise programme.\nESC 2021\nESC 2021\n3636 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................ symptoms, weight, heart rate, and BP, can be collected frequently, stored in an electronic health record and used to guide patients (directly or through a healthcare professional), to adjust therapy or to seek further advice. Home telemonitoring (HTM) can help main- tain quality of care, facilitate rapid access to care when needed, reduce patient travel costs, and minimize the frequency of clinic vis- its. 355   Enforced cessation of face-to-face consultations in many coun- tries during the recent COVID-19 pandemic have highlighted some of the potential advantages of HTM. 356\nTrials of HTM are diverse. Patients are usually required to make measurements and, as for many other aspects of HF management, adherence may be incomplete. HTM may be provided as a local, regional, or national service. Systems that focus on optimizing management rather than detecting and managing medical emer- gencies need only to be staffed during standard working hours. Some systems are designed also to offer support at any time requested by the patient. The comparative effectiveness and cost effectiveness of each strategy is uncertain. Systems that focus on continuous optimization of care (a health maintenance approach) rather than trying to anticipate and manage episodes of worsening (a strategy that is plagued by a large number of false-positive alerts), appear more successful. 357   HTM is an efficient method for providing patient education and motivation and aiding delivery of care, but it should be adapted to work in synergy with existing healthcare provision. 358\nA Cochrane systematic review conducted in 2017 identified 39 relevant trials of HTM, largely based on assessments of symptoms, weight, heart rate and rhythm, and BP and found that HTM was asso- ciated with a reduction in all-cause mortality of 20% and HF hospital- ization of 37%. 359   Since then, several neutral trials and at least one positive trial have been published. 357 , 360 \u0002 364   These are unlikely to change the positive results of the systematic review. Importantly, if social distancing and the ‘green’ agenda are important, HTM only needs to show that it is not inferior to contemporary methods of delivering care to be an appropriate means of supporting care. 356\nWhether wearable technologies for monitoring heart rate and rhythm or lung congestion (bio-impedance or lung radar) offer addi- tional benefits to conventional HTM described above is uncertain. 365 \u0002 367\nMany implanted therapeutic devices can provide, wirelessly and remotely, information either on the device itself (generator and lead function), arrhythmias, or on patient physiology (heart rate, activity, heart sounds, bio-impedance). There is strong evidence that moni- toring can detect device malfunction earlier than by conventional monitoring and that it may be useful for detecting arrhythmias such as AF. However, there is little evidence that device monitoring reduces admissions for HF or mortality. 368 \u0002 370 , 371\nDevices that only provide a monitoring function are also available. Implantable loop-recorders can be injected subcutaneously and used to monitor heart rate and rhythm, activity, and bio-impedance. Monitoring devices can also be placed in the pulmonary artery to monitor pressure wirelessly, although the external reader required to detect the device signal is rather bulky and requires patient co- operation. A rise in diastolic pulmonary artery pressure may be one of the earliest signs of congestion. A preliminary, but fairly substantial, trial showed a reduction in the risk of recurrent HF hospitalization. 372\nA much larger trial has completed recruitment (GUIDE-HF). 373\nThus, non-invasive HTM may be considered for patients with HF in order to reduce the risk of recurrent CV and HF hospitalizations and CV death; further evidence on management guided by implanted systems is awaited. 374\n",
      "keywords": [
        "data",
        "care",
        "heart failure",
        "recommended",
        "level b",
        "support",
        "telemonitoring",
        "health",
        "provide",
        "should be considered",
        "enables",
        "diastolic",
        "optimize",
        "alcohol",
        "digital",
        "patients",
        "may be considered",
        "weight",
        "information",
        "remotely",
        "their",
        "cardiomyopathy",
        "such",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3637",
          "page_number": 38,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nNon-invasive HTM may be considered for\npatients with HF in order to reduce the risk of\nrecurrent CV and HF hospitalizations and CV\ndeath.374 | IIb | B | \nMonitoring of pulmonary artery pressure using a\nwireless haemodynamic monitoring system may\nbe considered in symptomatic patients with HF\nin order to improve clinical outcomes.372 | IIb | B | ESC 2021",
          "bbox": [
            311.5187518780048,
            146.79535115559895,
            556.6571655273438,
            268.14717538016185
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "61",
      "title": "10 Advanced heart failure",
      "start_page": 38,
      "end_page": 38,
      "content": "",
      "keywords": [
        "advanced",
        "failure",
        "heart"
      ],
      "tables": []
    },
    {
      "number": "62",
      "title": "10.1 Epidemiology, diagnosis, and prognosis Many patients with HF progress into a phase of advanced HF, charac- terized by persistent symptoms despite maximal therapy. 375 \u0002 377   The prevalence of ad",
      "start_page": 38,
      "end_page": 39,
      "content": "The updated HFA-ESC 2018 criteria for the definition of advanced HF are reported in  Table  13 . 376   A severely reduced LVEF is common but not required for a diagnosis of advanced HF as it may develop in patients with HFpEF as well. In addition to the reported criteria, extra-cardiac organ dysfunction due to HF (e.g. cardiac cachexia, liver or kidney dysfunction) or type II pulmonary hypertension may be present, but are not required for the definition of advanced HF. 376\nThe Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles, developed to classify patients with a potential indication for durable MCS devices, describes clinical parameters and characteristics consistent with a need for advanced therapies ( Table  14 ). 381   This classification has also been shown to be useful in estimating the prognosis of patients under- going urgent heart transplantation 382   or LV assist device (LVAD) implantation, 383   and for risk assessment in ambulatory advanced HF patients. 384\nPrognostic stratification is important to identify the ideal time for referral to an appropriate centre (i.e. one capable of providing advanced HF therapies), to properly convey expectations to patients and families, and to plan treatment and follow-up strategies\nRecommendations for telemonitoring\nRecommendations Class a Level b\nNon-invasive HTM may be considered for patients with HF in order to reduce the risk of\nrecurrent CV and HF hospitalizations and CV\ndeath. 374\nIIb B\nMonitoring of pulmonary artery pressure using a\nwireless haemodynamic monitoring system may\nbe considered in symptomatic patients with HF in order to improve clinical outcomes. 372\nIIb B\nCV = cardiovascular; HF = heart failure; HTM = home telemonitoring; LVEF = left ventricular ejection fraction. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................................................................\nESC Guidelines 3637\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 13 Criteria for deﬁnition of advanced heart failure\n",
      "keywords": [
        "therapy",
        "progress",
        "heart failure",
        "pulmonary hypertension",
        "indication",
        "level b",
        "hfpef",
        "advanced",
        "persistent",
        "hypertension",
        "lvef",
        "prognosis",
        "charac",
        "patients",
        "may be considered",
        "into",
        "maximal",
        "ejection fraction",
        "symptoms",
        "despite",
        "phase",
        "terized",
        "many",
        "prevalence",
        "epidemiology",
        "diagnosis"
      ],
      "tables": [
        {
          "title": "3638 ESC Guidelines",
          "page_number": 39,
          "content": "All the following criteria must be present despite optimal medical treatment: | ESC 2021\n1. Severe and persistent symptoms of heart failure [NYHA class III (advanced) or IV]. | \n2. Severe cardiac dysfunction defined by at least one of the following:\n• LVEF < _30%\n• Isolated RV failure (e.g., ARVC)\n• Non-operable severe valve abnormalities\n• Non-operable severe congenital abnormalities\n• Persistently high (or increasing) BNP or NT-proBNP values and severe LV diastolic dysfunction or structural abnormalities (according to the definitions\nof HFpEF). | \n3. Episodes of pulmonary or systemic congestion requiring high-dose i.v. diuretics (or diuretic combinations) or episodes of low output requiring inotropes\nor vasoactive drugs or malignant arrhythmias causing >1 unplanned visit or hospitalization in the last 12 months. | \n4. Severe impairment of exercise capacity with inability to exercise or low 6MWT distance (<300 m) or pVO <12 mL/kg/min or <50% predicted value,\n2\nestimated to be of cardiac origin. | ",
          "bbox": [
            43.50363404410226,
            81.70927429199219,
            554.2129516601562,
            243.83630981445313
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3638 ESC Guidelines",
          "page_number": 39,
          "content": "Profile |  | Time frame for intervention\nProfile 1. Critical cardiogenic shock\nPatient with life-threatening hypotension despite rapidly escalating inotropic support,\ncritical organ hypoperfusion, often confirmed by worsening acidosis and/or lactate lev-\nels. “Crash and burn.” |  | Definitive intervention needed within hours.\nProfile 2. Progressive decline\nPatient with declining function despite i.v. inotropic support, may be manifest by wor-\nsening renal function, nutritional depletion, inability to restore volume balance. “Sliding\non inotropes.” Also describes declining status in patients unable to tolerate inotropic\ntherapy. |  | Definitive intervention needed within few days.\nProfile 3. Stable on inotrope or inotrope-dependent\nPatient with stable blood pressure, organ function, nutrition, and symptoms on continu-\nous i.v. inotropic support (or a temporary circulatory support device or both) but dem-\nonstrating repeated failure to wean from support due to recurrent symptomatic\nhypotension or renal dysfunction. “Dependent stability.” |  | Definitive intervention elective over a period of weeks to\nfew months.\nProfile 4. Frequent Flyer\nPatient can be stabilized close to normal volume status but experiences daily symptoms\nof congestion at rest or during activities of daily living. Doses of diuretics generally fluc-\ntuate at very high levels. More intensive management and surveillance strategies should\nbe considered, which may in some cases reveal poor compliance that would compro-\nmise outcomes with any therapy. Some patients may shuttle between 4 and 5. |  | Definitive intervention elective over a period of weeks to\nfew months.\nProfile 5. Housebound\nComfortable at rest and with activities of daily living but unable to engage in any other\nactivity, living predominantly within the house. Patients are comfortable at rest without\ncongestive symptoms, but may have underlying refractory elevated volume status, often\nwith renal dysfunction. If underlying nutritional status and organ function are marginal,\npatients may be more at risk than INTERMACS 4, and require definitive intervention. |  | Variable urgency, depends upon maintenance of nutrition,\norgan function, and activity.\nProfile 6. Exertion limited\nPatient without evidence of fluid overload, comfortable at rest and with activities of\ndaily living and minor activities outside the home but fatigues after the first few minutes\nof any meaningful activity. Attribution to cardiac limitation requires careful measure-\nment of peak oxygen consumption, in some cases with haemodynamic monitoring, to\nconfirm severity of cardiac impairment. “Walking wounded.” |  | Variable, depends upon maintenance of nutrition, organ\nfunction, and activity level.",
          "bbox": [
            43.50363404410226,
            326.89208984375,
            547.5462454336661,
            728.5849173409598
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "63",
      "title": "All the following criteria must be present despite optimal medical treatment:",
      "start_page": 39,
      "end_page": 39,
      "content": "",
      "keywords": [
        "medical",
        "treatment",
        "optimal",
        "criteria",
        "present",
        "must",
        "following",
        "despite"
      ],
      "tables": []
    },
    {
      "number": "64",
      "title": "1. Severe and persistent symptoms of heart failure [NYHA class III (advanced) or IV].",
      "start_page": 39,
      "end_page": 39,
      "content": "",
      "keywords": [
        "advanced",
        "persistent",
        "failure",
        "severe",
        "heart",
        "nyha",
        "class",
        "symptoms"
      ],
      "tables": []
    },
    {
      "number": "65",
      "title": "2. Severe cardiac dysfunction deﬁned by at least one of the following: •   LVEF <_30% •   Isolated RV failure (e.g., ARVC) •   Non-operable severe valve abnormalities •   Non-operable severe congenita",
      "start_page": 39,
      "end_page": 39,
      "content": "of HFpEF).\n",
      "keywords": [
        "congenita",
        "hfpef",
        "isolated",
        "failure",
        "operable",
        "lvef",
        "severe",
        "arvc",
        "least",
        "cardiac",
        "following",
        "dysfunction",
        "valve",
        "abnormalities"
      ],
      "tables": []
    },
    {
      "number": "66",
      "title": "3. Episodes of pulmonary or systemic congestion requiring high-dose i.v. diuretics (or diuretic combinations) or episodes of low output requiring inotropes or vasoactive drugs or malignant arrhythmias",
      "start_page": 39,
      "end_page": 39,
      "content": "",
      "keywords": [
        "arrhythmias",
        "output",
        "combinations",
        "systemic",
        "malignant",
        "diuretic",
        "requiring",
        "inotropes",
        "vasoactive",
        "episodes",
        "congestion",
        "dose",
        "high",
        "diuretics",
        "pulmonary",
        "drugs"
      ],
      "tables": []
    },
    {
      "number": "67",
      "title": "4. Severe impairment of exercise capacity with inability to exercise or low 6MWT distance (<300 m) or pVO 2  <12 mL/kg/min or <50% predicted value,",
      "start_page": 39,
      "end_page": 40,
      "content": "estimated to be of cardiac origin.\n6MWT = 6-minute walk test; ARVC = arrhythmogenic right ventricular cardiomyopathy; BNP = B-type natriuretic peptide; HFpEF = heart failure with preserved ejection fraction; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; pVO 2  = peak oxygen consumption; RV = right ventricular. Modiﬁed from   376 .\nESC 2021\nTable 14 Interagency Registry for Mechanically Assisted Circulatory Support proﬁle descriptions of patients with advanced heart failure\nProfile Time frame for intervention\nProﬁle 1. Critical cardiogenic shock\nPatient with life-threatening hypotension despite rapidly escalating inotropic support, critical organ hypoperfusion, often conﬁrmed by worsening acidosis and/or lactate lev-\nels. “Crash and burn.”\nDeﬁnitive intervention needed within hours.\nProﬁle 2. Progressive decline Patient with declining function despite i.v. inotropic support, may be manifest by wor-\nsening renal function, nutritional depletion, inability to restore volume balance. “Sliding\non inotropes.” Also describes declining status in patients unable to tolerate inotropic therapy.\nDeﬁnitive intervention needed within few days.\nProﬁle 3. Stable on inotrope or inotrope-dependent\nPatient with stable blood pressure, organ function, nutrition, and symptoms on continu-\nous i.v. inotropic support (or a temporary circulatory support device or both) but dem- onstrating repeated failure to wean from support due to recurrent symptomatic\nhypotension or renal dysfunction. “Dependent stability.”\nDeﬁnitive intervention elective over a period of weeks to\nfew months.\nProﬁle 4. Frequent Flyer Patient can be stabilized close to normal volume status but experiences daily symptoms\nof congestion at rest or during activities of daily living. Doses of diuretics generally ﬂuc-\ntuate at very high levels. More intensive management and surveillance strategies should be considered, which may in some cases reveal poor compliance that would compro-\nmise outcomes with any therapy. Some patients may shuttle between 4 and 5.\nDeﬁnitive intervention elective over a period of weeks to\nfew months.\nProﬁle 5. Housebound\nComfortable at rest and with activities of daily living but unable to engage in any other activity, living predominantly within the house. Patients are comfortable at rest without\ncongestive symptoms, but may have underlying refractory elevated volume status, often\nwith renal dysfunction. If underlying nutritional status and organ function are marginal, patients may be more at risk than INTERMACS 4, and require deﬁnitive intervention.\nVariable urgency, depends upon maintenance of nutrition, organ function, and activity.\nProﬁle 6. Exertion limited\nPatient without evidence of ﬂuid overload, comfortable at rest and with activities of daily living and minor activities outside the home but fatigues after the ﬁrst few minutes\nof any meaningful activity. Attribution to cardiac limitation requires careful measure-\nment of peak oxygen consumption, in some cases with haemodynamic monitoring, to conﬁrm severity of cardiac impairment. “Walking wounded.”\nVariable, depends upon maintenance of nutrition, organ function, and activity level.\nContinued\n3638 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................... ( Figure  4 ). 376   Patients with contraindications to MCS or heart trans- plantation should be considered for palliative care (see  section 10.2.4 ). Despite many prognostic parameters  ( Supplementary Table 13 ) , predicting outcomes remains difficult and patients are often referred to advanced HF centres too late. Identifying warning signs in patients with non-advanced symptoms may allow early referral so that MCS and heart transplantation may be offered before the development of end-organ failure ( Figure  5 ;  Supplementary Table 14 ) . 376 , 386   An organi- zational model between centres with different levels of care com- plexity, based on a ‘Hub and Spoke’ network is the key to good patient management. 376\n",
      "keywords": [
        "distance",
        "hfpef",
        "ejection fraction",
        "blood pressure",
        "impairment",
        "lvef",
        "heart failure",
        "bnp",
        "severe",
        "inability",
        "nt-probnp",
        "should be considered",
        "nyha",
        "capacity",
        "predicted",
        "cardiomyopathy",
        "value",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3639",
          "page_number": 40,
          "content": "Profile |  | Time frame for intervention | ESC 2021\nProfile 7. Advanced NYHA class III symptoms\nPatient without current or recent episodes of unstable fluid balance, living comfortably\nwith meaningful activity limited to mild physical exertion. |  | Heart transplantation or MCS may not be currently\nindicated. | \nModifiers for profiles |  | Possible profiles that can be modified | \nTemporary MCS can modify profile only in hospitalized patients. They include IABP,\nECMO, TandemHeart, LVAD, Impella. |  | 1, 2, 3 | \nArrhythmia can modify any profile. They include recurrent ventricular tachyarrhythmias\nthat have recently contributed substantially to clinical compromise, frequent ICD shocks\nor requirement for external defibrillation, usually more than twice weekly. |  | 1\u00027 | \nFrequent episodes of HF decompensation characterize patients requiring frequent\nemergency visits or hospitalizations for diuretics, ultrafiltration, or temporary i.v. vaso-\nactive therapy. Frequent episodes may be considered as at least two emergency visits/\nadmissions in the past 3 months or three in the past 6 months. |  | 3 if at home, 4, 5, 6. Rarely for profile 7. | ",
          "bbox": [
            48.02293038368225,
            71.3199462890625,
            557.6139526367188,
            243.3099136352539
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "68",
      "title": "10.2 Management In patients with advanced HF, pharmacological therapy and short- term MCS may be needed until the implantation of long-term MCS or heart transplantation becomes available.",
      "start_page": 40,
      "end_page": 45,
      "content": "10.2.1 Pharmacological therapy and renal replacement Inotropes may improve haemodynamic parameters, reducing con- gestion, augmenting cardiac output, and aiding peripheral perfusion. Although not proven, this may help to prevent worsening end-organ function. Conversely, traditional inotropes may favor myocardial ischaemia and/or tachyarrhythmias and worsen the clinical course. 387 , 388   They can be used as palliative therapy for the relief of symptoms in patients without other treatment options. Intermittent long-term use of inotropes may be considered in outpatients to improve functional class and QOL. 389 , 390\nKidney dysfunction and loop diuretic resistance often characterize the clinical course of patients with advanced HF. Doubling of the loop diuretic dose is proposed, in the first instance, followed by con- comitant administration of thiazides or metolazone (see  section 11.3.3 ). 145   In patients who fail to respond to diuretic-based strategies, renal replacement therapies should be considered. Ultrafiltration is one of the most common approaches. It may be considered in those\nwith diuretic resistance even if data about its effects on outcomes are unsettled. 391 , 392\n10.2.2 Mechanical circulatory support MCS can improve survival and symptoms of patients with advanced HF. 376 , 393   The use of MCS should be considered for the different sce- narios listed in  Table  15 . Indications for short- and long-term MCS should be based on the INTERMACS profiles  (Table  14 ,  Figure  4 ).\nShort-term mechanical circulatory support Short-term MCS devices are indicated to reverse critical end- organ hypoperfusion and hypoxia in the setting of cardiogenic shock. They can be used for a short, limited, period of time, from a few days up to several weeks. The aim is to support the central nervous system and organ perfusion, to reverse acidosis and multi-organ failure until the patient’s outcome becomes clearer be that of cardiac recovery, transition to durable MCS or heart transplantation, or, in some cases, towards a more palliative approach. The care of patients on short-term MCS is complex and requires dedicated expertise including having specific plans for stopping support when neither cardiac nor brain injury recovers. Short-term MCS should be used in patients with INTERMACS profiles 1 or 2 as a bridge to decision (BTD), bridge to recovery (BTR), bridge to bridge (BTB) for either long-term MCS or urgent heart transplantation ( Figure  4 ). 394   Further details about short- term MCS are reported in the  Supplementary text 11.4 .\nLong-term mechanical circulatory support Long-term MCS is indicated in selected patients when MT is insuffi- cient or when short-term MCS has not led to cardiac recovery or clinical improvement, to prolong life and improve QOL, or to keep the patient alive until transplantation (bridge to transplantation, BTT) or to reverse contraindications to heart transplantation (bridge to candidacy, BTC), or as destination therapy (DT) ( Table  15 ). Long-term MCS should be considered in patients with INTERMACS profiles 2 to 4 and also in patients with INTERMACS\nTable 14 Continued\nProfile Time frame for intervention\nProﬁle 7. Advanced NYHA class III symptoms Patient without current or recent episodes of unstable ﬂuid balance, living comfortably\nwith meaningful activity limited to mild physical exertion.\nHeart transplantation or MCS may not be currently\nindicated.\nModiﬁers for proﬁles Possible proﬁles that can be modiﬁed\nTemporary MCS can modify proﬁle only in hospitalized patients. They include IABP, ECMO, TandemHeart, LVAD, Impella. 1, 2, 3\nArrhythmia can modify any proﬁle. They include recurrent ventricular tachyarrhythmias\nthat have recently contributed substantially to clinical compromise, frequent ICD shocks or requirement for external deﬁbrillation, usually more than twice weekly.\n1 \u0002 7\nFrequent episodes of HF decompensation characterize patients requiring frequent\nemergency visits or hospitalizations for diuretics, ultraﬁltration, or temporary i.v. vaso-\nactive therapy. Frequent episodes may be considered as at least two emergency visits/ admissions in the past 3 months or three in the past 6 months.\n3 if at home, 4, 5, 6. Rarely for proﬁle 7.\nECMO = extracorporeal membrane oxygenation; HF = heart failure; IABP = intra-aortic balloon pump; ICD = implantable cardioverter-deﬁbrillator; INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support; i.v. = intravenous; LVAD = left ventricular assist device; MCS = mechanical circulatory support; NYHA = New York Heart Association. Modiﬁed from   381 .\nESC 2021\nESC Guidelines 3639\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nManagement of patients with advanced heart failure a\nWeaning from MCS support LVAD-DT (Class IIa)\nList for HT or de-listing with very close follow-up in case of meaningful improvement (Class I)\nWithdrawal of MCS support\nAdvanced HF therapies (HT/LVAD) can be deferred. Very close follow-up\nContraindications for HT\nN\nCardiac, neurological and end-organ recovered\nNeurological and end-organ recovered but  no cardiac\nrecovery\nPersistence of severe brain damage and severe irreversible end-organ damage\nPotentially reversible\nHigh risk b\nContraindication reversed\nLVAD-BTC (Class IIa)\nShort-term MCS BTD/BTR/BTB/BTT (Class IIa)\nINTERMACS >4 “Stable ambulatory” INTERMACS 3–4 INTERMACS 2 INTERMACS 1\nY\nN Y\nY\nY N\nN\nFigure 4  Algorithm for the treatment of patients with advanced heart failure. BTB = bridge to bridge; BTC= bridge to candidacy; BTD= bridge to decision; BTR= bridge to recovery; BTT= bridge to transplantation; CA= cardiac amyloidosis; DT= destination therapy; ESC= European Society of Cardiology; HCM=hypertrophic cardiomyopathy; HF= heart failure; HFA= Heart Failure Association; HT =heart transplantation; INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support; LVAD= left ventricular assist device; LVAD-BTC= left ventricular assist device  \u0002 bridge to candidacy; LVAD-DT= left ventricular assist device  \u0002  destination therapy; MCS= mechanical circulatory support.   a This algorithm can be applied to all patients with advanced HF defined according to the ESC/HFA criteria, 376   with exception of HCM, CA, arrhythmic storm, adult congenital heart dis- ease, refractory angina.   b Recurrent hospitalization, progressive end-organ failure, refractory congestion, inability to perform cardiopulmonary exercise test or peak oxygen consumption <12 mL/min/kg or <50% of expected value. 385   Colour code for classes of recommendation: Green for Class of recommen- dation I and Yellow for Class of recommendation IIa (see  Table  1  for further details on classes of recommendation).\n3640 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nAny of these characteristics\nVery limited life expectancy and/or poor QOL conditions that may impair follow-up and/or worsened prognosis after advanced HF therapies (HT/LT-MCS) a\nN\nTriage of patients with advanced heart failure and appropriate timing of referral\n>1 admission or unplanned visit to HF clinic within last 12 months Prior inotropic use Intolerant to beta-blocker or RASi/ARNI LVEF <20% Worsening RV function Worsening renal function Worsening liver function Ventricular arrhythmias/ICD shocks Need for escalating diuretic doses for persistent congestion SBP <90 mmHg and/or signs of peripheral hypoperfusion\nY\nN\nNYHA III–IV despite optimal medical therapy (including ICD/CRT when indicated) NYHA class II\nManage in local HF service\nRefer to or discuss with advanced HF centre Re-evaluation every 3–6 months Palliative care\nY\nFigure 5  Triage of patients with advanced heart failure and appropriate timing of referral. 376   ARNI= angiotensin receptor-neprilysin inhibitor; CRT= cardiac resynchronization therapy; HF= heart failure; HT= heart transplantation; ICD= implantable cardioverter-defibrillator; LT-MCS= long-term mechanical circulatory support; LVEF= left ventricular ejection fraction; NYHA= New York Heart Association; RASi= renin-angiotensin system inhibitor; RV= right ventricular; SBP= systolic blood pressure; QOL= quality of life.   a Limited life expectancy may be due by major comorbidities such as cancer, dementia, end-stage organ dysfunction; other conditions that may impair follow-up or worsen post-treatment prognosis include frailty, irreversible cogni- tive dysfunction, psychiatric disorder, or psychosocial issues.\nESC Guidelines 3641\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................................................................................\nprofile 5 \u0002 6, when they have high-risk characteristics. Patients with no irreversible end-organ failure other than cardiac, recovering from INTERMACS level 1 while on short-term MCS, may also qualify for long-term MCS ( Figure  4 ). 376 , 378 , 383 , 395 \u0002 402   The characteristics of patients potentially eligible for implantation of an LVAD are reported in  Table  16 . The details of the devices and studies on long-term MCS are sum- marized in  Supplementary Table 15 . Current 2-year survival rates in patients receiving the latest continuous-flow LVADs are comparable to those after heart\ntransplantation, although adverse events negatively affect QOL. Among patients with continuous flow LVADs, actuarial survival was reported of 80% at 1 year and 70% at 2 years. 403 , 404   Two-year sur- vival was 84.5% and survival free of disabling stroke or need of reop- eration for LVAD malfunction was 76.9% with a centrifugal-flow LVAD in MOMENTUM 3. 405   The fully magnetically levitated centrifugal-flow LVAD has significantly reduced pump thrombosis. In MOMENTUM 3, the need for reoperation to replace a malfunction- ing device was 2.3% per 24 months, with only 0.6% per 24 months risk of pump replacement because of pump thrombosis. Stroke (namely, disabling stroke), major bleeding, and gastrointestinal hae- morrhage were also lower in the centrifugal-flow pump group than in the axial-flow pump group. However, the incidence of all bleeding events, thromboembolism and driveline infection remained similar to that with older devices. 402\nData on fully magnetically centrifugal-flow LVAD use in real-world studies with the 2-year outcomes from the ELEVATE registry showed an overall survival of 74.5%, with gastrointestinal bleeding in 9.7%, stroke in 10.2%, and pump thrombosis in 1.5% of patients. 406\nAccording to the IMACS Registry, a new composite endpoint includ- ing QOL and adverse events beyond survival was proposed to help in guiding decision making. In this sense ‘living well at one year’ defined as freedom from death, stroke, bleeding requiring operation, RV assist device, pump replacement, or device-related infection within the first year, was 56.8% after isolated, centrifugal flow- LVAD. 383\nAlthough now outdated, REMATCH was the only RCT comparing an LVAD as DT with OMT in patients with advanced HF, NYHA class IV and a contraindication to transplantation. REMATCH showed lower all-cause mortality with LVAD therapy when com- pared with medical treatment (primary endpoint). However, there were high mortality rates at 2 years in both arms. 378   Other studies were not randomized (INTrEPID, ROADMAP) 396 , 407 , 408   or com- pared different devices (ADVANCE, ENDURANCE, MOMENTUM 3). 399 , 402 , 409   The two strategies of early LVAD implantation vs. medi- cal treatment with LVAD implantation only after serious deteriora- tion of the patient’s condition are currently being compared in a\nTable 15 Terms describing various indications for mechanical circulatory support\nBridge to decision (BTD)/\nBridge to bridge (BTB)\nUse of short-term MCS (ECMO or Impella) in patients with cardiogenic shock until haemodynamics and end-organ\nperfusion are stabilized, contraindications for long-term MCS are excluded (brain damage after resuscitation) and additional therapeutic options including long-term VAD therapy or heart transplant can be evaluated.\nBridge to candidacy (BTC) Use of MCS (usually LVAD) to improve end-organ function and/or to make an ineligible patient eligible for heart\ntransplantation.\nBridge to transplantation (BTT) Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise at high risk of death before trans- plantation until a donor organ becomes available.\nBridge to recovery (BTR) Use of MCS (short-term or long-term) to keep a patient alive until cardiac function recovers sufﬁciently to remove\nMCS.\nDestination therapy (DT) Long-term use of MCS (LVAD) as an alternative to transplantation in patients with end-stage HF ineligible for transplantation.\nBiVAD = biventricular assist device; ECMO = extracorporeal membrane oxygenation; HF = heart failure; LVAD = left ventricular assist device; MCS = mechanical circulatory support; TAH = total artiﬁcial heart; VAD = ventricular assist device.\nESC 2021\nTable 16 Patients potentially eligible for implantation of a left ventricular assist device\nPatients with persistence of severe symptoms despite optimal medical and device therapy, without severe right ventricular dysfunction and/or\nsevere TR, with a stable psychosocial background and absence of major\ncontraindications*, and who have at least one of the following:\n\u0004  LVEF <25% and unable to exercise for HF or, if able to perform cardi-\nopulmonary exercise testing, with peak VO 2  <12 mL/kg/min and/or\n<50% predicted value.\n\u0004  >_3 HF hospitalizations in previous 12 months without an obvious pre- cipitating cause.\n\u0004  Dependence on i.v. inotropic therapy or temporary MCS.\n\u0004  Progressive end-organ dysfunction (worsening renal and/or hepatic\nfunction, type II pulmonary hypertension, cardiac cachexia) due to reduced perfusion and not to inadequately low ventricular ﬁlling\npressure (PCWP >_20 mmHg and SBP <_90 mmHg or cardiac index\n<_2 L/min/m 2 ).\nHF = heart failure; i.v. = intravenous; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; PCWP = pulmonary capillary wedge pressure; SBP = systolic blood pressure; TR = tricuspid regurgitation; VO 2  = oxygen consumption. *Stable psychosocial background includes demonstrated understanding of the technology and patient living in the same household with a caregiver that will help the patient (i.e. living alone and poor psychosocial background is LVAD con- traindication). Major contraindications include contraindication to long-term oral anticoagulation, infection, severe renal dysfunction, ventricular arrhythmias.\nESC 2021\n3642 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ..................................................... prospective trial, Early-VAD (ClinicalTrials.gov Identifier: NCT02387112). Also, the Swedish evaluation of LVAD (SweVAD) study is comparing the survival of patients with advanced HF ineligible for heart transplantation prospectively randomized to LVAD as DT vs. MT (ClinicalTrials.gov Identifier: NCT02592499). 410\n10.2.3 Heart transplantation Heart transplantation remains the gold standard for the treatment of advanced HF in the absence of contraindications. Post-transplant 1- year survival is around 90% with a median survival of 12.5 years. 385 , 411 , 412   Transplantation significantly improves QOL and func- tional status, although, for unclear reasons, the percentage of patients returning to work is lower than expected. 412   Apart from primary graft dysfunction, the main challenges after heart transplantation relate to either the efficacy or side effects of immunosuppression (e.g. rejection, infection, cardiac allograft vasculopathy, late graft dys- function, malignancy, renal failure, hypertension, diabetes mellitus). Organ donor shortage remains the main limitation to heart trans- plantation. Thus, the donor heart criteria have now been extended to allow an increased upper limit of the donor age, particularly in Europe. Moreover, careful recipient selection is needed, based on\npre-transplant and post-transplant life expectancy (both are influ- enced by pre-operative status and comorbidities). The main indications and contraindications for heart transplanta- tion are listed in  Table  17 . 376 , 385\nActive infection is a relative contraindication to transplant but in some cases of infected LVADs it may actually be an indication. Elderly age is not an absolute contraindication. Although patients aged <65 years might be more appropriate candidates due to their overall life expectancy, most programmes accept patients up to 70 years of age, and biological age as well as chronological age must be taken into account. Surgical complexity [previous sternotomies, mediastinal radiation, adult congenital heart disease (ACHD)] should also be considered. The decision pathway to transplantation or LVAD is never straightforward and is unique to each patient. Eligibility for each option may change according to the particular conditions of each patient, which may also change over time. Other factors, not related to the patient, such as time on the heart transplant waiting list, the\nTable 17 Heart transplantation: indications and contraindications\nIndications\nAdvanced HF 376\nNo other therapeutic option, except for LVAD as BTT\nContraindications\nActive infection a\nSevere peripheral arterial or cerebrovascular disease\nPharmacologic irreversible pulmonary hypertension (LVAD should be\nconsidered to reverse elevated pulmonary vascular resistance with subse-\nquent re-evaluation to establish candidacy)\nMalignancy with poor prognosis (a collaboration with oncology specialists\nshould occur to stratify each patient as regards their risk of tumour pro-\ngression or recurrence which increases with the use of immunosuppression)\nIrreversible liver dysfunction (cirrhosis) or irreversible renal dysfunction\n(e.g. creatinine clearance <30 mL/min/1.73 m 2 ). Combined heart-liver or\nheart-kidney transplant may be considered\nSystemic disease with multiorgan involvement\nOther serious comorbidity with poor prognosis\nPre-transplant BMI >35 kg/m 2   (weight loss is recommended to achieve a\nBMI <35 kg/m 2 )\nCurrent alcohol or drug abuse\nPsychological instability that jeopardizes proper follow-up and intensive\ntherapeutic regime after heart transplantation\nInsufﬁcient social supports to achieve compliant care in the outpatient\nsetting\nBMI = body mass index; BTT = bridge to transplantation; HF = heart failure; LVAD = left ventricular assist device. a Active infection is a relative contraindication to transplant although in some cases of infected LVADs it may actually be an indication. Adapted from Crespo-Leiro et al. 376\nRecommendations for the treatment of patients with advanced heart failure\nRecommendations Class a Level b\nPatients being considered for long-term MCS must\nhave good compliance, appropriate capacity for device handling and psychosocial support. 414 \u0002 416\nI C\nHeart transplantation is recommended for\npatients with advanced HF, refractory to medi- cal/device therapy and who do not have absolute\ncontraindications.\nI C\nLong-term MCS should be considered in patients\nwith advanced HFrEF despite optimal medical and device therapy, not eligible for heart transplantation\nor other surgical options, and without severe right\nventricular dysfunction, to reduce the risk of death and improve symptoms. 378 , 396 , 397 , 401 , 402 , 404 , 417\nIIa A\nLong-term MCS should be considered in patients\nwith advanced HFrEF refractory to optimal med- ical and device therapy as a bridge to cardiac\ntransplantation in order to improve symptoms,\nreduce the risk of HF hospitalization and the risk of premature death. 398 \u0002 400 , 402 , 404\nIIa B\nRenal replacement therapy should be considered\nin patients with refractory volume overload and\nend-stage kidney failure.\nIIa C\nContinuous inotropes and/or vasopressors may\nbe considered in patients with low cardiac out-\nput and evidence of organ hypoperfusion as bridge to MCS or heart transplantation. 389 , 390\nIIb C\nUltraﬁltration may be considered in refractory\nvolume overload unresponsive to diuretic\ntreatment. 391 , 392\nIIb C\nHF = heart failure; HFrEF = heart failure with reduced ejection fraction; MCS = mechanical circulatory support. a Class of recommendation. b Level of evidence.\nESC 2021\nESC 2021\n. .......................................................................................................................\nESC Guidelines 3643\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................................................................................................................................................... centre’s surgical experience, and resources, can also influence deci- sion making. 413\n10.2.4 Symptom control and end-of-life care While the disease trajectory of each patient with HF is unique, there is a generalizable pattern of gradual decline, punctuated by episodes of acute deterioration leading either to sudden death or death due to progressive HF. Communication about the disease trajectory and anticipatory planning should start when a patient is diagnosed with advanced HF. Indications for and key components of a palliative care service are reported in  Tables  18  and  19 . 312 , 418\nA team-based approach to palliative and end-of-life care for patients with HF has been proposed. 419   Specific models of palliative care for patients with advanced HF have been also reported. They reduce hospitalizations, without a clear effect on survival, and have some effects on QOL and symptom burden. 420 , 421\nSymptom assessment should be performed on a regular basis. In addition to clinical assessment, symptoms can be assessed using the Numeric Rating Scale, the Edmonton Symptom Assessment Scale (ESAS) or ESAS-HF, or the Integrated Palliative care Outcome Scale.\n",
      "keywords": [
        "therapy",
        "implantation",
        "class i",
        "elderly",
        "term",
        "long",
        "transplantation",
        "blood pressure",
        "sbp",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "indication",
        "contraindication",
        "level b",
        "class iii",
        "hfref",
        "until",
        "advanced",
        "anticoagulation",
        "hypertension",
        "lvef",
        "crt",
        "heart",
        "should be considered",
        "management",
        "class ii",
        "short",
        "alcohol",
        "icd"
      ],
      "tables": [
        {
          "title": "3642 ESC Guidelines",
          "page_number": 43,
          "content": "Bridge to decision (BTD)/\nBridge to bridge (BTB) | Use of short-term MCS (ECMO or Impella) in patients with cardiogenic shock until haemodynamics and end-organ\nperfusion are stabilized, contraindications for long-term MCS are excluded (brain damage after resuscitation) and\nadditional therapeutic options including long-term VAD therapy or heart transplant can be evaluated. | ESC 2021\nBridge to candidacy (BTC) | Use of MCS (usually LVAD) to improve end-organ function and/or to make an ineligible patient eligible for heart\ntransplantation. | \nBridge to transplantation (BTT) | Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise at high risk of death before trans-\nplantation until a donor organ becomes available. | \nBridge to recovery (BTR) | Use of MCS (short-term or long-term) to keep a patient alive until cardiac function recovers sufficiently to remove\nMCS. | \nDestination therapy (DT) | Long-term use of MCS (LVAD) as an alternative to transplantation in patients with end-stage HF ineligible for\ntransplantation. | ",
          "bbox": [
            43.48136152539934,
            81.74666526100852,
            553.0789794921875,
            219.84269205729166
          ],
          "function_potential": "raw"
        },
        {
          "title": "3642 ESC Guidelines",
          "page_number": 43,
          "content": "Patients with persistence of severe symptoms despite optimal medical\nand device therapy, without severe right ventricular dysfunction and/or\nsevere TR, with a stable psychosocial background and absence of major\ncontraindications*, and who have at least one of the following: | ESC 2021\n\u0004 LVEF <25% and unable to exercise for HF or, if able to perform cardi-\nopulmonary exercise testing, with peak VO <12 mL/kg/min and/or\n2\n<50% predicted value. | \n\u0004 >3 HF hospitalizations in previous 12 months without an obvious pre-\n_\ncipitating cause. | \n\u0004 Dependence on i.v. inotropic therapy or temporary MCS. | \n\u0004 Progressive end-organ dysfunction (worsening renal and/or hepatic\nfunction, type II pulmonary hypertension, cardiac cachexia) due to\nreduced perfusion and not to inadequately low ventricular filling\npressure (PCWP >20 mmHg and SBP <90 mmHg or cardiac index\n_ _\n<2 L/min/m2).\n_ | ",
          "bbox": [
            43.48136152539934,
            304.31376393636066,
            289.739990234375,
            490.4446258544922
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3643",
          "page_number": 44,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nPatients being considered for long-term MCS must\nhave good compliance, appropriate capacity for\ndevice handling and psychosocial support.414\u0002416 | I | C | \nHeart transplantation is recommended for\npatients with advanced HF, refractory to medi-\ncal/device therapy and who do not have absolute\ncontraindications. | I | C | \nLong-term MCS should be considered in patients\nwith advanced HFrEF despite optimal medical and\ndevice therapy, not eligible for heart transplantation\nor other surgical options, and without severe right\nventricular dysfunction, to reduce the risk of death\nand improve symptoms.378,396,397,401,402,404,417 | IIa | A | \nLong-term MCS should be considered in patients\nwith advanced HFrEF refractory to optimal med-\nical and device therapy as a bridge to cardiac\ntransplantation in order to improve symptoms,\nreduce the risk of HF hospitalization and the risk\nof premature death.398\u0002400,402,404 | IIa | B | \nRenal replacement therapy should be considered\nin patients with refractory volume overload and\nend-stage kidney failure. | IIa | C | \nContinuous inotropes and/or vasopressors may\nbe considered in patients with low cardiac out-\nput and evidence of organ hypoperfusion as\nbridge to MCS or heart transplantation.389,390 | IIb | C | \nUltrafiltration may be considered in refractory\nvolume overload unresponsive to diuretic\ntreatment.391,392 | IIb | C | ",
          "bbox": [
            311.5483725411551,
            321.18279622395835,
            556.7866641773898,
            700.5502297537668
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3643",
          "page_number": 44,
          "content": "Indications | ESC 2021\nAdvanced HF376 | \nNo other therapeutic option, except for LVAD as BTT | \nContraindications | \nActive infectiona | \nSevere peripheral arterial or cerebrovascular disease | \nPharmacologic irreversible pulmonary hypertension (LVAD should be\nconsidered to reverse elevated pulmonary vascular resistance with subse-\nquent re-evaluation to establish candidacy) | \nMalignancy with poor prognosis (a collaboration with oncology specialists\nshould occur to stratify each patient as regards their risk of tumour pro-\ngression or recurrence which increases with the use of\nimmunosuppression) | \nIrreversible liver dysfunction (cirrhosis) or irreversible renal dysfunction\n(e.g. creatinine clearance <30 mL/min/1.73 m2). Combined heart-liver or\nheart-kidney transplant may be considered | \nSystemic disease with multiorgan involvement | \nOther serious comorbidity with poor prognosis | \nPre-transplant BMI >35 kg/m2 (weight loss is recommended to achieve a\nBMI <35 kg/m2) | \nCurrent alcohol or drug abuse | \nPsychological instability that jeopardizes proper follow-up and intensive\ntherapeutic regime after heart transplantation | \nInsufficient social supports to achieve compliant care in the outpatient\nsetting | ",
          "bbox": [
            48.03963497706822,
            361.94227600097656,
            293.2829895019531,
            680.0826538085937
          ],
          "function_potential": "raw"
        },
        {
          "title": "3644 ESC Guidelines",
          "page_number": 45,
          "content": "Progressive functional decline (physical and mental) and dependence in\nmost activities of daily living. | ESC 2021\nSevere heart failure symptoms with poor QOL despite optimal pharma-\ncological and non-pharmacological therapies. | \nFrequent admissions to hospital or other serious episodes of decompen-\nsation despite optimal treatment. | \nHeart transplantation and MCS ruled out. | \nCardiac cachexia. | \nClinically judged to be close to end of life. | ",
          "bbox": [
            43.49992195765177,
            361.28977966308594,
            288.7480163574219,
            476.61729125976564
          ],
          "function_potential": "raw"
        },
        {
          "title": "3644 ESC Guidelines",
          "page_number": 45,
          "content": "Focus on improving or maintaining the QOL of a patient and his/her fam-\nily as well as possible until he/she dies. | ESC 2021\nFrequent assessment of symptoms (including dyspnoea and pain) result-\ning from advanced heart failure and other comorbidities and focus on\nsymptom relief. | \nAccess for the patient and his/her family to psychological support and spi-\nritual care according to need. | \nAdvanced care planning, taking into account preferences for place of\ndeath and resuscitation (which may include deactivating devices, such as\nICD or long-term MCS that may require a multidisciplinary team\ndecision). | ",
          "bbox": [
            43.49992195765177,
            559.7432963053385,
            288.7480163574219,
            696.6936218261719
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "69",
      "title": "Treatment for symptoms needs to be considered and might include additional intervention on top of OMT:",
      "start_page": 45,
      "end_page": 45,
      "content": "•   Breathlessness: repeat doses of opioids may be considered for the relief of dyspnoea; however, their effectiveness is not demon- strated. 422 , 423   While using opioids, all patients should be guided about opioid side effects such as constipation and nausea, urinary retention, and mental status changes. Benzodiazepines may be considered as a second- or third-line treatment, when opioids and non-pharmacological measures have failed to control breath- lessness. Increasing the inspired oxygen concentration may pro- vide relief of dyspnoea. •   Pain: non-pharmacologic management can be helpful. In addition, opioid, oxycodone, hydromorphone, and fentanyl are generally viewed as safe options and can be provided orally, intravenously, and transdermally, especially in the hospital or in patient palliative care or hospice setting. 424\n•   Anxiety and depression: adequate conventional treatment should be offered.\nProactive decisions and advanced planning with regard to palliative and end-of-life care discussions should be documented, regularly reviewed, and routinely communicated to all those involved in the patient’s care. Healthcare providers should make sure that patients’ and carer preferences are followed, wherever possible. They should also take into account that patients may choose not to, or may not be in a position to, express preferences (e.g. due to symptoms of depression or cognitive impairment).\n",
      "keywords": [
        "treatment",
        "considered",
        "might",
        "intervention",
        "include",
        "needs",
        "may be considered",
        "additional",
        "symptoms"
      ],
      "tables": []
    },
    {
      "number": "70",
      "title": "11 Acute heart failure",
      "start_page": 45,
      "end_page": 45,
      "content": "",
      "keywords": [
        "heart",
        "failure",
        "acute"
      ],
      "tables": []
    },
    {
      "number": "71",
      "title": "11.1 Epidemiology, diagnosis and prognosis AHF refers to rapid or gradual onset of symptoms and/or signs of HF, severe enough for the patient to seek urgent medical atten- tion, leading to an unplanne",
      "start_page": 45,
      "end_page": 45,
      "content": "AHF may be the first manifestation of HF (new onset) or, more frequently, be due to an acute decompensation of chronic HF. Compared to patients with acutely decompensated CHF, those with new onset HF may have a higher in-hospital mortality 425   but have lower post-discharge mortality and rehospitalization rates. 425 , 428 , 431 , 432   Specific extrinsic factors may precipitate, but not cause, AHF in patients with pre-existing cardiac dysfunction ( Supplementary Table 16 ) . Clinical severity and in-hospital trajec- tory are determined by the complex interplay between precipi- tants, the underlying cardiac substrate, and the patient’s comorbidities.\nTable 18 Patients with heart failure in whom end-of-life care should be considered\nProgressive functional decline (physical and mental) and dependence in most activities of daily living.\nSevere heart failure symptoms with poor QOL despite optimal pharma-\ncological and non-pharmacological therapies.\nFrequent admissions to hospital or other serious episodes of decompen- sation despite optimal treatment.\nHeart transplantation and MCS ruled out.\nCardiac cachexia.\nClinically judged to be close to end of life.\nMCS = mechanical circulatory support; QOL = quality of life.\nTable 19 Key components of palliative care service in patients with advanced heart failure\nFocus on improving or maintaining the QOL of a patient and his/her fam-\nily as well as possible until he/she dies.\nFrequent assessment of symptoms (including dyspnoea and pain) result- ing from advanced heart failure and other comorbidities and focus on\nsymptom relief.\nAccess for the patient and his/her family to psychological support and spi-\nritual care according to need.\nAdvanced care planning, taking into account preferences for place of\ndeath and resuscitation (which may include deactivating devices, such as\nICD or long-term MCS that may require a multidisciplinary team decision).\nICD = implantable cardioverter-deﬁbrillator; MCS = mechanical circulatory sup- port; QOL = quality of life.\n",
      "keywords": [
        "seek",
        "heart failure",
        "medical",
        "leading",
        "diagnosis",
        "patient",
        "rapid",
        "prognosis",
        "urgent",
        "should be considered",
        "tion",
        "signs",
        "refers",
        "gradual",
        "onset",
        "icd",
        "enough",
        "atten",
        "severe",
        "unplanne",
        "epidemiology",
        "symptoms"
      ],
      "tables": []
    },
    {
      "number": "72",
      "title": "ESC 2021 ESC 2021",
      "start_page": 45,
      "end_page": 47,
      "content": "3644 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................ The diagnostic workup of AHF starts at the time of the first medi- cal contact, and is continued throughout the initial patient pathway, aiming to identify the clinical presentation and to diagnose and manage any potentially reversible causes/precipitants/coexisting life-threatening conditions in a timely manner ( Figure  6 ). Diagnostic tests are outlined at  Table  20 . In addition to clinical signs and symp- toms, diagnostic workup includes ECG and echocardiography, if pos- sible. Additional investigations, i.e. chest X-ray and lung ultrasound may be used to confirm AHF diagnosis, especially when NP testing is not available. Plasma NP levels (BNP or NT-proBNP or MR- proANP) should be measured if the diagnosis is uncertain and a point-of-care assay is available. Normal concentrations of NPs make the diagnosis of AHF unlikely. Cut-offs for acute HF are: BNP <100\npg/mL, NT-proBNP <300 pg/mL and MR-proANP <120 pg/ mL. 74 , 433 \u0002 435   However, elevated NP values are associated with a wide range of cardiac and non-cardiac conditions  (Table  6 ) . Low con- centrations can be detected in some patients with advanced decom- pensated end-stage HF, obesity, flash pulmonary oedema or right- sided AHF. Higher levels can be found in the patients with concomi- tant AF and/or reduced renal function. 74\nAmong other laboratory tests, troponin is useful for the detection of acute coronary syndrome (ACS) although elevated levels are detected in the vast majority of patients with AHF. 436 \u0002 438   Blood urea nitrogen or urea, serum creatinine, electrolytes (sodium, potassium, chloride), and antigen carbohydrate 125 may help tailor treat- ment. 439 , 440   Detection of abnormal liver function identifies patients\nDiagnostic workup of new onset acute heart failure\nElectrocardiogram Pulse oximetry Echocardiography Initial laboratory investigations a\nChest X-ray Lung ultrasound Other specific evaluations b\nPatient history, signs and/or symptoms suspected of acute HF\nNatriuretic peptide testing\nBNP <100 pg/mL NT-proBNP <300 pg/mL MR-proANP <120 pg/mL\nBNP  ≥  100 pg/mL NT-proBNP  ≥ 300 pg/mL c\nMR-proANP  ≥ 120 pg/mL\nAcute heart failure ruled out Acute heart failure confirmed\nComprehensive echocardiography\nFigure 6  Diagnostic workup of new onset acute heart failure. ACS = acute coronary syndrome; BNP= B-type natriuretic peptide; CT= computed tomography; HF= heart failure; MR-proANP= mid-regional pro-atrial natriuretic peptide; NT-proBNP= N-terminal pro-B-type natriuretic peptide; TSH = thyroid-stimulating hormone.   a Initial laboratory exams include troponin, serum creatinine, electrolytes, blood urea nitrogen or urea, TSH, liver function tests as well as D-dimer and procalcitonin when pulmonary embolism or infection are suspected, arterial blood gas analysis in case of respiratory distress, and lactate in case of hypoperfusion.   b Specific evaluation includes coronary angiography, in case of suspected ACS, and CT in case of suspected pulmonary embolism.   c Rule-in values for the diagnosis of acute HF: >450 pg/mL if aged <55 years, >900 pg/mL if aged between 55 and 75 years and >1800 pg/mL if aged >75 years. 433 , 434\nESC Guidelines 3645\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................... with a poor prognosis. 441   Since both hypothyroidism and hyperthyr- oidism may precipitate AHF, thyroid-stimulating hormone (TSH) should be assessed in those with newly diagnosed AHF. Arterial blood gas analysis should be performed when a precise measurement of O 2  and CO 2  partial pressure is needed (i.e. patients with respira- tory distress). Lactate and pH levels should be measured in patients with cardiogenic shock. D-dimer should be measured when acute pulmonary embolism is suspected. Procalcitonin may be used for the diagnosis of pneumonia and antibiotic therapy may have an indication when plasma levels are >0.2  l g/L. However, no impact of a strategy based on routine procalcitonin measurements on outcomes was shown in a prospective, controlled, trial. 442   Pulse oximetry should be measured routinely at the time of first presentation of patients with\nAHF and continuous monitoring may be needed in the first hours or days. 443 , 444\n",
      "keywords": [
        "obesity",
        "angiography",
        "electrocardiogram",
        "echocardiography",
        "bnp",
        "heart failure",
        "troponin",
        "nt-probnp",
        "creatinine",
        "pulmonary embolism",
        "indication",
        "ecg"
      ],
      "tables": [
        {
          "title": "3646 ESC Guidelines",
          "page_number": 47,
          "content": "Exam |  | Time of measurement |  | Possible findings |  | Diagnostic value for\nAHF |  | Indication | ESC 2021\nECG |  | Admission, during hospitali-\nzation,a,b pre-discharge |  | Arrhythmias, myocardial\nischaemia |  | Exclusion of ACS or\narrhythmias |  | Recommended | \nChest-X ray |  | Admission, during\nhospitalizationa |  | Congestion, lung infection |  | Confirmatory |  | May be considered | \nLUS |  | Admission, during hospitali-\nzation,a pre-discharge |  | Congestion |  | Confirmatory |  | May be considered | \nEchocardiography |  | Admission, during hospitali-\nzation,a pre-discharge |  | Congestion, cardiac dys-\nfunction, mechanical causes |  | Major |  | Recommended | \nNatriuretic peptides\n(BNP, NT-proBNP,\nMR-proANP) |  | Admission, pre-discharge |  | Congestion |  | High negative predictive\nvalue |  | Recommended | \nSerum troponin |  | Admission |  | Myocardial injury |  | Exclusion of ACS |  | Recommended | \nSerum creatinine |  | Admission, during hospitali-\nzation,a pre-discharge |  | Renal dysfunction |  | None |  | Recommended for prognos-\ntic assessment | \nSerum electrolytes\n(sodium, potassium,\nchloride) |  | Admission, during hospitali-\nzation,a pre-discharge |  | Electrolyte disorders |  | None |  | Recommended for prognos-\ntic assessment and\ntreatment | \nIron status (transferrin,\nferritin) |  | Pre-discharge |  | Iron depletion |  | None |  | Recommended for prognos-\ntic assessment and\ntreatment | \nTSH |  | Admission |  | Hypo- hyperthyroidism |  | None |  | Recommended when hypo-\nhyperthyroidism is\nsuspected | \nD-dimer |  | Admission |  | Pulmonary embolism |  | Useful to exclude pulmo-\nnary embolism |  | Recommended when pul-\nmonary embolism is\nsuspected | \nProcalcitonin |  | Admission |  | Pneumonia |  | Useful for diagnosis of\npneumonia |  | May be done when pneu-\nmonia is suspected | \nLactate |  | Admission, during\nhospitalizationa |  | Lactic acidosis |  | Useful to assess perfusion\nstatus |  | Recommended when\nperipheral hypoperfusion is\nsuspected | \nPulse oximetry and\narterial blood gas\nanalysis |  | Admission, during\nhospitalizationa |  | Respiratory failure |  | Useful to assess respiratory\nfunction |  | Recommended when respi-\nratory failure is suspected | ",
          "bbox": [
            43.52087728438839,
            75.62799072265625,
            553.0789794921875,
            520.967565536499
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "73",
      "title": "11.2 Clinical presentations Four major clinical presentations can be described with possible overlaps between them ( Table  21 ). 1 , 425 , 445   Clinical presentations are mainly based on the presenc",
      "start_page": 47,
      "end_page": 58,
      "content": "11.2.1 Acute decompensated heart failure Acute decompensated heart failure (ADHF) is the most common form of AHF, accounting for 50 \u0002 70% of presentations. 426 , 427 , 432   It\nTable 20 Diagnostic tests in patients with acute heart failure\nExam Time of measurement Possible findings Diagnostic value for AHF Indication\nECG Admission, during hospitali-\nzation, a,b   pre-discharge\nArrhythmias, myocardial\nischaemia\nExclusion of ACS or\narrhythmias\nRecommended\nChest-X ray Admission, during\nhospitalization a Congestion, lung infection Conﬁrmatory May be considered\nLUS Admission, during hospitali-\nzation, a   pre-discharge\nCongestion Conﬁrmatory May be considered\nEchocardiography Admission, during hospitali-\nzation, a   pre-discharge\nCongestion, cardiac dys-\nfunction, mechanical causes\nMajor Recommended\nNatriuretic peptides\n(BNP, NT-proBNP, MR-proANP)\nAdmission, pre-discharge Congestion High negative predictive\nvalue\nRecommended\nSerum troponin Admission Myocardial injury Exclusion of ACS Recommended\nSerum creatinine Admission, during hospitali-\nzation, a   pre-discharge\nRenal dysfunction None Recommended for prognos-\ntic assessment\nSerum electrolytes\n(sodium, potassium,\nchloride)\nAdmission, during hospitali-\nzation, a   pre-discharge\nElectrolyte disorders None Recommended for prognos-\ntic assessment and\ntreatment\nIron status (transferrin, ferritin) Pre-discharge Iron depletion None Recommended for prognos- tic assessment and\ntreatment\nTSH Admission Hypo- hyperthyroidism None Recommended when hypo- hyperthyroidism is\nsuspected\nD-dimer Admission Pulmonary embolism Useful to exclude pulmo-\nnary embolism\nRecommended when pul-\nmonary embolism is suspected\nProcalcitonin Admission Pneumonia Useful for diagnosis of\npneumonia\nMay be done when pneu-\nmonia is suspected\nLactate Admission, during hospitalization a Lactic acidosis Useful to assess perfusion status Recommended when peripheral hypoperfusion is\nsuspected\nPulse oximetry and arterial blood gas\nanalysis\nAdmission, during hospitalization a Respiratory failure Useful to assess respiratory function Recommended when respi- ratory failure is suspected\nACS = acute coronary syndrome; AHF = acute heart failure; BNP = B-type natriuretic peptide; ECG = electrocardiogram; LUS = lung ultrasound; MR-proANP = mid-regional pro-atrial natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSH = thyroid-stimulating hormone. a Based on clinical conditions. b Continuous ECG monitoring can be considered based on clinical conditions.\nESC 2021\n3646 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................................................. usually occurs in patients with history of HF and previous cardiac dysfunction across the spectrum of LVEF and may include RV dys- function. Distinct from the acute pulmonary oedema phenotype, it has a more gradual onset, and the main alteration is progressive fluid retention responsible for systemic congestion. Sometimes, congestion is associated with hypoperfusion. 426   The objectives of treatment are identification of precipitants, decongestion, and in rare instances, correction of hypoperfusion ( Figure  7 ).\n11.2.2 Acute pulmonary oedema Acute pulmonary oedema is related to lung congestion. Clinical crite- ria for acute pulmonary oedema diagnosis include dyspnoea with orthopnoea, respiratory failure (hypoxaemia-hypercapnia), tachyp- noea, >25 breaths/min, and increased work of breathing. 448\nThree therapies should be commenced, if indicated. First, oxygen, given as continuous positive airway pressure, non-invasive positive- pressure-ventilation and/or high-flow nasal cannula, should be started. Second, i.v. diuretics should be administered, and third, i.v. vasodilators may be given if systolic BP (SBP) is high, to reduce LV afterload ( Figure  8 ). In a few cases of advanced HF, acute pulmonary oedema may be associated with low cardiac output and, in this case, inotropes, vasopressors, and/or MCS are indicated to restore organ perfusion.\n11.2.3 Isolated right ventricular failure RV failure is associated with increased RV and atrial pressure and systemic congestion. RV failure may also impair LV filling, and\nultimately reduce systemic cardiac output, through ventricular interdependence. 449\nDiuretics are often the first option of therapy for venous conges- tion. Noradrenaline and/or inotropes are indicated for low cardiac output and haemodynamic instability. Inotropes reducing cardiac fill- ing pressures may be preferred (i.e. levosimendan, phosphodiester- ase type III inhibitors). Since inotropic agents may aggravate arterial hypotension, they may be combined with norepinephrine if needed ( Figure  9 ). 449\n11.2.4 Cardiogenic shock Cardiogenic shock is a syndrome due to primary cardiac dysfunction resulting in an inadequate cardiac output, comprising a life- threatening state of tissue hypoperfusion, which can result in multi- organ failure and death. 450 \u0002 452   Cardiac insult causing severe impair- ment of cardiac performance may be acute, as a result of the acute loss of myocardial tissue (acute MI, myocarditis) or may be progres- sive as seen in patients with chronic decompensated HF who may experience a decline in disease stability as a result of the natural pro- gression of advanced HF and/or specific precipitants. 426\nDiagnosis of cardiogenic shock mandates the presence of clini- cal signs of hypoperfusion, such as cold sweated extremities, oli- guria, mental confusion, dizziness, narrow pulse pressure. In addition, biochemical manifestations of hypoperfusion, elevated serum creatinine, metabolic acidosis and elevated serum lactate are present and reflect tissue hypoxia and alterations of cellular\nTable 21 Clinical presentations of acute heart failure\nAcute decompensated heart failure Acute pulmonary oedema Isolated right ventricular failure Cardiogenic shock\nMain mechanisms LV dysfunction\nSodium and water renal retention\nIncreased afterload and/or\npredominant LV diastolic dysfunction\nValvular heart disease\nRV dysfunction and/or\npre-capillary pulmonary hypertension\nSevere cardiac dysfunction\nMain cause of symptoms Fluid accumulation, increased intraventricular pressure Fluid redistribution to the lungs and acute respira-\ntory failure\nIncreased central venous pressure and often sys-\ntemic hypoperfusion\nSystemic hypoperfusion\nOnset Gradual (days) Rapid (hours) Gradual or rapid Gradual or rapid\nMain haemodynamic abnormalities Increased LVEDP and PCWP a\nLow or normal cardiac output\nNormal to low SBP\nIncreased LVEDP and PCWP a\nNormal cardiac output\nNormal to high SBP\nIncreased RVEDP Low cardiac output\nLow SBP\nIncreased LVEDP and PCWP a\nLow cardiac output\nLow SBP\nMain clinical presentations 1 , 446\nWet and warm OR Dry and cold Wet and warm b Dry and cold OR Wet and cold Wet and cold\nMain treatment Diuretics\nInotropic agents/vasopressors (if peripheral hypoperfu-\nsion/hypotension)\nShort-term MCS or RRT if needed\nDiuretics\nVasodilators b Diuretics for peripheral\ncongestion Inotropic agents/vasopres-\nsors (if peripheral hypo-\nperfusion/hypotension) Short-term MCS or RRT if\nneeded\nInotropic agents/\nvasopressors Short-term MCS\nRRT\nLV = left ventricular; LVEDP = left ventricular end-diastolic pressure; MCS = mechanical circulatory support; PCWP = pulmonary capillary wedge pressure; RV = right ventricular; RVEDP = right ventricular end-diastolic pressure; RRT = renal replacement therapy; SBP = systolic blood pressure. a May be normal with low cardiac output. b Wet and cold proﬁle with need of inotropes and/or vasopressors may rarely occur.\nESC 2021\nESC Guidelines 3647\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................ metabolism leading to organ dysfunction. 437 , 453   Of note, hypoper- fusion is not always accompanied by hypotension, as BP may be preserved by compensatory vasoconstriction (with/without pressor agents), albeit at the cost of impaired tissue perfusion and oxygenation. 426 , 427 , 450 , 454\nManagement of cardiogenic shock should start as early as pos- sible. Early identification and treatment of the underlying cause, concomitant with haemodynamic stabilization and management of organ dysfunction, are key components of its management ( Figure 10 ,  Supplementary text 11.1 ;  Supplementary Figure 2 ).\nN\nManagement of patients with acute decompensated heart failure\nCongestion/Fluid overload\nY\nHypoperfusion\nMedical therapy optimization (Class I)\nLoop diuretics a\n(Class I)\nLoop diuretics a  (Class I) and consider inotropes (Class IIb)\nCongestion relief Hypoperfusion and congestion relief\nN\nIncrease diuretic doses (Class I) and/or combine diuretics (Class IIa)\nConsider vasopressors\n(Class IIb) (i.e. norepinephrine)\nDiuretic resistance or end-stage renal failure Persistent hypoperfusion Organ damage N N\nY\nRenal replacement therapy (Class IIa)\nOR\nConsider palliative care\nMCS (Class IIa)\nAND/OR\nRenal replacement therapy (Class IIa)\nOR\nConsider palliative care\nN Y\nY Y\nN\nFigure 7  Management of acute decompensated heart failure. MCS= mechanical circulatory support.   a Adequate diuretic doses to relieve congestion and close monitoring of diuresis is recommended (see  Figure 13 ) regardless of perfusion status.\n3648 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................... 11.3 Management 11.3.1 General aspects Management can be subdivided in three stages (pre-hospital, in-hos- pital, and pre-discharge), having different goals and requiring different approaches ( Figure  11 ).\nPre-hospital phase In the pre-hospital setting, AHF patients should benefit from non- invasive monitoring, including pulse oximetry, BP, heart rate respira- tory rate, and a continuous ECG, instituted within minutes of patient contact and in the ambulance if possible. 305   Oxygen therapy may be given based on clinical judgment unless oxygen saturation is <90% in which case it should be administered. In patients with respiratory dis- tress, respiratory rate >25 breaths/min, oxygen saturation <90%, non-invasive ventilation should be initiated. 444 , 448   Although therapeu- tic tools may be available in the prehospital setting, whether more effective pre-hospital care would alter the clinical outcome remains\nto be proven in randomized clinical trials. 455   Furthermore, pre- hospital management should not delay the rapid transfer of AHF patients to the most appropriate medical setting. 455 , 456\nIn-hospital management Diagnostic workup and appropriate pharmacological and non- pharmacological treatment must be started promptly and in parallel ( Figure  12 ). AHF patients are triaged to the appropriate level of care according to the degree of haemodynamic instability and severity of the critical illness. Disposition decisions are important components of the initial phase of management (see  Supplementary text 11.2  and Supplementary Tables 17 \u0002 19 ). The type and intensity of in-hospital monitoring depends on clinical severity, settings of care and in-hospital course (see  Supplementary text 11.3 ). As AHF is a heterogeneous condition, management may differ according to the main clinical presentation. Management starts with the search for specific causes of AHF. 1 , 305 , 430   These include\nManagement of patients with pulmonary oedema\nSBP  ≥ 110 mmHg\nLoop diuretics (Class I) and/or vasodilators (Class IIb)\nN\nY\nN\nY\nSigns of hypoperfusion\nLoop diuretics (Class I) and inotropes/vasopressors (Class IIb)\nLoop diuretics (Class I)\nCongestion relief N Y\nMedical therapy optimization (Class I)\nConsider RRT, MCS, other devices (Class IIa)\nOR\nConsider palliative care\nOxygen (Class I) or ventilatory support (Class IIa)\nFigure 8  Management of pulmonary oedema. MCS= mechanical circulatory support; RRT= renal replacement therapy; SBP =systolic blood pressure.\nESC Guidelines 3649\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nManagement of patients with isolated right ventricular failure\nY\nSpecific treatments\nACS with RV involvement or acute pulmonary embolism\nN\nLoop diuretics (Class I) Consider careful fluid administration\nMarked congestion\nY\nRVAD\nAND/OR\nRenal replacement therapy\nOR\nConsider palliative care\nN Y\nOptimize fluid status\nN\nPeripheral hypoperfusion/ persistent hypotension N\nVasopressors and/or inotropes a\n(Class IIb)\nRelief of signs and symptoms\nY\nFollow-up\nFigure 9  Management of right ventricular failure. ACS= acute coronary syndrome; RV= right ventricular; RVAD= right ventricular assist device. a Inotropes alone in case of hypoperfusion without hypotension.\n3650 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .................... ACS, a hypertensive emergency, rapid arrhythmias or severe brady- cardia/conduction disturbance, acute mechanical causes such as acute valve regurgitation or acute pulmonary embolism, infection, including myocarditis, and tamponade (CHAMPIT) ( Figure  12 ). After exclusion of these conditions, which need to be treated/corrected urgently, management of AHF differs according to the clinical presentations ( Figures  7 \u0002 10 ).\nPre-discharge phase Details on this phase are shown in  section 11.3.11 .\n11.3.2 Oxygen therapy and/or ventilatory support In AHF, oxygen should not be used routinely in non-hypoxaemic patients, as it causes vasoconstriction and a reduction in cardiac out- put. 457   Oxygen therapy is recommended in patients with AHF and\nMCS (Class IIa)\nAND/OR\nRenal replacement therapy (Class IIa)\nOR\nConsider palliative care\nManagement of patients with cardiogenic shock\nIdentify and treat other specific causes b\nACS and/or mechanical complications N Y\nEmergency PCI or surgical treatment a\nConsider oxygen (Class I) or ventilatory support (Class IIa)\nConsider inotropes/ vasopressors (Class IIb)\nConsider short-term MCS (Class IIa) AND AND\nImprovement of hypoperfusion and organ dysfunction N Y\nWeaning from inotropes/vasopressors and/or MCS\nContinue aetiological treatment if needed and medical therapy optimization (Class I)\nFigure 10  Management of cardiogenic shock. ACS = acute coronary syndrome; BTT =bridge to transplantation; MCS= mechanical circulatory support; PCI= percutaneous coronary intervention.   a PCI in ACS, pericardiocentesis in tamponade, mitral valve surgery in papillary muscle rupture. In case of inter- ventricular septum rupture, MCS as BTT should be considered.   b Other causes include acute valve regurgitation, pulmonary embolism, infection, acute myocarditis, arrhythmia (see  Figure  12 ).\nESC Guidelines 3651\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................................... SpO 2  <90% or PaO 2  <60 mmHg to correct hypoxaemia. In chronic obstructive pulmonary disease (COPD), hyper-oxygenation may increase ventilation \u0002 perfusion mismatch, suppress ventilation and lead to hypercapnia. During oxygen therapy, acid-base balance and SpO 2  should be monitored. Non-invasive positive pressure ventilation, either continuous posi- tive airway pressure and pressure support, improves respiratory fail- ure, increases oxygenation and pH, and decreases the partial pressure of carbon dioxide (pCO 2 ) and work of breathing. Although a large randomized trial had neutral results, meta-analyses suggest it may improve dyspnoea and reduce the need for intubation and mortality, compared with traditional oxygen therapy. 1 , 458 , 459   Non- invasive positive pressure ventilation should be started as soon as possible in patients with respiratory distress (respiratory rate >25 breaths/min, SpO 2  <90%) to improve gas exchange and reduce the rate of endotracheal intubation. 448 , 459   The fraction of inspired oxygen (FiO 2 ) should be increased up to 100%, if necessary, according to oxygen saturation level.\nBlood pressure should be monitored regularly during non-invasive positive pressure ventilation. The increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease car- diac output and BP and should therefore be used with caution in patients with reduced preload reserve and hypotension. The increase in pulmonary vascular resistance and RV afterload may also be detri- mental in RV dysfunction. 448\nIntubation is recommended for progressive respiratory failure in spite of oxygen administration or non-invasive ventilation ( Supplementary Table 20 ). 448\n11.3.3 Diuretics Intravenous diuretics are the cornerstone of AHF treatment. They increase renal excretion of salt and water and are indicated for the treatment of fluid overload and congestion in the vast majority of AHF patients.\nDetermine aetiology Alleviate symptoms Improve congestion and organ perfusion Restore oxygenation Limit organ damage (cardiac, renal, hepatic, gut) Prevent thromboembolism\nClose monitoring of vital signs and grading severity of symptoms/signs Disposition decisions: ICU/ICCU ward Initial treatment to support circulatory and respiratory functions (vasodilators, vasopressors, inotropes, diuretics, supplemental O 2 )\nIdentify aetiology and relevant co-morbidities and start targeted treatment Titrate therapy to control symptoms and to relieve congestion, manage hypoperfusion and optimize blood pressure Initiate and up-titrate disease- modifying pharmacological therapy Consider device therapy in appropriate patients\nGoals\nProcedures Phases\nDetermine aetiology Improve signs and symptoms Limit organ damage Prevent thromboembolism\nImprove symptoms and quality  of life Achieve full congestion relief Prevent early readmission Improve survival\nInitiate and up-titrate disease- modifying pharmacological and device therapy Develop a care plan with the identification of caregivers, a schedule for up-titration and monitoring of pharmacological therapy, review of device therapy Enrolment in a disease management programme\nImmediate\nPre-discharge and long-term\nIntermediate\nPhases\nFigure 11  Stages of management of patients with acute heart failure. ICCU= intensive coronary care unit; ICU= intensive care unit.\n3652 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................... Loop diuretics are commonly used due to their rapid onset of action and efficacy. Data defining their optimal dosing, timing, and method of administration are limited. No difference in the primary efficacy outcome of patients’ symptoms global assessment was shown with a high-dose regimen, compared with a low-dose regi- men, in the DOSE trial. However, there was a greater relief of dysp- noea, change in weight and net fluid loss (with no prognostic role for increases in serum creatinine) in the higher-dose regimen. 460 \u0002 462\nHigh diuretic doses may cause greater neurohormonal activation and electrolyte abnormalities and are often associated with poorer out- comes, although a cause and effect relation cannot be proven by these retrospective analyses. 463 \u0002 466   Based on these observations, it may be appropriate, when starting i.v. diuretic treatment, to use low doses, to assess the diuretic response and increase the dose when that is insufficient. Diuretic treatment should be started with an initial i.v. dose of furosemide, or equivalent dose of bumetanide or torasemide,\ncorresponding to 1 \u0002 2 times the daily oral dose taken by the patient before admission. If the patient was not on oral diuretics, a starting dose of 20 \u0002 40 mg of furosemide, or a bolus of 10 \u0002 20 mg i.v. torase- mide, can be used. 145 , 467   Furosemide can be given as 2 \u0002 3 daily boluses or as a continuous infusion. Daily single bolus administrations are discouraged because of the possibility of post-dosing sodium retention. 145 , 461   With continuous infusion, a loading dose may be used to achieve steady state earlier. Diuretic response should be evaluated shortly after start of diuretic therapy and may be assessed by performing a spot urine sodium content measurement after 2 or 6 h and/or by measuring the hourly urine output. A satisfactory diu- retic response can be defined as a urine sodium content >50 \u0002 70 mEq/L at 2 h and/or by a urine output >100 \u0002 150 mL/h dur- ing the first 6 h. 145 , 468   If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled, with a further assessment of diuretic response. 145   If the diuretic response remains inadequate, e.g. <100 mL hourly diuresis despite doubling loop diuretic dose,\nIdentification of acute aetiology\nCardiogenic shock and/or respiratory failure\nN\nManagement of patients with suspected acute heart failure\nPharmacological support\nVentilatory support\nMCS\nY\nacute  C oronary syndrome H ypertension emergency A rrhythmia M echanical cause a\nP ulmonary embolism I nfections T amponade\nC H A M P I T\nY Immediate initiation of specific treatment\nFurther treatment b\nN\nUrgent phase after first medical contact\nImmediate phase (initial 60–120 min)\nFigure 12  Initial management of acute heart failure. MCS= mechanical circulatory support.   a Acute mechanical cause: myocardial rupture complicating acute coronary syndrome (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis.   b See  Figures  7 \u0002 10  for specific treatments according to different clinical presentations.\nESC Guidelines 3653\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........................................................... concomitant administration of other diuretics acting at different sites, namely thiazides or metolazone or acetazolamide, may be consid- ered. However, this combination requires careful monitoring of serum electrolytes and renal function ( Figure  13 ). 145 , 469 , 470   This strat- egy, based on early and frequent assessment of diuretic response, allows starting treatment with relatively low doses of loop diuretics, with frequent dose adjustments that may be less likely to cause dehy- dration and increase in serum creatinine. The loop diuretic dose should be progressively decreased when a significant negative fluid balance has been obtained. However, it should be pointed out that this algorithm is entirely based on expert opinion, to date. 145 , 461\nTransition to oral treatment should be commenced when the patient’s clinical condition is stable. It is recommended that, after achievement of congestion relief, oral loop diuretics are continued at the lowest dose possible to avoid congestion. 463 , 471   Care must also be taken to avoid patients being discharged from hospital with persis- tent congestion, as this is a major predictor of increased deaths and rehospitalizations. 462 , 472   Hence, care should be taken to achieve adequate decongestion and establish an appropriate long-term diu- retic dose before discharge. 427 , 473\n11.3.4 Vasodilators Intravenous vasodilators, namely nitrates or nitroprusside ( Supple- mentary Table 21 ), dilate venous and arterial vessels leading to a reduction in venous return to the heart, less congestion, lower after- load, increased stroke volume and consequent relief of symptoms. Nitrates act mainly on peripheral veins whereas nitroprusside is more a balanced arterial and venous dilator. 474 , 475   Because of their mechanisms of action, i.v. vasodilators may be more effective than diuretics in those patients whose acute pulmonary oedema is caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation. 427 , 476 \u0002 478   However, two recent randomized trials comparing usual care with early inten- sive and sustained vasodilation failed to show a beneficial effect of i.v. vasodilators vs. high-dose diuretics. 479 , 480   No recommendation favouring a regimen based on vasodilator treatment vs. usual care can thus be given, to date. Intravenous vasodilators may be considered to relieve AHF symp- toms when SBP is >110 mmHg. They may be started at low doses and uptitrated to achieve clinical improvement and BP control. Nitrates are generally administered with an initial bolus followed by\nManagement of diuretic therapy in patients with acute heart failure\nOn oral loop diuretic\n1–2 times daily oral dose i.v. ≥ 20–40 mg i.v. furosemide\nUrinary spot sodium     after 2 h  ≥ 50–70 mEq/L Urine output                after 6 h       ≥ 100–150 mL/h\nDouble dose i.v. until maximum i.v. dose a Repeat similar dose i.v. every 12 h\nCheck serum creatinine and electrolytes at least every 24 h\nContinue until complete decongestion\nCombination diuretic therapies b\nN Y\nY N\n≥ Urinary spot sodium     50–70 mEq/L at 2–6 h\n≥ Urine output                100–150 mL/h\nY N\nFigure 13  Diuretic therapy (furosemide) in acute heart failure. i.v.= intravenous.   a The maximal daily dose for i.v. loop diuretics is generally considered furosemide 400 \u0002 600 mg though up to 1000 mg may be considered in patients with severely impaired kidney function.   b Combination therapy is the addi- tion to the loop diuretic of a diuretic with a different site of action, e.g. thiazides or metolazone or acetazolamide. Modified from   145 .\n3654 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................\ncontinuous infusion. However, they may also be given as repeated boluses. Nitroglycerine can be given as 1 \u0002 2 mg boluses in severely hypertensive patients with acute pulmonary oedema. 477   Care should be taken to avoid hypotension due to an excessive decrease in preload and afterload. For this reason, they should be used with extreme caution in patients with LVH and/or severe aortic stenosis. However, favorable effects were described in patients with LV sys- tolic dysfunction and aortic stenosis when vasodilators were given with careful monitoring of haemodynamic parameters. 481\n11.3.5 Inotropes Inotropes are still needed for treatment of patients with low cardiac output and hypotension ( Table  22 ). They should be reserved for patients with LV systolic dysfunction, low cardiac output and low SBP (e.g. <90 mmHg) resulting in poor vital organ perfusion. However, they must be used with caution starting at low doses and uptitrating them with close monitoring. 387 , 388\nInotropes, especially those with adrenergic mechanisms, can cause sinus tachycardia, increase ventricular rate in patients with AF, may induce myocardial ischaemia and arrhythmias, and increase mor- tality. 387 , 388 , 430 , 478 Levosimendan or type-3-phosphodiesterase inhibitors may be preferred over dobutamine for patients on beta-blockers as they act through independent mechanisms. 482 , 483\nExcessive peripheral vasodilation and hypotension can be major limi- tations of type-3-phosphodiestaerase inhibitors or levosimendan, especially when administered at high doses and/or when commenced with a bolus dose. 482 , 484\n11.3.6 Vasopressors Vasopressors used for the treatment of AHF are reported in  Table  22 . Among drugs with a prominent peripheral arterial vasoconstrictor action, norepinephrine may be preferred in patients with severe hypotension. The aim is to increase perfusion to the vital organs. However, this is at the expense of an increase in LV afterload. Therefore, a combination of norepinephrine and inotropic agents may be considered, especially in patients with advanced HF and car- diogenic shock. Some studies, though with limitations, support the use of norepi- nephrine as first choice, compared with dopamine or epinephrine. Dopamine was compared with norepinephrine as a first-line vaso- pressor therapy in patients with shock and was associated with more\narrhythmic events and with a greater mortality in patients with car- diogenic shock but not in those with hypovolaemic or septic shock. Although the trial included 1679 patients, significance was seen only in a subgroup analysis of the 280 patients with cardiogenic shock and <10% of the patients had MI. As there were no data regarding revas- cularization, this limits the generalizability of the results. 485   In another prospective randomized trial epinephrine was compared with nore- pinephrine in patients with cardiogenic shock due to acute MI. 486   The trial was stopped prematurely due to a higher incidence of refractory shock with epinephrine. Epinephrine was also associated with higher heart rate and lactic acidosis. Despite limitations related to its rela- tively small sample size, short time of follow-up and lack of data regarding the maximum reached dose, the study suggests superior efficacy and safety with norepinephrine. These data are consistent with a meta-analysis including 2583 patients with cardiogenic shock showing a three-fold increase in the risk of death with epinephrine, compared with norepinephrine, in patients with cardiogenic shock. 487   However, the lack of information about dose, duration of treatment, and aetiology, makes these results partially explorative.\n11.3.7 Opiates Opiates relieve dyspnoea and anxiety. They may be used as sedative agents during non-invasive positive pressure ventilation to improve patient adaptation. Dose-dependent side effects include nausea, hypotension, bradycardia, and respiratory depression. Retrospective\nTable 22 Inotropes and/or vasopressors used to treat acute heart failure\nDrug Infusion rate\nDobutamine 2 \u0002 20  l g/kg/min (beta þ )\nDopamine 3 \u0002 5  l g/kg/min; inotropic (beta þ ) >5  l g/kg/min: inotropic (beta þ ), vasopressor (alpha þ )\nMilrinone 0.375 \u0002 0.75  l g/kg/min\nEnoximone 5 \u0002 20  l g/kg/min\nLevosimendan 0.1  l g/kg/min, which can be decreased to 0.05\nor increased to 0.2  l g/kg/min\nNorepinephrine 0.2 \u0002 1.0  l g/kg/min\nEpinephrine 0.05 \u0002 0.5  l g/kg/min\nESC 2021\nRecommendations for the initial treatment of acute heart failure\nRecommendations Class a Level b\nOxygen and ventilatory support\nOxygen is recommended in patients with SpO 2 <90% or PaO 2  <60 mmHg to correct\nhypoxaemia.\nI C\nIntubation is recommended for progressive res-\npiratory failure persisting in spite of oxygen administration or non-invasive ventilation. 448\nI C\nNon-invasive positive pressure ventilation\nshould be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO 2 <90%) and started as soon as possible in order\nto decrease respiratory distress and reduce the rate of mechanical endotracheal intubation. 448\nIIa B\nDiuretics\nIntravenous loop diuretics are recommended for\nall patients with AHF admitted with signs/symp- toms of ﬂuid overload to improve symptoms. 145\nI C\nCombination of a loop diuretic with thiazide-\ntype diuretic should be considered in patients\nwith resistant oedema who do not respond to an increase in loop diuretic doses. 145\nIIa B\nVasodilators\nIn patients with AHF and SBP >110 mmHg, i.v.\nvasodilators may be considered as initial therapy to improve symptoms and reduce\ncongestion. 475 \u0002 477 , 479 , 480\nIIb B\nContinued . ...............................................................................................\nESC Guidelines 3655\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .........................................................................................................\nanalyses suggest that morphine administration is associated with a greater frequency of mechanical ventilation, prolonged hospitalization, more intensive care unit admissions, and increased mortality. 488 \u0002 491\nThus, routine use of opiates in AHF is not recommended although they may be considered in selected patients, particularly in case of severe/intractable pain or anxiety or in the setting of palliation.\n11.3.8 Digoxin Digoxin should be considered in patients with AF with a rapid ven- tricular rate (>110 b.p.m.) despite beta-blockers (see also  section 12.1.1 ). 151 , 492 , 493   It can be given in boluses of 0.25 \u0002 0.5 mg i.v., if not used previously. However, in patients with comorbidities (i.e. CKD) or other factors affecting digoxin metabolism (including other drugs) and/or the elderly, the maintenance dose may be difficult to estimate theoretically and measurements of serum digoxin concentrations should be performed. Digitoxin is a potential alternative to digoxin and is currently being evaluated in a randomized placebo-controlled trial (ClinicalTrials.gov Identifier: NCT03783429). 158\n11.3.9 Thromboembolism prophylaxis Thromboembolism prophylaxis with heparin (e.g. low-molecular- weight heparin) or another anticoagulant is recommended, unless contraindicated or unnecessary (because of existing treatment with oral anticoagulants). 494 , 495\n11.3.10 Short-term mechanical circulatory support In patients presenting with cardiogenic shock, short-term MCS may be necessary to augment cardiac output and support end-organ per- fusion. Short-term MCS can be used as a BTR, BTD or BTB. 450 - 452\nThe initial improvements in cardiac output, BP and arterial lactate may be counterbalanced by significant complications. High-quality evidence regarding outcomes remains scarce. Hence, the unselected use of MCS in patients with cardiogenic shock is not supported and they require specialist multidisciplinary expertise for implantation and management, similar to that outlined for advanced HF centres ( Supplementary text 11 .4;  Supplementary Table 22 , see also  section 10.2.2 ). 376 , 496   Recent studies show that a ‘standardized team-based approach’ using predefined algorithms for early MCS implant coupled with close monitoring (invasive haemodynamics, lactate, markers of end-organ damage) may potentially translate into improved survival. 497 \u0002 499\nThe Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP- SHOCK-II) trial showed no difference in 30-day, as well as in long- term, mortality between intra-aortic balloon pump (IABP) and OMT in patients with cardiogenic shock following acute MI who underwent early revascularization. 500 \u0002 502   According to these results, IABP is not routinely recommended in cardiogenic shock post-MI. However, it may still be considered in cardiogenic shock, especially if not due to ACS, and refractory to drug therapy, as a BTD, BTR, or BTB. Other short-term MCS were compared with IABP in small, randomized trials and propensity-matched analyses with inconclusive results. 503 \u0002 507   Similarly, RCTs comparing extracorporeal membrane oxygenation (ECMO) with IABP or MT are lacking. A meta-analysis including only observational studies showed favourable outcomes in patients with cardiogenic shock or cardiac arrest treated with veno- arterial (VA)-ECMO compared to controls. 508   VA-ECMO may also be considered in fulminant myocarditis and other conditions causing severe cardiogenic shock. 509   Depending on the severity of myocar- dial dysfunction and/or concomitant mitral or aortic regurgitation, VA-ECMO may increase LV afterload with an increase in LV end-\nInotropic agents\nInotropic agents may be considered in patients\nwith SBP <90 mmHg and evidence of hypoperfu-\nsion who do not respond to standard treatment, including ﬂuid challenge, to improve peripheral\nperfusion and maintain end-organ function. 387\nIIb C\nInotropic agents are not recommended rou- tinely, due to safety concerns, unless the patient\nhas symptomatic hypotension and evidence of\nhypoperfusion. 387 , 467 , 478\nIII C\nVasopressors\nA vasopressor, preferably norepinephrine, may\nbe considered in patients with cardiogenic shock\nto increase blood pressure and vital organ perfusion. 485 \u0002 487\nIIb B\nOther drugs\nThromboembolism prophylaxis (e.g. with\nLMWH) is recommended in patients not already anticoagulated and with no contraindication to\nanticoagulation, to reduce the risk of deep\nvenous thrombosis and pulmonary embolism. 494 , 495\nI A\nRoutine use of opiates is not recommended,\nunless in selected patients with severe/intract- able pain or anxiety. 488 , 489\nIII C\nAHF = acute heart failure; i.v. = intravenous; LMWH = low-molecular-weight hep- arin; PaO 2  = partial pressure of oxygen; SBP = systolic blood pressure; SpO 2  = transcutaneous oxygen saturation. a Class of recommendation. b Level of evidence.\nESC 2021\nRecommendations for the use of short-term mechanical circulatory support in patients with cardiogenic shock\nRecommendations Class a Level b\nShort-term MCS should be considered in\npatients with cardiogenic shock as a BTR, BTD, BTB. Further indications include treatment of\nthe cause of cardiogenic shock or long-term\nMCS or transplantation.\nIIa C\nIABP may be considered in patients with cardio-\ngenic shock as a BTR, BTD, BTB, including treat-\nment of the cause of cardiogenic shock (i.e. mechanical complication of acute MI) or long-\nterm MCS or transplantation. 450\nIIb C\nIABP is not routinely recommended in post-MI\ncardiogenic shock. 500 \u0002 502 III B\nBTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to recovery; IABP = intra-aortic balloon pump; MCS = mechanical circulatory support; MI = myocardial infarction. a Class of recommendation. b Level of evidence.\nESC 2021\n. ..............................................................\n3656 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................\ndiastolic pressure and pulmonary congestion. In these cases, LV unloading is mandatory and can be achieved by means of transeptal/ ventricular apex vent or adding an unloading device such as the Impella device. 510 , 511\n11.3.11 Pre-discharge assessment and post-discharge management planning A significant proportion of patients with AHF are discharged with minimal or no weight loss and, more importantly, persistent conges- tion. 427 , 472   Persistent congestion before discharge is associated with a higher risk of readmission and mortality. 426 , 472   Treatment, including diuretic dose, should therefore be optimized in order to keep the patient free of congestion. In those admitted with ADHF, oral OMT should be continued, except for possible dose reduction or withdrawal if there is haemo- dynamic instability (symptomatic hypotension), severely impaired renal function or hyperkalaemia. Once haemodynamic stabilization is achieved with i.v. therapy, treatment should be optimized before dis- charge. 467   Treatment optimization has three major aims. First, to relieve congestion. Second, to treat comorbidities, such as iron defi- ciency, that have an impact on post-discharge outcome. 512   Third, to initiate, or restart oral, OMT with beneficial effects on outcome. Doses may be uptitrated before discharge and/or in the early post- discharge phase. Studies have shown that such optimization of medical treatment is associated with a lower risk of 30-day readmission, although prospec- tive randomized trials have not been performed, to date. 103 , 467 , 513\nRetrospective analyses show that discontinuation or dose reduction of beta-blocker therapy during an AHF hospitalization is associated with worse outcomes. 514   Initiation of ARNI in recently hospitalized stable patients with HFrEF, including those who are ACE-I/ARB naı¨ve, is safe and may be considered in this setting. 106 , 107   Safety and better outcome have also been recently shown in a prospective randomized trial with sotagliflozin in diabetic patients hospitalized for HF, irrespective of their LVEF. 136\nIt is recommended to have one follow-up visit within 1 to 2 weeks after discharge. 515 , 516   Components of this follow-up visit should include monitoring of signs and symptoms of HF, assessment of vol- ume status, BP, heart rate, and laboratory measurements including renal function, electrolytes, and possibly NPs. Iron status and hepatic function should also be assessed when not done before discharge. Based on clinical evaluation and laboratory exams, further optimiza- tion and/or initiation of disease-modifying treatment for HFrEF should occur. Retrospective studies show that such an approach is associated with lower 30-day readmission rates although prospective randomized trials have not been performed, to date. 513 , 516 \u0002 518\n",
      "keywords": [
        "diastolic dysfunction",
        "presentations",
        "described",
        "aortic stenosis",
        "anticoagulant",
        "elderly",
        "class i",
        "four",
        "blood pressure",
        "sbp",
        "possible",
        "heart failure",
        "overlaps",
        "them",
        "table",
        "recommended",
        "pulmonary hypertension",
        "systolic dysfunction",
        "indication",
        "contraindication",
        "ecg",
        "level b",
        "hfref",
        "mainly",
        "anticoagulation",
        "hypertension",
        "lvef",
        "bnp",
        "tachycardia",
        "echocardiography"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3647",
          "page_number": 48,
          "content": " |  | Acute decompensated\nheart failure |  | Acute pulmonary\noedema |  | Isolated right\nventricular failure |  | Cardiogenic shock | ESC 2021\nMain mechanisms |  | LV dysfunction\nSodium and water renal\nretention |  | Increased afterload and/or\npredominant LV diastolic\ndysfunction\nValvular heart disease |  | RV dysfunction and/or\npre-capillary pulmonary\nhypertension |  | Severe cardiac dysfunction | \nMain cause of\nsymptoms |  | Fluid accumulation, increased\nintraventricular pressure |  | Fluid redistribution to the\nlungs and acute respira-\ntory failure |  | Increased central venous\npressure and often sys-\ntemic hypoperfusion |  | Systemic hypoperfusion | \nOnset |  | Gradual (days) |  | Rapid (hours) |  | Gradual or rapid |  | Gradual or rapid | \nMain haemodynamic\nabnormalities |  | Increased LVEDP and PCWPa\nLow or normal cardiac output\nNormal to low SBP |  | Increased LVEDP and\nPCWPa\nNormal cardiac output\nNormal to high SBP |  | Increased RVEDP\nLow cardiac output\nLow SBP |  | Increased LVEDP and\nPCWPa\nLow cardiac output\nLow SBP | \nMain clinical\npresentations1,446 |  | Wet and warm OR Dry and\ncold |  | Wet and warmb |  | Dry and cold OR Wet and\ncold |  | Wet and cold | \nMain treatment |  | Diuretics\nInotropic agents/vasopressors\n(if peripheral hypoperfu-\nsion/hypotension)\nShort-term MCS or RRT if\nneeded |  | Diuretics\nVasodilatorsb |  | Diuretics for peripheral\ncongestion\nInotropic agents/vasopres-\nsors (if peripheral hypo-\nperfusion/hypotension)\nShort-term MCS or RRT if\nneeded |  | Inotropic agents/\nvasopressors\nShort-term MCS\nRRT | ",
          "bbox": [
            48.051513799031575,
            81.2979736328125,
            557.6139526367188,
            361.03656101226807
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3655",
          "page_number": 56,
          "content": "Drug | Infusion rate | ESC 2021\nDobutamine | 2\u000220 lg/kg/min (betaþ) | \nDopamine | 3\u00025 lg/kg/min; inotropic (betaþ)\n>5 lg/kg/min: inotropic (betaþ), vasopressor (alphaþ) | \nMilrinone | 0.375\u00020.75 lg/kg/min | \nEnoximone | 5\u000220 lg/kg/min | \nLevosimendan | 0.1 lg/kg/min, which can be decreased to 0.05\nor increased to 0.2 lg/kg/min | \nNorepinephrine | 0.2\u00021.0 lg/kg/min | \nEpinephrine | 0.05\u00020.5 lg/kg/min | ",
          "bbox": [
            48.05273661893957,
            91.33294677734375,
            293.2829895019531,
            218.23591831752233
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3655",
          "page_number": 56,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nOxygen and ventilatory support |  |  | \nOxygen is recommended in patients with SpO\n2\n<90% or PaO <60 mmHg to correct\n2\nhypoxaemia. | I | C | \nIntubation is recommended for progressive res-\npiratory failure persisting in spite of oxygen\nadministration or non-invasive ventilation.448 | I | C | \nNon-invasive positive pressure ventilation\nshould be considered in patients with respiratory\ndistress (respiratory rate >25 breaths/min, SpO\n2\n<90%) and started as soon as possible in order\nto decrease respiratory distress and reduce the\nrate of mechanical endotracheal intubation.448 | IIa | B | \nDiuretics |  |  | \nIntravenous loop diuretics are recommended for\nall patients with AHF admitted with signs/symp-\ntoms of fluid overload to improve symptoms.145 | I | C | \nCombination of a loop diuretic with thiazide-\ntype diuretic should be considered in patients\nwith resistant oedema who do not respond to\nan increase in loop diuretic doses.145 | IIa | B | \nVasodilators |  |  | \nIn patients with AHF and SBP >110 mmHg, i.v.\nvasodilators may be considered as initial therapy\nto improve symptoms and reduce\ncongestion.475\u0002477,479,480 | IIb | B | ",
          "bbox": [
            311.4074078728171,
            400.5527862548828,
            556.4976835704986,
            746.3012608119419
          ],
          "function_potential": "raw"
        },
        {
          "title": "3656 ESC Guidelines",
          "page_number": 57,
          "content": "Inotropic agents |  |  | \nInotropic agents may be considered in patients\nwith SBP <90 mmHg and evidence of hypoperfu-\nsion who do not respond to standard treatment,\nincluding fluid challenge, to improve peripheral\nperfusion and maintain end-organ function.387 | IIb | C | \nInotropic agents are not recommended rou-\ntinely, due to safety concerns, unless the patient\nhas symptomatic hypotension and evidence of\nhypoperfusion.387,467,478 | III | C | \nVasopressors |  |  | \nA vasopressor, preferably norepinephrine, may\nbe considered in patients with cardiogenic shock\nto increase blood pressure and vital organ\nperfusion.485\u0002487 | IIb | B | \nOther drugs |  |  | \nThromboembolism prophylaxis (e.g. with\nLMWH) is recommended in patients not already\nanticoagulated and with no contraindication to\nanticoagulation, to reduce the risk of deep\nvenous thrombosis and pulmonary\nembolism.494,495 | I | A | \nRoutine use of opiates is not recommended,\nunless in selected patients with severe/intract-\nable pain or anxiety.488,489 | III | C | ESC 2021",
          "bbox": [
            42.449776306152344,
            59.86335754394531,
            287.67036527745864,
            369.3441630772182
          ],
          "function_potential": "raw"
        },
        {
          "title": "3656 ESC Guidelines",
          "page_number": 57,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nShort-term MCS should be considered in\npatients with cardiogenic shock as a BTR, BTD,\nBTB. Further indications include treatment of\nthe cause of cardiogenic shock or long-term\nMCS or transplantation. | IIa | C | \nIABP may be considered in patients with cardio-\ngenic shock as a BTR, BTD, BTB, including treat-\nment of the cause of cardiogenic shock (i.e.\nmechanical complication of acute MI) or long-\nterm MCS or transplantation.450 | IIb | C | 21\nIABP is not routinely recommended in post-MI\ncardiogenic shock.500\u0002502 | III | B | ESC 20",
          "bbox": [
            306.94997119903564,
            512.8612019856771,
            552.085951063368,
            683.4292449951172
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3657",
          "page_number": 58,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that patients hospitalized for\nHF be carefully evaluated to exclude persistent\nsigns of congestion before discharge and to opti-\nmize oral treatment.427,472 | I | C | \nIt is recommended that evidence-based oral\nmedical treatment be administered before\ndischarge.103,513 | I | C | \nAn early follow-up visit is recommended at 1\u00022\nweeks after discharge to assess signs of conges-\ntion, drug tolerance and start and/or uptitrate\nevidence-based therapy.517,518 | I | C | \nFerric carboxymaltose should be considered for\niron deficiency, defined as serum ferritin <100\nng/mL or serum ferritin 100\u0002299 ng/mL with\nTSAT <20%, to improve symptoms and reduce\nrehospitalizations.512 | IIa | B | ESC 2021",
          "bbox": [
            311.46182411595396,
            96.49192504882812,
            556.5992376154119,
            316.2292360578264
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "74",
      "title": "12 Cardiovascular comorbidities",
      "start_page": 58,
      "end_page": 58,
      "content": "",
      "keywords": [
        "cardiovascular",
        "comorbidities"
      ],
      "tables": []
    },
    {
      "number": "75",
      "title": "12.1 Arrhythmias and conduction disturbances 12.1.1 Atrial fibrillation AF and HF frequently coexist. 519 , 520   They can cause or exacerbate each other through mechanisms such as structural cardiac ",
      "start_page": 58,
      "end_page": 61,
      "content": "impairment. 519 \u0002 523   The proportion of patients with HF who develop AF increases with age and HF severity. When AF causes HF the clini- cal course seems more favourable than with other causes of HF (so called tachycardiomyopathy). 524   In contrast, development of AF in patients with chronic HF is associated with worse prognosis, includ- ing stroke and increased mortality. 525 , 526\nThe management of patients with concomitant HF and AF is sum- marized in  Figure  14 . 7 , 521   It includes:\n(1) Identification and treatment of possible causes or triggers of AF (2) Management of HF (3) Prevention of embolic events (4) Rate control (5) Rhythm control\nIdentification of triggers and management of heart failure Potential causes or precipitating factors such as hyperthyroidism, electrolyte disorders, uncontrolled hypertension, mitral valve dis- ease, and infection should be identified and corrected. Worsening congestion due to AF should be managed with diu- retics. Congestion relief may reduce sympathetic drive and ventricu- lar rate and increase the chance of spontaneous return to SR. The presence of AF may reduce or abolish the prognostic benefits of beta-blockers and renders ivabradine ineffective. 12 , 125   Some treat- ments for HF decrease the risk of developing AF, including ACE-I, slightly, and CRT, probably. 7 , 527\nPrevention of embolic events Unless contraindicated, an oral, long-term anticoagulant is recom- mended in all patients with HF and paroxysmal, persistent, or perma- nent AF. Direct-acting oral anticoagulants (DOACs) are preferred\nRecommendations for pre-discharge and early post-dis- charge follow-up of patients hospitalized for acute heart failure\nRecommendations Class a Level b\nIt is recommended that patients hospitalized for\nHF be carefully evaluated to exclude persistent\nsigns of congestion before discharge and to opti- mize oral treatment. 427 , 472\nI C\nIt is recommended that evidence-based oral\nmedical treatment be administered before\ndischarge. 103 , 513\nI C\nAn early follow-up visit is recommended at 1 \u0002 2\nweeks after discharge to assess signs of conges-\ntion, drug tolerance and start and/or uptitrate evidence-based therapy. 517 , 518\nI C\nFerric carboxymaltose should be considered for\niron deﬁciency, deﬁned as serum ferritin <100\nng/mL or serum ferritin 100 \u0002 299 ng/mL with TSAT <20%, to improve symptoms and reduce\nrehospitalizations. 512\nIIa B\nHR = heart failure; TSAT = transferrin saturation. a Class of recommendation. b Level of evidence.\nESC 2021\n. ..............................................................................\nESC Guidelines 3657\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nManagement of atrial fibrillation in patients with HFrEF\nHaemodynamic instability\nAnticoagulation for preventing embolic events (Class I)\nTreatment of trigger(s) (Class I)\nOptimization of heart failure therapies (Class I)\nOR\nBeta-blockers (Class IIa)\nDigoxin/digitoxin (Class IIa)\nAmiodarone i.v. (Class IIa)\nOR\nRate control\nSymptom improvement\nSinus rhythm\nAmiodarone (Class IIb)\nECV (Class IIb)\nRhythm control\nPV ablation (Class IIa)\nECV (Class I)\nRhythm control\nOR\nAmiodarone (Class IIb)\nRhythm control\nPV ablation (Class IIa)\nAVN ablation (Class IIb)\nRate control\nSinus rhythm\nFollow-up N\nN\nN\nY\nY\nY\nY N\nOR\nOR\nFigure 14  Management of atrial fibrillation in patients with heart failure with reduced ejection fraction. AF= atrial fibrillation; AVN= atrioventricular node; ECV= electrical cardioversion; HF= heart failure; i.v.= intravenous; PV= pulmonary vein. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see Table  1  for further details on classes of recommendation).\n3658 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ for the prevention of thromboembolic events in patients with AF and without severe mitral stenosis and/or mechanical valve prosthesis, as they have similar efficacy to vitamin K antagonists (VKAs) but a lower risk of intracranial haemorrhage. 528\nLA appendage closure can be considered in patients with HF and AF who have a contraindication to oral anticoagulation though data from randomized trials have not included patients with contraindica- tions to oral anticoagulants. 529 , 530\nRate control Data regarding rate control are not conclusive for the patients with AF and HF. A strategy of lenient rate control, defined by a resting heart rate <110 b.p.m., was compared to a strategy of strict rate con- trol, defined by a heart rate <80 b.p.m. at rest and <110 b.p.m. during moderate exercise, in RACE II and in a pooled analysis of RACE and AFFIRM. 152 , 531   The studies showed no differences in outcome between the two strategies. However, only 10% of the patients in RACE II and 17% of those in the pooled analysis had a history of HF hospitalization or NYHA class II \u0002 III, respectively. 152 , 531   Higher heart rates are associated with worse outcomes in observational stud- ies. 532 , 533   Thus, a lenient rate control is an acceptable initial approach with, however, treatment targeting a lower heart rate in case of per- sistent symptoms or cardiac dysfunction likely related to tachycardia (e.g. tachycardia-induced cardiomyopathy). 7 , 534\nBeta-blockers can be used for rate control in patients with HFrEF or HFmrEF because of their established safety in these patients (see section 5.3.2 ). 7 , 534 , 535   Digoxin or digitoxin can be considered when the ventricular rate remains high, despite beta-blockers, or when beta-blockers are contraindicated or not tolerated. 151 , 493 , 536   It may therefore be considered also an alternative to beta-blockers. For patients with NYHA class IV and/or haemodynamic instability, i.v. amiodarone can be considered to reduce ventricular rate. 537   For HFpEF, there is a paucity of evidence to demonstrate efficacy of any agent. The RATE-AF trial compared digoxin with bisoprolol in patients with persistent AF and NYHA class II \u0002 IV symptoms. Compared with bisoprolol, digoxin had the same effect on QOL at 6 months (primary endpoint) and a better effect on EHRA and NYHA functional class. 536   Only 19% of the patients had LVEF <50% so that most of the patients can be considered as having HFmrEF or HFpEF. 536\nAV node ablation can be considered in patients with poor ventric- ular rate control despite medical treatment not eligible for rhythm control by catheter ablation or in patients with biventricular pacing. 7 , 538 \u0002 540\nRhythm control Urgent electrical cardioversion is recommended in the setting of acute worsening HF in patients presenting with rapid ventricular rates and haemodynamic instability, after consideration of the thromboem- bolic risk. Cardioversion should be considered also to improve symp- toms in patients who have persistent and symptomatic AF, despite optimal pharmacological management. In patients who do not receive chronic therapy with oral anticoagulant and with AF onset >48 h, at least 3 weeks of therapeutic anticoagulation or a transoeso- phageal echocardiography is needed before cardioversion. 7   When pharmacological cardioversion is preferred, amiodarone is the drug of choice as other antiarrhythmic drugs (i.e. propafenone, flecainide,\ndronedarone) are associated with worse outcomes in HFrEF. 186 , 534 , 541 \u0002 544   Amiodarone can help maintain HF patients in SR after cardioversion. 545 , 546\nTrials including patients with HF and comparing rate control and rhythm control strategies with the latter based on antiarrhythmic drugs failed to show any benefit of one strategy over the oth- er. 547 \u0002 550   More recently, EAST-AFNET 4, enrolling patients with early AF, 28.6% with HF, was stopped early after a median follow-up of 5.1 years for a lower occurrence of the primary outcome of death, stroke, or hospitalization for worsening HF or ACS in the patients assigned to early rhythm control vs. those assigned to usual care. 551\nHowever, the patients assigned to the rhythm control strategy had a closer follow-up, which may have influenced their better outcome. Catheter ablation was performed in a minority of the patients in the rhythm control arm (19.4%). 551\nLA catheter ablation was compared with MT, rate or rhythm con- trol strategy, in 363 patients with persistent or paroxysmal AF, LVEF <35% and an implanted device (ICD or CRT-D) enrolled in the CASTLE-AF trial. 552   The primary endpoint of all-cause death or HF hospitalizations occurred in fewer patients in the ablation group vs. the MT group, 51 patients (28.5%) vs. 82 (44.6%) [hazard ratio (HR); 95% confidence interval (CI), 0.62; 0.43 \u0002 0.87;  P  =0.007]. Also, other endpoints, all-cause or CV death or worsening HF, were reduced by catheter ablation. 552   This trial suggests that catheter ablation can improve the prognosis of patients with HFrEF. However, it enrolled a highly selected population, 363 of 3013 patients, was not blinded, had crossovers between the two treatment strategies and the number of events observed was low: 24 (13.4%) vs. 46 (25.0%) all-cause deaths and 37 (20.7%) vs. 66 (35.9%) HF hospitalizations in the ablation and MT groups, respectively. 552\nThe CABANA trial was an investigator-initiated, open-label, multi- centre, randomized trial enrolling 2204 patients with symptomatic AF. The trial failed to show a benefit of AF ablation strategy over medical care on the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest in the overall population. 553\nIn an analysis of the 778 patients (35%) with NYHA class symptoms >II, the primary outcome occurred in 34 patients (9.0%) in the cathe- ter ablation group vs. 49 (12.3%) in the drug therapy group (HR; 95% CI, 0.64; 0.41 \u0002 0.99). 554   However, also in this trial, the number of events was small and HF was defined based only on symptoms with LVEF available in 73% of the patients and >50% and 40 \u0002 49% in 79% and 11.7% of the cases, respectively. 554   Both CASTLE-AF and CABANA showed a highly significant effect of catheter ablation on patients’ symptoms. 552 \u0002 554\nTwo other prospective trials enrolled patients with HFrEF and persistent AF, who were randomized to catheter ablation or MT in one trial (AMICA trial,  n  = 140), and to catheter ablation or amio- darone in the other one (AATAC trial,  n  = 203). 555 , 556   The first trial failed to show any difference in the LVEF increase between the two groups. 555   The second trial showed superiority of catheter ablation with respect of AF recurrence, the primary endpoint, with also a reduction in unplanned hospitalizations and mortality. 556   In contrast with the AMICA trial, 555   but in accordance with CASTLE-AF, 552\nAATAC also showed a benefit of catheter ablation on LVEF. 556\nIn conclusion, there is insufficient evidence in favour of a strategy of rhythm control with antiarrhythmic drugs vs. rate control in patients with HF and AF. 547 \u0002 551   The results of randomized trials with\nESC Guidelines 3659\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................\ncatheter ablation vs. MT showed a consistent improvement in symp- toms whereas the results on mortality and hospitalization were obtained with a relatively small number of events not permitting to draw definitive conclusions. 152 , 548 \u0002 550 , 552 \u0002 554 , 557\n12.1.2 Ventricular arrhythmias Ventricular arrhythmias may be a complication, and in some instan- ces, a cause of HF. Frequent ventricular premature beats (VPBs) may\nlead to reversible systolic dysfunction. Possible factors may include dyssynchrony and abnormal calcium handling. 560\nInitial management of ventricular arrhythmias in HF should include correction of potential precipitants (including electrolyte abnormal- ities, particularly hypo/hyperkalaemia, and pro-arrhythmic drugs) as well as the optimization of HF drug therapy. Although ischaemia may be a triggering factor, revascularization has not been shown to reduce risk of ventricular arrhythmias. 561\nAmiodarone is effective also for suppression of ventricular arrhythmias. However, it does not reduce the incidence of sudden cardiac death or overall mortality. 161   For patients with premature ventricular contraction (PVC)-induced CMP, amiodarone administra- tion may be considered to reduce recurrent arrhythmias and improve symptoms and LV function, although its side effects should be taken into consideration. Other drugs are discussed in Supplementary text 12 .1. Radiofrequency ablation of VPBs may improve LV function and, possibly, outcomes in patients with tachycardiomyopathy when VPBs contribute to LV dysfunction. 562   A sustained reduction in the baseline PVC burden has been associated with a lower risk of cardiac mortal- ity, cardiac transplantation, or hospitalization for HF during follow- up. 563 , 564\n12.1.3 Symptomatic bradycardia, pauses and atrio- ventricular block Indications for pacemaker therapy do not differ in patients with HF from those with other CV disease. There is ample evidence that RV pacing may have an adverse effect on LV systolic function leading, in the long term, to HF. 565   Patients with HFrEF requiring frequent ven- tricular pacing, e.g. with AV block or slow AF, and who have systolic dysfunction, should be implanted with CRT rather than a standard pacemaker to avoid adverse outcomes, as shown in the BLOCK-HF (Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block) trial. 216   In the quest for a more physiological alternative to RV pacing, physiological pacing is being increasingly adopted. 566   In a non-randomized comparison of 304 con- secutive patients with His bundle pacing and 433 consecutive patients with RV pacing, the former group had less HF hospitalization and a trend in reduced mortality. 567   Although the technique is promising, more data are needed to confirm its role.\n",
      "keywords": [
        "arrhythmias",
        "class i",
        "anticoagulant",
        "heart failure",
        "other",
        "recommended",
        "contraindication",
        "systolic dysfunction",
        "disturbances",
        "frequently",
        "mechanisms",
        "level b",
        "coexist",
        "hfref",
        "hfpef",
        "anticoagulation",
        "hypertension",
        "lvef",
        "echocardiography",
        "tachycardia",
        "crt",
        "each",
        "should be considered",
        "class ii",
        "mitral stenosis",
        "cause",
        "such",
        "icd",
        "bradycardia",
        "conduction"
      ],
      "tables": [
        {
          "title": "3660 ESC Guidelines",
          "page_number": 61,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAnticoagulation |  |  | \nLong-term treatment with an oral anticoagulant\nis recommended in all patients with AF, HF, and\nCHADS-VASc score >2 in men or >3 in\n2 2 _ _\nwomen.7 | I | A | \nDOACs are recommended in preference to\nVKAs in patients with HF, except in those with\nmoderate or severe mitral stenosis or mechani-\ncal prosthetic heart valves.528,558 | I | A | \nLong-term treatment with an oral anticoagulant\nshould be considered for stroke prevention in\nAF patients with a CHADS -VASc score of 1 in\n2 2\nmen or 2 in women.7,559 | IIa | B | \nRate control |  |  | \nBeta-blockers should be considered for short-\nand long-term rate control in patients with HF\nand AF.535 | IIa | B | \nDigoxin should be considered when the ventric-\nular rate remains high, despite beta-blockers, or\nwhen beta-blockers are contraindicated or not\ntolerated.536 | IIa | C | \nCardioversion |  |  | \nUrgent ECV is recommended in the setting of\nacute worsening of HF in patients presenting\nwith rapid ventricular rates and haemodynamic\ninstability. | I | C | \nCardioversion may be considered in patients in\nwhom there is an association between AF and\nworsening of HF symptoms despite optimal\nmedical treatment.7,541 | IIb | B | \nAF catheter ablation |  |  | \nIn cases of a clear association between paroxys-\nmal or persistent AF and worsening of HF symp-\ntoms, which persist despite MT, catheter\nablation should be considered for the prevention\nor treatment of AF.552\u0002554,557 | IIa | B | ESC 2021",
          "bbox": [
            42.51080375493959,
            86.47422485351562,
            287.64541965060766,
            555.8641553606305
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "76",
      "title": "12.2 Chronic coronary syndromes CAD is the most common cause of HF in industrialized, middle- income, and increasingly in low-income, countries. It should be con- sidered as possible cause of HF in al",
      "start_page": 61,
      "end_page": 63,
      "content": "Documentation of ischaemia using non-invasive and invasive tests can be difficult in patients with HF because of the possible exercise intolerance and the effects of increased end-diastolic LV pressures. Coronary angiography or CTCA can be performed to establish the\nRecommendations for the treatment of atrial ﬁbrilla- tion in patients with heart failure\nRecommendations Class a Level b\nAnticoagulation\nLong-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and\nCHA 2 DS 2 -VASc score >_2 in men or >_3 in\nwomen. 7\nI A\nDOACs are recommended in preference to VKAs in patients with HF, except in those with\nmoderate or severe mitral stenosis or mechani-\ncal prosthetic heart valves. 528 , 558\nI A\nLong-term treatment with an oral anticoagulant\nshould be considered for stroke prevention in\nAF patients with a CHA 2 DS 2 -VASc score of 1 in men or 2 in women. 7 , 559\nIIa B\nRate control\nBeta-blockers should be considered for short-\nand long-term rate control in patients with HF and AF. 535\nIIa B\nDigoxin should be considered when the ventric-\nular rate remains high, despite beta-blockers, or\nwhen beta-blockers are contraindicated or not tolerated. 536\nIIa C\nCardioversion\nUrgent ECV is recommended in the setting of\nacute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic\ninstability.\nI C\nCardioversion may be considered in patients in whom there is an association between AF and\nworsening of HF symptoms despite optimal\nmedical treatment. 7 , 541\nIIb B\nAF catheter ablation\nIn cases of a clear association between paroxys-\nmal or persistent AF and worsening of HF symp-\ntoms, which persist despite MT, catheter ablation should be considered for the prevention\nor treatment of AF. 552 \u0002 554 , 557\nIIa B\nAF = atrial ﬁbrillation; CHA 2 DS 2 -VASc = congestive heart failure or left ventricu- lar dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)- Vascular disease, Age 65 \u0002 74, Sex category (female) (score); DOAC = direct- acting oral anticoagulant; ECV = electrical cardioversion; HF = heart failure; MT = medical therapy; VKA = vitamin K antagonist. a Class of recommendation. b Level of evidence.\nESC 2021\n3660 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .............................................................. presence and extent of CAD and evaluate the potential indication for revascularization (see  section 4.3 ). 5\n12.2.1 Medical therapy Beta-blockers are the mainstay of therapy in patients with HFrEF and CAD because of their prognostic benefit. 116 \u0002 120 , 568   Ivabradine should be considered as an alternative to beta-blockers (when contraindi- cated) or as additional anti-anginal therapy in patients in SR whose heart rate is >_70 b.p.m. 139 , 569   Other anti-anginal drugs (e.g. amlodipine, felodipine, nicorandil, ranolazine, and oral or transdermal nitrates) are effective for treating symptoms, although data about their effects on outcomes are neutral or lacking. 5 , 570 \u0002 574   Trimetazidine seems to have additive effects, such as improvement of LV function and exercise capacity, in patients with HFrEF and CCS already on beta-block- ers. 575 \u0002 577   Trimetazidine and other anti-anginal drugs may be consid- ered in patients with HF and angina despite beta-blocker and/or ivabradine. Short-acting nitrates should be used with caution in patients with HF as they cause hypotension. Diltiazem and verapamil increase HF-related events in patients with HFrEF and are contraindicated. 578\nAn algorithm for the use of anti-anginal medications in patients with HFrEF is reported in  Figure  15 .\nBeta-blockers, long-acting nitrates, calcium channel blockers (CCBs), ivabradine, ranolazine, trimetazidine, nicorandil and their combinations should be considered in HFpEF for angina relief but without a foreseen benefit on HF and coronary end points. Low-dose of rivaroxaban [2.5 mg twice daily (b.i.d.)] did not add prognostic benefit in patients with HFrEF and CCS in the COMMANDER-HF trial, a study to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, MI or stroke in participants with HF and CAD following an episode of decompen- sated HF. 579   This trial included patients with HFrEF and a recent episode of worsening HF occurring within 21 days from the time of enrolment. These patients are at high risk of HF-related events and these were the main cause of deaths and hospitalizations in the trial. Rivaroxaban had no effect on these events. In contrast, in a non-pre-specified subgroup analysis of the COMPASS trial, low dose of rivaroxaban, on top of aspirin, was associated with a reduc- tion in ischaemic events in patients with HF, mainly HFmrEF or HFpEF. 580   Based on these data, low-dose rivaroxaban may be con- sidered in patients with CAD (or peripheral artery disease) and\nUse of anti-anginal medications in patients with CCS and HFrEF\nBeta-blockers (Class I)\nPersistence of CCS symptoms\nIn absence of improvement\nTrimetazidine (Class IIb)\nNicorandil (Class IIb) OR\nOR\nOR\nFelopidine (Class IIb)\nRanolazine (Class IIb)\nNitrates (Class IIb)\nAmlodipine (Class IIb)\nIvabradine (Class IIa)\nHR <70 bpm, and/or atrial fibrillation HR ≥ 70 bpm, and sinus rhythm\nDiltiazem (Class III)\nVerapamil (Class III)\nFigure 15  Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction. CCS = chronic coronary syndrome; HFrEF= heart failure with reduced ejection fraction; HR= heart rate. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see Table  1  for further details on classes of recommendation).\nESC Guidelines 3661\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...............................................................\nHF, LVEF >40% and SR, when at high risk of stroke and with a low haemorrhagic risk.\n12.2.2 Myocardial revascularization Data on the benefit of myocardial revascularization in patients with HF are limited. STICH compared coronary artery bypass grafting (CABG) with MT in patients with CAD, amenable by CABG, and with reduced LV function (EF <_35%). At a median follow-up of 56 months, there was no significant difference between the CABG group and the MT group in the rate of death from any cause, primary outcome of the trial. 89\nThe extended follow-up report showed a significant reduction of death in the CABG group vs. the control group (58.9% vs. 66.1%; HR 0.84; 95% CI, 0.73 \u0002 0.97;  P  = 0.02) over 10 years. 581   CV death and the combined endpoint of all-cause death or hospitalization for CV causes were also significantly reduced after CABG at 10 years of follow-up. 581   Post hoc analyses of the STICH trial suggested that neither myocardial viability, angina, nor ischaemia were related with outcomes after revascularization. 92 , 93 , 582   The Heart Failure Revascularisation Trial (HEART) was under-powered, with only 138 of the planned 800 patients to be enrolled, and failed to show differ- ences in outcomes between HF patients receiving CABG or MT. 583\nThere are currently no reported RCTs comparing percutaneous coronary intervention (PCI) with MT in patients with HFrEF. However, the REVIVED-BCIS2 trial has finished recruitment (ClinicalTrials.gov Identifier: NCT01920048). 584   There are also no randomized studies comparing PCI with CABG as such randomized trials excluded patients with HFrEF. In one prospective registry, including 4616 patients with multivessel disease and HFrEF, propensity-score matched comparisons showed similar survival (mean follow-up 2.9 years) in PCI vs. CABG group with PCIs associ- ated with a higher risk of MI, particularly in patients with incomplete revascularization, and CABG associated with a higher risk of stroke. 585   A propensity-matched analysis showed a significantly lower risk of death or major CV events in diabetic patients with LV dysfunction and multivessel disease treated with CABG compared with PCI. 586   CABG was associated with better outcome than PCI also in patients with moderate or severe LV dysfunction and left main or complex coronary disease. 587 , 588   Two meta-analyses confirmed that CABG is associated with better outcomes, including mortality, MI, and repeated revascularization, compared with PCI and/or MT. 589 , 590\n",
      "keywords": [
        "class i",
        "anticoagulant",
        "angiography",
        "sidered",
        "middle",
        "possible",
        "heart failure",
        "should",
        "recommended",
        "income",
        "indication",
        "level b",
        "peripheral artery",
        "class iii",
        "hfref",
        "hfpef",
        "female",
        "anticoagulation",
        "hypertension",
        "lvef",
        "diabetic",
        "should be considered",
        "common",
        "coronary artery",
        "mitral stenosis",
        "industrialized",
        "coronary",
        "cause",
        "diastolic",
        "increasingly"
      ],
      "tables": [
        {
          "title": "3662 ESC Guidelines",
          "page_number": 63,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nCABG should be considered as the first-choice\nrevascularization strategy, in patients suitable for\nsurgery, especially if they have diabetes and for\nthose with multivessel disease.581,587,588,590 | IIa | B | \nCoronary revascularization should be considered\nto relieve persistent symptoms of angina (or an\nangina-equivalent) in patients with HFrEF, CCS,\nand coronary anatomy suitable for revasculariza-\ntion, despite OMT including anti-anginal drugs. | IIa | C | \nIn LVAD candidates needing coronary revascula-\nrization, CABG should be avoided, if possible. | IIa | C | \nCoronary revascularization may be considered\nto improve outcomes in patients with HFrEF,\nCCS, and coronary anatomy suitable for revas-\ncularization, after careful evaluation of the indi-\nvidual risk to benefit ratio, including coronary\nanatomy (i.e. proximal stenosis >90% of large\nvessels, stenosis of left main or proximal LAD),\ncomorbidities, life expectancy, and patient’s\nperspectives. | IIb | C | \nPCI may be considered as an alternative to\nCABG, based on Heart Team evaluation, consid-\nering coronary anatomy, comorbidities, and sur-\ngical risk. | IIb | C | ESC 2021",
          "bbox": [
            306.91002516313034,
            96.49192504882812,
            552.0477576622596,
            413.451160975865
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "77",
      "title": "12.3 Valvular heart disease 12.3.1 Aortic stenosis Aortic stenosis may cause or worsen HF by increasing LV afterload and causing LV hypertrophy and remodelling. 591   When HF symp- toms occur in patie",
      "start_page": 63,
      "end_page": 67,
      "content": "corrected (i.e. anaemia, hyperthyroidism, arteriovenous shunts) before proceeding to aortic valve intervention. 592   An aortic valve intervention is recommended in patients with HF symptoms and severe, high-gradient aortic stenosis, regardless of LVEF. Management of patients with low-flow low-gradient aortic stenosis is reported in  Figure  16 . 592\nIntervention is recommended in patients with a life expectancy >1 year, avoiding futility. Transcatheter aortic valve implantation (TAVI) has been shown to be non-inferior to surgical aortic valve replace- ment (SAVR) in reducing clinical events (including mortality and dis- abling stroke) in patients at high and intermediate risk for surgery. 593 \u0002 600   In low-risk patients, mean age in the RCTs comparing TAVI and SAVR was >70 years and follow-up was restricted to 2 years. Therefore, SAVR is recommended in patients aged <75 years and at low surgical risk (STS-PROM score or EuroSCORE II <4%), whereas TAVI is recommended in those aged >75 years or at high/ prohibitive surgical risk (STS-PROM score or EuroSCORE II >8%). In all the other cases, the choice between TAVI and SAVR should be made by the Heart Team, weighing the pros and cons of each proce- dure, according to age, life expectancy, individual patient preference and other features including clinical and anatomical aspects. Aortic\nRecommendations for myocardial revascularization in patients with heart failure with reduced ejection fraction\nRecommendations Class a Level b\nCABG should be considered as the ﬁrst-choice\nrevascularization strategy, in patients suitable for\nsurgery, especially if they have diabetes and for those with multivessel disease. 581 , 587 , 588 , 590\nIIa B\nCoronary revascularization should be considered\nto relieve persistent symptoms of angina (or an\nangina-equivalent) in patients with HFrEF, CCS, and coronary anatomy suitable for revasculariza-\ntion, despite OMT including anti-anginal drugs.\nIIa C\nIn LVAD candidates needing coronary revascula- rization, CABG should be avoided, if possible. IIa C\nCoronary revascularization may be considered\nto improve outcomes in patients with HFrEF,\nCCS, and coronary anatomy suitable for revas- cularization, after careful evaluation of the indi-\nvidual risk to beneﬁt ratio, including coronary\nanatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal LAD),\ncomorbidities, life expectancy, and patient’s\nperspectives.\nIIb C\nPCI may be considered as an alternative to\nCABG, based on Heart Team evaluation, consid-\nering coronary anatomy, comorbidities, and sur- gical risk.\nIIb C\nCABG = coronary artery bypass graft; CCS = chronic coronary syndrome; HFrEF = heart failure with reduced ejection fraction; LAD = left anterior descending artery; LVAD = left ventricular assist device; OMT = optimal medical therapy; PCI = percutaneous coronary intervention. a Class of recommendation. b Level of evidence.\nESC 2021\n. ....................................................................................................................\n3662 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ........ valve interventions should be performed only in centres having both interventional cardiology and cardiac surgery services on site and a structured collaborative Heart Team approach.\nBalloon aortic valvuloplasty may be considered in highly sympto- matic patients with AHF (i.e. cardiogenic shock) as bridge to TAVI or SAVR, or in advanced HF as BTR or DT.\nManagement of patients with heart failure and suspected severe low-flow low-gradient AS a\nDobutamine echo\nLVEF < 50%\nOR\nTAVI (Class I)\nSAVR (Class I)\nY N\nFlow reserve c\nClinical and echo criteria b\nHigh calcium score d by CT\nY\nSevere low-flow  low-gradient AS\nN\nMedical therapy optimization (Class I)\nHeart Team g\n(Class I) Heart Team g\n(Class I) Follow-up\nY\nf N\ne\nY\nf\nOR\nTAVI (Class IIa)\nSAVR (Class IIa)\nN Y Y\nFigure 16  Management of patients with severe low-flow low-gradient aortic stenosis and heart failure. AS= aortic stenosis; CT = computed tomogra- phy; EuroSCORE II= European System for Cardiac Operative Risk Evaluation II; LVEF= left ventricular ejection fraction; OMT = optimal medical therapy; SAVR= surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI= transcatheter aortic valve implantation.   a Valve area <_1 cm 2 , peak velocity <4.0 m/s, mean gradient <40; stroke volume index <_35 mL/m 2 .   b Age >70 years, typical symptoms without other explanations, left ventricular hypertrophy or reduced left ventricular longitudinal function, mean gradient 30 \u0002 40 mmHg, valve area <_0.8 cm 2 , stroke volume index <_35 mL/m 2   assessed by techniques other than standard Doppler.   c Flow reserve is defined as stroke volume index increase >20%.   d AS is very likely if calcium score is >_3000 in men and >_1600 in women. AS is likely if calcium score is >_2000 in men and >_1200 in women. AS is unlikely if calcium score is <1600 in men and <800 in women.   e Increase in valve area to >1.0 cm 2   in response to flow increase (flow reserve) during dobutamine echo. f Increase in mean gradient to at least 40 mmHg without significant change in valve area in response to flow increase (flow reserve) during dobutamine echo.   g SAVR is recommended in patients aged <75 years and low surgical risk (STS-PROM score or EuroSCORE II <4%), whereas TAVI in those aged >75 years or at high/prohibitive surgical risk (STS-PROM score or EuroSCORE II >8%). In all the other cases, the choice between TAVI and SAVR is rec- ommended to be decided by the Heart Team, weighing the pros and cons of each procedure, according to age, life expectancy, individual patient prefer- ence and features including clinical and anatomical aspects. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see  Table  1  for further details on classes of recommendation).\nESC Guidelines 3663\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .......................... 12.3.2 Aortic regurgitation Severe aortic regurgitation can lead to progressive LV dilation with subsequent dysfunction, HF, and poor prognosis. MT can improve HF symptoms in patients with severe aortic regurgitation. In particular, inhibitors of the RAAS can be useful. 601\nBeta-blockers should be cautiously used as they prolong diastole and may worsen aortic regurgitation. Aortic valve surgery is recommended in patients with severe aortic regurgitation and HF symptoms regardless of LVEF. 592 , 602 , 603   In case\nof high or prohibitive surgical risk, TAVI has been used to treat also aortic regurgitation. 604\n12.3.3 Mitral regurgitation Primary (organic) mitral regurgitation Primary mitral regurgitation (MR) is caused by abnormalities of the valve apparatus and can cause HF. Surgery, preferably repair, is recommended in patients with severe primary MR and HF symptoms. If surgery is contraindicated\nManagement of secondary mitral regurgitation in patients with HFrEF\nPCI (Class IIb)\nCABG and mitral valve surgery (Class IIa)\nHeart Team (Class I)\nNeed for coronary revascularization OMT including CRT if indicated\nY N\nY\nHigh surgical risk\nPersistence of HF symptoms a\nand significant SMR b\nN\nMT optimization and implant CRT if indicated (Class I)\nY N\nN Y\nConsider surgery if low-risk (Class IIb)\nPercutaneous EE mitral valve repair (Class IIa)\nConsider percutaneous EE mitral valve repair to improve symptoms or as BTT or to LVAD (Class IIb)\nMaintain ongoing therapy. Consider palliative care and/or MCS or HT, if possible\nHeartTeam (Class I) Follow-up\nEchocardiographic and clinical criteria for outcome improvement after percutaneous EE mitral valve repair c\nN Y\nFigure 17  Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction. BTT= bridge to transplantation; CABG= coronary artery bypass graft; CRT = cardiac resynchronization therapy; EE= edge-to-edge; EROA= effective regurgitant orifice area; HF= heart failure; LVAD= left ventricular assist device; LVEF= left ventricular ejection fraction; LVESD=left ventricular end-systolic diameter; MCS= mechanical cir- culatory support; MT =medical therapy; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI= percutaneous coronary interven- tion; SMR= secondary mitral regurgitation; TR= tricuspid regurgitation.   a NYHA class II \u0002 IV.   b Moderate-to-severe or severe (EROA >_30 mm 2 ).   c All of the following criteria must be fulfilled: LVEF 20 \u0002 50%, LVESD <70 mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe right ventricu- lar dysfunction or severe TR, absence of haemodynamic instability. 612   Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb (see  Table  1  for further details on classes of recommendation).\n3664 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ..................................... or considered at high risk, then percutaneous repair may be considered. 592 , 605\nSecondary (functional) mitral regurgitation Secondary mitral regurgitation (SMR) is mostly a disease of the left ventricle. It can also be caused by mitral annulus enlargement due to LA dilation. 606   Moderate or severe SMR is associated with an extremely poor prognosis in patients with HF. 607 , 608   The assess- ment of MR aetiology and severity should be performed by an experienced echocardiographer applying a multi-parametric approach, and ideally in stable patient conditions, after optimization of medical and resynchronization therapies. Being SMR a dynamic condition, echocardiographic quantification during exercise may be helpful in patients with moderate SMR at rest and symptoms during physical activity. 609   Early referral of patients with HF and moderate or severe MR to a multidisciplinary Heart Team, including HF spe- cialists, is recommended for assessment and treatment planning. The Heart Team has to verify, first of all, that the patient is on optimal therapy, including CRT, when indicated ( Figure  17 ). In patients with severe SMR and HFrEF requiring revascularization, mitral valve surgery and CABG should be considered. Isolated mitral valve surgery may be considered in symptomatic patients with severe SMR despite optimal therapy and low surgical risk. 592\nTwo randomized trials, MITRA-FR and COAPT, evaluated the effectiveness of percutaneous edge-to-edge mitral valve repair plus OMT compared to OMT alone, in symptomatic patients with reduced LVEF (15 \u0002 40% in MITRA-FR and 20 \u0002 50% in COAPT) and moderate-to-severe or severe SMR [effective regurgitant orifice area (EROA) >_ 20 mm 2   in MITRA-FR and EROA >_ 30 mm 2   in COAPT]. 610 \u0002 612   MITRA-FR failed to show any benefit from the intervention on all-cause mortality or HF hospitalization at 12 months (primary endpoint; HR 1.16, 95% CI 0.73 \u0002 1.84) and at 24 months. 610 , 611   In contrast, COAPT showed a significant reduction in hospitalization for HF at 24 months (primary endpoint; HR 0.53, 95% CI 0.40 \u0002 0.70) and mortality (secondary endpoint; HR 0.62, 95% CI 0.46 \u0002 0.82). 612   Differences in patient selection, concomitant MT, echocardiographic assessment, procedural issues and severity of SMR in relation to the degree of LV dilatation may be responsible for the diverging results of the MITRA-FR and COAPT trials. 613 \u0002 615\nThus, percutaneous edge-to-edge mitral valve repair should be con- sidered for outcome improvement only in carefully selected patients who remain symptomatic (NYHA class II \u0002 IV) despite OMT, with moderate-to-severe or severe SMR (EROA >_30 mm 2 ), favourable anatomical conditions, and fulfilling the inclusion criteria of the COAPT study (i.e. LVEF 20 \u0002 50%, LV end-systolic diameter <70 mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe RV dysfunction, absence of severe TR, absence of haemo- dynamic instability) ( Figure  17 ). 615 , 616\nPercutaneous edge-to-to edge mitral valve repair may also be considered to improve symptoms in patients with advanced HF, severe SMR and severe symptoms despite OMT. In these patients, cardiac transplantation or LVAD implantation must also be considered. 376 , 617\nOther percutaneous mitral valve repair systems, such as indirect annuloplasty, are available for treatment of SMR. This approach has a shorter learning curve and lesser technical requirements than percu- taneous edge-to-to edge mitral valve repair and does not preclude\ndifferent procedures once it is performed. A sham-controlled randomized trial testing a transcatheter indirect mitral annuloplasty device met its primary endpoint of mitral regurgitant volume reduc- tion with reverse LV and LA remodelling at 12 months. 618   Further studies confirmed favourable results on LA volumes and LV remodel- ling with trends towards improvement in mean 6MWT distance and symptoms and a reduction in HF hospitalizations in an IPD meta-ana- lysis. 619 \u0002 622   Transcatheter mitral valve replacement is also emerging as a possible alternative option, but randomized trials are still lacking. 623\nMitral valve interventions are not recommended in patients with a life expectancy of <1 year due to extra-cardiac conditions. 592\nRecommendations for the management of valvular heart disease in patients with heart failure\nRecommendations Class a Level b\nAortic stenosis\nAortic valve intervention, TAVI or SAVR, is rec- ommended in patients with HF and severe high-\ngradient aortic stenosis to reduce mortality and\nimprove symptoms. 594\nI B\nIt is recommended that the choice between TAVI and SAVR be made by the Heart Team,\naccording to individual patient preference and\nfeatures including age, surgical risk, clinical, ana- tomical and procedural aspects, weighing the\nrisks and beneﬁts of each approach. 592\nI C\nSecondary mitral regurgitation\nPercutaneous edge-to-edge mitral valve repair should be considered in carefully selected\npatients with secondary mitral regurgitation, not\neligible for surgery and not needing coronary revascularization, who are symptomatic c   despite\nOMT and who fulﬁl criteria d   for achieving a\nreduction in HF hospitalizations. 612\nIIa B\nIn patients with HF, severe secondary mitral\nregurgitation and CAD who need revasculariza-\ntion, CABG and mitral valve surgery should be considered.\nIIa C\nPercutaneous edge-to-edge mitral valve repair\nmay be considered to improve symptoms in\ncarefully selected patients with secondary mitral regurgitation, not eligible for surgery and not\nneeding coronary revascularization, highly symp-\ntomatic despite OMT and who do not fulﬁl crite- ria for reducing HF hospitalization. 617\nIIb C\nCABG = coronary artery bypass graft; CAD = coronary artery disease; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; NYHA = New York Heart Association; OMT = optimal medical therapy; SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation; TR = tricuspid regurgitation. a Class of recommendation. b Level of evidence. c NYHA class II \u0002 IV. d All of the following criteria must be fulﬁlled: LVEF 20 \u0002 50%, LVESD <70 mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe right ventricular dysfunction or severe TR, absence of haemodynamic instability. 612\nESC 2021\n. ......................................................................................................................................\nESC Guidelines 3665\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 12.3.4 Tricuspid regurgitation Tricuspid regurgitation (TR) can be caused by or be a consequence of RV dysfunction and HF. The management of HF with TR includes MT (i.e. diuretics, neurohormonal antagonists). Transcatheter ther- apy and surgery may be considered in selected cases. 592   A multidisci- plinary Heart Team, including HF specialists, should be considered for assessment and treatment planning. Tricuspid valve surgery is recommended in patients with severe TR requiring left-sided cardiac surgery. It should be also considered in patients with moderate TR and tricuspid annulus dilatation requir- ing left-sided cardiac surgery and in symptomatic patients with iso- lated severe TR. 592   However, surgery in isolated TR is burdened by high in-hospital mortality (8.8%) although the advanced stage of HF may have influenced these data. 624   Transcatheter techniques have recently emerged as potential treatment options of TR. Preliminary results show improvement in TR severity and symptoms with low complication rates. 625   Further prospective studies are needed to show the prognostic impact of these treatments in HF patients.\n",
      "keywords": [
        "aortic stenosis",
        "class i",
        "patie",
        "afterload",
        "heart failure",
        "echo",
        "recommended",
        "when",
        "level b",
        "physical activity",
        "causing",
        "hfref",
        "worsen",
        "disease",
        "symp",
        "valve repair",
        "lvef",
        "crt",
        "heart",
        "should be considered",
        "class ii",
        "coronary artery",
        "toms",
        "cause",
        "remodelling",
        "mitral regurgitation",
        "nyha",
        "aortic",
        "may be considered",
        "tricuspid"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3665",
          "page_number": 66,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAortic stenosis |  |  | \nAortic valve intervention, TAVI or SAVR, is rec-\nommended in patients with HF and severe high-\ngradient aortic stenosis to reduce mortality and\nimprove symptoms.594 | I | B | \nIt is recommended that the choice between\nTAVI and SAVR be made by the Heart Team,\naccording to individual patient preference and\nfeatures including age, surgical risk, clinical, ana-\ntomical and procedural aspects, weighing the\nrisks and benefits of each approach.592 | I | C | \nSecondary mitral regurgitation |  |  | \nPercutaneous edge-to-edge mitral valve repair\nshould be considered in carefully selected\npatients with secondary mitral regurgitation, not\neligible for surgery and not needing coronary\nrevascularization, who are symptomaticc despite\nOMT and who fulfil criteriad for achieving a\nreduction in HF hospitalizations.612 | IIa | B | \nIn patients with HF, severe secondary mitral\nregurgitation and CAD who need revasculariza-\ntion, CABG and mitral valve surgery should be\nconsidered. | IIa | C | \nPercutaneous edge-to-edge mitral valve repair\nmay be considered to improve symptoms in\ncarefully selected patients with secondary mitral\nregurgitation, not eligible for surgery and not\nneeding coronary revascularization, highly symp-\ntomatic despite OMT and who do not fulfil crite-\nria for reducing HF hospitalization.617 | IIb | C | ESC 2021",
          "bbox": [
            311.42217799595426,
            233.8757751464844,
            556.5633437212775,
            625.2561776297433
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "78",
      "title": "12.4 Hypertension Arterial hypertension is a leading risk factor for the development of HF. Almost two-thirds of HF patients have a past history of hyperten- sion. 104 , 626   Clinical trials evaluati",
      "start_page": 67,
      "end_page": 67,
      "content": "ARBs, ACE-I, and CCBs cause more effective LVH regression than beta-blockers or diuretics. 632   Poorly controlled hypertension may precipitate episodes of decompensation. Causes of secondary hyper- tension, such as renal vascular or parenchymal disease, primary aldos- teronism and obstructive sleep apnoea (OSA), should be ruled out or, if confirmed, considered for treatment. Treatment of hyperten- sion is an important issue in patients with HFpEF, but the optimal treatment strategy is uncertain. The treatment strategy used in HFrEF should also be considered in HFpEF. 4\nBP targets are uncertain in both HFrEF and HFpEF. However, eval- uation of patient’s age and comorbidities (i.e. diabetes, CKD, CAD, valvular heart disease and stroke) can be helpful to personalize the BP target. 4   Every effort should be made to reach target doses of evidence-based medications in HFrEF patients, despite slight hypo- tension. 4 , 633   Conversely, in HFpEF patients with LVH and limited pre- load reserve, hypotension should be avoided.\n",
      "keywords": [
        "evaluati",
        "almost",
        "history",
        "trials",
        "development",
        "sion",
        "leading",
        "arterial",
        "hfref",
        "thirds",
        "hfpef",
        "hyperten",
        "clinical",
        "hypertension",
        "patients",
        "risk",
        "diabetes",
        "past",
        "age",
        "factor"
      ],
      "tables": []
    },
    {
      "number": "79",
      "title": "12.5 Stroke HF and stroke frequently coexist because of an overlap of shared risk factors and subsequent mechanisms. 519 , 634   A higher risk of stroke is present also in HF patients in SR. 39 , 426 ",
      "start_page": 67,
      "end_page": 67,
      "content": "As a temporal trend, the incidence of stroke is higher in the first 30 days after HF diagnosis or an episode of HF decompensation and decreases in the first 6 months following the acute event. 637 , 639\nPatients with stroke and HF have higher mortality, more severe neu- rological deficits and longer hospital stays than those without HF. 637 , 640   Similarly, patients with HF and stroke have a higher mortal- ity than patients without stroke. 640   In COMMANDER-HF, 47.5% of strokes were either disabling, 16.5%, or fatal, 31%. 637\nPatients with HF and concomitant AF, including paroxysmal AF, have a CHA 2 DS 2 -VASc score of at least 1 and have therefore an indi- cation to anticoagulation. The indication to antithrombotic strategies in patients with HF and SR is controversial. In the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, war- farin reduced ischaemic stroke as compared with aspirin, but increased major haemorrhages and did not influence the primary endpoint of ischaemic stroke, intracerebral haemorrhage, or death. 641   Meta-analyses confirm an increased risk of bleeding out- weighing ischaemic stroke prevention in placebo-controlled trials in patients with HFrEF and SR. 642   In COMMANDER-HF, rivaroxaban 2.5 mg b.i.d. did not improve the composite outcome of all-cause mortality, MI or stroke, nor did it favourably influence HF-related deaths or HF hospitalizations. 579   There are no data to support a rou- tine strategy of anticoagulation in patients with HFrEF in SR who do not have history of paroxysmal AF. However, low-dose rivaroxaban may be considered in patients with concomitant CCS or peripheral artery disease, a high risk of stroke and no major haemorrhagic risk (see  section 12.2 ). Patients with visible intraventricular thrombus or at high throm- botic risk, such as those with history of peripheral embolism or some patients with PPCM or LV non-compaction (LVNC), should be con- sidered for anticoagulation. 3 , 643 \u0002 645\n",
      "keywords": [
        "indication",
        "stroke",
        "mechanisms",
        "coexist",
        "peripheral artery",
        "hfref",
        "also",
        "shared",
        "anticoagulation",
        "factors",
        "because",
        "higher",
        "subsequent",
        "patients",
        "overlap",
        "may be considered",
        "risk",
        "ejection fraction",
        "present",
        "frequently"
      ],
      "tables": []
    },
    {
      "number": "80",
      "title": "13 Non-cardiovascular comorbidities",
      "start_page": 67,
      "end_page": 67,
      "content": "",
      "keywords": [
        "cardiovascular",
        "comorbidities"
      ],
      "tables": []
    },
    {
      "number": "81",
      "title": "13.1 Diabetes Treatment of HF is similar in patients with and without diabetes. 6 , 646",
      "start_page": 67,
      "end_page": 68,
      "content": "Conversely, antidiabetic drugs differ in their effects in patients with HF and preference must be given to drugs that are both safe and reduce HF-related events. 6 , 646 , 647\n3666 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................ The SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin, ertugliflozin and sotagliflozin were studied in patients with established CV disease in the EMPA-REG OUTCOME and VERTIS-CV trials, with established CV disease or CV risk factors in the CANVAS and DECLARE-TIMI 58 trials, and with CKD and CV risk in the SCORED trial, respectively. 293 \u0002 297   A small proportion of patients had a history of HF. Empagliflozin and canagliflozin reduced the primary composite endpoint of major CV adverse events, including CV death or non- fatal MI or non-fatal stroke, and HF hospitalizations in EMPA-REG OUTCOME and CANVAS, respectively. 293 , 294   Empagliflozin also reduced all-cause death or CV death alone. 293   The effects on the pri- mary endpoint were driven by the reduction in HF-related events. 293 , 294   In DECLARE-TIMI 58, dapagliflozin did not reduce major CV events but reduced the co-primary efficacy endpoint of CV death or HF hospitalization and HF hospitalization alone. 295   In VERTIS-CV, neither the primary major CV event endpoint nor the key secondary outcome of CV death or HF hospitalization were reduced significantly by ertugliflozin, although there was a statistically significant reduction in HF hospitalization and repeated hospitaliza- tions. 297 , 648   In SCORED, sotagliflozin reduced CV deaths and HF hospitalizations. 296   In a meta-analysis of these trials and one further trial in patients with CKD (CREDENCE), overall SGLT2 inhibitors reduced HF and CV hospitalization by 22%. 649   SGLT2 inhibitors were well tolerated, although they may cause genital fungal skin infec- tions and, rarely, diabetic ketoacidosis. 293 \u0002 295   Trial results with dapa- gliflozin and empagliflozin in patients with HFrEF, with or without diabetes, and with the SGLT1/2 inhibitor sotagliflozin in patients with type 2 diabetes stabilized after hospitalization for acute HF or within 3 days after discharge, further support the administration of these agents (see  section 5.3.5  and  section 11.3.11 ). 108 , 109 , 136\nEMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and VERTIS-CV also showed a reduction in worsening renal function, end-stage renal disease or death from renal causes, with SGLT2 inhibitors. Based on these results, the SGLT inhibitors canagliflozin, dapagli- flozin, empagliflozin, ertugliflozin or sotagliflozin are recommended to prevent HF and CV death and worsening kidney function in patients with type 2 diabetes and CV disease and/or CV risk factors, or CKD. Dapagliflozin and empagliflozin are also indicated for the treatment of patients with type 2 diabetes and HFrEF (see section 5.3.5  and  section 11.2.4 ) and sotagliflozin was shown to reduce CV deaths and HF rehospitalizations in patients recently hos- pitalized for HF. 6 , 296 , 646 , 647 , 650\nMetformin is thought to be safe in patients with HF, compared with insulin and sulfonylureas, based on observational studies. 651 , 652\nHowever, it is not recommended in patients with an eGFR <30 mL/ min/1.73 m 2   or hepatic impairment because of the risk of lactic acido- sis. It has not been studied in controlled outcome trials, to date. 6 , 646\nRegarding dipeptidyl peptidase-4 (DPP-4) inhibitors, HF hospital- izations were increased by 27% in one trial with saxagliptin in patients with diabetes. 653   However, no difference over placebo for HF events was found with alogliptin, sitagliptin, and linagliptin. 654 \u0002 656   Vidagliptin was associated with an increase in LV volumes and a numerically greater number of deaths and CV events in a small trial in patients with diabetes and HF. 657   Overall, the effects on mortality or CV events were neutral in the DPP-4 inhibitor trials and meta-\nanalyses. 658 , 659   These drugs are therefore not recommended to reduce CV events in diabetic patients with HF. Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of MI, stroke, and CV death in patients with diabetes, although prob- ably do not reduce incident HF. 6 , 660   Liraglutide had no effect on LVEF, increased heart rate, and increased serious cardiac events in a randomized placebo-controlled trial in 241 patients with HFrEF with and without diabetes. 661   Neutral results on the primary endpoint were found in another trial in 300 patients with a numerical increase in deaths and HF hospitalizations, compared with placebo. 662   GLP-1 receptor agonists are therefore not recommended for the preven- tion of HF events. Insulin is needed in patients with type 1 diabetes and to control hyperglycaemia in some patients with type 2 diabetes, especially when beta-cell function is exhausted. It is a sodium-retaining hor- mone and concern has been raised that it may exacerbate fluid reten- tion in patients with HF. However, in a RCT that included patients with type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose, insulin did not increase the risk of incident HF. 663   Use of insulin was associated with poorer outcomes in retrospective analy- ses of randomized trials and administrative databases. 664 , 665   If insulin is needed in a patient with HF, the patient should be monitored for evidence of worsening of HF after treatment initiation. Sulfonylureas were associated with a higher risk of HF events in some analyses. 666 , 667   Therefore, they are not a preferred treatment in patients with HF and, if needed, patients should be monitored for evidence of worsening of HF after treatment initiation. 6 , 646\nThiazolidinediones (glitazones) cause sodium and water retention and an increased risk of worsening HF and hospitalization. 668   They are contraindicated in patients with HF.\n",
      "keywords": [
        "hfref",
        "treatment",
        "glucose",
        "diabetes",
        "lvef",
        "sglt2",
        "patients",
        "diabetic",
        "recommended",
        "metformin",
        "egfr",
        "insulin",
        "glp-1",
        "without",
        "similar"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3667",
          "page_number": 68,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nSGLT2 inhibitors (canagliflozin, dapagliflozin,\nempagliflozin, ertugliflozin, sotagliflozin) are rec-\nommended in patients with T2DM at risk of CV\nevents to reduce hospitalizations for HF, major\nCV events, end-stage renal dysfunction, and CV\ndeath.293\u0002297 | I | A | \nSGLT2 inhibitors (dapagliflozin, empagliflozin,\nand sotagliflozin) are recommended in patients\nwith T2DM and HFrEF to reduce hospitalizations\nfor HF and CV death.108,109,136 | I | A | ESC 2021",
          "bbox": [
            311.5187518780048,
            463.5212829589844,
            556.6571655273438,
            608.8782261439732
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "82",
      "title": "13.2 Thyroid disorders Assessment of thyroid function is recommended in all patients with HF as both hypo- and hyperthyroidism may cause or precipitate HF. 669",
      "start_page": 68,
      "end_page": 69,
      "content": "Subclinical hypothyroidism and isolated low triiodothyronine levels\nRecommendations for the treatment of diabetes in heart failure\nRecommendation Class a Level b\nSGLT2 inhibitors (canagliﬂozin, dapagliﬂozin,\nempagliﬂozin, ertugliﬂozin, sotagliﬂozin) are rec-\nommended in patients with T2DM at risk of CV events to reduce hospitalizations for HF, major\nCV events, end-stage renal dysfunction, and CV\ndeath. 293 \u0002 297\nI A\nSGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients\nwith T2DM and HFrEF to reduce hospitalizations\nfor HF and CV death. 108 , 109 , 136\nI A\nCV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejec- tion fraction; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus. a Class of recommendation. b Level of evidence.\nESC 2021\n. ............................................................................\nESC Guidelines 3667\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ were associated with poorer outcomes in observational studies in patients with HF. 670 , 671   Treatment of thyroid disorders should be guided by general endocrine guidelines. There are no randomized trials evaluating the efficacy of thyroid replacement therapy in subclinical hypothyroidism, but there is a general agreement to correct it when the TSH is >10 mIU/L, particularly in patients <70 years. Correction may also be considered at lower TSH levels (7 \u0002 10 mIU/L). 672 \u0002 674\n",
      "keywords": [
        "hfref",
        "precipitate",
        "cause",
        "glucose",
        "diabetes",
        "disorders",
        "heart failure",
        "sglt2",
        "patients",
        "both",
        "hypo",
        "recommended",
        "assessment",
        "thyroid",
        "hyperthyroidism",
        "level b",
        "function"
      ],
      "tables": []
    },
    {
      "number": "83",
      "title": "13.3 Obesity Obesity is a risk factor for hypertension and CAD and is also associ- ated with an increased risk of HF. There is possibly a stronger associa- tion with HFpEF. 258 , 675 \u0002 677   Once obes",
      "start_page": 69,
      "end_page": 69,
      "content": "Body fat has a major impact on the diagnostic and prognostic value of multiple parameters. Obese patients with HF have lower NP con- centrations due to increased expression of clearance receptors and augmented peptide degradation by the adipose tissue. 74   Peak oxygen consumption adjusted for body weight underestimates exercise capacity in obese patients and an adjustment for lean body mass should be used for risk stratification. 96\nObesity may be a major cause of HFpEF and obese HFpEF patients display several pathophysiologic mechanisms that differ from non- obese patients with HFpEF. 258 , 675 \u0002 677 , 685   Caloric restriction and exercise training had additive beneficial effects on exercise capacity and QOL of patients with obesity and HFpEF in a randomized trial. 337\n",
      "keywords": [
        "hfpef",
        "also",
        "hypertension",
        "tion",
        "increased",
        "ated",
        "associ",
        "obesity",
        "associa",
        "obes",
        "weight",
        "stronger",
        "risk",
        "there",
        "possibly",
        "risk stratification",
        "once",
        "factor",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "84",
      "title": "13.4 Frailty, cachexia, sarcopenia Frailty is a multidimensional dynamic state, independent of age, that makes the individual more vulnerable to the effect of stressors. 686   HF and frailty are two d",
      "start_page": 69,
      "end_page": 69,
      "content": "Frailty is more prevalent in patients with HF than in the general pop- ulation and may occur in up to 45% of the patients, according to a recent meta-analysis. 687 , 688   Patients with HF are up to six times more likely to be frail, and frail people have a significantly increased risk of developing HF. 689 , 690   Frailty is associated with a higher risk of death, hospitalizations, and functional decline as well as with a longer dura- tion of hospital stay. 691 \u0002 693   The treatment of frailty in HF should be multifactorial and targeted to its main components and may include physical rehabilitation with exercise training, nutritional supplementa- tion as well as an individualized approach to treating comorbidities. 686\nCachexia is defined as a ‘complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass’. 694   Its major clinical feature is a >5% oedema-free body weight loss during the previous 12 months or less. 694 , 695   Cachexia is a generalized wasting process that may coexist with frailty and may occur in 5 \u0002 15% of patients with HF, especially those with HFrEF and more advanced disease status. It is associated with reduced functional capacity and decreased survival. 695 \u0002 698   As it is associated with other chronic diseases, such as cancer, alternative, non-cardiac causes for cachexia should always be investigated. 699\nSarcopenia is defined by the presence of low muscle mass together with low muscle function, strength, or performance. 698   It is usually identified by an appendicular skeletal muscle mass, defined as the sum of the muscle mass of the four limbs, 2 standard deviation below the mean of a healthy reference group aged 18 \u0002 40years with a cut-off value of 7.26 kg/m 2   for men. 688 , 700 , 701   It occurs physiologically with aging. However, it is accelerated by chronic diseases, such as cancer and HF. Sarcopenia can be found in 20 \u0002 50% of patients with HFrEF and is often associated with frailty and increased morbidity and mortal- ity. It is a major determinant of outcomes outweighing the effect of body weight and BMI. 684 , 698 , 701 , 702   So far, the most effective strategy for sarcopenia treatment is resistance exercise training, possibly com- bined with a protein intake of 1 \u0002 1.5 g/kg/day. 698 , 703   Drug treatments, including anabolic compounds like testosterone, growth hormone, ghrelin receptor agonists, were tested in small studies, showing favour- able results mostly in terms of exercise capacity and muscle strength. 697 , 703 \u0002 705   There are no data showing a favourable impact of sarcopenia treatment on outcomes. However, exercise training has favourable effects in patients with HF (see  section 9.4 ). 95 , 323 \u0002 329\n",
      "keywords": [
        "hfref",
        "stressors",
        "multidimensional",
        "independent",
        "effect",
        "sarcopenia",
        "individual",
        "cachexia",
        "makes",
        "frailty",
        "state",
        "bmi",
        "vulnerable",
        "more",
        "weight",
        "metabolic syndrome",
        "dynamic",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "85",
      "title": "13.5 Iron deficiency and anaemia Iron deficiency and anaemia are common in patients with HF, being independently associated with reduced exercise capacity, recurrent HF hospitalizations, and high CV a",
      "start_page": 69,
      "end_page": 70,
      "content": "According to the World Health Organization criteria, anaemia is defined as a haemoglobin concentration <12 g/dL in women and <13 g/dL in men. In patients with HF, iron deficiency is defined as either a serum ferritin concentration <100 ng/mL or 100 \u0002 299 ng/ mL with transferrin saturation (TSAT) <20%. 708 \u0002 710   Ferritin tissue expression and concentration in the peripheral blood is increased by inflammation and several disorders such as infection, cancer, liver dis- ease, and HF itself. Hence, higher cut-off values have been applied for the definition of iron deficiency in patients with HF. 709 \u0002 711   Another marker reflecting depleted intracellular iron can be high serum solu- ble transferrin receptors, which derives from proteolysis of the mem- brane transferrin receptor. Its synthesis is increased in case of iron deficiency and is not affected by inflammation. High serum soluble transferrin receptors identify patients at high risk of death beyond standard prognostic variables. 711 , 712   However, its applicability for iron supplementation therapy has not been demonstrated yet. Iron deficiency, which can be present independently of anaemia, is present in up to 55% of chronic HF patients and in up to 80% of those with AHF. 713 \u0002 716   It may be caused by increased loss, reduced intake or absorption (i.e. malnutrition, gut congestion) and/or impaired iron metabolism caused by the chronic inflammatory activation of HF, although the exact cause of iron deficiency in HF remains unknown. Iron deficiency may impair functional capacity, precipitate circulatory\n3668 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ......................................................................................................................................................................... decompensation, promote skeletal muscle dysfunction, and is associ- ated with frailty, irrespective of anaemia. 716 \u0002 718\nIt is recommended that all patients with HF are regularly screened for anaemia and iron deficiency with full blood count, serum ferritin concentration, and TSAT. The detection of anaemia and/or iron defi- ciency should prompt appropriate investigation to define their cause. Darbepoetin-alpha failed to reduce all-cause death or HF hospital- ization and increased the risk of thromboembolic events in the only large-scale randomized trial in patients with HFrEF and mild to mod- erate anaemia. 719   As a result, erythropoietin stimulating agents are not indicated for the treatment of anaemia in HF.\nRCTs have shown that iron supplementation with i.v. ferric car- boxymaltose is safe and improves symptoms, exercise capacity, and QOL of patients with HFrEF and iron deficiency. 720 \u0002 723   Meta- analyses of RCTs showed also a reduction in the risk of the combined endpoints of all-cause death or CV hospitalization, CV death or HF hospitalization, CV death or recurrent CV or HF hospitaliza- tions. 724 , 725   The favourable effects of iron supplementation were independent from anaemia coexistence. 726   In AFFIRM-AHF, patients hospitalized for HF with LVEF <50% and concomitant iron deficiency were randomized to i.v. ferric carboxymaltose or placebo, repeated at 6- and then 12-week intervals if indicated according to repeat iron studies. 512   Administration of ferric carboxymaltose did not signifi- cantly reduce the primary composite outcome of total HF hospital- izations and CV death at 52 weeks (rate ratio 0.79, 95% CI 0.62 \u0002 1.01,  P  = 0.059). However, it reduced the composite endpoint\nof first HF hospitalization or CV death (HR 0.80, 95% CI 0.66 \u0002 0.98, P  = 0.030) and total HF hospitalizations (rate ratio 0.74, 95% CI 0.58 \u0002 0.94,  P  = 0.013). 512   Therefore, iron supplementation with i.v. ferric carboxymaltose should be considered for the improvement of symptoms, exercise capacity, and QOL in patients with HF and LVEF <45%. It should also be considered for the reduction of HF rehospi- talizations in patients with LVEF <50% recently hospitalized for wor- sening HF. Ongoing trials are expected to provide more evidence on the effects of ferric carboxymaltose in patients with HFpEF. In addi- tion, large outcomes trials with other iron formulations are ongoing in HFrEF, HFpEF, and AHF. 727   Oral iron therapy is not effective in iron repletion and did not improve exercise capacity in patients with HFrEF and iron deficiency. 728   It is therefore not recommended for the treatment of iron deficiency in the patients with HF.\n",
      "keywords": [
        "independently",
        "recurrent",
        "recommended",
        "hfref",
        "hfpef",
        "lvef",
        "iron",
        "anaemia",
        "deficiency",
        "should be considered",
        "high",
        "common",
        "associated",
        "patients",
        "hospitalizations",
        "capacity",
        "being",
        "reduced",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3669",
          "page_number": 70,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that all patients with HF be\nperiodically screened for anaemia and iron defi-\nciency with a full blood count, serum ferritin\nconcentration, and TSAT. | I | C | \nIntravenous iron supplementation with ferric\ncarboxymaltose should be considered in symp-\ntomatic patients with LVEF <45% and iron defi-\nciency, defined as serum ferritin <100 ng/mL or\nserum ferritin 100\u0002299 ng/mL with TSAT\n<20%, to alleviate HF symptoms, improve exer-\ncise capacity and QOL.720,722,724 | IIa | A | \nIntravenous iron supplementation with ferric\ncarboxymaltose should be considered in symp-\ntomatic HF patients recently hospitalized for HF\nand with LVEF <50% and iron deficiency, defined\nas serum ferritin <100 ng/mL or serum ferritin\n100\u0002299 ng/mL with TSAT <20%, to reduce\nthe risk of HF hospitalization.512 | IIa | B | ESC 2021",
          "bbox": [
            47.14195919036865,
            236.88036092122397,
            292.26566908094617,
            479.44218880789623
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "86",
      "title": "13.6 Kidney dysfunction CKD and HF frequently coexist. 471 , 707 , 729   They share common risk factors, such as diabetes or hypertension. CKD may worsen CV func- tion causing hypertension and vascula",
      "start_page": 70,
      "end_page": 71,
      "content": "While CKD and worsening renal function both appear more common in HFpEF as compared to in HFmrEF and HFrEF, perhaps due to shared pathophysiological mechanisms, they appear to be less associated with worse outcomes in HFpEF than in HFmrEF and HFrEF. 732 , 733\nCKD is a major independent determinant of increased mortality and morbidity in HF. 471 , 734 \u0002 736   However, there are settings in which changes in serum creatinine are not associated with worse outcomes. When RAAS inhibitors, ARNI or SGLT2 inhibitors are started, the ini- tial decrease in the glomerular filtration pressure may decrease GFR and increase serum creatinine. However, these changes are generally transient and occur despite improvement in patient outcomes and slower worsening of renal function in the long term. For instance, in EMPEROR-Reduced, the placebo-corrected eGFR dip induced by empagliflozin at week 4 was of 2.4 mL/min/1.73 m 2   for patients with CKD and 2.7 mL/min/1.73 m 2   for those without CKD, corresponding to a decrease from baseline of 5.2% and 3.8%, respectively. This was followed by a slower slope of eGFR decline and by a reduced rate of the composite kidney outcome with empagliflozin vs. placebo, with no difference between patients with or without CKD at baseline. 109 , 737\nThus, with respect to the initiation of RAAS inhibitors, ARNI or SGLT2 inhibitors, a transient decrease in renal function should not prompt their interruption. An increase in serum creatinine of <50% above baseline, as long as it is <266  l mol/L (3 mg/dL), or a decrease in eGFR of <10% from baseline, as long as eGFR is >25 mL/min/1.73 m 2 , can be considered as acceptable (see  section 5.3  and  Supplementary Table 8 ). Also, with respect to diuretic therapy, small and transient rises in serum creatinine during treatment of acute HF are not associ- ated with poorer outcomes when the patient is free of congestion. 108 , 109 , 460 \u0002 462 , 471 , 729 , 737 \u0002 740\nRandomized trials have shown that patients with HF and concomi- tant CKD are at higher risk of events but the beneficial effects of MT\nRecommendations for the management of anaemia and iron deﬁciency in patients with heart failure\nRecommendations Class a Level b\nIt is recommended that all patients with HF be periodically screened for anaemia and iron deﬁ-\nciency with a full blood count, serum ferritin\nconcentration, and TSAT.\nI C\nIntravenous iron supplementation with ferric carboxymaltose should be considered in symp-\ntomatic patients with LVEF <45% and iron deﬁ-\nciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100 \u0002 299 ng/mL with TSAT\n<20%, to alleviate HF symptoms, improve exer-\ncise capacity and QOL. 720 , 722 , 724\nIIa A\nIntravenous iron supplementation with ferric\ncarboxymaltose should be considered in symp-\ntomatic HF patients recently hospitalized for HF and with LVEF <50% and iron deﬁciency, deﬁned\nas serum ferritin <100 ng/mL or serum ferritin\n100 \u0002 299 ng/mL with TSAT <20%, to reduce the risk of HF hospitalization. 512\nIIa B\nHF = heart failure; LVEF = left ventricular ejection fraction; QOL = quality of life; TSAT = transferrin saturation. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 3669\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................................................................................................................................................... are similar, if not greater, than in the patients with normal renal func- tion. 206 , 471 , 741 , 742   Beta-blockers reduce mortality in HFrEF patients with moderate (eGFR 45 \u0002 59 mL/min/1.73 m 2 ) and moderately severe (eGFR 30 \u0002 44 mL/min/1.73 m 2 ) renal dysfunction, whereas limited evidence is available regarding patients with severe renal impairment (eGFR <30 mL/min/1.73 m 2 ). 743   Sacubitril/valsartan, compared with enalapril, led to a slower decline in renal function, despite a slight increase in the urinary albumin/creatinine ratio, and improved CV outcomes to a similar extent in patients with CKD vs. the others in PARADIGM-HF. 127   SGLT2 inhibitors lead to a slower decline in renal function, compared with placebo, both in patients with HFrEF and in those with CKD. 108 , 109 , 737 , 738 , 744   The improve- ment in cardiac output after CRT or LVAD implantation may be associated with, at least, a transient improvement in renal func- tion. 471 , 745 , 746   The benefits of ICDs may be reduced in patients with severe renal dysfunction because of the competing risk of non- arrhythmic causes of death. 747 \u0002 749\nThere is little direct evidence to support any recommendations for treatment of HF patients with severe CKD as to date, RCTs excluded patients with advanced stages of CKD, i.e. eGFR <30 mL/ min/1.73 m 2   ( Supplementary Table 23 ) . Cut-off values for inclusion were lower in recent trials: 25 mL/min/1.73 m 2   in DAPA-CKD, 20 mL/min/1.73 m 2   in EMPEROR-Reduced and GALACTIC-HF, and 15 mL/min/1.73 m 2   in VICTORIA, respectively. 109 , 141 , 737 , 738 , 750\nDespite differences in baseline characteristics between patients with severely impaired renal function and the others, no interaction between drug effects and renal function was noted in subgroup analy- sis of these trials. 109 , 141 , 738 , 750\n",
      "keywords": [
        "heart failure",
        "func",
        "recommended",
        "level b",
        "coexist",
        "causing",
        "hfref",
        "hfpef",
        "kidney",
        "worsen",
        "hypertension",
        "lvef",
        "crt",
        "should be considered",
        "factors",
        "tion",
        "common",
        "such",
        "share",
        "creatinine",
        "egfr",
        "dysfunction",
        "risk",
        "ejection fraction",
        "diabetes",
        "diuretic",
        "hfmref",
        "sglt2",
        "they",
        "vascula"
      ],
      "tables": []
    },
    {
      "number": "87",
      "title": "13.7 Electrolyte disorders: hypokalaemia, hyperkalaemia, hyponatraemia, hypochloraemia Electrolyte disturbances are frequent in patients with HF and may often be iatrogenic. 751   Serum potassium leve",
      "start_page": 71,
      "end_page": 72,
      "content": "Hypokalaemia is defined as serum potassium <3.5 mmol/L and may occur in up to 50% of patients with HF. 759   Hypokalaemia is often induced by loop and thiazide diuretic administration. It may cause lethal ventricular arrhythmias and increase CV mortality. Its treat- ment includes the use of RAAS inhibitors, potassium-sparing diu- retics, and prescription of oral potassium supplements (i.e. potassium chloride tablets). When oral administration is not possible, potassium supplementation by infusion may be necessary (20 to 40 mmol of potassium in 250 \u0002 1000 mL of normal saline). Potassium-rich solu- tion should be infused at slow rate through a large vein using a venous catheter. Hyperkalaemia is defined as serum potassium >5 mmol/L and can be classified as mild (>5.0 to <5.5 mmol/L), moderate (5.5 to 6.0 mmol/L), or severe (>6.0 mmol/L). 760   It is associated with an increased risk of hospitalization and death. 752 , 753 , 755 , 756 , 761 , 762\nHyperkalaemia can be associated with the administration of RAAS inhibitors, CKD and increased absorption. 760   Among patients with HF, the prevalence of hyperkalaemia at any given time among patients\nwith HF appears to be less than 5%, 757   but the incidence is much higher, at up to 40% in chronic HF and 73% in CKD over follow-up durations of approximately 1 year. 753 , 756 , 757 , 763 \u0002 765   In PARADIGM- HF, treatment with sacubitril/valsartan was associated with lower risk of severe hyperkalaemia, compared with enalapril. 128   Life-threatening hyperkalaemia requires immediate treatment with a combination of calcium carbonate and/or sodium bicarbonate, insulin, with or with- out glucose, and beta adrenoceptor agonists [e.g. salbutamol, off- label use in some European Union (EU) countries]. These agents favour potassium entry into the cells and do not increase potassium excretion. Thus, they only provide temporary benefit and rebound hyperkalaemia can occur after few hours. Loop diuretics can be administered to facilitate potassium loss. Potassium binders bind to potassium in the gastrointestinal tract reducing its absorption. They can be used for acute and chronic potassium lowering. They include sodium polystyrene sulfonate, cal- cium polystyrene sulfonate, and the much better tolerated patiromer sorbitex calcium and sodium zirconium cyclosilicate (SZC). Sodium polystyrene sulfonate is still indicated in anuric or severely oliguric patients, but it should not be used in the medium or long term as it may cause severe gastrointestinal side effects, including bowel necrosis. 760   Patiromer or SZC increase faecal potassium excretion and act mainly in the colon. Both compounds are effective in normal- izing elevated potassium levels, maintaining normokalaemia over time and preventing the recurrence of hyperkalaemia and can be consid- ered for treatment of hyperkalaemia 766 \u0002 768   (see  Supplementary Table 24 ). Renal dysfunction and hyperkalaemia are the major causes of underuse of RAAS inhibitors, particularly MRA, in clinical practice. 342 , 753 , 758 , 769 \u0002 771   Administration of the potassium-lowering agents, patiromer or SZC, may allow their initiation or uptitration in a larger proportion of patients. This hypothesis was tested in double- blind, placebo-controlled, randomized trials with patiromer or pla- cebo administration to patients with CKD and hyperkalaemia, or dis- continuation of RAAS inhibitors for hyperkalaemia, and with an indication for spironolactone for HF and/or resistant hypertension. Patiromer was more likely to lower serum potassium and decreased episodes of hyperkalaemia than spironolactone initiation and uptitration. 772 \u0002 775   The ongoing RCT DIAMOND (NCT03888066) is testing the impact on clinical outcomes of a strategy based on patiromer administration, compared with placebo, in patients with HFrEF who are hyperkalaemic while on RAAS inhibitors or with a history of hyperkalaemia with subsequent reduction or discontinua- tion of a RAAS inhibitor 776 , 777   (see  Supplementary text 13 .1 ). Hyponatraemia is defined as a serum sodium concentration lower than 136 mmol/L. It is common in HF and may be present in up to 30% of patients admitted to hospital with HF. It reflects neurohormo- nal activation and is a powerful independent marker of poor out- comes in patients with acute or chronic HF. 778 , 779\nSevere hyponatraemia may cause neurologic symptoms (seizures, obtundation, delirium) due to cerebral oedema and may require immediate treatment with hypertonic saline with serum sodium increases by 1 \u0002 2 mmol/L per hour, though less than 8 mmol/L in 24 h as a more rapid correction increases the risk of myelinolysis. Intravenous treatment is not required when hyponatraemia is less\n3670 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................................................................................................................................... severe, e.g. >124 mmol/L, and in the absence of symptoms. As the pathogenesis of hyponatraemia in HF is dilutional, e.g. caused by water retention induced by increased vasopressin secretion, treat- ment is based on water restriction or vasopressin antagonists. Fluid restrictions to less than 800 \u0002 1000 mL/day may be indicated to achieve a negative water balance and treat hyponatraemia. Water restriction was associated with improved QOL in a small, random- ized study but with only slight increases in serum sodium in an obser- vational registry. 780 , 781   Tolvaptan, an orally active selective arginine vasopressin V2 receptor antagonist, can be considered to increase serum sodium and diuresis in patients with persistent hyponatraemia and congestion. However, no effects on outcomes have been shown in RCTs 782 \u0002 785   (see  Supplementary text 13 .1 ). The infusion of hyper- tonic saline combined with loop diuretics was associated with an increase in serum sodium levels and greater diuretic efficacy in small trials and observational studies. 786 \u0002 788\nHypochloraemia (<96 mmol/L) is a powerful independent predic- tor of mortality in patients with acute and chronic HF. 439 , 789 \u0002 792\nSerum chloride may have a direct role in the control of renin secre- tion and the response to loop or thiazide diuretics. 439 , 793   The car- bonic anhydrase inhibitor acetazolamide increases chloride reabsorption causing a greater bicarbonate and sodium excretion in the proximal tubule of the nephron. It can increase serum chloride levels and diuresis in patients with severe HF at risk of diuretic resist- ance. 145 , 794   It is currently being tested in a multicentre randomized study in decompensated HF. 469\n",
      "keywords": [
        "indication",
        "disturbances",
        "insulin",
        "electrolyte",
        "hypokalaemia",
        "potassium",
        "hfref",
        "glucose",
        "frequent",
        "hypertension",
        "disorders",
        "often",
        "hypochloraemia",
        "iatrogenic",
        "leve",
        "patients",
        "hyponatraemia",
        "diuretic",
        "serum",
        "hyperkalaemia"
      ],
      "tables": []
    },
    {
      "number": "88",
      "title": "13.8 Lung disease, sleep-disordered breathing Overall, COPD affects about 20% of patients with HF and has a major impact on symptoms and outcomes. 795 \u0002 797   Due to the overlap in symptoms and signs,",
      "start_page": 72,
      "end_page": 72,
      "content": "Treatment of HF is generally well tolerated in COPD. 800   Beta- blockers can worsen pulmonary function in individual patients but are not contraindicated in either COPD or asthma, as stated in the Global initiative for chronic Obstructive Lung Disease (GOLD) and the Global INitiative for Asthma (GINA), respectively. 801 , 802   GINA states that asthma should not be regarded as an absolute contraindi- cation to the use of cardioselective beta-blockers (bisoprolol, meto- prolol succinate, or nebivolol) with consideration of relative risks and benefits. In clinical practice, starting with low doses of cardioselective beta-blockers combined with close monitoring for signs of airway obstruction (wheezing, shortness of breath with lengthening of the expiration) should be encouraged. Although not tested in HF patients, inhaled corticosteroids and beta-adrenergic agonists do not\nseem to increase CV events, including HF, in patients at high risk. 803 , 804   Moreover, optimal COPD management can improve car- diac function. 805\nSleep-disordered breathing occurs in more than one third of patients with HF and is even more prevalent in patients with AHF. The most common types are: central sleep apnoea (CSA, similar to Cheyne-Stokes respiration), OSA, and a mixed pattern of the two. CSA and OSA have been shown to be associated with a worse prog- nosis in HF. OSA is associated with an increased risk of incident HF in men. CSA is the most common form of sleep-disordered breathing in HFrEF and HFmrEF is the most common cause of CSA. 806 , 807\nPatients with HF can be investigated for sleep-disordered breath- ing. History taking should involve partners. Questionnaires are instru- mental in identifying patients at risk. Home monitoring can usually identify and distinguish the type of sleep apnoea. However, overnight polysomnography remains the definitive investigation. 807   The use of adaptive servo-ventilation in patients with HFrEF and predominantly CSA is not recommended, based on the results of SERVE-HF, which was neutral regarding the composite primary endpoint of death from any cause or lifesaving CV intervention, but showed an increase in both all-cause mortality and CV mortality with adaptive servo-venti- lation. 808   Transvenous phrenic nerve stimulation was tested in a pro- spective, multicentre, randomized trial involving 151 patients with CSA. 809   The primary efficacy endpoint was the reduction of the apnoea-hypopnoea index from baseline to 6 months and was achieved by a larger percentage of patients with the active treatment. Other measurements of sleep quality and QOL were improved and no difference in any safety endpoint was found between active treat- ment and control. 809   Similar results were observed in the 96 patients with HF. 810\nPatients with HFrEF being considered for a sleep-disordered breathing treatment with positive pressure airway mask must undergo formal sleep study to document the predominant type of sleep apnoea (central vs. obstructive). When sleep-disordered breathing is caused by OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure, bi-level positive airway pressure, and adaptive servo- ventilation. However, none of these interventions has been shown to have beneficial effects on outcomes in HF. 807   When sleep- disordered breathing is caused by CSA, positive pressure airway masks are contraindicated in HFrEF patients. 808   In these patients, implantable phrenic nerve stimulation can be considered for sympto- matic relief.\n",
      "keywords": [
        "lung",
        "recommended",
        "sleep",
        "hfref",
        "disordered",
        "disease",
        "copd",
        "signs",
        "about",
        "overall",
        "patients",
        "outcomes",
        "overlap",
        "impact",
        "major",
        "hfmref",
        "breathing",
        "affects",
        "symptoms"
      ],
      "tables": []
    },
    {
      "number": "89",
      "title": "13.9 Hyperlipidaemia and lipid-modifying therapy Two large RCTs, including mainly patients with HFrEF, as well as a meta-analysis of 24 RCTs, showed no benefit of statin treatment on CV mortality or s",
      "start_page": 72,
      "end_page": 73,
      "content": "ESC Guidelines 3671\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................................................................................................................................................... recommended. Because there is no evidence of harm in patients on statin treatment after the occurrence of HF, there is no need for sta- tin discontinuation for patients already treated.\n",
      "keywords": [
        "therapy",
        "showed",
        "large",
        "recommended",
        "meta",
        "hfref",
        "well",
        "mainly",
        "benefit",
        "lipid",
        "treatment",
        "hyperlipidaemia",
        "statin",
        "patients",
        "including",
        "modifying",
        "analysis",
        "mortality",
        "rcts"
      ],
      "tables": []
    },
    {
      "number": "90",
      "title": "13.10 Gout and arthritis Hyperuricemia is a common finding in patients with CHF with a prev- alence up to 50%. 816 , 817   Hyperuricemia may be caused or aggravated by diuretic treatment and it is rel",
      "start_page": 73,
      "end_page": 73,
      "content": "With respect to treatment of acute gout attacks, non-steroidal anti-inflammatory drugs (NSAIDs) can worsen renal function and precipitate acute HF decompensation. Colchicine should be pre- ferred as it is associated with less side effects. 824   However, it, too, should be used with caution in patients with severe renal dysfunction and is contraindicated in patients on dialysis. An increase in ventricu- lar vulnerability was shown in experimental models. 825\nArthritis is a common comorbidity and is a common cause of both self-taken and prescribed NSAIDs. These agents are relatively contra- indicated as they may precipitate acute decompensation in patients with HF. 826   Rheumatoid arthritis is associated with a two- to three- fold increase in the risk of HF and this increased risk is independent of ischaemic heart disease, suggesting a direct role in HF pathophysi- ology. 827 , 828   The safety of disease-modifying drugs used for the treat- ment of rheumatoid arthritis has not been established in HF. High doses of anti-tumour necrosis factor alpha agents were associated with worsening HF in initial trials and should be used with caution. No adverse effects were noted with lower doses. 829 \u0002 831\n",
      "keywords": [
        "treatment",
        "hyperuricemia",
        "aggravated",
        "finding",
        "diuretic",
        "patients",
        "alence",
        "gout",
        "arthritis",
        "common",
        "prev",
        "caused"
      ],
      "tables": []
    },
    {
      "number": "91",
      "title": "13.11 Erectile dysfunction Erectile dysfunction is a serious problem in HF patients due to its association with CV risk factors, comorbidities (e.g. diabetes), life- style (e.g. inactivity), and treat",
      "start_page": 73,
      "end_page": 73,
      "content": "Optimal assessment should include both questions assessing the presence of erectile dysfunction and factors that can be related to erectile dysfunction. Numerous classes of CV drugs, particularly diu- retics and beta-blockers, have been implicated causing erectile dys- function. However, the relationships between many contemporary CV drugs and erectile dysfunction is not clear. 834   For the treatment of erectile dysfunction, phosphodiesterase type 5 inhibitors are gen- erally safe and effective in patients with compensated HF. 834 , 835   No\nstudies have shown one agent to be more effective or safer than the others. However, phosphodiesterase type 5 inhibitors should not be used in patients receiving nitrates and nitrates should not be adminis- tered to patients within 24 h of sildenafil or vardenafil administration or within 48 h of tadalafil administration. 834\n",
      "keywords": [
        "association",
        "life",
        "style",
        "risk",
        "problem",
        "serious",
        "diabetes",
        "comorbidities",
        "patients",
        "inactivity",
        "factors",
        "erectile",
        "treat",
        "dysfunction"
      ],
      "tables": []
    },
    {
      "number": "92",
      "title": "13.12 Depression Depression affects 20% of patients with HF and is severe in half of them. Its occurrence is higher in women and it is associated with worse clinical status and a poor prognosis. 836 \u0002",
      "start_page": 73,
      "end_page": 73,
      "content": "There is still no consensus on the best therapy for HF patients with depression. Psychosocial intervention may improve depressive symptoms but has no effect on prognosis of depressed patients with HF. 839   Depressive symptoms may improve with selective serotonin reuptake inhibitors but trials specifically designed to assess the effect of these drugs in patients with HF and depression have failed to show any significant benefit over placebo on both symptoms and out- comes. 840 , 841   Interestingly, patients improved also in the placebo arm showing the importance of better care in these patients. Both trials showed the safety of sertraline and escitalopram, respectively. 840 , 841\nTricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, worsening HF, and arrhythmias. 837 , 838\n",
      "keywords": [
        "half",
        "status",
        "higher",
        "worse",
        "poor",
        "clinical",
        "prognosis",
        "severe",
        "patients",
        "depression",
        "them",
        "women",
        "affects",
        "associated",
        "occurrence"
      ],
      "tables": []
    },
    {
      "number": "93",
      "title": "13.13 Cancer HF occurs in patients with cancer as a result of the interaction among anticancer therapy, cancer itself, and patients’ CV background (risk factors and coexisting CV disease). 842 \u0002 846  ",
      "start_page": 73,
      "end_page": 74,
      "content": "The prevention of HF in patients with cancer undergoing potential cardiotoxic therapies requires careful patient’s assessment and man- agement before, during, and after cancer therapy, preferably in the context of an integrated Cardio-Oncology service ( Figure  18 ). 845 , 859 , 860   A CV baseline risk assessment for all patients scheduled to receive potentially cardiotoxic cancer therapies using the HFA-ICOS risk assessment is advisable. 846   Baseline CV risk assessment forms have been developed for different potentially car- diotoxic cancer therapies. History of HF or CMP characterizes patients as being at very high risk or at high risk for all cancer thera- pies, except anti-androgen treatments for prostate cancer. An LVEF <50% is an additional factor for high-risk patients and elevated levels\n3672 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .................................................. of NPs or troponin at baseline are additional criteria of medium risk for most of the cancer treatments. 846\nDuring cancer treatment with potential cardiotoxic therapies, LV systolic function can be monitored through echocardiography. Chemotherapy should be reconsidered and treatment with an ACE-I and a beta-blocker (preferably carvedilol) should be started in patients who develop LV systolic dysfunction, defined as 10% or more absolute reduction in LVEF to a value below 50%. 844 , 861 \u0002 864\nGlobal longitudinal strain can detect cardiac dysfunction at an earlier stage. 865 , 866   A >_12% relative reduction in global longitudinal strain was compared with an LVEF decline in a prospective randomized trial in high-risk patients undergoing potentially cardiotoxic chemother- apy. Compared to treatment based on LVEF, treatment based on changes in global longitudinal strain led to the same decrease in LVEF (primary endpoint) but with fewer patients who developed cardiac dysfunction at the end of the study, thus suggesting usefulness of global longitudinal strain for the early detection of cardiotoxicity. 867\nPromising results for the early detection of cardiac dysfunction have also been obtained through monitoring of biomarkers, such as NPs and troponin. 868 , 869   Patients on immunotherapy with immune check- point inhibitors are at increased risk of myocarditis and should be monitored for related symptoms and signs and by weekly assessment of cardiac troponin during at least the first 6 weeks of therapy and managed accordingly. 870\nTiming of the imaging procedures and biomarkers assessment depend on the anticancer treatment and patient’s risk profile ( Figure  18 ). 865   In general, all patients scheduled for potential cardi- otoxic therapies must undergo a baseline evaluation that would define the level of risk for cardiotoxicity (low, medium, or high) and the intensity of monitoring and follow-up during and after cancer treatment. 865   Cancer survivors exposed to potentially cardiotoxic therapies should be periodically monitored in the long term as HF may develop several years after cancer therapy. 865 , 871\nTable 23 Cancer drugs causing heart failure\nCancer therapy Indication\nAnthracycline chemotherapy\n(doxorubicin, epirubicin, daunorubicin, idarubicin)\nBreast cancer, lymphoma, acute leukaemia, sarcoma\nHER2-targeted therapies\n(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib, neratinib,\ntucatinib)\nHER2 þ  breast cancer\nHER2 þ  gastric cancer\nVEGF inhibitors TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib, cabozantinib, regorafenib,\nlenvatinib, vandetinib) and antibodies (bevacizumab, ramucirumab)\nVEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon cancer, sarcoma, GIST\nAntibodies: breast cancer, ovarian cancer, gastric cancer, gastro-oesopha-\ngeal cancer, colon cancer\n",
      "keywords": [
        "therapy",
        "heart failure",
        "systolic dysfunction",
        "indication",
        "occurs",
        "interaction",
        "result",
        "disease",
        "cancer",
        "echocardiography",
        "lvef",
        "factors",
        "background",
        "coexisting",
        "patients",
        "itself",
        "among",
        "risk",
        "systolic",
        "anticancer",
        "troponin"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3673",
          "page_number": 74,
          "content": "Cancer therapy | Indication | ESC 2021\nAnthracycline chemotherapy\n(doxorubicin, epirubicin, daunorubicin, idarubicin) | Breast cancer, lymphoma, acute leukaemia, sarcoma | \nHER2-targeted therapies\n(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib, neratinib,\ntucatinib) | HER2þ breast cancer\nHER2þ gastric cancer | \nVEGF inhibitors\nTKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib, cabozantinib, regorafenib,\nlenvatinib, vandetinib) and antibodies (bevacizumab, ramucirumab) | VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon\ncancer, sarcoma, GIST\nAntibodies: breast cancer, ovarian cancer, gastric cancer, gastro-oesopha-\ngeal cancer, colon cancer | \nMulti-targeted kinase inhibitors:\nsecond and third generation BCR-ABL TKIs (ponatinib, nilotinib, dasatinib,\nbosutinib) | Chronic myeloid leukaemia | \nProteasome inhibitors\n(carfilzomib, bortezomib, ixazomib)\nImmunomodulatory drugs\n(lenalidomide, pomalidomide) | Multiple myeloma | \nCombination RAF and MEK inhibitors\n(dabrafenibþtrametinib, vemurafenibþcobimetinib, encorafenibþ\nbinimetinib) | RAF mutant melanoma | \nAndrogen deprivation therapies\nGnRH agonists (goserelin, leuprorelin)\nAntiandrogrens (abiraterone) | Prostate cancer, breast cancer | \nImmune checkpoint inhibitors:\nanti-programmed cell death 1 inhibitors\n(nivolumab, pembrolizumab)\nanti-cytotoxic T-lymphocyte-associated\nprotein 4 inhibitor (ipilimumab)\nanti-programmed death-ligand 1 inhibitors\n(avelumab, atezolizumab, durvalumab) | Melanoma (metastatic and adjuvant)\nMetastatic renal cancer, non-small cell lung cancer, small cell lung cancer,\nrefractory Hodgkin’s lymphoma, metastatic triple negative breast cancer,\nmetastatic urothelial cancer, liver cancer, MMR-deficient cancer | ",
          "bbox": [
            48.04631681442261,
            81.79153442382812,
            557.6139526367188,
            452.6120038713728
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "94",
      "title": "Multi-targeted kinase inhibitors:",
      "start_page": 74,
      "end_page": 76,
      "content": "second and third generation BCR-ABL TKIs (ponatinib, nilotinib, dasatinib,\nbosutinib)\nChronic myeloid leukaemia\nProteasome inhibitors (carﬁlzomib, bortezomib, ixazomib)\nImmunomodulatory drugs\n(lenalidomide, pomalidomide)\nMultiple myeloma\nCombination RAF and MEK inhibitors\n(dabrafenib þ trametinib, vemurafenib þ cobimetinib, encorafenib þ\nbinimetinib)\nRAF mutant melanoma\nAndrogen deprivation therapies GnRH agonists (goserelin, leuprorelin)\nAntiandrogrens (abiraterone)\nProstate cancer, breast cancer\nImmune checkpoint inhibitors: anti-programmed cell death 1 inhibitors\n(nivolumab, pembrolizumab)\nanti-cytotoxic T-lymphocyte-associated protein 4 inhibitor (ipilimumab)\nanti-programmed death-ligand 1 inhibitors\n(avelumab, atezolizumab, durvalumab)\nMelanoma (metastatic and adjuvant) Metastatic renal cancer, non-small cell lung cancer, small cell lung cancer,\nrefractory Hodgkin’s lymphoma, metastatic triple negative breast cancer,\nmetastatic urothelial cancer, liver cancer, MMR-deﬁcient cancer\nGIST = gastrointestinal stromal tumour; GnRH = gonadotropin-releasing hormone; HER2 = human epidermal growth factor receptor 2; MEK = mitogen-activated protein kinase; MMR = mismatch repair; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor.\nESC 2021\nESC Guidelines 3673\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nManagement of patients receiving potential cardiotoxic treatments\nBaseline risk assessment including clinical assessment, ECG, resting echocardiogram and cardiac biomarkers (NP, troponin)\nPre-existing heart failure or high-risk cardiovascular disease\nMedium- and high-risk patient b\nIncreased c  surveillance with ECG and cardiac biomarkers during treatment\nReassessment at 3 months and 12 months after completion of cancer therapy\nLow-risk patient b\nStandard surveillance d\nBefore cardiotoxic  cancer treatment a\nAfter cardiotoxic  cancer treatment a\nDuring cardiotoxic  cancer treatment a\nReassessment at 12 months after completion of cancer therapy\nSurveillance every 5 years following therapies with established cardiotoxicity (e.g. high-dose anthracycline chemotherapy) e\nFollow-up by heart failure or cardio-oncology team for new heart failure or left ventricular systolic dysfunction\nFigure 18  Management of patients with cancer and heart failure. ECG= electrocardiogram; HER2= human epidermal growth factor receptor 2; HF= heart failure; HFA= Heart Failure Association; ICOS= International Cardio-Oncology Society; MEK= mitogen-activated protein kinase; NP=natriuretic peptide; VEGF= vascular endothelial growth factor.   a Anthracycline chemotherapy, trastuzumab and HER2 targeted therapies, VEGF inhibitors, proteasome inhibitors, combination RAF þ MEK inhibitors.   b Low, medium and high risk may be calculated using the HFA-ICOS baseline cardiovascular risk proformas. 846  c Increased surveillance is intended between 1 and 4 weeks.   d Standard surveillance is intended every 3 months.   e 5 yearly surveillance at follow-up= clinical review every 5 years with history, examination, NP and troponin levels, and echocardiogram. 865\n3674 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .................................................................................................\n",
      "keywords": [
        "targeted",
        "multi",
        "inhibitors",
        "cardiovascular risk",
        "systolic",
        "electrocardiogram",
        "kinase",
        "heart failure",
        "troponin",
        "systolic dysfunction",
        "ecg"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3675",
          "page_number": 76,
          "content": "Patients with HF are at increased risk of infections and have poorer out-\ncomes once infected. | ESC 2021\nTelemonitoring avoids the risks of infections caused by close contact. It is\nuseful during pandemic conditions. | \nTelemonitoring may be implemented for patients’ follow-up in pandemic\nconditions. | \nDuring pandemics, HF patients should be screened for infection at the\ntime of hospitalization, in case of urgent admissions, or before elective\nhospitalizations. | \nCareful assessment of fluid status, in addition to clinical signs of HF, is\nmandatory during hospitalization in patients with concomitant sepsis.\nRepeated measures of inferior vena cava diameter and collapsibility by\nechocardiography may be used to assess fluid status. | \nOMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2\ninhibitors), should be continued in chronic HF patients whenever BP and\nhaemodynamic conditions permit and considering drug interaction with\ninfection related therapies and side effect profile. | ",
          "bbox": [
            312.38549150739397,
            81.70929463704427,
            558.7479858398438,
            293.0463073730469
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3675",
          "page_number": 76,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \nIt is recommended that cancer patients at\nincreased risk for cardiotoxicity, defined by a\nhistory or risk factors of CV disease, previous\ncardiotoxicity or exposure to cardiotoxic\nagents, undergo CV evaluation before sched-\nuled anticancer therapy, preferably by a cardi-\nologist with experience/interest in Cardio-\nOncology. | I | C | \nTreatment with an ACE-I and a beta-blocker\n(preferably carvedilol) should be considered in\ncancer patients developing LV systolic dys-\nfunction, defined as a 10% or more decrease\nin LVEF and to a value lower than 50%, during\nanthracycline chemotherapy.861,862 | IIa | B | \nA baseline CV risk assessment should be con-\nsidered in all cancer patients scheduled to\nreceive a cancer treatment with the potential\nto cause heart failure.846,865 | IIa | C | ESC 2021",
          "bbox": [
            47.14195919036865,
            86.47422485351562,
            292.26566908094617,
            329.04225485665455
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "95",
      "title": "13.14 Infection Infective disorders may worsen HF symptoms and be a precipitant factor for AHF. 872 , 873   Severe sepsis and pneumonia can cause myo- cardial injury and depress cardiac function leadi",
      "start_page": 76,
      "end_page": 76,
      "content": "",
      "keywords": [
        "worsen",
        "sepsis",
        "cause",
        "disorders",
        "cardial",
        "severe",
        "pneumonia",
        "injury",
        "infective",
        "cardiac",
        "function",
        "infection",
        "leadi",
        "depress",
        "precipitant",
        "factor",
        "symptoms"
      ],
      "tables": []
    },
    {
      "number": "96",
      "title": "14 Special conditions",
      "start_page": 76,
      "end_page": 76,
      "content": "",
      "keywords": [
        "conditions",
        "special"
      ],
      "tables": []
    },
    {
      "number": "97",
      "title": "14.1 Pregnancy 14.1.1 Pregnancy in pre-existing heart failure Women with pre-existing HF have a higher risk of pregnancy-related CV complications including HF decompensation. Moderate- and high-risk p",
      "start_page": 76,
      "end_page": 78,
      "content": "algorithm for the management of HF patients before and during preg- nancy is reported in  Figure  19 . Pre-pregnancy management includes the modification of existing HF medications to avoid foetal harm. ACE-Is, ARBs, ARNI, MRAs, ivabradine, and SGLT2 inhibitors are contraindicated and should be stopped prior to conception with close clinical and echocardio- graphic monitoring. Beta-blockers should be continued and switched to beta-1-selective blockers (bisoprolol, metoprolol succinate). Hydralazine, oral nitrates and methyldopa can be started if required. Therapeutic anticoagulation with low-molecular-weight heparin (LMWH), in the first and last trimesters, and VKAs, with the usual tar- get international normalized ratios (INRs) or LMWH for the second trimester, is recommended for patients with HF and AF. DOACs should be avoided. 884\nAssessment of patients with HF in pre-pregnancy or at presenta- tion with a new pregnancy should include a clinical assessment (symptoms, clinical examination, BP, SaO 2 ), ECG and resting echo- cardiography. The modalities of delivery should be planned by cardi- ologists, obstetricians, and anaesthesiologists around 35 weeks in a multidisciplinary Pregnancy Heart Team. Bimonthly assessments for women in mWHO II \u0002 III, and monthly assessments for women with pre-existing HF in mWHO III, must be performed. Women with advanced HF (LVEF <30%, NYHA class III \u0002 IV) in mWHO IV who are pregnant can be referred to a specialist centre for counselling regarding any consideration of termination of pregnancy. The deci- sion regarding modalities of delivery can be planned by cardiologists, obstetricians, and anaesthesiologists around 35 weeks in a multidisci- plinary Pregnancy Heart Team and discussed with the patient. 884\n14.1.2 New heart failure presenting during pregnancy The increased demands on ventricular function due to the increased circulating volume and cardiac output of pregnancy can unmask pre-\nRecommendations for the management of patients with cancer and heart failure\nRecommendation Class a Level b\nIt is recommended that cancer patients at\nincreased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease, previous\ncardiotoxicity or exposure to cardiotoxic\nagents, undergo CV evaluation before sched- uled anticancer therapy, preferably by a cardi-\nologist with experience/interest in Cardio-\nOncology.\nI C\nTreatment with an ACE-I and a beta-blocker\n(preferably carvedilol) should be considered in\ncancer patients developing LV systolic dys- function, deﬁned as a 10% or more decrease\nin LVEF and to a value lower than 50%, during\nanthracycline chemotherapy. 861 , 862\nIIa B\nA baseline CV risk assessment should be con- sidered in all cancer patients scheduled to\nreceive a cancer treatment with the potential\nto cause heart failure. 846 , 865\nIIa C\nACE-I = angiotensin-converting enzyme inhibitor; CV = cardiovascular; LV = left ventricular; LVEF = left ventricular ejection fraction. a Class of recommendation. b Level of evidence.\nTable 24 Infections in patients with heart failure\nPatients with HF are at increased risk of infections and have poorer out-\ncomes once infected.\nTelemonitoring avoids the risks of infections caused by close contact. It is useful during pandemic conditions.\nTelemonitoring may be implemented for patients’ follow-up in pandemic\nconditions.\nDuring pandemics, HF patients should be screened for infection at the time of hospitalization, in case of urgent admissions, or before elective\nhospitalizations.\nCareful assessment of ﬂuid status, in addition to clinical signs of HF, is mandatory during hospitalization in patients with concomitant sepsis.\nRepeated measures of inferior vena cava diameter and collapsibility by\nechocardiography may be used to assess ﬂuid status.\nOMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2 inhibitors), should be continued in chronic HF patients whenever BP and\nhaemodynamic conditions permit and considering drug interaction with\ninfection related therapies and side effect proﬁle.\nACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BP = blood pressure; HF = heart failure; MRA = mineralocorticoid receptor antagonist; OMT = optimal medical therapy; SGLT2 = sodium-glucose co-transporter 2.\nESC 2021\nESC 2021\n. .........................................................................\nESC Guidelines 3675\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............... existing, but previously undiagnosed, causes of HF such as CMPs and valve diseases. 885   Symptoms are more likely to occur in the second trimester when the demand for an increased cardiac output is the highest. Severe emotionally stressful episodes during pregnancy and delivery can also cause Takotsubo syndrome. 884 , 885\nPPCM presents as HF secondary to LV systolic dysfunction, usually shown by an LVEF <45%, occurring towards the end of pregnancy (third trimester) or in the months following delivery without any other identifiable cause. The majority of PPCM cases are diagnosed in post-partum. The prevalence ranges from 1:100 in Nigeria to 1:1000\nManagement of patients with heart failure before and during pregnancy\nBi-monthly or  monthly review (mWHO II)\nCounselling including risk assessment and education a\nCardiac assessment including clinical assessment, ECG, echocardiogram\nReview HF therapy and switch to non-teratogenic HF medication\nModerate and high-risk HF patients  (mWHO II, II–III and IV)\nReferral  to a specialist centre for high-risk pregnancies with multidisciplinary Pregnancy Heart Team\nReassessment at the beginning of the second trimester i.e. 20 weeks\nReassessment at 20 weeks\nLow-risk HF patients (mWHO I)\nDiscuss with a specialist centre for high-risk pregnancies\nReassessment at the beginning of the second trimester i.e. 20 weeks\nMonthly review  (mWHO III)\nUrgent counselling for consideration of pregnancy termination (mWHO IV)\nPre-pregnancy\nAt pregnancy diagnosis or planning\nDuring pregnancy\nFigure 19  Management of patients with heart failure before and during pregnancy. ECG= electrocardiogram; HF= heart failure; mWHO= modified World Health Organization.   a Advice regarding contraception, HF medication, to contact HF specialist when planning pregnancy.\n3676 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ...................................................................................................................................................................... in South Africa and 1:1500 in Germany. 643   Prospective large cohort studies report a 6-month mortality ranging from 2.0% in Germany to 12.6% in a 206 PPCM patient cohort from South Africa. 643\nPPCM frequently presents with acute HF but may also present with ventricular arrhythmias and/or cardiac arrest. An LVEF <30%, marked LV dilatation, LV end-diastolic diameter >6.0 cm, and RV involvement are associated with adverse outcomes. 643   Cardiac recovery may occur in the first 3 \u0002 6 months though it may be delayed to up to 2 years. Recovery rates vary among regions, from 75% to less than 50%. 886 \u0002 888\nAssessment and management of pregnant patients presenting with HF depends upon the clinical setting and severity of presentation. Detailed cardiac assessment with echocardiography, NP levels, foetal ultrasound and foetal monitoring is recommended. In cases of new HF or if there is diagnostic uncertainty non-contrast CMR may be considered. Milder cases can be treated with oral diuretics, beta-blockers, hydralazine and oral nitrates. Pregnant women presenting with signs of acute HF require urgent hospital admission. In case of PPCM pre- senting with severe HF and cardiogenic shock requiring inotropic or vasopressor support, transfer to an advanced HF centre, where ECMO, LVAD and/or cardiac transplantation can be performed, is recommended. Urgent delivery by caesarean section (irrespective of gestation) should be considered with MCS immediately available. Adrenergic agents (dobutamine, adrenaline) may have detrimental effects. 889   When a PPCM patient is haemodynamically unstable, levo- simendan or MCS may be considered. LVAD implantation as a BTT or BTR should be considered in refractory cases of cardiogenic shock. 643   Bromocriptine has been proposed for patients with acute PPCM to reduce the production of a cleaved 16 kDa prolactin frag- ment, which may contribute to the pathophysiology of PPCM. Bromocriptine was tested in a randomized trial in 63 patients com- paring its long-term, 8 weeks, with its short-term, 1-week, treatment. It was associated with recovery of LV function, with no difference between the two regimens and in line with the results of a previous international PPCM registry. 890 , 891   Bromocriptine may be considered for treatment of PPCM. Untoward effects of treatment, including deep venous thrombosis and cessation of lactation, must be consid- ered if it is initiated. It should therefore be accompanied by prophy- lactic (or therapeutic) anticoagulation.\n",
      "keywords": [
        "moderate",
        "complications",
        "blood pressure",
        "heart failure",
        "echo",
        "recommended",
        "systolic dysfunction",
        "existing",
        "level b",
        "ecg",
        "class iii",
        "glucose",
        "failure",
        "anticoagulation",
        "echocardiography",
        "lvef",
        "heart",
        "should be considered",
        "related",
        "high",
        "higher",
        "diastolic",
        "electrocardiogram",
        "pregnancy",
        "women",
        "arb",
        "nyha",
        "weight",
        "may be considered",
        "decompensation"
      ],
      "tables": []
    },
    {
      "number": "98",
      "title": "14.2 Cardiomyopathies 14.2.1 Epidemiology and diagnosis CMPs can be either inherited (genetic/familial) and/or acquired. They can also be accelerated by disease modifiers. 892 \u0002 894   They are a heter",
      "start_page": 78,
      "end_page": 79,
      "content": "Direct causes of CMPs include pathogenic gene variants (muta- tions), toxins, auto-immunity, storage diseases, infections, and tachyarrhythmias. Disease modifiers, conditions that may aggravate or trigger a CMP, include epigenetic factors and acquired modifiers, such as pregnancy and most CV comorbidities. It is important to\nconsider this key interaction between genetic and acquired causes during the diagnostic workup. 897   Identification of an acquired cause of the CMP does not exclude an underlying pathogenic gene variant, whereas the latter may require an additional acquired cause and/or disease modifier to become manifest clinically. The commonest causes and disease modifiers are shown in  Table  25 . The key elements of the diagnostic workup for all patients with HF and CMP are reported in  Table  26 . 892 , 894 , 895 , 898 , 899   Specifics aspects of diagnosis and treatment are summarized in  Tables  27 \u0002 29 . Clinical history, laboratory tests, and imaging are the first-line investigations. Echocardiography is central for the diagnosis and monitoring of HCM, DCM, and AC. CMR imaging provides more detailed morpho- logical and prognostic information and should be performed at baseline. The prevalence of gene mutations may vary according to the morphological phenotype or the underlying acquired cause. Gene mutations occur in up to 40% of DCM, 60% of HCM, and 15% in chemotherapy-induced, alcoholic or peripartum CMPs. 895 , 898 , 900 \u0002 905   The prevalence of genetic mutations is over 10% also in non-familial DCM. 898 , 906   Finding a pathogenic gene var- iant in a patient with CMP allows better prediction of the disease out- come and progression, may contribute to the indications for device implantation and inform genetic counselling for families. Endomyocardial biopsy (EMB) with immunohistochemical quantifi- cation of inflammatory cells remains the gold standard investigation for the identification of cardiac inflammation. It may confirm the diag- nosis of auto-immune disease in patients with DCM and suspected giant cell myocarditis, eosinophilic myocarditis, vasculitis and sarcoi- dosis. 893 , 907   It may also help for the diagnosis of storage diseases, including amyloid or Fabry disease, if imaging or genetic testing does not provide a definitive diagnosis (see also  section 14.6 ). EMB might be considered also in HCM if genetic or acquired causes cannot be identified. The risks and benefits of EBM should be evaluated and this procedure should be reserved for specific situations where its results may affect treatment.\n14.2.2 Treatment The current pharmacological treatment of HF in DCM, HCM, or AC patients does not differ from general HF management, except for peculiar aspects reported in  Tables  27 \u0002 29 . A pilot randomized study, TRED-HF, investigated the possibility of withdrawing medical treat- ment in those patients with non-ischaemic DCM who had had partial to complete recovery of LVEF (>40%). However, relapse of DCM within 6 months was observed in 44% of patients, and rapid LV remodelling with early tissue and functional changes, even amongst patients who did not relapse, was found. 271 , 908\nIn a phase 3, randomized, double-blind, placebo-controlled trial (EXPLORER-HCM), treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive HCM. This offers the possibility of disease-specific treatment for inherited CMPs.   909\nICD implantation should be considered for patients with DCM, HCM, or AC (see  section 6 ). 895 , 910 \u0002 912   The strength of the indication varies according to the clinical risk factors for sudden cardiac death with higher priority being given to those patients with significant LGE\nESC Guidelines 3677\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 25 Possible causes and disease modiﬁers of most frequent cardiomyopathies\nCause Disease modifier Phenotype\nGenetic mutations\nLMNA x DCM\nTTN x x DCM, (HCM)\nRBM20 x DCM\nMYH7 x DCM, HCM\nMYPC x DCM, HCM\nTNNT x DCM, HCM\nPLN x DCM, HCM, AC\nDSP x x AC, DCM, myocarditis\nSCN5a x x AC, (DCM)\nTropomyosin-1 x DCM\nHaemochromatosis (HFE gene, C282Y) x HCM, DCM\nGalactosidase-A (Fabry disease) x HCM\nNeuromuscular disorders\nDuchenne muscular dystrophy, Becker muscular dystrophy,\nmyotonic dystrophy\nx DCM\nSyndromic disorders\nMitochondrial X-linked mutations x DCM\nAcquired diseases\nInfection (viruses) x x Myocarditis, DCM\nImmuno-mediated diseases (rheumathoid arthritis, systemic\nlupus erythematosus, dermatomyositis)\nx x Myocarditis, DCM\nToxic (alcohol, amphetamines, cocaine) x x DCM, myocarditis\nDrugs (anthracyclines, trastuzumab, immune checkpoint inhibitors) x x DCM, myocarditis\nOverload (haemochromoatosis) x x HCM, DCM\nPeripartum (pregnancy) x x DCM\nComorbidities with possible interactions with the gene mutations and an effect on phenotype and outcome\nTachy-arrhythmias x x DCM\nDiabetes mellitus x x DCM, HCM\nHypertension x x DCM, HCM\nHypo- and hyperthyroidism x DCM, HCM, myocarditis\nAC = arrhythmogenic cardiomyopathy; DCM = dilated cardiomyopathy; DSP = desmoplakin; HCM = hypertrophic cardiomyopathy; LMNA = lamin A/C; MYH7 (gene) = myosin heavy chain 7; MYPC = myosin-binding protein C; PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20; SCN5a = sodium channel alpha unit 5; TTN = titin; TNNT = troponin-T.\nTable 26 Initial diagnostic assessment in patients with suspected cardiomyopathy\nHistory  including detailed questions on any systemic disease, toxic agents (chemotherapy, alcohol, drugs), and familial history of cardiac or neuromuscular\ndisease, or sudden cardiac death in family members at young age (<50 years).\nLaboratory exams  including cardiac and muscular enzymes, liver and renal function, haemoglobin, white blood cell count (including differential white blood cell count to detect eosinophilia), natriuretic peptides, thyroid function tests, iron status, and markers of systemic auto-immune disease (hsCRP, anti-\nnuclear antibodies, soluble IL-2 receptor).\nStandard 12-lead ECG and echocardiography  to detect arrhythmias and assess cardiac structure and function and concomitant abnormalities.\nInvasive coronary angiography or CTCA  to rule out signiﬁcant CAD in patients with cardiac dysfunction.\nCMR imaging  with T1 and T2 sequencing and LGE to visualize structural changes, storage, inﬁltration, inﬂammation, ﬁbrosis and scarring.\nGenetic counselling and genetic testing  should be performed depending on age, family history, cardiac phenotype.\n24 or 48-hour ambulatory ECG monitoring  to detect atrial and ventricular arrhythmias.\nCAD = coronary artery disease; CMR = cardiac magnetic resonance; CTCA = computed tomography coronary angiography; ECG = electrocardiogram; hsCRP = high-sensitivity C-reactive protein; IL-2 = interleukin-2; LGE = late gadolinium enhancement.\n",
      "keywords": [
        "angiography",
        "indication",
        "ecg",
        "diagnosis",
        "also",
        "disease",
        "echocardiography",
        "hypertension",
        "lvef",
        "cmps",
        "should be considered",
        "coronary artery",
        "cardiomyopathies",
        "epidemiology",
        "familial",
        "inherited",
        "alcohol",
        "icd",
        "electrocardiogram",
        "modifiers",
        "accelerated",
        "family history",
        "nyha",
        "heter",
        "either",
        "genetic",
        "diabetes",
        "troponin",
        "age",
        "acquired"
      ],
      "tables": [
        {
          "title": "3678 ESC Guidelines",
          "page_number": 79,
          "content": " |  | Cause |  | Disease modifier |  | Phenotype | ESC 2021\nGenetic mutations |  |  |  |  |  |  | \nLMNA |  | x |  |  |  | DCM | \nTTN |  | x |  | x |  | DCM, (HCM) | \nRBM20 |  | x |  |  |  | DCM | \nMYH7 |  | x |  |  |  | DCM, HCM | \nMYPC |  | x |  |  |  | DCM, HCM | \nTNNT |  | x |  |  |  | DCM, HCM | \nPLN |  | x |  |  |  | DCM, HCM, AC | \nDSP |  | x |  | x |  | AC, DCM, myocarditis | \nSCN5a |  | x |  | x |  | AC, (DCM) | \nTropomyosin-1 |  | x |  |  |  | DCM | \nHaemochromatosis (HFE gene, C282Y) |  | x |  |  |  | HCM, DCM | \nGalactosidase-A (Fabry disease) |  | x |  |  |  | HCM | \nNeuromuscular disorders |  |  |  |  |  |  | \nDuchenne muscular dystrophy, Becker muscular dystrophy,\nmyotonic dystrophy |  | x |  |  |  | DCM | \nSyndromic disorders |  |  |  |  |  |  | \nMitochondrial X-linked mutations |  | x |  |  |  | DCM | \nAcquired diseases |  |  |  |  |  |  | \nInfection (viruses) |  | x |  | x |  | Myocarditis, DCM | \nImmuno-mediated diseases (rheumathoid arthritis, systemic\nlupus erythematosus, dermatomyositis) |  | x |  | x |  | Myocarditis, DCM | \nToxic (alcohol, amphetamines, cocaine) |  | x |  | x |  | DCM, myocarditis | \nDrugs (anthracyclines, trastuzumab, immune checkpoint inhibitors) |  | x |  | x |  | DCM, myocarditis | \nOverload (haemochromoatosis) |  | x |  | x |  | HCM, DCM | \nPeripartum (pregnancy) |  | x |  | x |  | DCM | \nComorbidities with possible interactions with the gene mutations and an effect on phenotype and outcome |  |  |  |  |  |  | \nTachy-arrhythmias |  | x |  | x |  | DCM | \nDiabetes mellitus |  | x |  | x |  | DCM, HCM | \nHypertension |  | x |  | x |  | DCM, HCM | \nHypo- and hyperthyroidism |  |  |  | x |  | DCM, HCM, myocarditis | ",
          "bbox": [
            43.50900091607887,
            81.29803466796875,
            553.0789794921875,
            498.63890293666293
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "99",
      "title": "ESC 2021 ESC 2021",
      "start_page": 79,
      "end_page": 81,
      "content": "3678 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 27 Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy: speciﬁc aspects of diagnosis and treatment\nDiagnostic criteria and deﬁnitions 894 , 895\nDCM: LV dilatation and systolic dysfunction in the absence of known abnormal loading conditions or signiﬁcant CAD.\nHNDC: LV or biventricular global systolic dysfunction (LVEF <45%) without dilatation in the absence of known abnormal loading conditions or signiﬁcant\nCAD. DCM and HNDC can be considered “familial” if two or more ﬁrst- or second-degree relatives have DCM or HNDC, or a ﬁrst-degree relative has autopsy\nproven DCM and sudden death at <50 years of age.\nGenetic counselling and testing 892 , 894 , 898 , 916\nIndication.  All patients with a diagnosis of DCM or HNDC and all ﬁrst-degree adult relatives of these patients and a deﬁnite disease-causing mutation, regardless of their phenotype, in order to identify genetically affected individuals at a preclinical phase.\nFirst-degree adult relatives should have their evaluation repeated every 5 years or less when aged <50 years or non-diagnostic abnormalities are found.\nClinical evaluation, ECG, echocardiography and possibly CMR, must be performed in ﬁrst-degree relatives of patients. Results can identify patients with DCM or HNDC at highest risk of arrhythmia and/or deserving other speciﬁc treatments.\nEarly identiﬁcation of asymptomatic relatives may lead to early treatment and prevention of progression to HF and proper genetic counseling.\nMinimal set of genes a : TTN, LMNA, MHC, TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3, actin alpha cardiac muscle, nexilin, tropomyosin-1, vinculin.\nThe use of additional sequencing for the analysis of very large panel of genes may be considered when there is a clear familial history or structural pheno-\ntype, by preference combined with family segregation.\nEndomyocardial biopsy 97 , 907 , 917 \u0002 919\nIndication.  In suspected phenotypes requiring speciﬁc treatments (i.e. giant cell myocarditis, eosinophilic myocarditis, sarcoidosis, vasculitis, SLE, other\nsystemic, auto-immune inﬂammatory conditions, or storage diseases).\nNumber of samples . A minimum of 5 but possibly at least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for RNA viruses/viral replication. 918 , 919\nAetiology.  Search for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by quantitative rtPCR when\na viral aetiology is suspected. Viral mRNA for active viral replication should be assessed, if possible. Further assessment if indicated: CMV, HIV,  Borrelia burgdorferi  (Lyme disease),  Coxiella burnetii  (Q-fever),  Trypanosoma cruzi  (Chagas disease) and\nSARS-CoV-2.\nImmunohistochemistry . Quantiﬁcation of CD3-, CD4-, CD8- or CD45- staining lymphocytes and CD68 macrophages per mm 2 ; anti-HLA-DR. Histology . Haematoxylin and eosin staining, ﬁbrosis assessment with Masson’s Trichrome and Picrosirius Red, amyloid ﬁbrils detection with Congo Red.\nTherapeutic options 895 , 917\nHF treatment for HFrEF (see  sections 5  and  6 )\nLMNA, RBM20, PLN and FLN mutation . Higher risk of sudden cardiac death: early indication for primary prevention by ICD implantation should be\nconsidered (guided by risk factors as detailed). 920\nTTN mutation.  Higher rate of LV reverse remodeling (in up to 70%), but a higher risk of atrial and ventricular tachyarrhythmias.\nLyme disease ( Borrelia ).  Treatment with doxycycline.\nChagas disease ( Trypanosoma cruzi ).  Speciﬁc treatment according to current recommendations. 921 , 922\nAuto-immune/inﬂammatory.  Consider immunosuppressive therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis or vasculitis, and in\nhighly selected patients with increased cardiac inﬂammation of unknown origin based upon multidisciplinary counselling (cardiology and immunology).\nBAG3 = Bcl2-associated athanogene 3; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DCM = dilated cardiomyopathy; DNA = deoxyribonucleic acid; ECG = electrocardiogram; FLN = ﬁlamin; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HHV = human herpes virus; HIV = human immunodeﬁciency virus; HLA-DR = human leukocyte antigen-DR isotype; HNDC = hypokinetic non-dilated cardiomyopathy; ICD = implantable cardioverter-deﬁbrilla- tor; LMNA = lamin A/C; LV = left ventricular; LVEF = left ventricular ejection fraction; MHC = myosin heavy chain; MYPC = myosin-binding protein C; mRNA = messenger ribo- nucleic acid; NSVT = non-sustained ventricular tachycardia; PCR = polymerase chain reaction; PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20; RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SLE = systemic lupus erythemato- sus; TNNT = troponin-T; TTN = titin. a This list of genes is not exhaustive, and will change over time, with increasing knowledge of the pathogenicity. Contact the genetic department to ask which core panel of genes they are using. b Risk factors in patients with a conﬁrmed LMNA mutation: NSVT during ambulatory ECG monitoring, LVEF <45% at ﬁrst evaluation, male sex and non-missense mutations (insertion, deletion, truncations, or mutations affecting splicing).\nESC 2021\nESC Guidelines 3679\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nTable 28 Hypertrophic cardiomyopathy: speciﬁc aspects of diagnosis and treatment\nDeﬁnition 895 , 896 , 923\nWall thickness >14 mm in one or more LV myocardial segments not sufﬁciently explained solely by abnormal loading conditions.\nLVOTO >_30 mmHg at rest or exercise, asymmetric hypertrophy, or increased LGE in a patchy mid-wall pattern in the most hypertrophied segment, further suggest the presence of HCM.\nIt can be considered familial when two or more ﬁrst- or second-degree relatives with HCM or a ﬁrst-degree relative with autopsy proven HCM and\nsudden death at <50 years of age are detected.\nDifferential diagnosis\nIt might be difﬁcult with physiological hypertrophy induced by intense athletic training, severe hypertension or aortic stenosis and with isolated septal\nhypertrophy. Consider a genetic HCM if the degree of LV hypertrophy is disproportionate with respect to the acquired trigger.\nConsider amyloidosis as a cause when increased thickness of the interatrial septum, AV valve and/or RV free wall are detected (see  section 14.6 ).\nGenetic counselling and testing\nIndication.  Must be offered to all patients with a diagnosis of HCM to identify a possible underlying genetic cause and to all ﬁrst-degree adult relatives of\npatients with HCM and a deﬁnite disease-causing mutation, regardless of their phenotype, in order to identify genetically affected individuals at a preclinical\nphase. Clinical evaluation, ECG and echocardiography, must be performed in ﬁrst-degree relatives who have the same deﬁnite disease-causing mutation as the\nindex patient.\nWhen no deﬁnite genetic mutation is identiﬁed in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in ﬁrst-degree adult relatives and repeated every 2 \u0002 5 years or less if non-diagnostic abnormalities are present.\nMinimal set of genes a   (sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT, Troponin-C, MYPC, RMB20, PLN, Sodium channel\nalpha unit, BAG3, Actin Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin. 898 , 924 \u0002 926\nThe use of additional sequencing for the analysis of very large panel of genes may be considered if there is a clear familial history or structural phenotype,\nby preference combined with family segregation.\nSpeciﬁc conditions. Muscular weakness: consider mitochondrial X-linked mutations, glycogen storage disorders, FHLI mutations, Friedreich’s ataxia.\nSyndromic conditions (cognitive, visual impairment, drooping eyelid): consider mitochondrial X-linked mutations, Noonan syndrome, Danon disease.\nCafe´ au lait spots (lentigines): consider Leopard/Noonan syndrome\nEndomyocardial biopsy\nIndication.  It may be considered when the baseline clinical assessment suggests cardiac inﬂammation or storage disease which cannot be diagnosed by\nother means 896   (see also  Section 14.6 ).\nTherapeutic options 895 , 896 , 923\nWith LVOTO Avoid hypovolaemia (dehydration), arterial and venous dilators (nitrates and phosphodiesterase type 5 inhibitors), and digoxin.\nUse non-vasodilating beta-blockers or use verapamil if beta-blockers non-tolerated or ineffective.\nLow-dose loop or thiazide diuretics must be used with caution to improve dyspnoea associated with LVOTO, but avoiding hypovolaemia. Invasive treatment (septal reduction therapy by alcohol ablation or myomectomy), in experienced centres, may be considered in those patients with a\nresting or maximum provoked LVOT >_50 mmHg and/or who remain symptomatic (NYHA class III or IV, syncope) despite OMT.\nNovel drugs or devices may be considered once available. 909 , 927\nSymptomatic without LVOTO\nCautious use of low-dose loop or thiazide diuretics avoiding hypovolaemia.\nVerapamil/diltiazem if LVEF >50% and beta-blockers are not tolerated or ineffective.\nIndication to ICD Based on sudden cardiac death risk models. 928 \u0002 930\n",
      "keywords": [
        "aortic stenosis",
        "heart failure",
        "systolic dysfunction",
        "indication",
        "ecg",
        "class iii",
        "hfref",
        "echocardiography",
        "hypertension",
        "lvef",
        "tachycardia",
        "syncope",
        "should be considered",
        "coronary artery",
        "ventricular tachycardia",
        "alcohol",
        "icd",
        "electrocardiogram",
        "nyha",
        "aortic",
        "may be considered",
        "sex",
        "arrhythmia",
        "genetic",
        "primary prevention",
        "ejection fraction",
        "systolic",
        "ablation",
        "troponin",
        "age"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3679",
          "page_number": 80,
          "content": "Diagnostic criteria and definitions894,895 | ESC 2021\nDCM: LV dilatation and systolic dysfunction in the absence of known abnormal loading conditions or significant CAD.\nHNDC: LV or biventricular global systolic dysfunction (LVEF <45%) without dilatation in the absence of known abnormal loading conditions or significant\nCAD.\nDCM and HNDC can be considered “familial” if two or more first- or second-degree relatives have DCM or HNDC, or a first-degree relative has autopsy\nproven DCM and sudden death at <50 years of age. | \nGenetic counselling and testing892,894,898,916 | \nIndication. All patients with a diagnosis of DCM or HNDC and all first-degree adult relatives of these patients and a definite disease-causing mutation,\nregardless of their phenotype, in order to identify genetically affected individuals at a preclinical phase.\nFirst-degree adult relatives should have their evaluation repeated every 5 years or less when aged <50 years or non-diagnostic abnormalities are found.\nClinical evaluation, ECG, echocardiography and possibly CMR, must be performed in first-degree relatives of patients.\nResults can identify patients with DCM or HNDC at highest risk of arrhythmia and/or deserving other specific treatments.\nEarly identification of asymptomatic relatives may lead to early treatment and prevention of progression to HF and proper genetic counseling.\nMinimal set of genesa: TTN, LMNA, MHC, TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3, actin alpha cardiac muscle,\nnexilin, tropomyosin-1, vinculin.\nThe use of additional sequencing for the analysis of very large panel of genes may be considered when there is a clear familial history or structural pheno-\ntype, by preference combined with family segregation. | \nEndomyocardial biopsy97,907,917\u0002919 | \nIndication. In suspected phenotypes requiring specific treatments (i.e. giant cell myocarditis, eosinophilic myocarditis, sarcoidosis, vasculitis, SLE, other\nsystemic, auto-immune inflammatory conditions, or storage diseases).\nNumber of samples. A minimum of 5 but possibly at least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for RNA viruses/viral\nreplication.918,919\nAetiology. Search for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by quantitative rtPCR when\na viral aetiology is suspected. Viral mRNA for active viral replication should be assessed, if possible.\nFurther assessment if indicated: CMV, HIV, Borrelia burgdorferi (Lyme disease), Coxiella burnetii (Q-fever), Trypanosoma cruzi (Chagas disease) and\nSARS-CoV-2.\nImmunohistochemistry. Quantification of CD3-, CD4-, CD8- or CD45- staining lymphocytes and CD68 macrophages per mm2; anti-HLA-DR.\nHistology. Haematoxylin and eosin staining, fibrosis assessment with Masson’s Trichrome and Picrosirius Red, amyloid fibrils detection with Congo Red. | \nTherapeutic options895,917 | \nHF treatment for HFrEF (see sections 5 and 6) | \nLMNA, RBM20, PLN and FLN mutation. Higher risk of sudden cardiac death: early indication for primary prevention by ICD implantation should be\nconsidered (guided by risk factors as detailed).920 | \nTTN mutation. Higher rate of LV reverse remodeling (in up to 70%), but a higher risk of atrial and ventricular tachyarrhythmias. | \nLyme disease (Borrelia). Treatment with doxycycline. | \nChagas disease (Trypanosoma cruzi). Specific treatment according to current recommendations.921,922 | \nAuto-immune/inflammatory. Consider immunosuppressive therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis or vasculitis, and in\nhighly selected patients with increased cardiac inflammation of unknown origin based upon multidisciplinary counselling (cardiology and immunology). | ",
          "bbox": [
            48.021816744123186,
            91.71560668945312,
            557.6139526367188,
            551.4466125488282
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3680 ESC Guidelines",
          "page_number": 81,
          "content": "Definition895,896,923 | ESC 2021\nWall thickness >14 mm in one or more LV myocardial segments not sufficiently explained solely by abnormal loading conditions.\nLVOTO >30 mmHg at rest or exercise, asymmetric hypertrophy, or increased LGE in a patchy mid-wall pattern in the most hypertrophied segment,\n_\nfurther suggest the presence of HCM.\nIt can be considered familial when two or more first- or second-degree relatives with HCM or a first-degree relative with autopsy proven HCM and\nsudden death at <50 years of age are detected. | \nDifferential diagnosis | \nIt might be difficult with physiological hypertrophy induced by intense athletic training, severe hypertension or aortic stenosis and with isolated septal\nhypertrophy. Consider a genetic HCM if the degree of LV hypertrophy is disproportionate with respect to the acquired trigger.\nConsider amyloidosis as a cause when increased thickness of the interatrial septum, AV valve and/or RV free wall are detected (see section 14.6). | \nGenetic counselling and testing | \nIndication. Must be offered to all patients with a diagnosis of HCM to identify a possible underlying genetic cause and to all first-degree adult relatives of\npatients with HCM and a definite disease-causing mutation, regardless of their phenotype, in order to identify genetically affected individuals at a preclinical\nphase.\nClinical evaluation, ECG and echocardiography, must be performed in first-degree relatives who have the same definite disease-causing mutation as the\nindex patient.\nWhen no definite genetic mutation is identified in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography\nshould be considered in first-degree adult relatives and repeated every 2\u00025 years or less if non-diagnostic abnormalities are present.\nMinimal set of genesa (sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT, Troponin-C, MYPC, RMB20, PLN, Sodium channel\nalpha unit, BAG3, Actin Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.898,924\u0002926\nThe use of additional sequencing for the analysis of very large panel of genes may be considered if there is a clear familial history or structural phenotype,\nby preference combined with family segregation.\nSpecific conditions.\nMuscular weakness: consider mitochondrial X-linked mutations, glycogen storage disorders, FHLI mutations, Friedreich’s ataxia.\nSyndromic conditions (cognitive, visual impairment, drooping eyelid): consider mitochondrial X-linked mutations, Noonan syndrome, Danon disease.\nCafe´ au lait spots (lentigines): consider Leopard/Noonan syndrome | \nEndomyocardial biopsy | \nIndication. It may be considered when the baseline clinical assessment suggests cardiac inflammation or storage disease which cannot be diagnosed by\nother means896 (see also Section 14.6). | \nTherapeutic options895,896,923 | \nWith LVOTO\nAvoid hypovolaemia (dehydration), arterial and venous dilators (nitrates and phosphodiesterase type 5 inhibitors), and digoxin.\nUse non-vasodilating beta-blockers or use verapamil if beta-blockers non-tolerated or ineffective.\nLow-dose loop or thiazide diuretics must be used with caution to improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.\nInvasive treatment (septal reduction therapy by alcohol ablation or myomectomy), in experienced centres, may be considered in those patients with a\nresting or maximum provoked LVOT >50 mmHg and/or who remain symptomatic (NYHA class III or IV, syncope) despite OMT.\n_\nNovel drugs or devices may be considered once available.909,927 | \nSymptomatic without LVOTO\nCautious use of low-dose loop or thiazide diuretics avoiding hypovolaemia.\nVerapamil/diltiazem if LVEF >50% and beta-blockers are not tolerated or ineffective. | \nIndication to ICD\nBased on sudden cardiac death risk models.928\u0002930\nConsider ICD implantation if:\n- family history of sudden cardiac death in one or more first degree relatives under 40 years of age or sudden cardiac death in a first degree relative\nwith confirmed HCM at any age;\n- NSVT;\n- unexplained syncope.931 | \nFabry disease\nEnzyme replacement therapy (alpha-galactosidase A deficiency).895 | \nAmyloidosis. See section 14.6 and Figure 21. | ",
          "bbox": [
            43.4819326156225,
            81.70927429199219,
            554.2129516601562,
            698.6272766113282
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "100",
      "title": "Consider ICD implantation if:",
      "start_page": 81,
      "end_page": 82,
      "content": "- family history of sudden cardiac death in one or more ﬁrst degree relatives under 40 years of age or sudden cardiac death in a ﬁrst degree relative with conﬁrmed HCM at any age;\n- NSVT;\n- unexplained syncope. 931\nFabry disease\nEnzyme replacement therapy (alpha-galactosidase A deﬁciency). 895\nAmyloidosis.  See  section 14.6  and  Figure  21 .\nAV= atrio-ventricular; BAG3= Bcl2-associated athanogene 3; ECG= electrocardiogram; HCM= hypertrophic cardiomyopathy; ICD= implantable cardioverter-deﬁbrillator; LGE= late gadolinium enhancement; LMNA =lamin A/C; LV= left ventricular; LVEF= left ventricular ejection fraction; LVOT= left ventricular outﬂow tract; LVOTO= left ventricular out- ﬂow tract obstruction; MHC= myosin heavy chain; MYPC= myosin-binding protein C; NSVT= non-sustained ventricular tachycardia; NYHA= New York Heart Association; OMT = optimal medical therapy; PLN= phospholamban; RMB20= ribonucleic acid binding motif 20; RV= right ventricular; TNNT =troponin-T; TTN= titin. a The list of genes is not exhaustive, and will change over time, with increasing knowledge of the pathogenicity. Contact the genetic department to ask which core panel of genes they are using.\nESC 2021\n3680 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .................. on CMR, younger age, or with a specific familial/genetic phenotype ( Tables  27 \u0002 29 ). Risk models for the prediction of ICD benefits were applied to the patients enrolled in DANISH and may help for the indi- cation to ICD implantation in DCM. 166 , 913   Treatment of HCM and AC, including indications for ICD, are detailed in previous documents. 895 , 896 , 899 , 912 , 914 , 915\n",
      "keywords": [
        "genetic",
        "ventricular tachycardia",
        "implantation",
        "ejection fraction",
        "electrocardiogram",
        "icd",
        "lvef",
        "troponin",
        "tachycardia",
        "syncope",
        "age",
        "family history",
        "nyha",
        "consider",
        "cardiomyopathy",
        "ecg",
        "sudden cardiac death"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3681",
          "page_number": 82,
          "content": "Definition | ESC 2021\nInherited heart muscle disease characterized by progressive fibrofatty replacement of the RV myocardium which may act as a substrate for ventricular\narrhythmias, unexplained syncope and/or sudden cardiac death.\nLV involvement and systolic dysfunction occurs in >30% of AC patients, therefore its phenotype may overlap with DCM. | \nDiagnosis933 | \nBased upon the evaluation of a combination of the genetic factors (most cases autosomal dominant desmosomal mutations), documentation of ventricular\narrhythmias and imaging criteria (echocardiography and MRI) of RV dysplasia with the fibrofatty replacement either or not confirmed by EMB. Specific ECG\nabnormalities can be present or absent. | \nGenetic counselling/testing898,912 | \nIndication. Must be offered to all patients with a suspected AC and has to be offered to all first-degree adult relatives of patients with AC and a definite\ndisease-causing mutation, regardless of their phenotype in order to identify genetically affected individuals at a preclinical phase.\nGenetic family screening can be also indicated for arrhythmic risk stratification purposes.\nClinical evaluation, ECG, echocardiography and possibly CMR have to be performed in first-degree relatives who have the same definite disease-causing\nmutation as the index patient.\nWhen no definite genetic mutation is identified in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography\nshould be considered in first-degree adult relatives and repeated every 2\u00025 years or less if non-diagnostic abnormalities are present.\nMinimal set of genes:\nDesmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2, DSG2 and DSC2a\nWith frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3, desmin, a-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2,\nTRPM4 or PLN variants in particular.\nIf mild LV hypertrophy: consider TNNT variants.\nCutaneous abnormalities, palmar and plantar hyperkeratosis: consider rare recessive mutations leading to Carvajal syndrome and Naxos disease. Plakoglobin\n(JUP).\nWith CMR presentation of myocarditis along AC: consider DSP gene variants.934,935 | \nEndomyocardial biopsy | \nIt should be reserved to highly selected cases after all non-invasive studies have been assessed. Fibrofatty replacement with or without replacement type fib-\nrosis at RV septal biopsies are the characteristic findings. EMB has low sensitivity for the diagnosis of AC in cases of focal distribution. | \nTherapeutic options | \nHF treatment for HFrEF (see sections 5 and 6).\nCompetitive sports should be avoided, limit activities to leisure-time activities.936\nIn patients with ventricular arrhythmias: beta-blockers must be titrated to the maximally tolerated dose as first-line therapy. Amiodarone can be considered\nin addition to beta-blockers or if beta-blockers contraindicated or not tolerated; ICD implantation is indicated if history of aborted sudden cardiac death or\nsustained and/or haemodynamically poorly tolerated ventricular tachycardia.910\u0002912\nIn patients with no ventricular arrhythmias: ICD can be considered (see section 6.1) even in patients with LMNA or FLNC gene mutations and LVEF\n<45%.912 | ",
          "bbox": [
            48.006585028863725,
            81.70927429199219,
            559.3150024414062,
            525.82734375
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "101",
      "title": "14.3 Left ventricular non-compaction LVNC is a very rare congenital CMP characterized by endomyo- cardial trabeculations that increase in number and prominence. In most cases, including when the condi",
      "start_page": 82,
      "end_page": 83,
      "content": "Table 29 Arrhythmogenic cardiomyopathy: speciﬁc aspects of diagnosis and treatment 912 , 915 , 932\nDeﬁnition\nInherited heart muscle disease characterized by progressive ﬁbrofatty replacement of the RV myocardium which may act as a substrate for ventricular\narrhythmias, unexplained syncope and/or sudden cardiac death. LV involvement and systolic dysfunction occurs in >30% of AC patients, therefore its phenotype may overlap with DCM.\nDiagnosis 933\nBased upon the evaluation of a combination of the genetic factors (most cases autosomal dominant desmosomal mutations), documentation of ventricular\narrhythmias and imaging criteria (echocardiography and MRI) of RV dysplasia with the ﬁbrofatty replacement either or not conﬁrmed by EMB. Speciﬁc ECG abnormalities can be present or absent.\nGenetic counselling/testing 898 , 912\nIndication.  Must be offered to all patients with a suspected AC and has to be offered to all ﬁrst-degree adult relatives of patients with AC and a deﬁnite\ndisease-causing mutation, regardless of their phenotype in order to identify genetically affected individuals at a preclinical phase. Genetic family screening can be also indicated for arrhythmic risk stratiﬁcation purposes.\nClinical evaluation, ECG, echocardiography and possibly CMR have to be performed in ﬁrst-degree relatives who have the same deﬁnite disease-causing\nmutation as the index patient. When no deﬁnite genetic mutation is identiﬁed in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography\nshould be considered in ﬁrst-degree adult relatives and repeated every 2 \u0002 5 years or less if non-diagnostic abnormalities are present.\nMinimal set of genes: Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2, DSG2 and DSC2 a\nWith frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3, desmin,  a -actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2,\nTRPM4 or PLN variants in particular. If mild LV hypertrophy: consider TNNT variants.\nCutaneous abnormalities, palmar and plantar hyperkeratosis: consider rare recessive mutations leading to Carvajal syndrome and Naxos disease. Plakoglobin\n(JUP). With CMR presentation of myocarditis along AC: consider  DSP  gene variants. 934 , 935\nEndomyocardial biopsy\nIt should be reserved to highly selected cases after all non-invasive studies have been assessed. Fibrofatty replacement with or without replacement type ﬁb-\nrosis at RV septal biopsies are the characteristic ﬁndings. EMB has low sensitivity for the diagnosis of AC in cases of focal distribution.\nTherapeutic options\nHF treatment for HFrEF (see  sections 5  and  6 ).\nCompetitive sports should be avoided, limit activities to leisure-time activities. 936\nIn patients with ventricular arrhythmias: beta-blockers must be titrated to the maximally tolerated dose as ﬁrst-line therapy. Amiodarone can be considered in addition to beta-blockers or if beta-blockers contraindicated or not tolerated; ICD implantation is indicated if history of aborted sudden cardiac death or\nsustained and/or haemodynamically poorly tolerated ventricular tachycardia. 910 \u0002 912\nIn patients with no ventricular arrhythmias: ICD can be considered (see  section 6.1 ) even in patients with LMNA or FLNC gene mutations and LVEF <45%. 912\nAC = arrhythmogenic cardiomyopathy; BAG3 = Bcl2-associated athanogene 3; CMR = cardiac magnetic resonance; DCM = dilated cardiomyopathy; DSC2 = desmocollin 2; DSG2 = desmoglein 2; DSP = desmoplakin; ECG = electrocardiogram; EMB = endomyocardial biopsy; FLN = ﬁlamin; FLNC = ﬁlamin C; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; JUP = junction plakoglobin; KCNH2 = potassium voltage-gated channel subfamily H member 2; KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM domain binding 3; LMNA = lamin A/C; LV = left ventricular; LVEF = left ventricular ejection frac- tion; MRI = magnetic resonance imaging; NKX2-5 = NK2 transcription factor related, locus 5; PLN = phospholamban; PKP2 = plakophilin 2; RMB20 = ribonucleic acid binding motif 20; RV = right ventricular; SCN5A = sodium channel alpha subunit 5; TMEM43 = transmembrane protein 43; TNNT = troponin-T; TRPM4 = transient receptor potential cation channel subfamily M member 4.\nESC 2021\nESC Guidelines 3681\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .............................................................................................................................................................. DCM and HCM phenotypes. Quite commonly individuals with features of LVNC are found in families where other affected rela- tives have typical HCM or DCM. Therefore, LVNC is not treated as a separate disease entity, but as a separate rare presentation of a genetic susceptibility to either HCM or DCM. 939\n",
      "keywords": [
        "mri",
        "increase",
        "endomyo",
        "rare",
        "characterized",
        "cardial",
        "heart failure",
        "prominence",
        "number",
        "systolic dysfunction",
        "indication",
        "when",
        "ecg",
        "lvnc",
        "hfref",
        "echocardiography",
        "lvef",
        "tachycardia",
        "syncope",
        "very",
        "should be considered",
        "left",
        "ventricular tachycardia",
        "condi",
        "electrocardiogram",
        "icd",
        "trabeculations",
        "ventricular",
        "genetic",
        "congenital"
      ],
      "tables": [
        {
          "title": "3682 ESC Guidelines",
          "page_number": 83,
          "content": "Infectious |  | ESC 2021\nViral | Parvovirus B19, human herpes virus-6, Epstein-\nBarr virus, enteroviruses, (coxsackievirus,\nadenovirus), CMV, HIV, SARS-CoV-2 | \nOthers | Borrelia, Coxiella burnetii (Q-fever) | \nSystemic disease |  | \nAuto-immune\nand others | Sarcoidosis, giant cell myocarditis, eosinophilic\nmyocarditis, SLE, ANCA-positive vasculitis,\nrheumatoid arthritis, any other auto-immune\ndisease | \nToxic |  | \nMedications | Immune check point inhibitors, anthracyclines,\nclozapine, adrenergic drugs, 5-fluorouracil | \nOther agents | Alcohol, amphetamines, cocaine | ",
          "bbox": [
            43.49472503662109,
            470.80706787109375,
            289.31500244140625,
            648.7160415649414
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "102",
      "title": "14.4 Atrial disease 14.4.1 Definition Atrial disease, also termed atrial failure or myopathy, can be defined as a complex of subclinical structural, electrophysiological, and func- tional changes that",
      "start_page": 83,
      "end_page": 83,
      "content": "14.4.2 Diagnosis Atrial size and function can be evaluated by multimodality imaging including two- and three-dimensional echocardiography, myocar- dial deformation, computed tomography (CT) and CMR. 944\nCardiac biomarkers, including high-sensitivity cardiac troponins and NPs, may assess pathophysiological aspects of atrial dis- ease. 945 \u0002 947   The increased levels of NPs in AF may also be an indi- cator of an underlying atrial disease. 942 , 948   A comprehensive characterization of atrial disease combining clinical, imaging, bio- chemical and molecular features is, however, still lacking.\n14.4.3 Management Atrial disease is an emerging therapeutic target in the prevention of AF, systemic thromboembolism, and perhaps HFpEF. 949   As atrial\ndisease appears to result from the intersection of shared risk factors and comorbidities predisposing to both AF and HF, diabetes mellitus, hypertension, obesity, smoking, and physical inactivity may be of para- mount importance for its development. 7 , 950   Effective management of HF and AF (see  section 12.1.1 ), as well as treatment of mitral regurgi- tation (see  section 12.3.3 ), may also be important to counteract atrial disease progression.\n",
      "keywords": [
        "changes",
        "func",
        "subclinical",
        "termed",
        "hfpef",
        "myopathy",
        "disease",
        "also",
        "defined",
        "failure",
        "echocardiography",
        "hypertension",
        "definition",
        "obesity",
        "complex",
        "electrophysiological",
        "smoking",
        "diabetes",
        "structural",
        "atrial",
        "tional"
      ],
      "tables": []
    },
    {
      "number": "103",
      "title": "14.5 Myocarditis 14.5.1 Epidemiology and diagnosis The incidence of acute myocarditis is estimated to be 1.5 million cases per year globally. 951   The contribution of myocarditis as a cause of HF var",
      "start_page": 83,
      "end_page": 83,
      "content": "Chronic, EMB proven, inflammation can be found in 9% to 30% of adult patients with a DCM. 918 , 953   The most frequent potential aetiologies triggering acute myocarditis in Europe are reported in  Table  30 . The clinical presentation of acute myocarditis may vary from mild symptoms to cardiogenic shock. Workup for the diagnosis of acute myocarditis in patients with HF is reported in  Table  31  and  Figure  20 . Specific criteria about biopsies and CMR are reported in  Tables  32 and  33 .\n14.5.2 Treatment Hospitalization for at least 48 h may be useful for patients with acute myocarditis and HF, especially when troponins are elevated and when cardiac dysfunction, and/or arrhythmias are present at initial presentation. Despite the lack of evidence in the specific setting of acute myocar- ditis, treatment of HFrEF is recommended in the presence of systolic LV dysfunction. Immunosuppression is only indicated in selected cases of acute myocarditis ( Table  34 ). Once cardiac enzymes decrease, arrhythmias are absent, and cardiac systolic dysfunction is stabilized, standard HF therapy should be continued for at least 6 months (see also  Figure  20 ). Immunosuppression has been considered for treatment of patients with chronic cardiac inflammation at EMB and no evidence of active viral infection. 918 , 919   This was associated with an improvement in car- diac function in small studies and with better outcomes in a retro- spective observational study. 953 , 963 , 964   Prospective trials with old or newer immunosuppressive/immunomodulatory drugs are needed. A placebo-controlled trial testing the effects of immunoadsorption with i.v. immunoglobulins on LV function is ongoing and other treatment options are being tested. 919\n",
      "keywords": [
        "hfref",
        "incidence",
        "estimated",
        "year",
        "million",
        "systolic",
        "myocarditis",
        "acute",
        "cause",
        "globally",
        "recommended",
        "cases",
        "systolic dysfunction",
        "contribution",
        "epidemiology",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "104",
      "title": "14.6 Amyloidosis 14.6.1 Epidemiology and diagnosis CA or amyloid cardiomyopathy is still an underdiagnosed cause of HF. 895 , 965 , 966   The two most prevalent forms of CA are light chain immunoglobu",
      "start_page": 83,
      "end_page": 86,
      "content": "Table 30 Aetiologies to be considered triggering acute myocarditis 917\nInfectious\nViral Parvovirus B19, human herpes virus-6, Epstein- Barr virus, enteroviruses, (coxsackievirus,\nadenovirus), CMV, HIV, SARS-CoV-2\nOthers Borrelia, Coxiella burnetii  (Q-fever)\nSystemic disease\nAuto-immune\nand others\nSarcoidosis, giant cell myocarditis, eosinophilic\nmyocarditis, SLE, ANCA-positive vasculitis,\nrheumatoid arthritis, any other auto-immune disease\nToxic\nMedications Immune check point inhibitors, anthracyclines,\nclozapine, adrenergic drugs, 5-ﬂuorouracil\nOther agents Alcohol, amphetamines, cocaine\nANCA = antineutrophil cytoplasmic antibody; CMV = cytomegalovirus; HIV = human immunodeﬁciency virus; SARS-CoV-2 = severe acute respiratory syn- drome coronavirus 2; SLE = systemic lupus erythematosus.\nESC 2021\n3682 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .......................... with unexplained LVH or HFpEF at hospitalization or severe aortic stenosis undergoing aortic valve replacement, aged above 65 years, may have wtTTR-CA. 967 \u0002 972\nDiagnosis and treatment of CA were recently reviewed. 973   Age >65 years and HF along with a LV wall thickness >12 mm at echocar- diography are major criteria for the suspicion of CA. 973   Criteria for a suspicion of CA and to confirm diagnosis are reported in  Table  35 , Supplementary Table 25 , and  Figure  21 . 973 , 974   Cardiac imaging and EMB or extra-cardiac biopsy are needed for the diagnosis of AL-CA\nin patients with abnormal haematological tests ( Figure 21 ). Technetium-labelled   99m Tc-PYP or DPD or HMDP scintigraphy with planar and SPECT imaging has a specificity and positive predictive value for TTR-CA of up to 100%. 975   In contrast, CMR has a sensitivity and specificity of 85% and 92%, respectively. 966 , 976   The hereditary form should be excluded by genetic testing. EMB is the gold standard for the diagnosis of TTR-CA with nearly 100% sensitivity and specific- ity if specimens are collected from >4 multiple sites and tested for amyloid deposits by Congo red staining. 966   However, a biopsy is not\nTable 31 Diagnostic workup in suspected acute myocarditis\nDeﬁnition of suspected acute myocarditis\nClinical presentation  þ  >_1 mandatory diagnostic test being positive (by preference CMR) in the absence of signiﬁcant coronary artery,\nvalvular or congenital heart disease, or other causes.\nSensitivity Speciﬁcity\nClinical presentation\nAcute/new onset chest pain, dyspnoea, signs of left and/or right HF, and/or unexplained arrhythmias or aborted sudden death. Low Low\nMandatory diagnostic tests\nECG New and dynamic ST-T abnormalities, including pseudo-infarct ST seg- ment elevation, atrial or ventricular arrhythmias, AV blocks, QRS\nabnormalities.\nHigh Low\nLaboratory tests Elevated troponins with dynamic changes consistent with myocardial\nnecrosis. Standard tests including white blood cells count to exclude\neosinophilia. 919 , 954\nIntermediate Low\nEchocardiography New structural or function abnormalities, regional wall motion abnormal- ities or global ventricular dysfunction without ventricular dilatation or\nwith, generally mild, dilatation, increased wall thickness due to myocardial\noedema, pericardial effusion, intracardiac thrombi, not explained by other conditions (e.g., CAD, ACS or valvular heart disease).\nHigh Low\nCMR Oedema, inﬂammation and ﬁbrosis detection, quantiﬁcation and localiza-\ntion through T1 and T2 mapping, extracellular volume assessment and\nLGE (see  Table  33 ). 955 , 956\nHigh Intermediate\nAdditional diagnostic tests\nCoronary angiography or CTCA Excludes signiﬁcant CAD or ACS in clinically suspected myocarditis. High High\nEndomyocardial biopsy For diagnosis and indication to speciﬁc treatment (see  Table  32 ). Intermediate High\nCardiac PET May be useful in patients who cannot undergo CMR or with suspected\nsystemic autoimmune disease or cardiac sarcoidosis. 919 , 957\nLow Low\nAdditional laboratory test Skeletal muscle enzymes, liver and renal function, natriuretic peptides,\nthyroid function tests, iron status, markers of systemic autoimmune\ndisease.\nLow Low\nCRP elevated in 80 \u0002 90% patients. 919 , 954 Intermediate Low\nPCR testing of common cardiotropic viruses. It can detect systemic infec-\ntion but does not prove cardiac infection and cannot substitute viral\ngenome analysis on EMB samples. 917\nCirculating IgG antibodies to cardiotropic viruses are common in the\nabsence of viral myocarditis. Very limited diagnostic usefulness. 917 , 918\nSpeciﬁc test for SARS-CoV-2, Borrelia, HIV or CMV if clinical suspicion.\nLow Low\nACS = acute coronary syndrome; AV = atrio-ventricular; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus; CRP = C-reactive pro- tein; CTCA = computed tomography coronary angiography; ECG = electrocardiogram; EMB = endomyocardial biopsy; HF = heart failure; HIV = human immunodeﬁciency virus; IgG = immunoglobulin G; LGE = late gadolinium enhancement; PCR = polymerase chain reaction; PET = positron emission tomography; QRS = Q, R and S waves (combination of three of the graphical deﬂections); SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; ST = ST segment of the electrocardiogram; ST-T = ST segment and T wave of the electrocardiogram.\nESC 2021\nESC Guidelines 3683\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nManagement of patients with heart failure and suspected myocarditis\nClinical history, signs and symptoms, ECG, laboratory, echocardiography, CMR imaging, coronary CT/CAG a\nTreatment of CAD if present and indicated Suspected auto-immunity, infectious, toxic\nHF treatment\nClinical stabilization  EMB if any doubt about diagnosis\nMaintain HF treatment Consider immunosuppressive therapy or anti-infection\nY\nN\nConsider MCS\nFigure 20  Management of patients with heart failure and acute myocarditis. ACS= acute coronary syndrome; CAD= coronary artery disease; CAG= coronary artery angiogram; CMR= cardiac magnetic resonance; CT= computed tomography; ECG =electrocardiogram; EMB= endomyocardial biopsy; HF= heart failure; MCS= mechanical circulatory support.   a To exclude CAD/ACS.\nTable 32 Endomyocardial biopsy in patients with suspected myocarditis\nIndication  (see also  section 4.3 ).\nProgressive or persistent severe cardiac dysfunction and/or life-threatening ventricular arrhythmias and/or Mobitz type 2 second-degree or higher AV block with lack of short-term (<1-2 weeks) expected response to usual medical treatment.\nThe aim is to identify aetiology and to indicate speciﬁc treatment (e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, systemic inﬂamma-\ntory disorders). 97 , 98 , 917 , 918 , 958\nNumber and sites of the samples A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left and/or right ven-\ntricle. CMR or PET guided sampling may be considered. 919\nAetiology Quantitative PCR viral genome analysis for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackievirus) by\nrtPCR.\nViral mRNA for active viral replication may be assessed although it has low sensitivity. On indication, search for CMV, HIV,  Borrelia, Coxiella burnetii  (Q-fever) and SARS-CoV-2.\nDiagnosis of inﬂammation\nImmunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45 antibodies for lymphocytes and anti-CD68 antibodies for macrophages and anti-\nHLA-DR antibodies. 907 , 917 , 918 , 959\nTherapeutic implications\nImmunosuppressive therapy  may be indicated based on the results of EMB as in giant cell myocarditis or eosinophilic myocarditis and, possibly, also in\nsarcoidosis, vasculitis or selected patients with increased cardiac inﬂammation of unknown origin based upon multidisciplinary counselling. 98 , 917 \u0002 919 , 954\nAntibiotics:  Borrelia  (Lyme disease).\nAntiviral therapy:  HIV, CMV, HHV6 pending on load and viral replication (mRNA).\nCMR = cardiac magnetic resonance; CMV = cytomegalovirus; DNA = deoxyribonucleic acid; EMB = endomyocardial biopsy; HHV = human herpes virus; HIV = human immuno- deﬁciency virus; HLA-DR = human leucocyte antigen-DR isotype; mRNA = messenger ribonucleic acid; PCR = polymerase chain reaction; PET = positron emission tomography; RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.\nESC 2021\n3684 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ......................................................................................\nneeded with a grade 2 \u0002 3 positivity of scintigraphy with SPECT ( Figure  21 ). 973\n14.6.2 Therapy of amyloidosis and heart failure Maintenance of euvolaemia is central to management but is chal- lenging due to the markedly reduced ventricular capacitance. 977   If HF symptoms are present, a loop diuretic, possibly with an MRA, may be given, but orthostatic hypotension may cause intolerance. Beta-blockers, digitalis, ACE-I, ARBs, or ARNI may not be well tol- erated because of hypotension, and their place in CA treatment is unsettled. Their withdrawal must be often considered due to hypotension and/or bradycardia. 973 , 974   CCB should be avoided as they may cause severe hypotension and fatigue, or form com- plexes with amyloid. 966\nAmyloid infiltration of the atrial wall leads to atrial myopathy and electromechanical dissociation with high embolic risk. Patients with CA and history of AF should receive anticoagulation. There is no evidence to support anticoagulation for patients in SR, yet. 7 , 978   Amiodarone is the preferred antiarrhythmic agent. 973\nTherapy of AL-CA is based on treatment of the underlying haema- tological problem with chemotherapy or autologous stem-cell transplant. TTR stabilization and reduction of its production are the basis of TTR-CA treatment. Liver and/or cardiac transplantation can be considered only in end-stage disease of familial TTR-CA. Tafamidis reduced all-cause mortality and CV hospitalizations in cardiac or non-cardiac biopsy-proven hereditary and wtTTR-CA, mainly in those patients with NYHA class I and II at baseline. Functional improvement occurred within 6 months, whereas the decrease in mortality took nearly 2 years to occur. 979 , 980\nIntravenous patisiran, a small RNA interfering molecule, or subcu- taneous inotersen, antisense oligonucleotide against TTR, may be considered in those patients with combined hTTR- polyneuropathy and CA ( Figure  21 ). 981 , 982   Off-label use of diflu- nisal may be considered in wtTTR-CA in combination with a pro- ton pump inhibitor. 983\n",
      "keywords": [
        "prevalent",
        "aortic stenosis",
        "class i",
        "angiography",
        "light",
        "heart failure",
        "indication",
        "amyloidosis",
        "still",
        "ecg",
        "hfpef",
        "underdiagnosed",
        "anticoagulation",
        "echocardiography",
        "hereditary",
        "amyloid",
        "forms",
        "orthostatic",
        "coronary artery",
        "cause",
        "alcohol",
        "electrocardiogram",
        "bradycardia",
        "chain",
        "nyha",
        "aortic",
        "may be considered",
        "genetic",
        "valve replacement",
        "most"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3683",
          "page_number": 84,
          "content": "Definition of suspected acute myocarditis |  |  |  | ESC 2021\nClinical presentation þ >1 mandatory diagnostic test being positive (by preference CMR) in the absence of significant coronary artery,\n_\nvalvular or congenital heart disease, or other causes. |  |  |  | \n |  | Sensitivity | Specificity | \nClinical presentation |  |  |  | \nAcute/new onset chest pain, dyspnoea, signs of left and/or right HF, and/or unexplained arrhythmias or aborted sudden death. |  | Low | Low | \nMandatory diagnostic tests |  |  |  | \nECG | New and dynamic ST-T abnormalities, including pseudo-infarct ST seg-\nment elevation, atrial or ventricular arrhythmias, AV blocks, QRS\nabnormalities. | High | Low | \nLaboratory tests | Elevated troponins with dynamic changes consistent with myocardial\nnecrosis.\nStandard tests including white blood cells count to exclude\neosinophilia.919,954 | Intermediate | Low | \nEchocardiography | New structural or function abnormalities, regional wall motion abnormal-\nities or global ventricular dysfunction without ventricular dilatation or\nwith, generally mild, dilatation, increased wall thickness due to myocardial\noedema, pericardial effusion, intracardiac thrombi, not explained by other\nconditions (e.g., CAD, ACS or valvular heart disease). | High | Low | \nCMR | Oedema, inflammation and fibrosis detection, quantification and localiza-\ntion through T1 and T2 mapping, extracellular volume assessment and\nLGE (see Table 33).955,956 | High | Intermediate | \nAdditional diagnostic tests |  |  |  | \nCoronary angiography or CTCA | Excludes significant CAD or ACS in clinically suspected myocarditis. | High | High | \nEndomyocardial biopsy | For diagnosis and indication to specific treatment (see Table 32). | Intermediate | High | \nCardiac PET | May be useful in patients who cannot undergo CMR or with suspected\nsystemic autoimmune disease or cardiac sarcoidosis.919,957 | Low | Low | \nAdditional laboratory test | Skeletal muscle enzymes, liver and renal function, natriuretic peptides,\nthyroid function tests, iron status, markers of systemic autoimmune\ndisease. | Low | Low | \n | CRP elevated in 80\u000290% patients.919,954 | Intermediate | Low | \n | PCR testing of common cardiotropic viruses. It can detect systemic infec-\ntion but does not prove cardiac infection and cannot substitute viral\ngenome analysis on EMB samples.917\nCirculating IgG antibodies to cardiotropic viruses are common in the\nabsence of viral myocarditis. Very limited diagnostic usefulness.917,918\nSpecific test for SARS-CoV-2, Borrelia, HIV or CMV if clinical suspicion. | Low | Low | ",
          "bbox": [
            48.02908470756129,
            81.49655151367188,
            557.6139526367188,
            546.2173828125
          ],
          "function_potential": "raw"
        },
        {
          "title": "3684 ESC Guidelines",
          "page_number": 85,
          "content": "Indication (see also section 4.3).\nProgressive or persistent severe cardiac dysfunction and/or life-threatening ventricular arrhythmias and/or Mobitz type 2 second-degree or higher AV block\nwith lack of short-term (<1-2 weeks) expected response to usual medical treatment.\nThe aim is to identify aetiology and to indicate specific treatment (e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, systemic inflamma-\ntory disorders).97,98,917,918,958 | ESC 2021\nNumber and sites of the samples\nA minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left and/or right ven-\ntricle. CMR or PET guided sampling may be considered.919 | \nAetiology\nQuantitative PCR viral genome analysis for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackievirus) by\nrtPCR.\nViral mRNA for active viral replication may be assessed although it has low sensitivity.\nOn indication, search for CMV, HIV, Borrelia, Coxiella burnetii (Q-fever) and SARS-CoV-2. | \nDiagnosis of inflammation\nImmunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45 antibodies for lymphocytes and anti-CD68 antibodies for macrophages and anti-\nHLA-DR antibodies.907,917,918,959 | \nTherapeutic implications\nImmunosuppressive therapy may be indicated based on the results of EMB as in giant cell myocarditis or eosinophilic myocarditis and, possibly, also in\nsarcoidosis, vasculitis or selected patients with increased cardiac inflammation of unknown origin based upon multidisciplinary counselling.98,917\u0002919,954\nAntibiotics: Borrelia (Lyme disease).\nAntiviral therapy: HIV, CMV, HHV6 pending on load and viral replication (mRNA). | ",
          "bbox": [
            43.473937352498375,
            439.44127655029297,
            553.64599609375,
            709.568310546875
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3685",
          "page_number": 86,
          "content": "HF therapy should be started if LV systolic dysfunction is present at pre-\nsentation and should be continued for at least 6 months upon complete\nfunctional recovery (EF >50%).918,919 | ESC 2021\nImmunosuppression for at least 6\u000212 months is required in acute myo-\ncarditis with clinical or EMB evidence of auto-immune disease, including\ngiant cell myocarditis, vasculitis or sarcoidosis.98,917\u0002919,953,954,961 | \nImmunosuppression is not advised on a routine basis in acute myocarditis\nwithout clinical or EMB-based evidence of auto-immune disease.917 Initial\nempirical administration of i.v. corticosteroids may be taken into consid-\neration in cases of high suspicion of immune-mediated myocarditis espe-\ncially if complicated by acute HF, malignant arrhythmias and/or high\ndegree AV block.954,962 | \nIntense sporting activities should be avoided as long as symptoms, cardiac\nenzymes elevated or ECG/imaging abnormalities are present and last for\nat least 6 months since complete recovery.936 | \nYearly follow-up for at least 4 years, with an ECG and echocardiography,\nis needed as acute myocarditis may lead to DCM in up to 20% of\ncases. | ",
          "bbox": [
            312.3821169535319,
            81.70929463704427,
            557.6139526367188,
            303.86864013671874
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3685",
          "page_number": 86,
          "content": "Indication\nIndicated at baseline, in all patients with clinical history þ ECG, elevated\ntroponin or echocardiographic abnormalities, and significant CAD\nexcluded or unlikely.\nAdvised at follow-up in patients with persistent dysfunction at echocar-\ndiography, arrhythmias or ECG abnormalities.a | ESC 2021\nMain findings\nAt baseline: T1-weighted (inflammation, injury) and T2-weighted (oedema)\nsequences, extracellular volume and LGE within 2 weeks after symptom\nonset.956,960\nAt follow up: LGE to evaluate the degree of scarring, T1 and T2 to identify\npersistent inflammation.a | \nDiagnostic significance\nAt least one T2-based criterion (global or regional increase of myocardial\nT2 relaxation time or an increased signal intensity in T2-weighted images),\nwith at least one T1-based criterion (increased myocardial T1, extracellu-\nlar volume, or LGE) in the acute phase.\nOnly one (i.e., T2-based or T1-based) marker may still support a diagnosis\nof acute myocardial inflammation in an appropriate clinical scenario, albeit\nwith less specificity in the acute phase.\nA negative T1/T2 scan does not exclude a still ongoing inflammatory proc-\ness in the chronic phase.a | ",
          "bbox": [
            48.02293038368225,
            91.71560668945312,
            293.2829895019531,
            371.44664001464844
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "105",
      "title": "14.7 Iron overload cardiomyopathy Iron overload results either from genetically determined increased intestinal iron absorption in the context of hereditary haemochro- matosis (primary iron overload) ",
      "start_page": 86,
      "end_page": 87,
      "content": "Table 33 Cardiac magnetic resonance in patients with suspected myocarditis 955 , 956\nIndication Indicated at baseline, in all patients with clinical history  þ  ECG, elevated\ntroponin or echocardiographic abnormalities, and signiﬁcant CAD\nexcluded or unlikely. Advised at follow-up in patients with persistent dysfunction at echocar-\ndiography, arrhythmias or ECG abnormalities. a\nMain ﬁndings At baseline: T1-weighted (inﬂammation, injury) and T2-weighted (oedema)\nsequences, extracellular volume and LGE within 2 weeks after symptom\nonset. 956 , 960\nAt follow up: LGE to evaluate the degree of scarring, T1 and T2 to identify\npersistent inﬂammation. a\nDiagnostic signiﬁcance\nAt least one T2-based criterion (global or regional increase of myocardial T2 relaxation time or an increased signal intensity in T2-weighted images),\nwith at least one T1-based criterion (increased myocardial T1, extracellu-\nlar volume, or LGE) in the acute phase. Only one (i.e., T2-based or T1-based) marker may still support a diagnosis\nof acute myocardial inﬂammation in an appropriate clinical scenario, albeit\nwith less speciﬁcity in the acute phase. A negative T1/T2 scan does not exclude a still ongoing inﬂammatory proc-\ness in the chronic phase. a\nCAD = coronary artery disease; CMR = cardiac magnetic resonance; ECG = elec- trocardiogram; LGE = late gadolinium enhancement. a It takes at least 3 months before CMR signs of oedema (secondary to inﬂamma- tion in the acute phase/baseline) disappear. At 6 months, T1 or T2 signs of oedema should have disappeared if inﬂammation would be completely absent. Still, the absence of T1 or T2 oedema does not exclude chronic low-grade inﬂammation.\nTable 34 Treatment and follow-up of acute myocarditis\nHF therapy should be started if LV systolic dysfunction is present at pre-\nsentation and should be continued for at least 6 months upon complete functional recovery (EF >50%). 918 , 919\nImmunosuppression for at least 6 \u0002 12 months is required in acute myo-\ncarditis with clinical or EMB evidence of auto-immune disease, including\ngiant cell myocarditis, vasculitis or sarcoidosis. 98 , 917 \u0002 919 , 953 , 954 , 961\nImmunosuppression is not advised on a routine basis in acute myocarditis\nwithout clinical or EMB-based evidence of auto-immune disease. 917   Initial\nempirical administration of i.v. corticosteroids may be taken into consid- eration in cases of high suspicion of immune-mediated myocarditis espe-\ncially if complicated by acute HF, malignant arrhythmias and/or high\ndegree AV block. 954 , 962\nIntense sporting activities should be avoided as long as symptoms, cardiac enzymes elevated or ECG/imaging abnormalities are present and last for\nat least 6 months since complete recovery. 936\nYearly follow-up for at least 4 years, with an ECG and echocardiography, is needed as acute myocarditis may lead to DCM in up to 20% of\ncases.\nAV = atrio-ventricular; DCM = dilated cardiomyopathy; ECG = electrocardio- gram; EF = ejection fraction; EMB = endomyocardial biopsy; HF = heart failure; i.v. = intravenous; LV = left ventricular.\nESC 2021\nESC 2021\n. .......................................................................\nESC Guidelines 3685\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ....................................................................................................\nAdditional iron-induced complications, such as liver disease and endocrine abnormalities, further contribute to cardiac deteriora- tion. 986 , 987   The end result is the development of iron overload\ncardiomyopathy (IOCM), which may have either a restrictive or a dilated phenotype, the former potentially evolving to the latter as the disease advances. Myocardial iron deposition can be accu- rately estimated by the CMRT2* technique; T2* values are corre- lated with left and right ventricular systolic function and predict the development of iron-induced HF or arrhythmias. 984\nPrevention of IOCM is successfully accomplished with iron chela- tors, including deferoxamine, deferiprone, and deferasirox, while established IOCM may be completely reversed by intensified and combined iron chelation therapy. 985\n",
      "keywords": [
        "heart failure",
        "systolic dysfunction",
        "indication",
        "overload",
        "genetically",
        "ecg",
        "determined",
        "results",
        "echocardiography",
        "iron",
        "hereditary",
        "coronary artery",
        "increased",
        "context",
        "intestinal",
        "either",
        "ejection fraction",
        "systolic",
        "matosis",
        "troponin",
        "absorption",
        "haemochro",
        "primary",
        "cardiomyopathy"
      ],
      "tables": [
        {
          "title": "3686 ESC Guidelines",
          "page_number": 87,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nTafamidis is recommended in patients with\ngenetic testing proven hTTR-CA and NYHA\nclass I or II symptoms to reduce symptoms, CV\nhospitalization and mortality.979 | I | B | \nTafamidis is recommended in patients with\nwtTTR-CA and NYHA class I or II symptoms to\nreduce symptoms, CV hospitalization and\nmortality.979 | I | B | ESC 2021",
          "bbox": [
            306.9837716909555,
            86.47422485351562,
            552.1214163643973,
            207.64579582214355
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3686 ESC Guidelines",
          "page_number": 87,
          "content": "Type |  | Red Flag |  | TTR |  | AL | ESC 2021\nExtracardiac |  | Polyneuropathy |  | X |  | X | \n |  | Dysautonomia |  | X |  | X | \n |  | Skin bruising |  |  |  | X | \n |  | Macroglossia |  |  |  | X | \n |  | Deafness |  | X |  |  | \n |  | Bilateral carpal tunnel syndrome |  | X |  |  | \n |  | Ruptured biceps tendon |  | X |  |  | \n |  | Lumbar spinal stenosis |  | X |  |  | \n |  | Vitreous deposits |  | Xa |  |  | \n |  | Family history |  | Xa |  |  | \n |  | Renal insufficiency |  |  |  | X | \n |  | Proteinuria |  |  |  | X | \nCardiac |  | Clinical\nHypotension or normotensive if\npreviously hypertensive |  | X |  | X | \n |  | ECG\nPseudo-infarct ECG pattern\nLow/decreased QRS voltage to\ndegree of LV thickness\nAV conduction disease |  | X\nX\nX |  | X\nX\nX | \n |  | Laboratory\nDisproportionally elevated NT-\nproBNP to degree of HF\nPersisting elevated troponin levels |  | X\nX |  | X\nX | \n |  | Echocardiography\nGranular sparkling of myocardium\nIncreased right ventricular wall\nthickness\nIncreased AV valve thickness\nPericardial effusion\nReduced longitudinal strain with\napical sparing pattern |  | X\nX\nX\nX\nX |  | X\nX\nX\nX\nX | \n |  | CMR\nSubendocardial LGE\nElevated native T1 values\nIncreased extracellular volume\nAbnormal gadolinium kinetics |  | X\nX\nX\nX |  | X\nX\nX\nX | ",
          "bbox": [
            43.473937352498375,
            91.54557800292969,
            288.7480163574219,
            578.2358660016741
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "106",
      "title": "14.8 Adult congenital heart disease The management of ACHD has been reviewed in detail in a recent ESC guideline. 988   HF is a common problem affecting 20 \u0002 50% of the ACHD population, and an importa",
      "start_page": 87,
      "end_page": 89,
      "content": "Importantly, ACHD patients with HF should be referred to expert centres. The general principles of management, while awaiting trans- fer to specialist centres, is summarized in  Table  36 .\nTable 35 “Red ﬂags” for most common forms of cardiac amyloidosis\nType Red Flag TTR AL\nExtracardiac Polyneuropathy X X\nDysautonomia X X\nSkin bruising X\nMacroglossia X\nDeafness X\nBilateral carpal tunnel syndrome X\nRuptured biceps tendon X\nLumbar spinal stenosis X\nVitreous deposits X a\nFamily history X a\nRenal insufﬁciency X\nProteinuria X\nCardiac Clinical\nHypotension or normotensive if previously hypertensive X X\nECG\nPseudo-infarct ECG pattern Low/decreased QRS voltage to\ndegree of LV thickness\nAV conduction disease\nX X\nX\nX X\nX\nLaboratory Disproportionally elevated NT-\nproBNP to degree of HF\nPersisting elevated troponin levels\nX\nX\nX\nX\nEchocardiography\nGranular sparkling of myocardium\nIncreased right ventricular wall thickness\nIncreased AV valve thickness\nPericardial effusion Reduced longitudinal strain with\napical sparing pattern\nX\nX\nX\nX X\nX\nX\nX\nX X\nCMR\nSubendocardial LGE Elevated native T1 values\nIncreased extracellular volume\nAbnormal gadolinium kinetics\nX X\nX\nX\nX X\nX\nX\nAL = light chain immunoglobulin; AV = atrio-ventricular; CA = cardiac amyloido- sis; CMR = cardiac magnetic resonance; ECG = electrocardiogram; HF = heart fail- ure; LGE = late gadolinium enhancement; LV = left ventricular; NT-proBNP = N- terminal pro-B-type natriuretic peptide; QRS = Q, R and S waves (combination of three of the graphical deﬂections); TTR = transthyretin. Modiﬁed from 973 . a Hereditary TTR-CA.\nRecommendations for the treatment of transthyretin amyloidosis-cardiac amyloidosis\nRecommendations Class a Level b\nTafamidis is recommended in patients with\ngenetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV\nhospitalization and mortality. 979\nI B\nTafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to\nreduce symptoms, CV hospitalization and\nmortality. 979\nI B\nCA = cardiac amyloidosis; CV = cardiovascular; hTTR = hereditary transthyretin; NYHA = New York Heart Association; wtTTR = wild-type transthyretin. a Class of recommendation. b Level of evidence.\nESC 2021\nESC 2021\n. .........................................................\n3686 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nDiagnosis and treatment of cardiac amyloidosis in heart failure patients\nCardiac amyloidosis suspected HF and LV wall thickness  ≥ 12 mm AND age  ≥ 65 or at least 1 red flag a\nSerum free light-chain assay Serum and urine protein electrophoresis with immunofixation\n99mTc-PYP, DPD or HMDP scintigraphy with SPECT\nHistological  confirmation to subtype (usually cardiac) b\nAmyloidosis unlikely\nHistological confirmation of diagnosis\n(cardiac/ extracardiac) c\nTafamidis (Class I)\nAmyloidosis unlikely\nBoth abnormal Abnormal haematology No myocardial uptake Normal haematology Grade 1 uptake Normal haematology Grade 2–3 uptake All normal\nATTR\nGenetic counselling\nCardiac amyloidosis on CMR imaging\nPositive or inconclusive Negative\nConsider patisiran or inotersen if hereditaryATTR and polyneuropathy\nFigure 21  Diagnosis and treatment of cardiac amyloidosis in heart failure patients. Based on. 973   ATTR = transthyretin amyloidosis; CMR = car- diac magnetic resonance; DPD = 3,3-diphosphono1,2-propanodicarboxylic acid; HF = heart failure; HMDP = hydroxymethylene diphosphonate; LV = left ventricular; SPECT = single-photon emission computed tomography; 99mTc-PYP = technetium-labelled   99m Tc-pyrophosphate.   a Red flags are listed in  Table  35 .   b Generally requires endomyocardial biopsy for a diagnosis of the cardiac subtype.   c Requires biopsy that may be cardiac or abdominal.\nESC Guidelines 3687\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ..........................................................................................................................................................\n",
      "keywords": [
        "class i",
        "reviewed",
        "heart failure",
        "recommended",
        "level b",
        "adult",
        "ecg",
        "detail",
        "disease",
        "echocardiography",
        "hereditary",
        "heart",
        "management",
        "importa",
        "common",
        "recent",
        "electrocardiogram",
        "nt-probnp",
        "family history",
        "nyha",
        "genetic",
        "guideline",
        "problem",
        "affecting",
        "congenital",
        "achd",
        "troponin",
        "population",
        "age",
        "stenosis"
      ],
      "tables": [
        {
          "title": "3688 ESC Guidelines",
          "page_number": 89,
          "content": "ACHD patients with chronic HF should be referred to specialized\ncentres. | ESC 2021\nSpecific guidelines for medical treatment of chronic HF in ACHD are\nlacking, and practitioners should follow the current guidelines for medical\ntreatment of HF. It remains unknown whether the long-term use of neu-\nrohormonal modulators affects clinical outcomes and prognosis in\nACHD. | \nSacubitril/valsartan may decrease morbidity,991\u0002993 however, no recom-\nmendation can be made at this moment based on the retrospective or\nanecdotical nature of these observations. | \nCo-morbidities in HF such as diabetes mellitus, AF, CSA, iron deficiency,\nand cachexia should be treated according to specific recommendations\nreported in this document. | \nIn a biventricular circulation, patients with an impaired systemic LV\nshould be treated with conventional HF therapy; this may also be consid-\nered in symptomatic patients with a failing systemic right ventricle. | \nDiuretics are recommended to control symptoms of fluid retention. | \nTreatment of symptomatic patients with a failing single ventricle in a\nFontan circulation, or in the case of a persistent right-to-left shunt, should\nalways be carefully initiated, taking the labile balance of ventricular pre-\nload and systemic afterload into account. | \nCRT may be a therapeutic option in ACHD patients with HF, but evi-\ndence in this specific setting is still lacking. Efficacy of CRT will depend on\nthe underlying structural and functional substrate, such as anatomy of the\nsystemic ventricle (left, right, or functionally single), presence and degree\nof structural systemic AV valve regurgitation, primary myocardial disease\nor scarring, and type of electrical conduction delay.988 | \nTreatment of acute HF in ACHD patients should be in an expert centre,\nwith proper knowledge of inotropes, the availability of extracorporeal\nmembrane oxygenation, and advanced bridging techniques.988,994 | \nTimely evaluation for transplantation by ACHD HF specialists in a trans-\nplant centre with ACHD expertise is recommended. | \nVentricular assist devices can bridge patients to transplantation, or in a\nsubgroup of patients, may be an option as destination therapy. | ",
          "bbox": [
            43.51291426022848,
            91.71558634440105,
            288.7480163574219,
            513.0656311035157
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "107",
      "title": "15 Key messages",
      "start_page": 89,
      "end_page": 95,
      "content": "(1) Patients with HF are classified based on their LVEF. Those with a LVEF between 41% and 49% are defined as ‘mildly reduced LVEF’ (HFmrEF). (2) Measurement of NPs and echocardiography have key roles in the diagnosis of HF.\n(3) ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors are recommended as cornerstone therapies for patients with HFrEF. (4) ICDs are recommended in selected patients with HFrEF of an ischaemic aetiology and should be considered in those with a non- ischaemic aetiology. (5) CRT-P/D is recommended in those patients with HFrEF, in sinus rhythm, with a LBBB >_150 ms and should be considered in those with a LBBB >_130 \u0002 149 ms or non-LBBB >_150 ms. (6) Advanced HF strategies (heart transplantation/MCS) may be appropriate in selected patients. (7) ACE-I/ARNI, beta-blockers, and MRA may be considered in patients with HFmrEF. (8) The diagnosis of HFpEF requires objective evidence of cardiac structural, or functional abnormalities as well as elevated plasma NP concentrations consistent with the presence of LV diastolic dysfunction and raised LV filling pressures. A diastolic stress test is recommended when these markers are equivocal. (9) To date, no treatment has been shown to reduce mortality and morbidity in patients with HFpEF. (10) It is recommended that all patients with HF be enrolled in a multi- disciplinary HF-MP. (11) Exercise is recommended for all patients who are able, to improve exercise capacity and QOL, and reduce HF hospitalization. (12) Patients with advanced HF refractory to medical/device therapy and who do not have absolute contraindications should be referred for consideration of heart transplantation. MCS should also be considered as BTT or DT in selected patients. (13) Four major clinical presentations of acute HF may occur: ADHF, acute pulmonary oedema, RV failure, and cardiogenic shock. (14) Treatment of acute HF is based on diuretics for congestion, ino- tropes, and short- term MCS for peripheral hypoperfusion. (15) Patients hospitalized for HF should be carefully evaluated to exclude persistent signs of congestion. Oral treatment should be optimized before discharge. (16) In addition to oral anticoagulation, a strategy of rhythm control including catheter ablation should be considered in patients whose symptoms and/or cardiac dysfunction are associated with AF. (17) SAVR or TAVI, as advised by the Heart Team, are recommended in patients with symptomatic severe aortic valve stenosis. (18) Patients with isolated significant SMR and COAPT criteria should be considered for percutaneous edge-to-edge repair, whereas those with SMR and CAD, who need revascularization, should be considered for surgery. (19) It is recommended that patients with type II diabetes are treated with SGLT2 inhibitors. (20) Patients should be periodically screened for anaemia and iron defi- ciency and i.v. iron supplementation with ferric carboxymaltose should be considered in symptomatic patients with LVEF <45% and iron deficiency, and in patients recently hospitalized for HF and with LVEF <_50% and iron deficiency.\nTable 36 Treatment of adult congenital heart disease and heart failure in specialized centres\nACHD patients with chronic HF should be referred to specialized centres.\nSpeciﬁc guidelines for medical treatment of chronic HF in ACHD are\nlacking, and practitioners should follow the current guidelines for medical treatment of HF. It remains unknown whether the long-term use of neu-\nrohormonal modulators affects clinical outcomes and prognosis in\nACHD.\nSacubitril/valsartan may decrease morbidity, 991 \u0002 993   however, no recom- mendation can be made at this moment based on the retrospective or\nanecdotical nature of these observations.\nCo-morbidities in HF such as diabetes mellitus, AF, CSA, iron deﬁciency, and cachexia should be treated according to speciﬁc recommendations\nreported in this document.\nIn a biventricular circulation, patients with an impaired systemic LV\nshould be treated with conventional HF therapy; this may also be consid- ered in symptomatic patients with a failing systemic right ventricle.\nDiuretics are recommended to control symptoms of ﬂuid retention.\nTreatment of symptomatic patients with a failing single ventricle in a\nFontan circulation, or in the case of a persistent right-to-left shunt, should always be carefully initiated, taking the labile balance of ventricular pre-\nload and systemic afterload into account.\nCRT may be a therapeutic option in ACHD patients with HF, but evi- dence in this speciﬁc setting is still lacking. Efﬁcacy of CRT will depend on\nthe underlying structural and functional substrate, such as anatomy of the\nsystemic ventricle (left, right, or functionally single), presence and degree of structural systemic AV valve regurgitation, primary myocardial disease\nor scarring, and type of electrical conduction delay. 988\nTreatment of acute HF in ACHD patients should be in an expert centre,\nwith proper knowledge of inotropes, the availability of extracorporeal membrane oxygenation, and advanced bridging techniques. 988 , 994\nTimely evaluation for transplantation by ACHD HF specialists in a trans-\nplant centre with ACHD expertise is recommended.\nVentricular assist devices can bridge patients to transplantation, or in a subgroup of patients, may be an option as destination therapy.\nACHD = adult congenital heart disease; AF = atrial ﬁbrillation; AV = atrioventricu- lar; CRT = cardiac resynchronization therapy; CSA = central sleep apnoea; HF = heart failure; LV = left ventricular.\nESC 2021\n3688 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 16 Gaps in evidence\nMajor advances in the diagnosis and treatment of patients with HF have occurred over recent years. Strong evidence for new treatment options have been given by recent RCTs and HF management may undergo major changes in the next years. New discoveries, however, pose new challenges and many areas with lack of evidence still remain. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.\n(1) Definition and epidemiology i. Further research into the underlying characteristics, patho- physiology, and diagnosis of HFmrEF and HFpEF ii. Consensus about normal values/ranges of EF iii. Better phenotyping of HFpEF iv. More information on the incidence and prevalence of ‘recovered LV’ systolic function (2) Diagnosis i. Definitive studies on the role of biomarkers, focusing on their additive value in the diagnosis of HF ii. More randomized studies on screening for HF in asympto- matic subjects that may translate into improved outcomes iii. Studies on biomarkers showing the impact on outcome of their measurements for the identification of subjects at risk of devel- oping HF as well as to guide treatment in patients with HF iv. Validated diagnostic protocols for the diagnosis of HFmrEF and HFpEF (3) Pharmacotherapy of CHF i. Pragmatic studies on the order of adding disease-modifying drugs for HFrEF ii. Specific therapies for HFmrEF and HFpEF and, likely, their dif- ferent phenotypes iii. More data and prospective clinical trials of HFrEF therapies in patients with eGFR <30 mL/min/1.73 m 2\niv. Further evidence from prospective RCTs for the treatment of specific HF phenotypes: myocarditis, cardiotoxicity, inherited CMPs, PPCM, amyloidosis v. Management strategies and therapies for ‘recovered LV’ sys- tolic function vi. More evidence on the effects of fluid restriction, dietary salt restriction, and nutrition (4) Devices and interventions i. Indications for ICDs in specific subgroups of HFmrEF/HFpEF and optimal selection of ICD candidates in HFrEF, including patients with ischaemic and non-ischaemic cardiomyopathy ii. More research on CRT efficacy in AF iii. Further prospective randomized studies showing the impact on outcomes of AF ablation strategies compared to OMT in HF patients iv. Further research on the percutaneous treatment of valve heart disease and its impact on patients’ outcomes and QOL v. Larger RCTs on CCM and baroreceptor stimulation in HFrEF (5) Disease management i. The role of remote monitoring strategies in HF in the post COVID-19 era ii. Studies on optimal models for follow-up of stable HF patients iii. Studies to determine specific options for palliative care\n(6) Advanced HF i. Better definition of risk profiles according to INTERMACS and other classifications ii. RCTs to establish the effects on outcomes of long-term MCS in hospitalized patients as well as in ambulatory outpatients (for instance INTERMACS 4 \u0002 6 profiles) iii. Advances in long-term MCS, including strategies to reduce the risk of bleeding, thromboembolic events, and infection iv. Advances in medical treatment for the many patients who can- not undergo MCS or heart transplantation including develop- ment of treatment strategies, novel inotropes or myotropes for patients with advanced HF (7) AHF i. Better definition and classification of patient phenotypes to facilitate improved treatment ii. Evidence-based use of imaging techniques and biomarkers that have an impact on patients’ clinical course iii. Development of better strategies for congestion relief, includ- ing monitoring of diuretic administration, and/or to improve organ perfusion iv. Identification of treatments with an impact on post-discharge outcomes v. New devices for short-term MCS vi. Definition of evidence-based treatment options and therapeu- tic algorithms for patients with cardiogenic shock\n(8) CV comorbidities\ni. RCTs showing best strategies for the treatment of ventricular arrhythmias ii. RCTs to establish the role of coronary revascularization pro- cedures in different patient subsets iii. RCTs to establish the impact on patients’ outcomes and/or QOL of percutaneous treatment of mitral or tricuspid valve disease in patients with HF\n(9) Non-CV comorbidities\ni. RCTs addressing cachexia and/or sarcopenia and/or frailty and showing the impact of treatment on QOL and/or outcome ii. RCTs of medical therapies or devices in patients with severe CKD and HF iii. RCTs showing the effects on outcomes of medical treatment of electrolyte abnormalities iv. RCTs showing the effects on outcomes of treatment of CSA v. Prospective studies showing the impact on outcomes and/or QOL of early diagnosis, better prevention and treatment of cardiotoxicity of cancer therapies vi. Better treatment of infections and prevention of cardiac injury with infection\n(10) Special conditions\ni. RCTs of treatment for PPCM ii. Better phenotyping of CMPs through genetic testing, bio- markers and imaging modalities, and tailoring of therapy iii. RCTs of treatment of different types of myocarditis, including immunosuppressive therapies iv. RCTs of new treatments of different forms of cardiac amyloid v. Better definition and treatment of LA myopathy.\nESC Guidelines 3689\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n17 ‘What to do’ and ‘what not to do’ messages from the guidelines\nRecommendations Class a Level b\nRecommendations for the diagnosis of chronic HF\nBNP/NT-proBNP. c I B\n12-lead ECG. I C\nTransthoracic echocardiography. I C\nChest radiography (X-ray). I C\nRoutine blood tests for comorbidities (including full blood count, urea and electrolytes, thyroid function, fasting glucose and HbA1c, lipids. Iron studies (TSAT and ferritin). I C\nCMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic\nwindows. I C\nCMR is recommended for the characterization of myocardial tissue in suspected inﬁltrative disease, Fabry disease, inﬂamma- tory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron overload/haemochromatosis. I C\nInvasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ven-\ntricular arrhythmias. I B\nCardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS. I C\nRight heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS. I C\nRecommendations for the treatment of HFrEF\nACE-I is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. I A\nBeta-blocker is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death. I A\nMRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. I A\nDapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. I A\nSacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF hospitaliza-\ntion and death. I B\nDiuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to alleviate HF symptoms,\nimprove exercise capacity and reduce HF hospitalizations. I C\nAn ARB c   is recommended to reduce the risk of HF hospitalization and CV death in symptomatic patients unable to tolerate\nan ACE-I or ARNI (patients should also receive a beta-blocker and an MRA). I B\nThe addition of an ARB (or renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with\nHF, because of the increased risk of renal dysfunction and hyperkalaemia. III C\nAn ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a\nventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional\nstatus, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.\nI A\nAn ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II \u0002 III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days—see below), and an LVEF <_35% despite\n>_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.\nI A\nICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis. III A\nICD therapy is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a VAD, or cardiac transplantation. III C\nCRT is recommended for symptomatic patients with HF in SR with a QRS duration >_150 ms and LBBB QRS morphology and\nwith LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality. I A\nCRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF. I A\nCRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high-\ndegree AV block. III A\nRecommendations for the treatment of HFmrEF and HFpEF\nDiuretics are recommended in patients with congestion and HFmrEF in order to alleviate symptoms and signs. I C\nContinued\n3690 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nScreening for, and treatment of, aetiologies, and CV and non-CV comorbidities is recommended in patients with HFpEF (see\nrelevant sections of this document). I C\nDiuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs. I C\nRecommendations for the prevention of chronic HF\nTreatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations. I A\nTreatment with statins is recommended in patients at high risk of CV disease or with CV disease in order to prevent or delay\nthe onset of HF, and to prevent HF hospitalizations. I A\nSGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with dia-\nbetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations. I A\nCounselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the\nonset of HF. I C\nOther recommendations for the management of chronic HF\nIt is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF hospitalization and mortality. I A\nSelf-management strategies are recommended to reduce the risk of HF hospitalization and mortality. I A\nEither home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF hospi-\ntalization and mortality. I A\nExercise is recommended for all patients who are able in order to improve exercise capacity and QOL, and reduce HF hospitalization. d I A\nRecommendations for treatment of patients with advanced HF\nPatients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psy-\nchosocial support. I C\nHeart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not\nhave absolute contraindications. I C\nRecommendations for treatment of patients with acute HF\nOxygen is recommended in patients with SpO 2  <90% or PaO 2  <60 mmHg to correct hypoxaemia. I C\nIntubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive ventilation. I C\nIntravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of ﬂuid overload to\nimprove symptoms. I C\nThromboembolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contra- indication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism. I A\nInotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension\nand evidence of hypoperfusion. III C\nRoutine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety. III C\nIABP is not routinely recommended in post-MI cardiogenic shock. III B\nRecommendations for management of patients after HF hospitalization\nIt is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before\ndischarge and to optimize oral treatment. I C\nIt is recommended that evidence-based oral medical treatment be administered before discharge. I C\nAn early follow-up visit is recommended at 1 \u0002 2 weeks after discharge to assess signs of congestion, drug tolerance, and start\nand/or uptitrate evidence-based therapy. I C\nRecommendations for treatment of patients with HF and AF\nLong-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and CHA 2 DS 2 -VASc score >2 in men or >3 in women. I A\nDOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral steno-\nsis or mechanical prosthetic heart valves. I A\nUrgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic instability. I C\nTreatment with the anti-arrhythmic agents ﬂecainide, encainide, disopyramide, dronedarone, and D-sotalol is not recom-\nmended due to safety concerns. III A\nContinued\nESC Guidelines 3691\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\nDiltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF\nhospitalization. III C\nRecommendations for treatment of patients with HF and aortic stenosis\nAortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms. I B\nIt is recommended that the choice between TAVI and SAVR be made by the Heart Team, according to individual patient pref-\nerence and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and beneﬁts of\neach approach.\nI C\nRecommendations for treatment of patients with HF and diabetes\nSGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with\nT2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death. I A\nSGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death. I A\nThiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF\nhospitalization. III A\nThe DPP-4 inhibitor saxagliptin is not recommended in patients with HF. III B\nRecommendations for treatment of patients with HF and iron deﬁciency\nIt is recommended that all patients with HF be periodically screened for anaemia and iron deﬁciency with a full blood count,\nserum ferritin concentration, and TSAT. I C\nTreatment of anaemia in HF with erythropoietin-stimulating agents is not recommended in the absence of other indications\nfor this therapy. III B\nRecommendation for treatment of patients with HF and sleep apnoea\nAdaptive servo-ventilation is not recommended in patients with HFrEF and a predominant CSA because of an increased all-\ncause and CV mortality. III A\nRecommendation for treatment of patients with HF and arthritis\nNSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. III B\nRecommendation for treatment of patients with HF and cancer\nIt is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease,\nprevious cardiotoxicity or exposure to cardiotoxic agents, undergo CV evaluation before scheduled anticancer therapy, pref- erably by a cardiologist with experience/interest in Cardio-Oncology.\nI C\nRecommendations for treatment of patients with HF and amyloidosis\nTafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce\nsymptoms, CV hospitalization and mortality. I B\nTafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitaliza-\ntion and mortality. I B\nACE-I = angiotensin-converting enzyme inhibitor; AF = atrial ﬁbrillation; AHF = acute heart failure; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; AV = atrio-ventricular; BNP = B-type natriuretic peptide; CHA 2 DS 2 -VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65 \u0002 74, Sex category (female) (score); CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CRT = cardiac resynchro- nization therapy; CSA = central sleep apnoea; CV = cardiovascular; DOAC = direct-acting oral anticoagulant; DPP-4 = dipeptidyl peptidase-4; ECG = electrocardiogram; ECV = electrical cardioversion; HbA1c = glycated haemoglobin; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; hTTR = hereditary transthyretin; IABP = intra-aortic balloon pump; ICD = implantable cardioverter-deﬁb- rillator; LBBB = left bundle branch block; LMWH = low-molecular-weight heparin; LV = left ventricular/ventricle; LVEF = left ventricular ejection fraction; MCS = mechanical cir- culatory support; MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist; NSAID = non-steroidal anti-inﬂammatory drug; NT-proBNP = N-terminal pro-B- type natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; PaO 2  = partial pressure of oxygen; QOL = quality of life; QRS = Q, R, and S waves (on an ECG); RV = right ventricular; SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2; SpO 2  = transcutaneous oxygen saturation; SR = sinus rhythm; T2DM = type 2 diabetes mellitus; TAVI = transcatheter aortic valve implantation; TSAT = transferrin saturation; VAD = ventricular assist device; VKA = vitamin K antagonist; wtTTR-CA = wild-type transthyretin cardiac amyloidosis. a Class of recommendation. b Level of evidence. c References are listed in section 4.2 for this item. d In those who are able to adhere to the exercise programme.\nESC 2021\n3692 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................... 18 Quality indicators\nQIs are tools that may be used to evaluate care quality, including that of processes of care and clinical outcomes. 995   They may also serve as a mechanism for enhancing adherence to guideline recommendations, through quality assurance endeavours and bench- marking of care providers. 996   As such, the role of QIs in driving qual- ity improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations, payers, and the public. 997\nThe ESC recognizes the need for measuring and reporting quality and outcomes of CV care. The methodology by which the ESC QIs\nare developed has been published 997   and, to date, a suite of QIs for an initial tranche of CV conditions has been produced. 998 , 999   To facili- tate quality improvement initiatives, the disease-specific ESC QIs are included in corresponding ESC Clinical Practice Guidelines. 7 , 1000   This is further enhanced by way of their integration in the ESC registries, such as the EURObservational Research Programme (EORP) and the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart) project. 1001\nFor patients with HF, QIs may help healthcare providers to simul- taneously operationalize discrete guideline recommendations and enable the discrimination between missed opportunities and appro- priate care. Furthermore, QIs allow the capture of patients’\nTable 37 Main European Society of Cardiology quality indicators for the evaluation of care and outcomes for patients with heart failure ( a full list is published in a separate article )\nDomain 1. Structural QIs a\nMain (1): Centre should have a dedicated multidisciplinary team to manage patients with HF\nNumerator:  Availability of a dedicated multidisciplinary team to manage patients with HF.\nDomain 2. Patient assessment b\nMain (1): Proportion of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)\nNumerator:  Number of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).\nDenominator:  Number of patients with HF.\nMain (2): Proportion of patients with HF who have a documentation of their ECG ﬁndings\nNumerator:  Number of patients with HF who have a documentation of their ECG ﬁndings.\nDenominator:  Number of patients with HF.\nMain (3): Proportion of patients with HF who have their NPs measured\nNumerator:  Number of patients with HF who have a documentation of their NPs levels. Denominator:  Number of patients with HF.\nDomain 3. Initial treatment\nMain (1). Proportion of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol\nsuccinate, or nebivolol in the absence of any contraindications\nNumerator:  Number of patients with HFrEF who are prescribed  the beta-blocker  bisoprolol, carvedilol, sustained-release metoprolol succinate, or\nnebivolol.\nDenominator:  Number of patients with HFrEF without any contraindications for  the beta-blocker  bisoprolol, carvedilol, sustained-release metoprolol succinate, and nebivolol.\nMain (2). Proportion of patients with HFrEF who are prescribed ACE inhibitor, ARB or ARNI in the absence of any contraindications\nNumerator:  Number of patients with HFrEF who are prescribed an ACE inhibitor, ARB or ARNI.\nDenominator:  Number of patients with HFrEF without any contraindications for ACE inhibitors, ARBs and ARNI.\nMain (3). Proportion of patients with HF who are prescribed diuretic therapy if they have evidence of ﬂuid retention\nNumerator:  Number of patients with HF, with evidence of ﬂuid retention who are prescribed diuretic therapy.\nDenominator:  Number of patients with HF who have evidence of ﬂuid retention and no contraindications for diuretic therapy.\nMain (4): Proportion of patients with HFrEF who are prescribed an MRA in the absence of any contraindications\nNumerator:  Number of patients with HFrEF who are prescribed an MRA. Denominator:  Number of patients with HFrEF without any contraindications for MRA.\nMain (5): Proportion of patients with HFrEF who are prescribed a SGLT2 inhibitor in the absence of any contraindications\nNumerator:  Number of patients with HFrEF who are prescribed a SGLT2 inhibitor.\nDenominator:  Number of patients with HFrEF without any contraindications for SGLT2 inhibitor.\nACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter- deﬁbrillator; IHD = ischaemic heart disease; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NP = natriu- retic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; QI = quality indicator; SGLT2 = sodium-glucose co-transporter 2. a Structural QIs are binary measurements (Yes/No), and thus, have only numerator deﬁnitions. b Blood tests include urea, creatinine, electrolytes, full blood count, glucose, glycated haemoglobin, thyroid-stimulating hormone, liver function test, lipids, and iron proﬁle.\nESC 2021\nESC Guidelines 3693\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ experience. As such, and in parallel with the writing of these guidelines, a suite of QIs for the evaluation of care and outcomes for patients with HF was developed. These QIs, alongside their specifica- tions and development process are published separately with a short summary shown in  Table  37 .\n",
      "keywords": [
        "diastolic dysfunction",
        "aortic stenosis",
        "anticoagulant",
        "angiography",
        "class i",
        "heart failure",
        "recommended",
        "indication",
        "ecg",
        "level b",
        "hfref",
        "hfpef",
        "female",
        "glucose",
        "stress test",
        "anticoagulation",
        "hypertension",
        "lvef",
        "bnp",
        "crt",
        "hereditary",
        "echocardiography",
        "should be considered",
        "class ii",
        "diastolic",
        "obesity",
        "alcohol",
        "icd",
        "electrocardiogram",
        "nt-probnp"
      ],
      "tables": [
        {
          "title": "3690 ESC Guidelines",
          "page_number": 91,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nRecommendations for the diagnosis of chronic HF |  |  | \nBNP/NT-proBNP.c | I | B | \n12-lead ECG. | I | C | \nTransthoracic echocardiography. | I | C | \nChest radiography (X-ray). | I | C | \nRoutine blood tests for comorbidities (including full blood count, urea and electrolytes, thyroid function, fasting glucose and\nHbA1c, lipids. Iron studies (TSAT and ferritin). | I | C | \nCMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic\nwindows. | I | C | \nCMR is recommended for the characterization of myocardial tissue in suspected infiltrative disease, Fabry disease, inflamma-\ntory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron overload/haemochromatosis. | I | C | \nInvasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ven-\ntricular arrhythmias. | I | B | \nCardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS. | I | C | \nRight heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS. | I | C | \nRecommendations for the treatment of HFrEF |  |  | \nACE-I is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. | I | A | \nBeta-blocker is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death. | I | A | \nMRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. | I | A | \nDapagliflozin or empagliflozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death. | I | A | \nSacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF hospitaliza-\ntion and death. | I | B | \nDiuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to alleviate HF symptoms,\nimprove exercise capacity and reduce HF hospitalizations. | I | C | \nAn ARBc is recommended to reduce the risk of HF hospitalization and CV death in symptomatic patients unable to tolerate\nan ACE-I or ARNI (patients should also receive a beta-blocker and an MRA). | I | B | \nThe addition of an ARB (or renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with\nHF, because of the increased risk of renal dysfunction and hyperkalaemia. | III | C | \nAn ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a\nventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional\nstatus, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI. | I | A | \nAn ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA\nclass II\u0002III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days—see below), and an LVEF <35% despite\n_\n>3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.\n_ | I | A | \nICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis. | III | A | \nICD therapy is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy\nunless they are candidates for CRT, a VAD, or cardiac transplantation. | III | C | \nCRT is recommended for symptomatic patients with HF in SR with a QRS duration >150 ms and LBBB QRS morphology and\n_\nwith LVEF <35% despite OMT in order to improve symptoms and reduce morbidity and mortality.\n_ | I | A | \nCRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an\nindication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF. | I | A | \nCRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high-\ndegree AV block. | III | A | \nRecommendations for the treatment of HFmrEF and HFpEF |  |  | \nDiuretics are recommended in patients with congestion and HFmrEF in order to alleviate symptoms and signs. | I | C | ",
          "bbox": [
            42.479948733715304,
            110.21129964192708,
            551.9618220094775,
            707.9711434500558
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3691",
          "page_number": 92,
          "content": "Screening for, and treatment of, aetiologies, and CV and non-CV comorbidities is recommended in patients with HFpEF (see\nrelevant sections of this document). | I | C | \nDiuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs. | I | C | \nRecommendations for the prevention of chronic HF |  |  | \nTreatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations. | I | A | \nTreatment with statins is recommended in patients at high risk of CV disease or with CV disease in order to prevent or delay\nthe onset of HF, and to prevent HF hospitalizations. | I | A | \nSGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with dia-\nbetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations. | I | A | \nCounselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the\nonset of HF. | I | C | \nOther recommendations for the management of chronic HF |  |  | \nIt is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF\nhospitalization and mortality. | I | A | \nSelf-management strategies are recommended to reduce the risk of HF hospitalization and mortality. | I | A | \nEither home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF hospi-\ntalization and mortality. | I | A | \nExercise is recommended for all patients who are able in order to improve exercise capacity and QOL, and reduce HF\nhospitalization.d | I | A | \nRecommendations for treatment of patients with advanced HF |  |  | \nPatients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psy-\nchosocial support. | I | C | \nHeart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not\nhave absolute contraindications. | I | C | \nRecommendations for treatment of patients with acute HF |  |  | \nOxygen is recommended in patients with SpO <90% or PaO <60 mmHg to correct hypoxaemia.\n2 2 | I | C | \nIntubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive\nventilation. | I | C | \nIntravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of fluid overload to\nimprove symptoms. | I | C | \nThromboembolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contra-\nindication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism. | I | A | \nInotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension\nand evidence of hypoperfusion. | III | C | \nRoutine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety. | III | C | \nIABP is not routinely recommended in post-MI cardiogenic shock. | III | B | \nRecommendations for management of patients after HF hospitalization |  |  | \nIt is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before\ndischarge and to optimize oral treatment. | I | C | \nIt is recommended that evidence-based oral medical treatment be administered before discharge. | I | C | \nAn early follow-up visit is recommended at 1\u00022 weeks after discharge to assess signs of congestion, drug tolerance, and start\nand/or uptitrate evidence-based therapy. | I | C | \nRecommendations for treatment of patients with HF and AF |  |  | \nLong-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and CHADS-VASc score >2 in\n2 2\nmen or >3 in women. | I | A | \nDOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral steno-\nsis or mechanical prosthetic heart valves. | I | A | \nUrgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and\nhaemodynamic instability. | I | C | \nTreatment with the anti-arrhythmic agents flecainide, encainide, disopyramide, dronedarone, and D-sotalol is not recom-\nmended due to safety concerns. | III | A | ",
          "bbox": [
            46.987862065895314,
            59.87815856933594,
            556.4977755033053,
            710.1312648228237
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3692 ESC Guidelines",
          "page_number": 93,
          "content": "Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF\nhospitalization. | III | C | \nRecommendations for treatment of patients with HF and aortic stenosis |  |  | \nAortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe high-gradient aortic stenosis to\nreduce mortality and improve symptoms. | I | B | \nIt is recommended that the choice between TAVI and SAVR be made by the Heart Team, according to individual patient pref-\nerence and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and benefits of\neach approach. | I | C | \nRecommendations for treatment of patients with HF and diabetes |  |  | \nSGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with\nT2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death. | I | A | \nSGLT2 inhibitors (dapagliflozin, empagliflozin, and sotagliflozin) are recommended in patients with T2DM and HFrEF to\nreduce hospitalizations for HF and CV death. | I | A | \nThiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF\nhospitalization. | III | A | \nThe DPP-4 inhibitor saxagliptin is not recommended in patients with HF. | III | B | \nRecommendations for treatment of patients with HF and iron deficiency |  |  | \nIt is recommended that all patients with HF be periodically screened for anaemia and iron deficiency with a full blood count,\nserum ferritin concentration, and TSAT. | I | C | \nTreatment of anaemia in HF with erythropoietin-stimulating agents is not recommended in the absence of other indications\nfor this therapy. | III | B | \nRecommendation for treatment of patients with HF and sleep apnoea |  |  | \nAdaptive servo-ventilation is not recommended in patients with HFrEF and a predominant CSA because of an increased all-\ncause and CV mortality. | III | A | \nRecommendation for treatment of patients with HF and arthritis |  |  | \nNSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF\nhospitalization. | III | B | \nRecommendation for treatment of patients with HF and cancer |  |  | \nIt is recommended that cancer patients at increased risk for cardiotoxicity, defined by a history or risk factors of CV disease,\nprevious cardiotoxicity or exposure to cardiotoxic agents, undergo CV evaluation before scheduled anticancer therapy, pref-\nerably by a cardiologist with experience/interest in Cardio-Oncology. | I | C | \nRecommendations for treatment of patients with HF and amyloidosis |  |  | \nTafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce\nsymptoms, CV hospitalization and mortality. | I | B | 21\nTafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitaliza-\ntion and mortality. | I | B | ESC 20",
          "bbox": [
            42.45230972766876,
            59.87815856933594,
            551.98779296875,
            516.973164149693
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3693",
          "page_number": 94,
          "content": "Domain 1. Structural QIsa | ESC 2021\nMain (1): Centre should have a dedicated multidisciplinary team to manage patients with HF | \nNumerator: Availability of a dedicated multidisciplinary team to manage patients with HF. | \nDomain 2. Patient assessmentb | \nMain (1): Proportion of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF) | \nNumerator: Number of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).\nDenominator: Number of patients with HF. | \nMain (2): Proportion of patients with HF who have a documentation of their ECG findings | \nNumerator: Number of patients with HF who have a documentation of their ECG findings.\nDenominator: Number of patients with HF. | \nMain (3): Proportion of patients with HF who have their NPs measured | \nNumerator: Number of patients with HF who have a documentation of their NPs levels.\nDenominator: Number of patients with HF. | \nDomain 3. Initial treatment | \nMain (1). Proportion of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol\nsuccinate, or nebivolol in the absence of any contraindications | \nNumerator: Number of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, or\nnebivolol.\nDenominator: Number of patients with HFrEF without any contraindications for the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol\nsuccinate, and nebivolol. | \nMain (2). Proportion of patients with HFrEF who are prescribed ACE inhibitor, ARB or ARNI in the absence of any contraindications | \nNumerator: Number of patients with HFrEF who are prescribed an ACE inhibitor, ARB or ARNI.\nDenominator: Number of patients with HFrEF without any contraindications for ACE inhibitors, ARBs and ARNI. | \nMain (3). Proportion of patients with HF who are prescribed diuretic therapy if they have evidence of fluid retention | \nNumerator: Number of patients with HF, with evidence of fluid retention who are prescribed diuretic therapy.\nDenominator: Number of patients with HF who have evidence of fluid retention and no contraindications for diuretic therapy. | \nMain (4): Proportion of patients with HFrEF who are prescribed an MRA in the absence of any contraindications | \nNumerator: Number of patients with HFrEF who are prescribed an MRA.\nDenominator: Number of patients with HFrEF without any contraindications for MRA. | \nMain (5): Proportion of patients with HFrEF who are prescribed a SGLT2 inhibitor in the absence of any contraindications | \nNumerator: Number of patients with HFrEF who are prescribed a SGLT2 inhibitor.\nDenominator: Number of patients with HFrEF without any contraindications for SGLT2 inhibitor. | ",
          "bbox": [
            48.03963497706822,
            252.94994099934897,
            553.0789794921875,
            674.2996398925782
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "108",
      "title": "19 Supplementary data",
      "start_page": 95,
      "end_page": 95,
      "content": "Supplementary data with additional  Supplementary Figures, Tables , and text complementing the full text are available on the  European Heart Journal  website and via the ESC website at www.escardio.org/guidelines.\n",
      "keywords": [
        "data",
        "supplementary"
      ],
      "tables": []
    },
    {
      "number": "109",
      "title": "20 Author information",
      "start_page": 95,
      "end_page": 95,
      "content": "Author/Task Force Member Affiliations: Marianna Adamo , Medical and Surgical Specialties, Radiological Sciences and Public, ASST Spedali Civili di Brescia, Brescia, Italy;  Andreas Baumbach , Barts Heart Centre, Queen Mary University of London, London, United Kingdom;  Michael Bo¨hm , Klinik fu¨r Innere Medizin III, Saarland University, Homburg/Saar, Saarland, Germany;  Haran Burri , Cardiology, University Hospital of Geneva, Geneva, Switzerland;  Jelena   \u0002 Celutkien _ e , Clinic of Cardiac and Vascular Diseases, Vilnius University, Faculty of Medicine, Vilnius, Lithuania; Ovidiu Chioncel , Emergency Institute for Cardiovascular Diseases ‘Prof. Dr.C.C.Iliescu’, University of Medicine Carol Davila, Bucuresti, Romania;  John G.F. Cleland , Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Wellbeing, Glasgow, Lanarkshire, United Kingdom;  Andrew J.S. Coats , University of Warwick, Coventry, United Kingdom;  Maria G. Crespo-Leiro , Cardiology, Complexo Hospitalario Universitario A Coru ~ na (CHUAC), CIBERCV, Universidade da Coru ~ na (UDC), Instituto de Investigaci \u0003 on Biomedica de A Coru ~ na (INIBIC), La Coru ~ na, Spain; Dimitrios Farmakis , University of Cyprus Medical School, Nicosia, Cyprus;  Roy S. Gardner , Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Clyderbank, Glasgow, Scotland, United Kingdom;  Martine Gilard , Cardiology, Brest University, Brest, France;  Stephane Heymans , Department of Cardiology, Maastricht University, CARIM School for Cardiovascular Diseases, Maastricht, Netherlands;  Arno W. Hoes , University Medical Center Utrecht, Utrecht, Netherlands;  Tiny Jaarsma , Department of Health, Medicine and Caring Science, Linko¨ping University, Linko¨ping, Sweden;  Ewa A. Jankowska , Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland;  Mitja Lainscak , Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia;  Carolyn S.P. Lam , National Heart Centre Singapore and Duke-National University of Singapore, Singapore; Alexander R. Lyon , Department of Cardiology, Royal Brompton Hospital, London, United Kingdom;  John J.V. McMurray , British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom;  Alexandre Mebazaa , Anesthesiology and Critical Care, Universite´ de Paris - Hoˆpital Lariboisie`re, Paris, France;  Richard Mindham , United Kingdom, ESC Patient Forum, Sophia Antipolis, France;  Claudio Muneretto , Cardiothoracic Surgery, Asst Spedali Civili University of Brescia, Brescia, Italy;\nMassimo Francesco Piepoli , Cardiology, Guglielmo da Saliceto Hospital, AUSL Piacenza, Piacenza, Italy;  Susanna Price , Cardiology & Adult Intensive Care Unit, Royal Brompton Hospital, London, United Kingdom;  Giuseppe M.C. Rosano , IRCCS San Raffaele, Roma, Italy;  Frank Ruschitzka , Department of Cardiology, University Hospital Zurich, Zurich, Switzerland;  Anne Kathrine Skibelund , Denmark, ESC Patient Forum, Sophia Antipolis, France.\n",
      "keywords": [
        "author",
        "information",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "110",
      "title": "21 Appendix",
      "start_page": 95,
      "end_page": 96,
      "content": "ESC Scientific Document Group Includes Document Reviewers and ESC National Cardiac Societies.\nDocument Reviewers:  Rudolf A. de Boer (CPG Review Coordinator) (Netherlands), P. Christian Schulze (CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Johann Bauersachs (Germany), Antoni Bayes-Genis (Spain), Michael A. Borger (Germany), Werner Budts (Belgium), Maja Cikes (Croatia), Kevin Damman (Netherlands), Victoria Delgado (Netherlands), Paul Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel (Austria), Justin Ezekowitz (Canada), Volkmar Falk (Germany), Laurent Fauchier (France), Gerasimos Filippatos (Greece), Alan Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale (United Kingdom), Finn Gustafsson (Denmark), Julie Harris (United Kingdom), Bernard Iung (France), Stefan Janssens (Belgium), Mariell Jessup (United States of America), Aleksandra Konradi (Russia), Dipak Kotecha (United Kingdom), Ekatirini Lambrinou (Cyprus), Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany), Christophe Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva (United Kingdom), Ale \u0002 s Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden), Donna Mancini (United States of America), Josep Masip (Spain), Davor Milicic (Croatia), Christian Mueller (Switzerland), Holger Nef (Germany), Jens-Cosedis Nielsen (Denmark), Lis Neubeck (United Kingdom), Michel Noutsias (Germany), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Piotr Ponikowski (Poland), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Dimitrios Richter (Greece), Evgeny Schlyakhto (Russia), Petar Seferovic (Serbia), Michele Senni (Italy), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Carlo Gabriele Tocchetti (Italy), Rhian Touyz (United Kingdom), Carsten Tschoepe (Germany), Johannes Waltenberger (Germany).\nESC National Cardiac Societies  actively involved in the review process of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:\nAlgeria:  Algerian Society of Cardiology, Messaad Krim;  Armenia: Armenian Cardiologists Association, Hamlet Hayrapetyan;  Austria: Austrian Society of Cardiology, Deddo Moertl;  Azerbaijan: Azerbaijan Society of Cardiology, Isakh Mustafayev;  Belarus: Belorussian Scientific Society of Cardiologists, Alena Kurlianskaya; Belgium:  Belgian Society of Cardiology, Michel Depauw;  Bosnia and Herzegovina:  Association of Cardiologists of Bosnia and Herzegovina, Zumreta Ku \u0002 sljugi \u0003 c;  Bulgaria:  Bulgarian Society of\n3694 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Cardiology, Plamen Gatzov;  Croatia:  Croatian Cardiac Society, Davor Milicic;  Cyprus:  Cyprus Society of Cardiology, Petros Agathangelou;  Czech Republic:  Czech Society of Cardiology, Vojt \u0002 ech Melenovsk \u0003 y;  Denmark:  Danish Society of Cardiology, Brian Bridal Løgstrup;  Egypt:  Egyptian Society of Cardiology, Ahmed Magdy Mostafa;  Estonia:  Estonian Society of Cardiology, Tiina Uuetoa;  Finland:  Finnish Cardiac Society, Johan Lassus;  France: French Society of Cardiology, Damien Logeart;  Georgia:  Georgian Society of Cardiology, Zviad Kipiani;  Germany:  German Cardiac Society, Johann Bauersachs;  Greece:  Hellenic Society of Cardiology, Christina Chrysohoou;  Hungary:  Hungarian Society of Cardiology, R \u0003 obert Sepp;  Iceland:  Icelandic Society of Cardiology, Inga J \u0003 ona Ingimarsd \u0003 ottir;  Ireland:  Irish Cardiac Society, Jim O’Neill;  Israel: Israel Heart Society, Israel Gotsman;  Italy:  Italian Federation of Cardiology, Massimo Iacoviello; Kazakhstan: Association of Cardiologists of Kazakhstan, Amina Rakisheva;  Kosovo (Republic of):  Kosovo Society of Cardiology, Gani Bajraktari;  Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova,  Latvia:  Latvian Society of Cardiology, Ginta Kamzola;  Lebanon:  Lebanese Society of Cardiology, Tony Abdel Massih;  Libya:  Libyan Cardiac Society, Hisham Benlamin;  Lithuania:  Lithuanian Society of Cardiology, Diana \u0002 Zaliaduonyt _ e; Luxembourg: Luxembourg Society of Cardiology, Stephanie Noppe;  Malta:  Maltese Cardiac Society, Alice Moore;  Moldova (Republic of):  Moldavian Society of Cardiology, Eleonora Vataman; Montenegro: Montenegro Society of Cardiology, Aneta Boskovic;  Morocco:  Moroccan Society of Cardiology, Ahmed Bennis;  Netherlands:  Netherlands Society of Cardiology, Olivier C. Manintveld;  North Macedonia : North Macedonian Society of Cardiology, Elizabeta Srbinovska Kostovska; Norway:  Norwegian Society of Cardiology, Geeta Gulati;  Poland: Polish Cardiac Society, Ewa Straburzy \u0003 nska-Migaj; Portugal: Portuguese Society of Cardiology, Jose´ Silva-Cardoso;  Romania: Romanian Society of Cardiology, Roxana Cristina Rimbas¸;  Russian Federation:  Russian Society of Cardiology, Yury Lopatin;  San Marino:  San Marino Society of Cardiology, Marina Foscoli;  Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;  Slovakia:  Slovak Society of Cardiology, Eva Goncalvesova;  Slovenia:  Slovenian Society of Cardiology, Zlatko Fras;  Spain:  Spanish Society of Cardiology, Javier Segovia;  Sweden:  Swedish Society of Cardiology, Krister Lindmark;  Switzerland:  Swiss Society of Cardiology, Micha T. Maeder; Syrian Arab Republic: Syrian Cardiovascular Association, Walid Bsata;  Tunisia:  Tunisian Society of Cardiology and Cardio-Vascular Surgery, Leila Abid;  Turkey:  Turkish Society of Cardiology, Hakan Altay;  Ukraine:  Ukrainian Association of Cardiology, Leonid Voronkov;  United Kingdom of Great Britain and Northern Ireland:  British Cardiovascular Society, Ceri Davies, Uzbekistan: Association of Cardiologists of Uzbekistan, Timur Abdullaev.\nESC Clinical Practice Guidelines Committee (CPG):  Colin N. Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena \u0002 Celutkien _ e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Jens-Cosedis Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Lis Neubeck (United Kingdom), Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United Kingdom).\n",
      "keywords": [
        "appendix",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "111",
      "title": "22 References",
      "start_page": 96,
      "end_page": 96,
      "content": "",
      "keywords": [
        "references"
      ],
      "tables": []
    },
    {
      "number": "112",
      "title": "1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Ros",
      "start_page": 96,
      "end_page": 97,
      "content": "ESC Guidelines 3695\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 9. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.  Eur Heart J 2016; 37 :455 \u0002 462. 10. Abdul-Rahim AH, Shen L, Rush CJ, Jhund PS, Lees KR, McMurray JJV, VICCTA- Heart Failure Collaborators. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.  Eur J Heart Fail 2018; 20 :1139 \u0002 1145. 11. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP- CHF) study.  Eur Heart J  2006; 27 :2338 \u0002 2345. 12. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Bohm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson A, Wikstrand J, Kotecha D, Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double- blind randomized trials.  Eur Heart J  2018; 39 :26 \u0002 35. 13. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381 :1609 \u0002 1620. 14. Lam CSP, Voors AA, Piotr P, McMurray JJV, Solomon SD. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. Eur Heart J  2020; 41 :2353 \u0002 2355. 15. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Bohm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferovic P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021; 23 :352 \u0002 380. 16. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, Donal E, Sade LE, Ernande L, Garbi M, Grapsa J, Hagendorff A, Kamp O, Magne J, Santoro C, Stefanidis A, Lancellotti P, Popescu B, Habib G, EACVI Scientific Documents Committee. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18 :1301 \u0002 1310. 17. Arrigo M, Huber LC, Winnik S, Mikulicic F, Guidetti F, Frank M, Flammer AJ, Ruschitzka F. Right ventricular failure: pathophysiology, diagnosis and treatment. Card Fail Rev  2019; 5 :140 \u0002 146. 18. Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschope C, de Boer RA. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2018; 20 :16 \u0002 37. 19. Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM, Pina IL, O’Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical implications of the New York Heart Association classification.  J Am Heart Assoc 2019; 8 :e014240. 20. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJV. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail 2016; 4 :816 \u0002 822. 21. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and pat- terns in heart failure incidence: a population-based study of 4 million individuals. Lancet  2018; 391 :572 \u0002 580. 22. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future.  Curr Heart Fail Rep  2014; 11 :404 \u0002 415.\n",
      "keywords": [
        "parissis",
        "cleland",
        "anker",
        "coats",
        "elderly",
        "voors",
        "heart failure",
        "linde",
        "falk",
        "gonzalez",
        "riley",
        "jankowska",
        "echocardiography",
        "pieske",
        "jessup",
        "diastolic",
        "harjola",
        "juanatey",
        "ponikowski",
        "ejection fraction",
        "nihoyannopoulos",
        "bueno"
      ],
      "tables": []
    },
    {
      "number": "113",
      "title": "23. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJ. Demographic and epidemiologic drivers of global car- diovascular mortality.  N Engl J Med  2015; ",
      "start_page": 97,
      "end_page": 99,
      "content": "3696 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 41. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population.  JAMA  2004; 292 :344 \u0002 350. 42. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nation- wide cohort study.  Circ Heart Fail  2017; 10 :e003875. 43. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, Butler J, Yancy CW, Fonarow GC. Precipitating clinical factors, heart failure characteriza- tion, and outcomes in patients hospitalized with heart failure with reduced, bor- derline, and preserved ejection fraction.  JACC Heart Fail  2016; 4 :464 \u0002 472. 44. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials.  Arch Intern Med  2002; 162 :1682 \u0002 1688. 45. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010.  JAMA Intern Med  2015; 175 :996 \u0002 1004. 46. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction.  JACC Heart Fail 2018; 6 :678 \u0002 685. 47. Motiejunaite J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi DJ, Kavoliuniene A, Celutkiene J, Parenica J, Lassus J, Kajimoto K, Sato N, Miro O, Peacock WF, Matsue Y, Voors AA, Lam CSP, Ezekowitz JA, Ahmed A, Fonarow GC, Gayat E, Regitz-Zagrosek V, Mebazaa A. The association of long-term out- come and biological sex in patients with acute heart failure from different geo- graphic regions.  Eur Heart J  2020; 41 :1357 \u0002 1364. 48. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.  Circ Heart Fail  2012; 5 :720 \u0002 726. 49. Clarke CL, Grunwald GK, Allen LA, Baron AE, Peterson PN, Brand DW, Magid DJ, Masoudi FA. Natural history of left ventricular ejection fraction in patients with heart failure.  Circ Cardiovasc Qual Outcomes  2013; 6 :680 \u0002 686. 50. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H, CHART-2 Investigators. Characterization of heart failure patients with mid-range left ven- tricular ejection fraction–a report from the CHART-2 Study.  Eur J Heart Fail 2017; 19 :1258 \u0002 1269. 51. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clin- ical outcomes for heart failure patients with a mid-range ejection fraction.  Eur J Heart Fail  2017; 19 :1597 \u0002 1605. 52. Lupon J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, Lopez- Ayerbe J, Domingo M, Nunez J, Zamora E, Moliner P, Diaz-Ruata P, Santesmases J, Bayes-Genis A. Dynamic trajectories of left ventricular ejection fraction in heart failure.  J Am Coll Cardiol  2018; 72 :591 \u0002 601. 53. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.  Eur Heart J  2013; 34 :1404 \u0002 1413. 54. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden.  Eur Heart J  2014; 35 :25 \u0002 32. 55. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.  Circulation  2009; 119 :515 \u0002 523. 56. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol  2009; 54 :1695 \u0002 1702. 57. Taylor CJ, Ordonez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study.  BMJ  2019; 364 :l223. 58. Lorenzoni G, Azzolina D, Lanera C, Brianti G, Gregori D, Vanuzzo D, Baldi I. Time trends in first hospitalization for heart failure in a community-based popula- tion.  Int J Cardiol  2018; 271 :195 \u0002 199. 59. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic?  Heart  2002; 87 :75 \u0002 76. 60. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends in heart failure hospitalization after acute myocardial infarction for Medicare benefi- ciaries: 1998-2010.  Circulation  2013; 128 :2577 \u0002 2584. 61. Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, Mamas MA, Khunti K, Kadam UT. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study.  Lancet Public Health  2019; 4 :e406 \u0002 e420. 62. Al-Mohammad A, Mant J, Laramee P, Swain S, Chronic Heart Failure Guideline Development Group. Diagnosis and management of adults\nwith chronic heart failure: summary of updated NICE guidance. BMJ 2010; 341 :c4130. 63. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care.  Health Technol Assess  2009; 13 :1 \u0002 207, iii. 64. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagno- sis in heart failure: which features are any use?  QJM  1997; 90 :335 \u0002 339. 65. Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, Zuithoff NP, Rutten FH, Hoes AW. Clinical evaluation of geriatric outpatients with sus- pected heart failure: value of symptoms, signs, and additional tests.  Eur J Heart Fail  2011; 13 :518 \u0002 527. 66. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physi- cal examination and additional testing in primary care patients with suspected heart failure.  Circulation  2011; 124 :2865 \u0002 2873. 67. Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, Patel PC, Mammen PP, Markham DW, Levine BD, Drazner MH. Characterization of a novel symptom of advanced heart failure: bendopnea.  JACC Heart Fail  2014; 2 :24 \u0002 31. 68. Gohar A, Rutten FH, den Ruijter H, Kelder JC, von Haehling S, Anker SD, Mockel M, Hoes AW. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.  Eur J Heart Fail  2019; 21 :1219 \u0002 1227. 69. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients.  Am J Cardiol  2008; 101 :25 \u0002 28. 70. Maisel A, Mueller C, Adams K, Jr., Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice.  Eur J Heart Fail  2008; 10 :824 \u0002 839. 71. Lancellotti P, Galderisi M, Edvardsen T, Donal E, Goliasch G, Cardim N, Magne J, Laginha S, Hagendorff A, Haland TF, Aaberge L, Martinez C, Rapacciuolo A, Santoro C, Ilardi F, Postolache A, Dulgheru R, Mateescu AD, Beladan CC, Deleanu D, Marchetta S, Auffret V, Schwammenthal E, Habib G, Popescu BA. Echo-Doppler estimation of left ventricular filling pressure: results of the multi- centre EACVI Euro-Filling study. Eur Heart J Cardiovasc Imaging 2017; 18 :961 \u0002 968. 72. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.  Eur Heart J  2003; 24 :1735 \u0002 1743. 73. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, Mant J, NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting.  BMJ  2015; 350 :h910. 74. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr, Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.  Eur J Heart Fail  2019; 21 :715 \u0002 731. 75. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic pepti- des, BNP and NT-proBNP: mechanisms and diagnostic implications for heart fail- ure.  Int J Cardiol  2014; 176 :611 \u0002 617. 76. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with pos- sible new heart failure in primary care.  Lancet  1997; 350 :1349 \u0002 1353. 77. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study.  Eur J Heart Fail  2005; 7 :537 \u0002 541. 78. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure.  J Card Fail  2011; 17 :729 \u0002 734. 79. Verdu JM, Comin-Colet J, Domingo M, Lupon J, Gomez M, Molina L, Casacuberta JM, Munoz MA, Mena A, Bruguera-Cortada J. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care.  Rev Esp Cardiol (Engl Ed)  2012; 65 :613 \u0002 619. 80. Taylor CJ, Roalfe AK, Iles R, Hobbs FR, investigators R, Barton P, Deeks J, McCahon D, Cowie MR, Sutton G, Davis RC, Mant J, McDonagh T, Tait L. Primary care REFerral for EchocaRdiogram (REFER) in heart failure: a diagnostic accuracy study.  Br J Gen Pract  2017; 67 :e94 \u0002 e102. 81. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt JU, Zamorano JL, European Association of Echocardiography. Stress\nESC Guidelines 3697\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Echocardiography Expert Consensus Statement–Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC).  Eur Heart J  2009; 30 :278 \u0002 289. 82. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, Edvardsen T, Garbi M, Ha JW, Kane GC, Kreeger J, Mertens L, Pibarot P, Picano E, Ryan T, Tsutsui JM, Varga A. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.  Eur Heart J Cardiovasc Imaging  2016; 17 :1191 \u0002 1229. 83. Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance.  Curr Heart Fail Rep  2015; 12 :276 \u0002 283. 84. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG. Clinical recommendations for cardi- ovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).  J Cardiovasc Magn Reson  2017; 19 :75. 85. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P. Screening for transthyretin amyloid cardiomy- opathy in everyday practice.  JACC Heart Fail  2019; 7 :709 \u0002 716. 86. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health.  Circ J 2015; 79 :1647 \u0002 1655. 87. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic pepti- des in cardiometabolic regulation and disease.  Nat Rev Cardiol  2014; 11 :403 \u0002 412. 88. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides.  J Cardiol  2011; 57 :131 \u0002 140. 89. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL, STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction.  N Engl J Med  2011; 364 :1607 \u0002 1616. 90. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery dis- ease and left ventricular dysfunction: a meta-analysis.  J Am Coll Cardiol 2002; 39 :1151 \u0002 1158. 91. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, Hachamovitch R. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hiber- nating myocardium.  Circ Cardiovasc Imaging  2013; 6 :363 \u0002 372. 92. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA, STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction.  N Engl J Med  2011; 364 :1617 \u0002 1625. 93. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial viability and long-term outcomes in ischemic cardiomyopathy.  N Engl J Med 2019; 381 :739 \u0002 748. 94. Corra U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, Lambrinou E, Pieske B, Piotrowicz E, Schmid JP, Seferovic PM, Anker SD, Filippatos G, Ponikowski PP. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the ESC.  Eur J Heart Fail  2014; 16 :929 \u0002 941. 95. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail  2011; 13 :347 \u0002 357. 96. Corra U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, Hairola VP, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J, Seferovic PM, Piepoli MF. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2018; 20 :3 \u0002 15. 97. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.  Eur Heart J  2007; 28 :3076 \u0002 3093.\n",
      "keywords": [
        "forouzanfar",
        "elderly",
        "demographic",
        "heart failure",
        "echo",
        "mensah",
        "systolic dysfunction",
        "epidemiologic",
        "diovascular",
        "global",
        "echocardiography",
        "naghavi",
        "bnp",
        "nguyen",
        "engl",
        "coronary artery",
        "murray",
        "drivers",
        "obesity",
        "barber",
        "nt-probnp",
        "feigin",
        "sex",
        "guideline",
        "moran",
        "ejection fraction",
        "systolic",
        "roth",
        "mortality",
        "cardiomyopathy"
      ],
      "tables": []
    },
    {
      "number": "114",
      "title": "98. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural his- tory and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.  N Engl J Med  1997; 336 :1860 ",
      "start_page": 99,
      "end_page": 101,
      "content": "3698 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 111. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.  JAMA  1995; 273 :1450 \u0002 1456. 112. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.  Circulation 1999; 100 :2312 \u0002 2318. 113. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.  N Engl J Med  1991; 325 :293 \u0002 302. 114. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).  Lancet  1999; 353 :2001 \u0002 2007. 115. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.  N Engl J Med  1996; 334 :1349 \u0002 1355. 116. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure.  N Engl J Med  2001; 344 :1651 \u0002 1658. 117. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in conges- tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283 :1295 \u0002 1302. 118. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.  Circulation  2002; 106 :2194 \u0002 2199. 119. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole- Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).  Eur Heart J  2005; 26 :215 \u0002 225. 120. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.  Lancet  1999; 353 :9 \u0002 13. 121. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.  N Engl J Med  1999; 341 :709 \u0002 717. 122. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms.  N Engl J Med  2011; 364 :11 \u0002 21. 123. Fowler MB. Effects of beta blockers on symptoms and functional capacity in heart failure.  Am J Cardiol  1997; 80 :55L \u0002 58L. 124. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P, CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.  Circulation  2005; 112 :2426 \u0002 2435. 125. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384 :2235 \u0002 2243. 126. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.  Lancet Diabetes Endocrinol  2017; 5 :333 \u0002 340. 127. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV. Renal effects and associated outcomes during angiotensin- neprilysin inhibition in heart failure.  JACC Heart Fail  2018; 6 :489 \u0002 498. 128. Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced risk of hyperkalemia\nduring treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial.  JAMA Cardiol  2017; 2 :79 \u0002 85. 129. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.  Eur J Heart Fail  2019; 21 :337 \u0002 341. 130. Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).  Circ Heart Fail  2018; 11 :e004745. 131. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsar- tan or enalapril in the PIONEER-HF trial.  Circulation  2019; 139 :2285 \u0002 2288. 132. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Kober L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjostrand M, Langkilde AM, McMurray JJV. Effects of dapagliflozin on symp- toms, function, and quality of life in patients with heart failure and reduced ejec- tion fraction: results from the DAPA-HF trial.  Circulation  2020; 141 :90 \u0002 99. 133. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Pina IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.  Eur Heart J  2021; 42 :1203 \u0002 1212. 134. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR- Reduced and DAPA-HF trials.  Lancet  2020; 396 :819 \u0002 829. 135. Jackson AM, Dewan P, Anand IS, Belohlavek J, Bengtsson O, de Boer RA, Bohm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukat A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O’Meara E, Sabatine MS, Sjostrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF.  Circulation  2020; 142 :1040 \u0002 1054. 136. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure.  N Engl J Med  2021; 384 :117 \u0002 128. 137. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evi- dence supporting the role of diuretics in heart failure: a meta analysis of rando- mised controlled trials.  Int J Cardiol  2002; 82 :149 \u0002 158. 138. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left- ventricular systolic function intolerant to angiotensin-converting-enzyme inhibi- tors: the CHARM-Alternative trial.  Lancet  2003; 362 :772 \u0002 776. 139. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.  Lancet 2010; 376 :875 \u0002 885. 140. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.  J Am Coll Cardiol  2012; 59 :1938 \u0002 1945. 141. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, VICTORIA Study Group. Vericiguat in patients with heart fail- ure and reduced ejection fraction.  N Engl J Med  2020; 382 :1883 \u0002 1893. 142. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN, African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.  N Engl J Med  2004; 351 :2049 \u0002 2057. 143. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.  N Engl J Med  1986; 314 :1547 \u0002 1552.\nESC Guidelines 3699\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 144. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure.  N Engl J Med  1997; 336 :525 \u0002 533. 145. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2019; 21 :137 \u0002 155. 146. Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simoes MV, Silvestre OM, Ribeiro ALP, Moura LZ, Beck-da-Silva L, Prado D, Sant’Anna RT, Bridi LH, Zimerman A, Raupp da Rosa P, Biolo A. Short-term diuretic with- drawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.  Eur Heart J  2019; 40 :3605 \u0002 3612. 147. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.  N Engl J Med  2001; 345 :1667 \u0002 1675. 148. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.  Clin Res Cardiol  2013; 102 :11 \u0002 22. 149. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrilla- tion.  Am J Cardiol  2015; 115 :901 \u0002 906. 150. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 2015; 36 :1831 \u0002 1838. 151. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data.  BMJ  2015; 351 :h4451. 152. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation.  N Engl J Med  2010; 362 :1363 \u0002 1373. 153. Bavishi C, Khan AR, Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis.  Int J Cardiol  2015; 188 :99 \u0002 101. 154. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.  Circ Arrhythm Electrophysiol 2015; 8 :49 \u0002 58. 155. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR, ROCKET Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation AF and adverse cardiovascular outcomes: retro- spective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin a K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 2015; 385 :2363 \u0002 2370. 156. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure.  JAMA 2003; 289 :871 \u0002 878. 157. Adams KF, Jr., Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis.  J Am Coll Cardiol  2005; 46 :497 \u0002 504. 158. Bavendiek U, Berliner D, Davila LA, Schwab J, Maier L, Philipp SA, Rieth A, Westenfeld R, Piorkowski C, Weber K, Hanselmann A, Oldhafer M, Schallhorn S, von der Leyen H, Schroder C, Veltmann C, Stork S, Bohm M, Koch A, Bauersachs J, DIGIT-HF Investigators and Committees. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail  2019; 21 :676 \u0002 684. 159. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrom U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE, GALACTIC-HF Investigators. Cardiac myosin activation with ome- camtiv mecarbil in systolic heart failure.  N Engl J Med  2021; 384 :105 \u0002 116. 160. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Kuˆ¡ber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV. Declining risk of sudden death in heart failure.  N Engl J Med 2017; 377 :41 \u0002 51.\n",
      "keywords": [
        "elderly",
        "heart failure",
        "berry",
        "natural",
        "african",
        "giant",
        "engl",
        "cooper",
        "shabetai",
        "multicenter",
        "idiopathic",
        "treatment",
        "study",
        "myocarditis",
        "group",
        "atrial fibrillation",
        "tory",
        "ace inhibitor",
        "ejection fraction",
        "systolic",
        "diabetes",
        "diuretic",
        "sglt2",
        "cell",
        "investigators"
      ],
      "tables": []
    },
    {
      "number": "115",
      "title": "161. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, ",
      "start_page": 101,
      "end_page": 106,
      "content": "3700 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Defibrillator implantation early after myocardial infarction.  N Engl J Med 2009; 361 :1427 \u0002 1436. 179. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardi- overter-defibrillators.  N Engl J Med  2005; 353 :1471 \u0002 1480. 180. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014; 2 :623 \u0002 629. 181. Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, Cleland JG, Levy WC, Francis DP. The effect of duration of follow-up and presence of com- peting risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?  Eur Heart J  2015; 36 :1676 \u0002 1688. 182. Miller RJ, Howlett JG, Exner DV, Campbell PM, Grant AD, Wilton SB. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis.  Can J Cardiol  2015; 31 :792 \u0002 799. 183. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.  Circ Cardiovasc Qual Outcomes  2015; 8 :179 \u0002 186. 184. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O’Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodar- one.  Circulation  2000; 101 :1297 \u0002 1302. 185. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J, Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure.  N Engl J Med  2008; 358 :2678 \u0002 2687. 186. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.  N Engl J Med  1991; 324 :781 \u0002 788. 187. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of pro- phylactic implantation of cardioverter-defibrillators without cardiac resynchro- nization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis.  Europace  2010; 12 :1564 \u0002 1570. 188. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM, Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Thune JJ. Age and outcomes of pri- mary prevention implantable cardioverter-defibrillators in patients with noni- schemic systolic heart failure.  Circulation  2017; 136 :1772 \u0002 1780. 189. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W, Krum H, Prasad S, McGavigan AD. Cardiovascular magnetic resonance-GUIDEd manage- ment of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial.  Ann Noninvasive Electrocardiol 2017; 22 :e12420. 190. Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, Umar F, Patel K, Panting J, Marshall H, Qiu T. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy.  J Am Coll Cardiol  2017; 70 :1216 \u0002 1227. 191. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, Sramko M, Masci PG, Barison A, McKenna P, Mordi I, Haugaa KH, Leyva F, Rodriguez Capitan J, Satoh H, Nabeta T, Dallaglio PD, Campbell NG, Sabate X, Cequier A. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail  2017; 5 :28 \u0002 38. 192. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O’Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.  JAMA  2013; 309 :896 \u0002 908. 193. Stewart GC, Weintraub JR, Pratibhu PP, Semigran MJ, Camuso JM, Brooks K, Tsang SW, Anello MS, Nguyen VT, Lewis EF, Nohria A, Desai AS, Givertz MM, Stevenson LW. Patient expectations from implantable defibrillators to prevent death in heart failure.  J Card Fail  2010; 16 :106 \u0002 113. 194. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA, 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W, MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming.  N Engl J Med  2012; 367 :2275 \u0002 2283. 195. Healey JS, Hohnloser SH, Glikson M, Neuzner J, Mabo P, Vinolas X, Kautzner J, O’Hara G, VanErven L, Gadler F, Pogue J, Appl U, Gilkerson J, Pochet T, Stein KM, Merkely B, Chrolavicius S, Meeks B, Foldesi C, Thibault B, Connolly SJ,\nShockless IMPLant Evaluation Investigators. Cardioverter defibrillator implanta- tion without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).  Lancet  2015; 385 :785 \u0002 791. 196. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.  JAMA  2013; 309 :1903 \u0002 1911. 197. Cleland JG, Buga L. Device therapy: defibrillators–a shocking therapy for cardio- myopathy?  Nat Rev Cardiol  2010; 7 :69 \u0002 70. 198. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A, Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implant- able defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.  JAMA  2002; 288 :3115 \u0002 3123. 199. Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood M, Kuschyk J, Jones P, Duffy E, Husby M, Stein K, Lambiase PD, Group EI. Implant and midterm outcomes of the subcutaneous implantable cardioverter- defibrillator registry: the EFFORTLESS study. J Am Coll Cardiol 2017; 70 :830 \u0002 841. 200. Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, Knops RE, Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD. Safety and effi- cacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry.  J Am Coll Cardiol 2015; 65 :1605 \u0002 1615. 201. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ, ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sud- den cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).  Eur Heart J  2015; 36 :2793 \u0002 2867. 202. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El- Chami MF, Bonnemeier H, Behr ER, Brouwer TF, Kaab S, Mittal S, Quast ABE, Smeding L, van der Stuijt W, de Weger A, de Wilde KC, Bijsterveld NR, Richter S, Brouwer MA, de Groot JR, Kooiman KM, Lambiase PD, Neuzil P, Vernooy K, Alings M, Betts TR, Bracke F, Burke MC, de Jong J, Wright DJ, Tijssen JGP, Wilde AAM, PRAETORIAN Investigators. Subcutaneous or trans- venous defibrillator therapy.  N Engl J Med  2020; 383 :526 \u0002 536. 203. Duncker D, Konig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator–the PROLONG Study.  J Am Heart Assoc  2017; 6 :e004512. 204. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, Zweibel S, Buxton AE, Elayi CS, Chung EH, Rashba E, Borggrefe M, Hue TF, Maguire C, Lin F, Simon JA, Hulley S, Lee BK, VEST Investigators. Wearable cardioverter- defibrillator after myocardial infarction.  N Engl J Med  2018; 379 :1205 \u0002 1215. 205. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC, Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multi- site biventricular pacing in patients with heart failure and intraventricular con- duction delay.  N Engl J Med  2001; 344 :873 \u0002 880. 206. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortal- ity in heart failure.  N Engl J Med  2005; 352 :1539 \u0002 1549. 207. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Torok T, Linde C, REVERSE Study Group. Prevention of disease progression by car- diac resynchronization therapy in patients with asymptomatic or mildly sympto- matic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.  J Am Coll Cardiol  2009; 54 :1837 \u0002 1846. 208. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortal- ity in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase].  Eur Heart J  2006; 27 :1928 \u0002 1932. 209. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert JC. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial.  Eur J Heart Fail 2012; 14 :628 \u0002 634. 210. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM, Comparison of Medical Therapy Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable\nESC Guidelines 3701\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350 :2140 \u0002 2150. 211. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.  Eur Heart J 2013; 34 :3547 \u0002 3556. 212. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure.  N Engl J Med  2010; 363 :2385 \u0002 2395. 213. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events.  N Engl J Med  2009; 361 :1329 \u0002 1338. 214. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA, 3rd, Foster E, Greenberg H, Kautzner J, Klempfner R, Kuniss M, Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem A, Solomon SD, Wilber D, Zareba W, Moss AJ. Survival with cardiac- resynchronization therapy in mild heart failure. N Engl J Med 2014; 370 :1694 \u0002 1701. 215. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.  J Am Coll Cardiol 2008; 52 :1834 \u0002 1843. 216. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS, Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK AF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction.  N Engl J Med  2013; 368 :1585 \u0002 1593. 217. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibril- lation: a randomized trial.  Eur Heart J  2011; 32 :2420 \u0002 2429. 218. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-anal- ysis.  Europace  2012; 14 :1490 \u0002 1497. 219. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P, Mabo P, Levy T, Gadler F, Bailleul C, Daubert JC. Comparative effects of per- manent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation.  Eur Heart J  2002; 23 :1780 \u0002 1787. 220. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR. Individual patient data network meta- analysis of mortality effects of implantable cardiac devices. Heart 2015; 101 :1800 \u0002 1806. 221. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to car- diac resynchronization therapy in heart failure patients with and without pre- vious right ventricular pacing.  Eur J Heart Fail  2014; 16 :1199 \u0002 1205. 222. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J, 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.  N Engl J Med  2013; 369 :1395 \u0002 1405. 223. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, Dickstein K, Ford I, Gorcsan J, 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J, Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial.  Eur Heart J  2015; 36 :1983 \u0002 1989. 224. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM, Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data.  JAMA Intern Med  2014; 174 :1340 \u0002 1348. 225. Sohaib SM, Finegold JA, Nijjer SS, Hossain R, Linde C, Levy WC, Sutton R, Kanagaratnam P, Francis DP, Whinnett ZI. Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ven- tricular pacing: evidence from randomized controlled trials.  JACC Heart Fail 2015; 3 :327 \u0002 336. 226. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).  J Am Coll Cardiol 2004; 43 :1459 \u0002 1465. 227. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, Daubert C, REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Long-term impact of cardiac resynchronization\ntherapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J  2013; 34 :2592 \u0002 2599. 228. Cleland JG, Mareev Y, Linde C. Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?  Eur Heart J  2015; 36 :1948 \u0002 1951. 229. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U, Alehagen U, Lund LH. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure.  Europace  2015; 17 :424 \u0002 431. 230. Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi A, Ahmed FZ, Mamas MA. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials.  Heart  2015; 101 :1456 \u0002 1462. 231. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA, PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16 :1160 \u0002 1165. 232. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart fail- ure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal  of 100 %  biventricular pacing neces- sary? J Am Coll Cardiol  2009; 53 :355 \u0002 360. 233. Hawkins NM, Petrie MC, Burgess MI, McMurray JJ. Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony.  J Am Coll Cardiol  2009; 53 :1944 \u0002 1959. 234. Beela AS, Unlu S, Duchenne J, Ciarka A, Daraban AM, Kotrc M, Aarones M, Szulik M, Winter S, Penicka M, Neskovic AN, Kukulski T, Aakhus S, Willems R, Fehske W, Faber L, Stankovic I, Voigt JU. Assessment of mechanical dyssyn- chrony can improve the prognostic value of guideline-based patient selection for cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging 2019; 20 :66 \u0002 74. 235. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, con- trolled trial.  J Am Coll Cardiol  2012; 59 :1509 \u0002 1518. 236. Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, Oyenuga OA, Onishi T, Soman P, Gorcsan J, 3rd. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial.  Circ Heart Fail  2013; 6 :427 \u0002 434. 237. Kosmala W, Marwick TH. Meta-analysis of effects of optimization of cardiac resynchronization therapy on left ventricular function, exercise capacity, and quality of life in patients with heart failure.  Am J Cardiol  2014; 113 :988 \u0002 994. 238. Whinnett ZI, Francis DP, Denis A, Willson K, Pascale P, van Geldorp I, De Guillebon M, Ploux S, Ellenbogen K, Haissaguerre M, Ritter P, Bordachar P. Comparison of different invasive hemodynamic methods for AV delay optimiza- tion in patients with cardiac resynchronization therapy: implications for clinical trial design and clinical practice.  Int J Cardiol  2013; 168 :2228 \u0002 2237. 239. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non- responders to cardiac resynchronization therapy: a practical guide.  Eur Heart J 2017; 38 :1463 \u0002 1472. 240. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, Dickstein K, Linde C, Vernooy K, Leyva F, Bauersachs J, Israel CW, Lund LH, Donal E, Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Cosedis Nielsen J, Steffel J, Vardas P, Coats A, Seferovic P, Edvardsen T, Heidbuchel H, Ruschitzka F, Leclercq C. Optimized implementation of cardiac resynchroniza- tion therapy: a call for action for referral and optimization of care: a joint posi- tion statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology.  Eur J Heart Fail 2020; 22 :2349 \u0002 2369. 240a.Glikson M, Nielsen JC, Michowitz Y, Kronborg MB, Auricchio A, Barbash IM, Barrabe´s JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thyle´n I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynch- ronization therapy.  Eur Heart J  2021; doi: 10.1093/eurheartj/ehab364 [Epub ahead of print]. 241. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuss G. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation.  JACC Heart Fail  2018; 6 :874 \u0002 883. 242. NICE: National Institute for Health and Care Excellence. Interventional proce- dures guidance. Cardiac contractility modulation device implantation for heart failure. www.nice.org.uk/guidance/ipg655 (28 May 2021).\n3702 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .......................................................................................................................................................................... 243. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Muller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction.  JACC Heart Fail  2015; 3 :487 \u0002 496. 244. Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT. Baroreflex activation therapy in patients with heart failure with reduced ejec- tion fraction.  J Am Coll Cardiol  2020; 76 :1 \u0002 13. 245. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial.  Lancet  2003; 362 :777 \u0002 781. 246. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone for heart fail- ure with preserved ejection fraction.  N Engl J Med  2014; 370 :1383 \u0002 1392. 247. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020; 141 :352 \u0002 361. 248. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitaliza- tions in heart failure: a review of statistical methodology, with application to CHARM-Preserved.  Eur J Heart Fail  2014; 16 :33 \u0002 40. 249. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).  J Am Coll Cardiol  2009; 53 :2150 \u0002 2158. 250. Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C. Cardiac resynchroniza- tion therapy in heart failure patients with less severe left ventricular dysfunc- tion.  Eur J Heart Fail  2015; 17 :135 \u0002 143. 251. Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, Nielsen CD, van der Harst P, Hoendermis E, Penicka M, Bartunek J, Fail PS, Kaye DM, Walton A, Petrie MC, Walker N, Basuray A, Yakubov S, Hummel SL, Chetcuti S, Forde- McLean R, Herrmann HC, Burkhoff D, Massaro JM, Cleland JGF, Mauri L. One- year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: a randomized clinical trial.  JAMA Cardiol  2018; 3 :968 \u0002 977. 252. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 :759 \u0002 766. 253. Dewan P, Jackson A, Lam CSP, Pfeffer MA, Zannad F, Pitt B, Solomon SD, McMurray JJV. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail 2020; 22 :898 \u0002 901. 254. Campbell RT, Petrie MC, McMurray JJV. Redefining heart failure phenotypes based on ejection fraction.  Eur J Heart Fail  2018; 20 :1634 \u0002 1635. 255. Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study.  JACC Cardiovasc Imaging  2015; 8 :656 \u0002 665. 256. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, Fornwalt BK. Routinely reported ejection fraction and mortality in clinical prac- tice: where does the nadir of risk lie?  Eur Heart J  2020; 41 :1249 \u0002 1257. 257. Stewart S, Playford D, Scalia GM, Currie P, Celermajer DS, Prior D, Codde J, Strange G, NEDA Investigators. Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.  Eur J Heart Fail 2021; 23 :406 \u0002 416. 258. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction.  Nat Rev Cardiol  2020; 17 :559 \u0002 573. 259. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algo- rithm: a consensus recommendation from the Heart Failure Association\n(HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40 :3297 \u0002 3317. 260. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, Hardin KM, Zampierollo GA, Jarolim P, Pappagianopoulos PP, Malhotra R, Nayor M, Lewis GD. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions.  Circulation  2019; 140 :353 \u0002 365. 261. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.  Circulation  2018; 138 :861 \u0002 870. 262. Segar MW, Patel KV, Berry JD, Grodin JL, Pandey A. Generalizability and impli- cations of the H2FPEF score in a cohort of patients with heart failure with pre- served ejection fraction.  Circulation  2019; 139 :1851 \u0002 1853. 263. Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, O’Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon SD. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail  2019; 21 :1288 \u0002 1291. 264. Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J, Paterson I, McAlister FA, Ezekowitz JA. External validation of the H2F-PEF model in diagnosing patients with heart failure and preserved ejection fraction. Circulation  2019; 139 :2377 \u0002 2379. 265. Sueta D, Yamamoto E, Nishihara T, Tokitsu T, Fujisue K, Oike F, Takae M, Usuku H, Takashio S, Arima Y, Suzuki S, Nakamura T, Ito M, Kanazawa H, Sakamoto K, Kaikita K, Tsujita K. H2FPEF score as a prognostic value in HFpEF patients.  Am J Hypertens  2019; 32 :1082 \u0002 1090. 266. Barandiaran Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens M, Heymans S, Beussink-Nelson L, Shah SJ, van Empel VPM. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection frac- tion.  Eur J Heart Fail  2020; 22 :413 \u0002 421. 267. Sanders-van Wijk S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens M, Weerts J, Knackstedt C, Uszko-Lencer N, Heymans S, van Empel V. The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with sus- pected heart failure with preserved ejection fraction.  Eur J Heart Fail 2021; 23 :838 \u0002 840. 268. Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW, Borlaug BA, Shah AM, Solomon SD. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community.  JACC Heart Fail 2020; 8 :640 \u0002 653. 269. Ouwerkerk W, Tromp J, Jin X, Jaufeerally F, Yeo PSD, Leong KTG, Ong HY, Ling LH, Loh SY, Sim D, Lee S, Soon D, Chin C, Richards AM, Lam CSP. Heart failure with preserved ejection fraction diagnostic scores in an Asian population. Eur J Heart Fail  2020; 22 :1737 \u0002 1739. 270. Playford D, Strange G, Celermajer DS, Evans G, Scalia GM, Stewart S, Prior D, NEDA Investigators. Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA).  Eur Heart J Cardiovasc Imaging  2021; 22 :505 \u0002 515. 271. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.  Lancet 2019; 393 :61 \u0002 73. 272. Lupon J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, Lopez- Ayerbe J, Domingo M, Nunez J, Zamora E, Moliner P, Santiago-Vacas E, Santesmases J, Bayes-Genis A. Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors.  Circ Heart Fail  2019; 12 :e005652. 273. Savarese G, Vedin O, D’Amario D, Uijl A, Dahlstrom U, Rosano G, Lam CSP, Lund LH. Prevalence and prognostic implications of longitudinal ejection frac- tion change in heart failure.  JACC Heart Fail  2019; 7 :306 \u0002 317. 274. Nauta JF, Hummel YM, van der Meer P, Lam CSP, Voors AA, van Melle JP. Correlation with invasive left ventricular filling pressures and prognostic rele- vance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a sys- tematic review in patients with heart failure with preserved ejection fraction. Eur J Heart Fail  2018; 20 :1303 \u0002 1311. 275. Sharifov OF, Schiros CG, Aban I, Denney TS, Gupta H. Diagnostic accuracy of tissue Doppler index E/e’ for evaluating left ventricular filling pressure and dia- stolic dysfunction/heart failure with preserved ejection fraction: a systematic review and meta-analysis.  J Am Heart Assoc  2016; 5 :e002078. 276. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C, Cunningham TF, Hardin KM, Baggish AL, Ho JE, Malhotra R, Lewis GD. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure.  Circ Heart Fail  2018; 11 :e004750.\nESC Guidelines 3703\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 277. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O’Mahony D, Polonski L, Taylor J. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP Investigators.  Eur J Heart Fail  1999; 1 :211 \u0002 217. 278. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction.  N Engl J Med  2008; 359 :2456 \u0002 2467. 279. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group trial.  Circulation  2006; 114 :397 \u0002 403. 280. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E, NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 2015; 373 :2314 \u0002 2324. 281. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WHW, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM, National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. JAMA 2018; 320 :1764 \u0002 1773. 282. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J, VITALITY-HFpEF Study Group. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial.  JAMA  2020; 324 :1512 \u0002 1521. 283. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, Jr., Parker J, Seferovic JP, Wilson P, Mittleman RS, Profy AT, Konstam MA. Effect of pralici- guat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. JAMA  2020; 324 :1522 \u0002 1531. 284. Omar W, Pandey A, Haykowsky MJ, Berry JD, Lavie CJ. The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure.  Curr Heart Fail Rep  2018; 15 :75 \u0002 80. 285. Kitzman DW, Upadhya B, Reeves G. Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient.  JACC Heart Fail  2015; 3 :442 \u0002 444. 286. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer RM, Verschuren WMM, Sato S, Njolstad I, Woodward M, Salomaa V, Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg P, Gallacher J, de la Camara AG, Volzke H, Dahm CC, Dale CE, Bergmann MM, Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD, Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG, 2nd, Linneberg A, Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, Grioni S, Palli D, Huerta JM, Price J, Sundstrom J, Arriola L, Arima H, Travis RC, Panagiotakos DB, Karakatsani A, Trichopoulou A, Kuhn T, Grobbee DE, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Despres JP, Cushman M, Cooper JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C, Tjonneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G, Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J, Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective stud- ies.  Lancet  2018; 391 :1513 \u0002 1523. 287. Kostis JB, Davis BR, Cutler J, Grimm RH, Jr., Berge KG, Cohen JD, Lacy CR, Perry HM, Jr., Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with iso- lated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278 :212 \u0002 216. 288. Group SR, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT.\nA randomized trial of intensive versus standard blood-pressure control.  N Engl J Med  2015; 373 :2103 \u0002 2116. 289. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta- analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med  2011; 171 :384 \u0002 394. 290. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older.  N Engl J Med 2008; 358 :1887 \u0002 1898. 291. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E, PROVE IT-TIMI Investigators. Intensive statin ther- apy and the risk of hospitalization for heart failure after an acute coronary syn- drome in the PROVE IT-TIMI 22 study.  J Am Coll Cardiol  2006; 47 :2326 \u0002 2331. 292. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart dis- ease.  J Card Fail  1997; 3 :249 \u0002 254. 293. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortal- ity in type 2 diabetes.  N Engl J Med  2015; 373 :2117 \u0002 2128. 294. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.  N Engl J Med  2017; 377 :644 \u0002 657. 295. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.  N Engl J Med  2019; 380 :347 \u0002 357. 296. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Diaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med  2020; 384 :129 \u0002 139. 297. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK, VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes.  N Engl J Med  2020; 383 :1425 \u0002 1435. 298. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smok- ing to mortality and morbidity in patients with left ventricular dysfunction.  J Am Coll Cardiol  2001; 37 :1677 \u0002 1682. 299. Dorans KS, Mostofsky E, Levitan EB, Hakansson N, Wolk A, Mittleman MA. Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men.  Circ Heart Fail  2015; 8 :422 \u0002 427. 300. Goncalves A, Claggett B, Jhund PS, Rosamond W, Deswal A, Aguilar D, Shah AM, Cheng S, Solomon SD. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study.  Eur Heart J  2015; 36 :939 \u0002 945. 301. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de Lemos JA, Berry JD. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis.  Circulation  2015; 132 :1786 \u0002 1794. 302. Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, Swedberg K, Maggioni A, Gamble G, Ariti C, Earle N, Whalley G, Poppe KK, Doughty RN, Bayes-Genis A, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.  Int J Obes (Lond) 2014; 38 :1110 \u0002 1114. 303. McDonagh TA, Blue L, Clark AL, Dahlstrom U, Ekman I, Lainscak M, McDonald K, Ryder M, Stromberg A, Jaarsma T, European Society of Cardiology Heart Failure Association Committee on Patient Care. European Society of Cardiology Heart Failure Association Standards for delivering heart failure care. Eur J Heart Fail  2011; 13 :235 \u0002 241. 304. Lainscak M, Blue L, Clark AL, Dahlstrom U, Dickstein K, Ekman I, McDonagh T, McMurray JJ, Ryder M, Stewart S, Stromberg A, Jaarsma T. Self-care manage- ment of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2011; 13 :115 \u0002 126. 305. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray JJ, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine\n3704 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .......................................................................................................................................................................... and the Society of Academic Emergency Medicine–short version.  Eur Heart J 2015; 36 :1958 \u0002 1966. 306. McDonagh TA, Gardner RS, Lainscak M, Nielsen OW, Parissis J, Filippatos G, Anker SD. Heart Failure Association of the European Society of Cardiology specialist heart failure curriculum.  Eur J Heart Fail  2014; 16 :151 \u0002 162. 307. Riley JP, Astin F, Crespo-Leiro MG, Deaton CM, Kienhorst J, Lambrinou E, McDonagh TA, Rushton CA, Stromberg A, Filippatos G, Anker SD. Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum.  Eur J Heart Fail  2016; 18 :736 \u0002 743. 308. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, Coppens M, Brian Haynes R, Connolly S. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis.  Eur J Heart Fail 2017; 19 :1427 \u0002 1443. 309. Jonkman NH, Westland H, Groenwold RH, Agren S, Anguita M, Blue L, Bruggink-Andre de la Porte PW, DeWalt DA, Hebert PL, Heisler M, Jaarsma T, Kempen GI, Leventhal ME, Lok DJ, Martensson J, Muniz J, Otsu H, Peters- Klimm F, Rich MW, Riegel B, Stromberg A, Tsuyuki RT, Trappenburg JC, Schuurmans MJ, Hoes AW. What are effective program characteristics of self- management interventions in patients with heart failure? An individual patient data meta-analysis.  J Card Fail  2016; 22 :861 \u0002 871. 310. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure.  Cochrane Database Syst Rev  2019; 1 :CD002752. 311. Kalogirou F, Forsyth F, Kyriakou M, Mantle R, Deaton C. Heart failure disease management: a systematic review of effectiveness in heart failure with pre- served ejection fraction.  ESC Heart Fail  2020; 7 :194 \u0002 212. 312. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, Di Stolfo G, Lambrinou E, Skibelund AK, Uchmanowicz I, Rutten FH, Celutkiene J, Piepoli MF, Jankowska EA, Chioncel O, Ben Gal T, Seferovic PM, Ruschitzka F, Coats AJS, Stromberg A, Jaarsma T. Integration of a palliative approach into heart fail- ure care: a European Society of Cardiology Heart Failure Association position paper.  Eur J Heart Fail  2020; 22 :2327 \u0002 2339. 313. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interventions to promote health-related quality of life in patients living with heart failure: a systematic review and meta-analysis. Heart Lung Circ 2020; 29 :1633 \u0002 1647. 314. Feltner C, Jones CD, Cene CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis.  Ann Intern Med  2014; 160 :774 \u0002 784. 315. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, Petrie MC, Connolly E, Norrie J, Round CE, Ford I, Morrison CE. Randomised con- trolled trial of specialist nurse intervention in heart failure. BMJ 2001; 323 :715 \u0002 718. 316. Lambrinou E, Kalogirou F, Lamnisos D, Sourtzi P. Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re- admissions: a systematic review and meta-analysis. Int J Nurs Stud 2012; 49 :610 \u0002 624. 317. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999; 159 :257 \u0002 261. 318. Ekman I, Wolf A, Olsson LE, Taft C, Dudas K, Schaufelberger M, Swedberg K. Effects of person-centred care in patients with chronic heart failure: the PCC- HF study.  Eur Heart J  2012; 33 :1112 \u0002 1119. 319. Riegel B, Bennett JA, Davis A, Carlson B, Montague J, Robin H, Glaser D. Cognitive impairment in heart failure: issues of measurement and etiology.  Am J Crit Care  2002; 11 :520 \u0002 528. 320. Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence.  Eur Heart J  2011; 32 :264 \u0002 268. 321. Abraityte A, Aukrust P, Kou L, Anand IS, Young J, McMurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T. T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clin Res Cardiol 2019; 108 :133 \u0002 141. 322. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O’Connor CM, Weinfurt KP, HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial.  JAMA  2009; 301 :1451 \u0002 1459. 323. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pina IL, HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF- ACTION randomized controlled trial.  JAMA  2009; 301 :1439 \u0002 1450.\n",
      "keywords": [
        "diastolic dysfunction",
        "fishbein",
        "cardiovascular risk",
        "antihypertensive",
        "elderly",
        "heart failure",
        "echo",
        "johnson",
        "bardy",
        "systolic dysfunction",
        "ethnic",
        "clapp",
        "physical activity",
        "hfpef",
        "atherosclerosis",
        "echocardiography",
        "hypertension",
        "crt",
        "fraulo",
        "mark",
        "mcnulty",
        "packer",
        "diastolic",
        "obesity",
        "alcohol",
        "icd",
        "statin",
        "older",
        "boineau",
        "troutman"
      ],
      "tables": []
    },
    {
      "number": "116",
      "title": "324. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D, O’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista LS, Jolly K, Myers J, Nilsson BB, Passino C, ",
      "start_page": 106,
      "end_page": 107,
      "content": "ESC Guidelines 3705\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ......................................................................................................................................................................... the NorthStar Investigators, all members of The Danish Heart Failure Clinics Network. Extended heart failure clinic follow-up in low-risk patients: a random- ized clinical trial (NorthStar).  Eur Heart J  2013; 34 :432 \u0002 442. 340. Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence- based therapy and survival in heart failure in Sweden 2003-2012.  Eur J Heart Fail 2016; 18 :503 \u0002 511. 341. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.  Eur J Heart Fail  2017; 19 :1270 \u0002 1279. 342. Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, Lund LH. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.  Eur J Heart Fail  2018; 20 :1326 \u0002 1334. 343. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson A, Jernberg T, Dahlstrom U. Association between enrolment in a heart failure quality registry and subsequent mortality–a nationwide cohort study.  Eur J Heart Fail 2017; 19 :1107 \u0002 1116. 344. Clark AL, Goode K, Cleland JG. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure.  Eur J Heart Fail 2008; 10 :696 \u0002 702. 345. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriu- retic peptide (N-BNP) concentrations.  Lancet  2000; 355 :1126 \u0002 1130. 346. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3- arm, prospective, randomized pilot study.  J Am Coll Cardiol  2010; 55 :645 \u0002 653. 347. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.  J Am Coll Cardiol  2007; 49 :1733 \u0002 1739. 348. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.  J Am Coll Cardiol  2009; 55 :53 \u0002 60. 349. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP, TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.  JAMA  2009; 301 :383 \u0002 392. 350. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Jr., Mark DB, Pina IL, Passmore G, Whellan DJ, Yang H, Cooper LS, Leifer ES, Desvigne-Nickens P, O’Connor CM. Effect of natriuretic peptide- guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial.  JAMA  2017; 318 :713 \u0002 720. 351. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriu- retic peptide-guided heart failure therapy: a meta-analysis.  Arch Intern Med 2010; 170 :507 \u0002 514. 352. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, O’Connor CM, Moertl D, Karlstrom P, Dahlstrom U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.  Eur Heart J 2014; 35 :1559 \u0002 1567. 353. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators. Changes in brain natriuretic pep- tide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).  Circulation  2003; 107 :1278 \u0002 1283. 354. Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart fail- ure.  J Am Coll Cardiol  2016; 68 :2425 \u0002 2436. 355. Brahmbhatt DH, Cowie MR. Remote management of heart failure: an overview of telemonitoring technologies.  Card Fail Rev  2019; 5 :86 \u0002 92. 356. Cleland JG, Clark RA, Pellicori P, Inglis SC. Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pan- demic: the advantages of universal access to home telemonitoring.  Eur J Heart Fail  2020; 22 :995 \u0002 998. 357. Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured tele- phone support or non-invasive telemonitoring for patients with heart failure. Heart  2017; 103 :255 \u0002 257.\n",
      "keywords": [
        "coats",
        "elderly",
        "heart failure",
        "myers",
        "connor",
        "smart",
        "taylor",
        "dalal",
        "bnp",
        "whellan",
        "keteyian",
        "jolly",
        "davos",
        "nilsson",
        "passino",
        "nt-probnp",
        "piepoli",
        "warren",
        "walker",
        "ejection fraction",
        "ciani",
        "evangelista",
        "dracup"
      ],
      "tables": []
    },
    {
      "number": "117",
      "title": "358. Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Bohm A, Cowie M, Crawford J, de Groot N, Dilaveris P, Hansen T, Koehler F, Krstacic G, Lambrinou E, Lancellotti P, Meier P, Neubeck L, Parati G, ",
      "start_page": 107,
      "end_page": 114,
      "content": "3706 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ......................................................................................................................................................................... 374. Dierckx R, Inglis SC, Clark RA, Prieto-Merino D, Cleland JG. Telemedicine in heart failure: new insights from the Cochrane meta-analyses.  Eur J Heart Fail 2017; 19 :304 \u0002 306. 375. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR, Whellan DJ, Albert NM, Krishnamani R, Rich MW, Walsh MN, Bonnell MR, Carson PE, Chan MC, Dries DL, Hernandez AF, Hershberger RE, Katz SD, Moore S, Rodgers JE, Rogers JG, Vest AR, Givertz MM, Heart Failure Society of America Guidelines Committee. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail 2015; 21 :519 \u0002 534. 376. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge-Caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, Hulsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska-Migaj E, McDonagh T, Seferovic P, Ruschitzka F. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20 :1505 \u0002 1535. 377. Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and ther- apeutic approaches.  JACC Heart Fail  2020; 8 :523 \u0002 536. 378. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL, Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure.  N Engl J Med 2001; 345 :1435 \u0002 1443. 379. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC, Jr., Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community.  Circulation  2007; 115 :1563 \u0002 1570. 380. Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, Aragam J, Benjamin EJ, Cheng S, Wang TJ, Mitchell GF, Vasan RS. Prevalence, neurohor- monal correlates, and prognosis of heart failure stages in the community.  JACC Heart Fail  2016; 4 :808 \u0002 815. 381. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced heart failure: the current picture.  J Heart Lung Transplant  2009; 28 :535 \u0002 541. 382. Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, Gonzalez-Vilchez F, Villa-Arranz A, Delgado-Jimenez J, Lage-Galle E, Perez-Villa F, Lambert- Rodriguez JL, Manito-Lorite N, Arizon-Del Prado JM, Brossa-Loidi V, Pascual- Figal D, Fuente-Galan Lde L, Sanz-Julve M, Muniz-Garcia J, Crespo-Leiro M. Preoperative INTERMACS profiles determine postoperative outcomes in crit- ically ill patients undergoing emergency heart transplantation: analysis of the Spanish National Heart Transplant Registry.  Circ Heart Fail  2013; 6 :763 \u0002 772. 383. Goldstein DJ, Meyns B, Xie R, Cowger J, Pettit S, Nakatani T, Netuka I, Shaw S, Yanase M, Kirklin JK. Third annual report from the ISHLT Mechanically Assisted Circulatory Support Registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 2019; 38 :352 \u0002 363. 384. Kittleson MM, Shah P, Lala A, McLean RC, Pamboukian S, Horstmanshof DA, Thibodeau J, Shah K, Teuteberg J, Gilotra NA, Taddei-Peters WC, Cascino TM, Richards B, Khalatbari S, Jeffries N, Stevenson LW, Mann D, Aaronson KD, Stewart GC, REVIVAL Investigators. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: a report from the REVIVAL Registry.  J Heart Lung Transplant  2020; 39 :16 \u0002 26. 385. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A, International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update.  J Heart Lung Transplant  2016; 35 :1 \u0002 23. 386. Baumwol J. \"I need help\"–a mnemonic to aid timely referral in advanced heart failure.  J Heart Lung Transplant  2017; 36 :593 \u0002 594. 387. Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristic A, Ruschitzka F, Seferovic PM, Skouri H, Zimmermann WH, Mebazaa A. Treatments targeting inotropy.  Eur Heart J 2019; 40 :3626 \u0002 3644. 388. Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, Bohm M, Allen LA, Teerlink JR, Rosano GMC, Lindenfeld J. Why has positive inotropy\nfailed in chronic heart failure? Lessons from prior inotrope trials.  Eur J Heart Fail 2019; 21 :1064 \u0002 1078. 389. Comin-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garcia Pinilla JM, Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, Gonzalez- Vilchez F, Lambert-Rodriguez JL, Grau M, Bruguera J, LION-HEART Study Investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail 2018; 20 :1128 \u0002 1136. 390. Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock DD, Dunlay SM. Ambulatory inotrope infusions in advanced heart failure: a sys- tematic review and meta-analysis.  JACC Heart Fail  2018; 6 :757 \u0002 767. 391. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E, Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syn- drome.  N Engl J Med  2012; 367 :2296 \u0002 2304. 392. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA, UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.  J Am Coll Cardiol 2007; 49 :675 \u0002 683. 393. Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.  Eur J Heart Fail  2017; 19 :595 \u0002 602. 394. Barge-Caballero E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez JL, Gonzalez-Costello J, Segovia-Cubero J, Castel-Lavilla MA, Delgado-Jimenez J, Garrido-Bravo IP, Rangel-Sousa D, Martinez-Selles M, De la Fuente-Galan L, Rabago-AracilJuan- G, Sanz-Julve M, Hervas-Sotomayor D, Mirabet-Perez S, Muniz J, Crespo-Leiro MG. Clinical outcomes of temporary mechanical circula- tory support as a direct bridge to heart transplantation: a nationwide Spanish registry.  Eur J Heart Fail  2018; 20 :178 \u0002 186. 395. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan MM, Kukucka M, de Jonge N, Loforte A, Lund LH, Mohacsi P, Morshuis M, Netuka I, Ozbaran M, Pappalardo F, Scandroglio AM, Schweiger M, Tsui S, Zimpfer D, Gustafsson F. 2019 EACTS Expert Consensus on long-term mechanical circulatory support.  Eur J Cardiothorac Surg  2019; 56 :230 \u0002 270. 396. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Pierson RN, 3rd, INTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial.  J Am Coll Cardiol  2007; 50 :741 \u0002 747. 397. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH, HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361 :2241 \u0002 2251. 398. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell SD, Conte JV, Aaronson KD, McGee EC, Jr., Cotts WG, DeNofrio D, Pham DT, Farrar DJ, Pagani FD. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).  J Am Coll Cardiol  2011; 57 :1890 \u0002 1898. 399. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CA. Intrapericardial left ventricular assist device for advanced heart failure.  N Engl J Med  2017; 376 :451 \u0002 460. 400. Truby LK, Farr MA, Garan AR, Givens R, Restaino SW, Latif F, Takayama H, Naka Y, Takeda K, Topkara VK. Impact of bridge to transplantation with continuous-flow left ventricular assist devices on posttransplantation mortality. Circulation  2019; 140 :459 \u0002 469. 401. Goldstein DJ, Naka Y, Horstmanshof D, Ravichandran AK, Schroder J, Ransom J, Itoh A, Uriel N, Cleveland JC, Jr., Raval NY, Cogswell R, Suarez EE, Lowes BD, Kim G, Bonde P, Sheikh FH, Sood P, Farrar DJ, Mehra MR. Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.  JAMA Cardiol 2020; 5 :411 \u0002 419. 402. Mehra MR, Uriel N, Naka Y, Cleveland JC, Jr., Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J, Ewald GA, Itoh A, Raval NY, Silvestry SC, Cogswell R, John R, Bhimaraj A, Bruckner BA, Lowes BD, Um JY, Jeevanandam V, Sayer G, Mangi AA, Molina EJ, Sheikh F, Aaronson K, Pagani FD, Cotts WG, Tatooles AJ, Babu A, Chomsky D, Katz JN, Tessmann PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldstein DJ,\nESC Guidelines 3707\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ MOMENTUM 3 Investigators. A fully magnetically levitated left ventricular assist device – final report.  N Engl J Med  2019; 380 :1618 \u0002 1627. 403. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 15,000 patients and counting.  J Heart Lung Transplant  2015; 34 :1495 \u0002 1504. 404. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, Kokkinidis DG. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis.  Ann Cardiothorac Surg  2018; 7 :3 \u0002 11. 405. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC, Jr., Yuzefpolskaya M, Salerno C, Walsh MN, Milano CA, Patel CB, Ewald GA, Itoh A, Dean D, Krishnamoorthy A, Cotts WG, Tatooles AJ, Jorde UP, Bruckner BA, Estep JD, Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S, Skipper ER, O’Connell JB, Heatley G, Sood P, Naka Y, MOMENTUM 3 Investigators. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med  2018; 378 :1386 \u0002 1395. 406. Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold-Herz M, Morshuis M, Shaw SM, Saeed D, Lavee J, Heatley G, Gazzola C, Garbade J. Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry.  Eur Heart J 2020; 41 :3801 \u0002 3809. 407. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O’Connell JB, Boyle AJ, Farrar DJ, Rogers JG, ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical man- agement in ambulatory heart failure patients: results from the ROADMAP study.  J Am Coll Cardiol  2015; 66 :1747 \u0002 1761. 408. Starling RC, Estep JD, Horstmanshof DA, Milano CA, Stehlik J, Shah KB, Bruckner BA, Lee S, Long JW, Selzman CH, Kasirajan V, Haas DC, Boyle AJ, Chuang J, Farrar DJ, Rogers JG, ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical man- agement in ambulatory heart failure patients: the ROADMAP study 2-year results.  JACC Heart Fail  2017; 5 :518 \u0002 527. 409. Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard Frazier O, Icenogle T, Najjar SS, Boyce SW, Acker MA, John R, Hathaway DR, Najarian KB, Aaronson KD, HeartWare Bridge to Transplant ADVANCE Trial Investigators. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial.  J Heart Lung Transplant  2013; 32 :675 \u0002 683. 410. Karason K, Lund LH, Dalen M, Bjorklund E, Grinnemo K, Braun O, Nilsson J, van der Wal H, Holm J, Hubbert L, Lindmark K, Szabo B, Holmberg E, Dellgren G, SweVAD Investigators. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial.  Eur J Heart Fail 2020; 22 :739 \u0002 750. 411. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Jr., Hsich E, Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, Zuckermann A, Stehlik J, International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report–2019; focus theme: donor and recipient size match.  J Heart Lung Transplant  2019; 38 :1056 \u0002 1066. 412. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, Yusen RD, Stehlik J, International Society for H, Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth official adult heart transplant report– 2013; focus theme: age.  J Heart Lung Transplant  2013; 32 :951 \u0002 964. 413. Guglin M, Zucker MJ, Borlaug BA, Breen E, Cleveland J, Johnson MR, Panjrath GS, Patel JK, Starling RC, Bozkurt B, ACC Heart Failure and Transplant Member Section and Leadership Council. Evaluation for heart transplantation and LVAD implantation: JACC Council perspectives.  J Am Coll Cardiol 2020; 75 :1471 \u0002 1487. 414. Bernhardt AM, Schloglhofer T, Lauenroth V, Mueller F, Mueller M, Schoede A, Klopsch C, Driveline Expert STagINg and carE DESTINE study group, a Ventricular Assist Device Driveline Infection Study Group. Prevention and early treatment of driveline infections in ventricular assist device patients – the DESTINE staging proposal and the first standard of care protocol.  J Crit Care 2020; 56 :106 \u0002 112. 415. DeFilippis EM, Breathett K, Donald EM, Nakagawa S, Takeda K, Takayama H, Truby LK, Sayer G, Colombo PC, Yuzefpolskaya M, Uriel N, Farr MA, Topkara VK. Psychosocial risk and its association with outcomes in continuous-flow left ventricular assist device patients.  Circ Heart Fail  2020; 13 :e006910. 416. Jaarsma T, Hill L, Bayes-Genis A, La Rocca HB, Castiello T, Celutkiene J, Marques- Sule E, Plymen CM, Piper SE, Riegel B, Rutten FH, Ben Gal T, Bauersachs J, Coats AJS, Chioncel O, Lopatin Y, Lund LH, Lainscak M, Moura B, Mullens W, Piepoli MF,\nRosano G, Seferovic P, Stromberg A. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2021; 23 :157 \u0002 174. 417. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ, HeartMate II Clinical Investigators. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support).  J Am Coll Cardiol 2014; 63 :1751 \u0002 1757. 418. Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clini- cal and patient-centred outcomes in patients with advanced heart failure: a sys- tematic review of randomized controlled trials. Eur J Heart Fail 2020; 22 :2340 \u0002 2346. 419. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart failure.  Heart Fail Clin  2015; 11 :479 \u0002 498. 420. Brannstrom M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail  2014; 16 :1142 \u0002 1151. 421. O’Donnell AE, Schaefer KG, Stevenson LW, DeVoe K, Walsh K, Mehra MR, Desai AS. Social worker-aided palliative care intervention in high-risk patients with Heart Failure (SWAP-HF): a pilot randomized clinical trial.  JAMA Cardiol 2018; 3 :516 \u0002 519. 422. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure–a pilot study. Eur J Heart Fail  2002; 4 :753 \u0002 756. 423. Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough.  J Palliat Med  2013; 16 :250 \u0002 255. 424. Blinderman CD, Billings JA. Comfort care for patients dying in the hospital.  N Engl J Med  2015; 373 :2549 \u0002 2561. 425. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L, EuroHeart Survey Investigators, Heart Failure Association of the European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospi- talized acute heart failure patients: description of population.  Eur Heart J 2006; 27 :2725 \u0002 2736. 426. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.  Eur J Heart Fail 2017; 19 :1242 \u0002 1254. 427. Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH, ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term out- comes: insights from the ESC-EORP-HFA heart failure long-term registry.  Eur J Heart Fail  2019; 21 :1338 \u0002 1352. 428. Miro O, Garcia Sarasola A, Fuenzalida C, Calderon S, Jacob J, Aguirre A, Wu DM, Rizzi MA, Malchair P, Haro A, Herrera S, Gil V, Martin-Sanchez FJ, Llorens P, Herrero Puente P, Bueno H, Dominguez Rodriguez A, Muller CE, Mebazaa A, Chioncel O, Alquezar-Arbe A, ICA-SEMES Research Group. Departments involved during the first episode of acute heart failure and subsequent emer- gency department revisits and rehospitalisations: an outlook through the NOVICA cohort.  Eur J Heart Fail  2019; 21 :1231 \u0002 1244. 429. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.  Circulation  2007; 116 :1482 \u0002 1487. 430. Tomasoni D, Lombardi CM, Sbolli M, Cotter G, Metra M. Acute heart failure: more questions than answers.  Prog Cardiovasc Dis  2020; 63 :599 \u0002 606. 431. Butt JH, Fosbol EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC, Gustafsson F, Madelaire C, Kristensen SL, Gislason GH, Torp-Pedersen C, Kober L, Schou M. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. Eur J Heart Fail  2020; 22 :1777 \u0002 1785. 432. Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, Takagi K, Alquezar-Arbe A, Lopez Diez MP, Martin E, Bibiano C, Escoda R, Gil C, Fuentes M, Llopis Garcia G, Alvarez Perez JM, Jerez A, Tost J, Llauger L, Romero R, Garrido JM, Rodriguez-Adrada E, Sanchez C, Rossello X, Parissis J, Mebazaa A, Chioncel O, Llorens P, ICA-SEMES Research Group. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship\n3708 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ with patient management and outcomes. Eur J Heart Fail 2019; 21 :1353 \u0002 1365. 433. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J  2006; 27 :330 \u0002 337. 434. Januzzi JL Jr, Chen-Tournoux AA, Christenson RH, Doros G, Hollander JE, Levy PD, Nagurney JT, Nowak RM, Pang PS, Patel D, Peacock WF, Rivers EJ, Walters EL, Gaggin HK, ICON-RELOADED Investigators. N-terminal pro-B-type natriu- retic peptide in the emergency department: the ICON-RELOADED study.  J Am Coll Cardiol  2018; 71 :1191 \u0002 1200. 435. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.  J Am Coll Cardiol  2010; 55 :2062 \u0002 2076. 436. Harjola VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, Bueno H, Celutkiene J, Chioncel O, Coats AJS, Collins SP, de Boer RA, Filippatos G, Gayat E, Hill L, Laine M, Lassus J, Lommi J, Masip J, Mebazaa A, Metra M, Miro O, Mortara A, Mueller C, Mullens W, Peacock WF, Pentikainen M, Piepoli MF, Polyzogopoulou E, Rudiger A, Ruschitzka F, Seferovic P, Sionis A, Teerlink JR, Thum T, Varpula M, Weinstein JM, Yilmaz MB. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2020; 22 :1298 \u0002 1314. 437. Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schafer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).  Eur J Heart Fail  2017; 19 :821 \u0002 836. 438. Harjola VP, Parissis J, Brunner-La Rocca HP, Celutkiene J, Chioncel O, Collins SP, De Backer D, Filippatos GS, Gayat E, Hill L, Lainscak M, Lassus J, Masip J, Mebazaa A, Miro O, Mortara A, Mueller C, Mullens W, Nieminen MS, Rudiger A, Ruschitzka F, Seferovic PM, Sionis A, Vieillard-Baron A, Weinstein JM, de Boer RA, Crespo-Leiro MG, Piepoli M, Riley JP. Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).  Eur J Heart Fail  2018; 20 :1081 \u0002 1099. 439. Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O’Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM, Hillege HL, van Veldhuisen DJ, Voors AA, Testani JM. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure.  Circ Heart Fail  2016; 9 . 440. Nunez J, Llacer P, Garcia-Blas S, Bonanad C, Ventura S, Nunez JM, Sanchez R, Facila L, de la Espriella R, Vaquer JM, Cordero A, Roque M, Chamorro C, Bodi V, Valero E, Santas E, Moreno MDC, Minana G, Carratala A, Rodriguez E, Mollar A, Palau P, Bosch MJ, Bertomeu-Gonzalez V, Lupon J, Navarro J, Chorro FJ, Gorriz JL, Sanchis J, Voors AA, Bayes-Genis A. CA125-guided diuretic treat- ment versus usual care in patients with acute heart failure and renal dysfunc- tion.  Am J Med  2020; 133 :370 \u0002 380 e374. 441. Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam- Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure.  Eur Heart J  2013; 34 :742 \u0002 749. 442. Mockel M, de Boer RA, Slagman AC, von Haehling S, Schou M, Vollert JO, Wiemer JC, Ebmeyer S, Mart \u0003 ın-S \u0003 anchez FJ, Maisel AS, Giannitsis E. Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18. Eur J Heart Fail  2020; 22 :267 \u0002 275. 443. Masip J, De Mendoza D, Planas K, Paez J, Sanchez B, Cancio B. Peripheral venous blood gases and pulse-oximetry in acute cardiogenic pulmonary oedema.  Eur Heart J Acute Cardiovasc Care  2012; 1 :275 \u0002 280. 444. Masip J, Gaya M, Paez J, Betbese A, Vecilla F, Manresa R, Ruiz P. Pulse oximetry in the diagnosis of acute heart failure. Rev Esp Cardiol (Engl Ed) 2012; 65 :879 \u0002 884. 445. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A,\nJanssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K, ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.  Eur Heart J  2005; 26 :384 \u0002 416. 446. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.  J Am Coll Cardiol  2003; 41 :1797 \u0002 1804. 447. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology, European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine.  Eur J Heart Fail  2010; 12 :423 \u0002 433. 448. Masip J, Peacock WF, Price S, Cullen L, Martin-Sanchez FJ, Seferovic P, Maisel AS, Miro O, Filippatos G, Vrints C, Christ M, Cowie M, Platz E, McMurray J, DiSomma S, Zeymer U, Bueno H, Gale CP, Lettino M, Tavares M, Ruschitzka F, Mebazaa A, Harjola VP, Mueller C, Acute Heart Failure Study Group of the Acute Cardiovascular Care Association and the Committee on Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology. Indications and practical approach to non-invasive ventilation in acute heart fail- ure.  Eur Heart J  2018; 39 :17 \u0002 25. 449. Harjola VP, Mebazaa A, Celutkiene J, Bettex D, Bueno H, Chioncel O, Crespo- Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J, Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A, Yilmaz MB, Konstantinides S. Contemporary management of acute right ventric- ular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology.  Eur J Heart Fail  2016; 18 :226 \u0002 241. 450. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, Harjola VP, Antohi EL, Arrigo M, Gal TB, Celutkiene J, Collins SP, DeBacker D, Iliescu VA, Jankowska E, Jaarsma T, Keramida K, Lainscak M, Lund LH, Lyon AR, Masip J, Metra M, Miro O, Mortara A, Mueller C, Mullens W, Nikolaou M, Piepoli M, Price S, Rosano G, Vieillard-Baron A, Weinstein JM, Anker SD, Filippatos G, Ruschitzka F, Coats AJS, Seferovic P. Epidemiology, pathophysiology and con- temporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2020; 22 :1315 \u0002 1341. 451. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019.  Eur Heart J  2019; 40 :2671 \u0002 2683. 452. Mebazaa A, Combes A, van Diepen S, Hollinger A, Katz JN, Landoni G, Hajjar LA, Lassus J, Lebreton G, Montalescot G, Park JJ, Price S, Sionis A, Yannopolos D, Harjola VP, Levy B, Thiele H. Management of cardiogenic shock complicating myocardial infarction.  Intensive Care Med  2018; 44 :760 \u0002 773. 453. Zymlinski R, Biegus J, Sokolski M, Siwolowski P, Nawrocka-Millward S, Todd J, Jankowska EA, Banasiak W, Cotter G, Cleland JG, Ponikowski P. Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion.  Eur J Heart Fail  2018; 20 :1011 \u0002 1018. 454. Menon V, Slater JN, White HD, Sleeper LA, Cocke T, Hochman JS. Acute myo- cardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry.  Am J Med  2000; 108 :374 \u0002 380. 455. Harjola P, Miro O, Martin-Sanchez FJ, Escalada X, Freund Y, Penaloza A, Christ M, Cone DC, Laribi S, Kuisma M, Tarvasmaki T, Harjola VP, EMS-AHF Study Group. Pre-hospital management protocols and perceived difficulty in diagnos- ing acute heart failure.  ESC Heart Fail  2020; 7 :289 \u0002 296. 456. Takahashi M, Kohsaka S, Miyata H, Yoshikawa T, Takagi A, Harada K, Miyamoto T, Sakai T, Nagao K, Sato N, Takayama M, Tokyo CCU Network Council. Association between prehospital time interval and short-term outcome in acute heart failure patients.  J Card Fail  2011; 17 :742 \u0002 747. 457. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJ. Potentially detrimental car- diovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction.  Heart  2010; 96 :533 \u0002 538. 458. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, 3CPO Trialists Noninvasive ventilation in acute cardiogenic pulmonary edema.  N Engl J Med  2008; 359 :142 \u0002 151. 459. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, Chen YW, He QY. Meta- analysis: noninvasive ventilation in acute cardiogenic pulmonary edema.  Ann Intern Med  2010; 152 :590 \u0002 600. 460. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ,\nESC Guidelines 3709\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Bart BA, Mascette AM, Braunwald E, O’Connor CM, Network NHFCR. Diuretic strategies in patients with acute decompensated heart failure.  N Engl J Med  2011; 364 :797 \u0002 805. 461. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review.  J Am Coll Cardiol 2020; 75 :1178 \u0002 1195. 462. Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, Tang WH, Testani JM. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial. J Card Fail 2016; 22 :753 \u0002 760. 463. Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.  Eur J Heart Fail 2016; 18 :328 \u0002 336. 464. Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, Ng LL, Anker SD, Samani NJ, Filippatos G, Cleland JG, Zannad F, Hillege HL, van Veldhuisen DJ, Metra M, Voors AA, Mullens W. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol 2020; 109 :1048 \u0002 1059. 465. Cubbon RM, Woolston A, Adams B, Gale CP, Gilthorpe MS, Baxter PD, Kearney LC, Mercer B, Rajwani A, Batin PD, Kahn M, Sapsford RJ, Witte KK, Kearney MT. Prospective development and validation of a model to predict heart failure hospitalisation.  Heart  2014; 100 :923 \u0002 929. 466. Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, Diaz-Molina B, Filippatos G, Lainscak M, Maggioni AP, McDonagh T, Mebazaa A, Metra M, Moura B, Mullens W, Piepoli MF, Rosano GMC, Ruschitzka F, Seferovic PM, Lund LH, Heart Failure Long-Term Registry Investigators Group. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP heart failure long-term registry.  Eur J Heart Fail  2020; 22 :1424 \u0002 1437. 467. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015; 17 :544 \u0002 558. 468. Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen HK, Hofman M, Nieuwland W, van Veldhuisen DJ, Voors AA, van der Meer P. Clinical importance of urinary sodium excretion in acute heart failure.  Eur J Heart Fail  2020; 22 :1438 \u0002 1447. 469. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail  2018; 20 :1591 \u0002 1600. 470. Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial.  JACC Heart Fail  2020; 8 :157 \u0002 168. 471. Damman K, Testani JM. The kidney in heart failure: an update.  Eur Heart J 2015; 36 :1437 \u0002 1444. 472. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC, Jr., Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.  Eur Heart J  2013; 34 :835 \u0002 843. 473. Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, Deedwania P, Filippatos G, Sheriff HM, Zeng Q, Morgan CJ, Wopperer S, Nguyen T, Allman RM, Fonarow GC, Ahmed A. Loop diuretic prescription and 30-day outcomes in older patients with heart failure.  J Am Coll Cardiol  2020; 76 :669 \u0002 679. 474. Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, Blatt A, Simovitz A, Shaham O, Faigenberg Z, Metzger M, Stav D, Yogev R, Golik A, Krakover R, Vered Z, Cotter G. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema.  J Am Coll Cardiol  2000; 36 :832 \u0002 837. 475. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treat- ment of decompensated congestive heart failure: a randomized controlled trial. JAMA  2002; 287 :1531 \u0002 1540. 476. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide\nversus high-dose furosemide plus low-dose isosorbide dinitrate in severe pul- monary oedema.  Lancet  1998; 351 :389 \u0002 393. 477. Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, Dunne R, Zalenski R. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis.  Ann Emerg Med 2007; 50 :144 \u0002 152. 478. Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro MG, Lund LH, Maggioni AP, Chioncel O, Akiyama E, Harjola VP, Seferovic P, Laroche C, Julve MS, Roig E, Ruschitzka F, Filippatos G, ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology heart failure long-term regis- try.  Eur J Heart Fail  2018; 20 :332 \u0002 341. 479. Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Muller B, Noveanu M, Socrates T, Ziller R, Bayes-Genis A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Munzel T, Erne P, Mueller C, Investigators G, Mueller C, Erne P, Muller B, Rickli H, Maeder M, Tavares de Oliveira M Jr, Munzel T, Bayes-Genis A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vogele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vogele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M. Effect of a strat- egy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial.  JAMA  2019; 322 :2292 \u0002 2302. 480. Freund Y, Cachanado M, Delannoy Q, Laribi S, Yordanov Y, Gorlicki J, Chouihed T, Feral-Pierssens AL, Truchot J, Desmettre T, Occelli C, Bobbia X, Khellaf M, Ganansia O, Bokobza J, Balen F, Beaune S, Bloom B, Simon T, Mebazaa A. Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: the ELISABETH randomized clinical trial.  JAMA  2020; 324 :1948 \u0002 1956. 481. Khot UN, Novaro GM, Popovic ZB, Mills RM, Thomas JD, Tuzcu EM, Hammer D, Nissen SE, Francis GS. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348 :1756 \u0002 1763. 482. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.  Eur J Heart Fail 2009; 11 :304 \u0002 311. 483. Metra M, Nodari S, D’Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedi- lol.  J Am Coll Cardiol  2002; 40 :1248 \u0002 1258. 484. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T, REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.  JACC Heart Fail  2013; 1 :103 \u0002 111. 485. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock.  N Engl J Med 2010; 362 :779 \u0002 789. 486. Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, Quenot JP, Kimmoun A, Cariou A, Lassus J, Harjola VP, Meziani F, Louis G, Rossignol P, Duarte K, Girerd N, Mebazaa A, Vignon P, Collaborators. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction.  J Am Coll Cardiol  2018; 72 :173 \u0002 182. 487. Leopold V, Gayat E, Pirracchio R, Spinar J, Parenica J, Tarvasmaki T, Lassus J, Harjola VP, Champion S, Zannad F, Valente S, Urban P, Chua HR, Bellomo R, Popovic B, Ouweneel DM, Henriques JPS, Simonis G, Levy B, Kimmoun A, Gaudard P, Basir MB, Markota A, Adler C, Reuter H, Mebazaa A, Chouihed T. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients.  Intensive Care Med  2018; 44 :847 \u0002 856. 488. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis.  Emerg Med J  2008; 25 :205 \u0002 209. 489. Gil V, Dominguez-Rodriguez A, Masip J, Peacock WF, Miro O. Morphine use in the treatment of acute cardiogenic pulmonary edema and its effects on patient outcome: a systematic review.  Curr Heart Fail Rep  2019; 16 :81 \u0002 88.\n3710 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 490. Miro O, Gil V, Martin-Sanchez FJ, Herrero-Puente P, Jacob J, Mebazaa A, Harjola VP, Rios J, Hollander JE, Peacock WF, Llorens P, ICA-SEMES Research Group. Morphine use in the ED and outcomes of patients with acute heart fail- ure: a propensity score-matching analysis based on the EAHFE registry.  Chest 2017; 152 :821 \u0002 832. 491. Caspi O, Naami R, Halfin E, Aronson D. Adverse dose-dependent effects of morphine therapy in acute heart failure.  Int J Cardiol  2019; 293 :131 \u0002 136. 492. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One 2018; 13 :e0193924. 493. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?  J Am Coll Cardiol  2003; 42 :1944 \u0002 1951. 494. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, Bramlage P, Riess H. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.  Am Heart J 2011; 161 :322 \u0002 328. 495. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoa- gulant prophylaxis to prevent symptomatic venous thromboembolism in hospi- talized medical patients.  Ann Intern Med  2007; 146 :278 \u0002 288. 496. Seferovic PM, Piepoli MF, Lopatin Y, Jankowska E, Polovina M, Anguita-Sanchez M, Stork S, Lainscak M, Milicic D, Milinkovic I, Filippatos G, Coats AJS, Heart Failure Association Board of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology quality of care centres pro- gramme: design and accreditation document.  Eur J Heart Fail  2020; 22 :763 \u0002 774. 497. Tehrani BN, Truesdell AG, Sherwood MW, Desai S, Tran HA, Epps KC, Singh R, Psotka M, Shah P, Cooper LB, Rosner C, Raja A, Barnett SD, Saulino P, deFilippi CR, Gurbel PA, Murphy CE, O’Connor CM. Standardized team-based care for cardiogenic shock.  J Am Coll Cardiol  2019; 73 :1659 \u0002 1669. 498. Basir MB, Kapur NK, Patel K, Salam MA, Schreiber T, Kaki A, Hanson I, Almany S, Timmis S, Dixon S, Kolski B, Todd J, Senter S, Marso S, Lasorda D, Wilkins C, Lalonde T, Attallah A, Larkin T, Dupont A, Marshall J, Patel N, Overly T, Green M, Tehrani B, Truesdell AG, Sharma R, Akhtar Y, McRae T, 3rd, O’Neill B, Finley J, Rahman A, Foster M, Askari R, Goldsweig A, Martin S, Bharadwaj A, Khuddus M, Caputo C, Korpas D, Cawich I, McAllister D, Blank N, Alraies MC, Fisher R, Khandelwal A, Alaswad K, Lemor A, Johnson T, Hacala M, O’Neill WW, National Cardiogenic Shock Initiative Investigators. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative.  Catheter Cardiovasc Interv  2019; 93 :1173 \u0002 1183. 499. Tehrani BN, Truesdell AG, Psotka MA, Rosner C, Singh R, Sinha SS, Damluji AA, Batchelor WB. A standardized and comprehensive approach to the man- agement of cardiogenic shock.  JACC Heart Fail  2020; 8 :879 \u0002 891. 500. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K, IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367 :1287 \u0002 1296. 501. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G, Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investi- gators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial.  Lancet  2013; 382 :1638 \u0002 1645. 502. Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, Bohm M, Werdan K, Felix SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S, IABP- SHOCK II Trial Investigators. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II Trial.  Circulation  2019; 139 :395 \u0002 403. 503. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J, Kastrati A, Schomig A. A randomized clinical trial to evaluate the safety and effi- cacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.  J Am Coll Cardiol  2008; 52 :1584 \u0002 1588. 504. Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, Vis MM, Wykrzykowska JJ, Koch KT, Baan J, de Winter RJ, Piek JJ, Lagrand WK, de Mol BA, Tijssen JG, Henriques JP. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction.  J Am Coll Cardiol  2017; 69 :278 \u0002 287. 505. Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, Pieri M, Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M, Eckner D, Twerenbold R, Nordbeck P, Salinger T, Abel P, Empen K, Busch MC,\nFelix SB, Sieweke JT, Moller JE, Pareek N, Hill J, MacCarthy P, Bergmann MW, Henriques JPS, Mobius-Winkler S, Schulze PC, Ouarrak T, Zeymer U, Schneider S, Blankenberg S, Thiele H, Schafer A, Westermann D. Impella sup- port for acute myocardial infarction complicated by cardiogenic shock. Circulation  2019; 139 :1249 \u0002 1258. 506. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufor C, Girotra S, Amin AP, Shah ND, Desai NR. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mor- tality and major bleeding among patients with acute myocardial infarction com- plicated by cardiogenic shock.  JAMA  2020; 323 :734 \u0002 745. 507. Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventric- ular assist device in severe refractory cardiogenic shock.  J Am Coll Cardiol 2011; 57 :688 \u0002 696. 508. Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand WK, Cherpanath TGV, Driessen AHG, de Mol B, Henriques JPS. Extracorporeal life support during cardiac arrest and cardiogenic shock: a sys- tematic review and meta-analysis.  Intensive Care Med  2016; 42 :1922 \u0002 1934. 509. Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock.  Lancet  2020; 396 :199 \u0002 212. 510. Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, Mullerleile K, Colombo A, Sydow K, De Bonis M, Wagner F, Reichenspurner H, Blankenberg S, Zangrillo A, Westermann D. Concomitant implantation of Impella((R)) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock.  Eur J Heart Fail  2017; 19 :404 \u0002 412. 511. Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bhama J, Kapur NK, Bansal A, Garcia J, Baker JN, Silvestry S, Holman WL, Douglas PS, O’Neill W. Benefits of a novel percutaneous ventricular assist device for right heart fail- ure: the prospective RECOVER RIGHT study of the Impella RP device.  J Heart Lung Transplant  2015; 34 :1549 \u0002 1560. 512. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM- AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet  2020; 396 :1895 \u0002 1904. 513. Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, con- tinuation, switching, and withdrawal of heart failure medical therapies during hospitalization.  JACC Heart Fail  2019; 7 :1 \u0002 12. 514. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker with- drawal in acute decompensated heart failure: a systematic review and meta- analysis.  JACC Heart Fail  2015; 3 :647 \u0002 653. 515. Metra M, Gheorghiade M, Bonow RO, Dei Cas L. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation 2010; 122 :1782 \u0002 1785. 516. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure.  Nat Rev Cardiol 2015; 12 :220 \u0002 229. 517. Lee KK, Yang J, Hernandez AF, Steimle AE, Go AS. Post-discharge Follow-up characteristics associated with 30-day readmission after heart failure hospitaliza- tion.  Med Care  2016; 54 :365 \u0002 372. 518. Edmonston DL, Wu J, Matsouaka RA, Yancy C, Heidenreich P, Pina IL, Hernandez A, Fonarow GC, DeVore AD. Association of post-discharge spe- cialty outpatient visits with readmissions and mortality in high-risk heart failure patients.  Am Heart J  2019; 212 :101 \u0002 112. 519. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure.  Nat Rev Cardiol  2016; 13 :131 \u0002 147. 520. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury.  JACC Heart Fail  2019; 7 :447 \u0002 456. 521. Gorenek B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M, Marin F, Masip J, Mueller C, Okutucu S, Poess J, Potpara TS, Price S, Lip GYH. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology.  Eur Heart J Acute Cardiovasc Care 2020; 9 :348 \u0002 357. 522. Slawik J, Adrian L, Hohl M, Lothschutz S, Laufs U, Bohm M. Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. Eur J Heart Fail  2019; 21 :482 \u0002 491. 523. Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins.  J Am Coll Cardiol  2016; 68 :2217 \u0002 2228.\nESC Guidelines 3711\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 524. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, van Veldhuisen DJ, Van Gelder IC. The importance of whether atrial fibrillation or heart failure develops first.  Eur J Heart Fail  2012; 14 :1030 \u0002 1040. 525. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.  Eur Heart J  2005; 26 :1303 \u0002 1308. 526. Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Køber L, McMurray JJV, PARADIGM-HF and ATMOSPHERE Investigators and Committees. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejec- tion fraction.  J Am Coll Cardiol  2017; 70 :2490 \u0002 2500. 527. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrilla- tion in patients with severe heart failure.  Circulation  2006; 114 :18 \u0002 25. 528. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.  Lancet 2014; 383 :955 \u0002 962. 529. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D, PROTECT AF Investigators. Percutaneous left atrial appendage clo- sure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013; 127 :720 \u0002 729. 530. Holmes DR, Jr., Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.  J Am Coll Cardiol  2014; 64 :1 \u0002 12. 531. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ, RACE and AFFIRM Investigators. Does intensity of rate-control influ- ence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies.  Europace  2006; 8 :935 \u0002 942. 532. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, Bhatt DL, Allen LA, Peterson PN, Ho PM, Lewis WR, Hernandez AF, Fonarow GC, Piccini JP. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines – Heart Failure Program).  Am J Cardiol  2020; 125 :894 \u0002 900. 533. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with pre- served ejection fraction.  Eur J Heart Fail  2019; 21 :471 \u0002 479. 534. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrilla- tion.  Lancet  2016; 388 :818 \u0002 828. 535. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Bohm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson A, Kjekshus J, Cleland JGF, Beta-Blockers in Heart Failure Collaborative Group. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 2017; 69 :2885 \u0002 2896. 536. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P, Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial.  JAMA  2020; 324 :2497 \u0002 2508. 537. Hofmann R, Steinwender C, Kammler J, Kypta A, Leisch F. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ven- tricular rate.  Int J Cardiol  2006; 110 :27 \u0002 32. 538. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis.  Circulation 2000; 101 :1138 \u0002 1144. 539. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial.  Europace  2007; 9 :498 \u0002 505. 540. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, Proclemer A, Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L, Grammatico A, Leyva F, Boriani G. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator thera- pies and hospitalizations.  Eur J Heart Fail  2018; 20 :1472 \u0002 1481. 541. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy\n(CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation  1998; 98 :2574 \u0002 2579. 542. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias.  Eur Heart J 1992; 13 :1251 \u0002 1258. 543. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation.  N Engl J Med  2011; 365 :2268 \u0002 2276. 544. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardi- ovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure.  Am J Cardiol  2012; 110 :607 \u0002 613. 545. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, Cleland JG. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009; 95 :924 \u0002 930. 546. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.  Eur Heart J  2000; 21 :66 \u0002 73. 547. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A com- parison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.  N Engl J Med  2002; 347 :1834 \u0002 1840. 548. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A com- parison of rate control and rhythm control in patients with atrial fibrillation.  N Engl J Med  2002; 347 :1825 \u0002 1833. 549. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U, STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.  J Am Coll Cardiol  2003; 41 :1690 \u0002 1696. 550. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial Fibrillation and Congestive Heart Failure Investigators Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358 :2667 \u0002 2677. 551. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns H, Breithardt G, EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation.  N Engl J Med 2020; 383 :1305 \u0002 1316. 552. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bansch D, CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure.  N Engl J Med  2018; 378 :417 \u0002 427. 553. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL, CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mor- tality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial.  JAMA  2019; 321 :1261 \u0002 1274. 554. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB, CABANA Investigators. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial.  Circulation  2021; 143 :1377 \u0002 1390. 555. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, Tilz RR, Piorkowski C, Geller L, Kleemann T, Hindricks G. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial.  Circ Arrhythm Electrophysiol  2019; 12 :e007731. 556. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci\n3712 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial.  Circulation  2016; 133 :1637 \u0002 1644. 557. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL, CABANA Investigators. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA  2019; 321 :1275 \u0002 1285. 558. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antago- nist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.  Eur J Heart Fail  2015; 17 :1192 \u0002 1200. 559. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboem- bolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study.  Sci Rep  2016; 6 :27410. 560. Latchamsetty R, Bogun F. Premature ventricular complex-induced cardiomyop- athy.  JACC Clin Electrophysiol  2019; 5 :537 \u0002 550. 561. Mondesert B, Khairy P, Schram G, Shohoudi A, Talajic M, Andrade JG, Dubuc M, Guerra PG, Macle L, Roy D, Dyrda K, Thibault B, Barrero M, Diaz A, Kouz S, McNicoll S, Nowakowska D, Rivard L. Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial infarction, and pre- served left ventricular ejection fraction.  Heart Rhythm  2016; 13 :1221 \u0002 1227. 562. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, Tan V, Lerman BB, Mittal S. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract.  Circulation  2005; 112 :1092 \u0002 1097. 563. Berruezo A, Penela D, Jauregui B, Soto-Iglesias D, Aguinaga L, Ordonez A, Fernandez-Armenta J, Martinez M, Tercedor L, Bisbal F, Acosta J, Marti-Almor J, Acena M, Anguera I, Rossi L, Linhart M, Borras R, Doltra A, Sanchez P, Ortiz-Perez JT, Perea RJ, Prat-Gonzalez S, Teres C, Bosch X. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction.  Europace  2019; 21 :1079 \u0002 1087. 564. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, Aguinaga L, Leite LR, Al-Khatib SM, Anter E, Berruezo A, Callans DJ, Chung MK, Cuculich P, d’Avila A, Deal BJ, Della Bella P, Deneke T, Dickfeld TM, Hadid C, Haqqani HM, Kay GN, Latchamsetty R, Marchlinski F, Miller JM, Nogami A, Patel AR, Pathak RK, Saenz Morales LC, Santangeli P, Sapp JL, Sarkozy A, Soejima K, Stevenson WG, Tedrow UB, Tzou WS, Varma N, Zeppenfeld K, ESC Scientific Document Group. 2019 HRS/EHRA/APHRS/LAHRS expert consensus state- ment on catheter ablation of ventricular arrhythmias. Europace 2019; 21 :1143 \u0002 1144. 565. Cho SW, Gwag HB, Hwang JK, Chun KJ, Park KM, On YK, Kim JS, Park SJ. Clinical features, predictors, and long-term prognosis of pacing-induced cardio- myopathy.  Eur J Heart Fail  2019; 21 :643 \u0002 651. 566. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study.  Circ Arrhythm Electrophysiol  2019; 12 :e006934. 567. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren JW, Dandamudi G, Vijayaraman P. Clinical outcomes of His bundle pacing com- pared to right ventricular pacing.  J Am Coll Cardiol  2018; 71 :2319 \u0002 2330. 568. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment.  BMC Med  2020; 18 :103. 569. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.  Eur Heart J  2009; 30 :2337 \u0002 2345. 570. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.  N Engl J Med  1996; 335 :1107 \u0002 1114. 571. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.  Circulation  1997; 96 :856 \u0002 863. 572. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet  2002; 359 :1269 \u0002 1275.\n",
      "keywords": [
        "anker",
        "aortic stenosis",
        "elderly",
        "neubeck",
        "bohm",
        "heart failure",
        "systolic dysfunction",
        "lambrinou",
        "groot",
        "coronary artery",
        "cowie",
        "dilaveris",
        "caiani",
        "hansen",
        "crawford",
        "frederix",
        "parati",
        "krstacic",
        "nt-probnp",
        "creatinine",
        "aortic",
        "older",
        "guideline",
        "atrial fibrillation",
        "ejection fraction",
        "meier",
        "systolic",
        "ablation",
        "dendale",
        "diuretic"
      ],
      "tables": []
    },
    {
      "number": "118",
      "title": "573. Kanamasa K, Hayashi T, Kimura A, Ikeda A, Ishikawa K. Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients.  A",
      "start_page": 114,
      "end_page": 115,
      "content": "ESC Guidelines 3713\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Treatment strategies in ischaemic left ventricular dysfunction: a network meta- analysis.  Eur J Cardiothorac Surg  2021; 59 :293 \u0002 301. 591. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto WY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK, Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017; 38 :3351 \u0002 3358. 592. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Johann B, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Ju¨ni P, Pierard L, Prendergast PD, Rafael S \u0003 adaba J, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease.  Eur Heart J  2021; doi:10.1093/eurheartj/ehab395. 593. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.  N Engl J Med  2010; 363 :1597 \u0002 1607. 594. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients.  N Engl J Med  2011; 364 :2187 \u0002 2198. 595. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK, US CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis.  N Engl J Med  2014; 370 :1790 \u0002 1798. 596. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J, Jr., Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW, Chenoweth S, Oh JK, CoreValve United States Clinical Investigators. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery.  J Am Coll Cardiol 2014; 63 :1972 \u0002 1981. 597. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG, PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.  N Engl J Med  2016; 374 :1609 \u0002 1620. 598. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP, SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients.  N Engl J Med  2017; 376 :1321 \u0002 1331. 599. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL, 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients.  N Engl J Med  2019; 380 :1706 \u0002 1715. 600. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low- risk patients.  N Engl J Med  2019; 380 :1695 \u0002 1705. 601. Elder DH, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, Rekhraj S, Lim TK, George J, Doney A, Pringle SD, Choy AM, Struthers AD, Lang CC. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study.  J Am Coll Cardiol  2011; 58 :2084 \u0002 2091. 602. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, Enriquez- Sarano M. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function.  Circulation 2002; 106 :2687 \u0002 2693.\n",
      "keywords": [
        "hayashi",
        "long",
        "aortic stenosis",
        "term",
        "heart failure",
        "both",
        "oral",
        "continuous",
        "ishikawa",
        "transdermal",
        "nitrates",
        "healed",
        "treatment",
        "kanamasa",
        "ikeda",
        "patients",
        "aortic",
        "increases",
        "myocardial",
        "aortic regurgitation",
        "valve replacement",
        "events",
        "cardiac",
        "infarction",
        "kimura",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "119",
      "title": "603. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler- Soler J. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surge",
      "start_page": 115,
      "end_page": 116,
      "content": "3714 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .......................................................................................................................................................................... 617. Godino C, Munafo A, Scotti A, Estevez-Loureiro R, Portoles Hernandez A, Arzamendi D, Fernandez Peregrina E, Taramasso M, Fam NP, Ho EC, Asgar A, Vitrella G, Raineri C, Adamo M, Fiorina C, Montalto C, Fraccaro C, Giannini C, Fiorelli F, Popolo Rubbio A, Ooms JF, Compagnone M, Maffeo D, Bettari L, Furholz M, Tamburino C, Petronio AS, Grasso C, Agricola E, Van Mieghem NM, Tarantini G, Curello S, Praz F, Pascual I, Potena L, Colombo A, Maisano F, Metra M, Margonato A, Crimi G, Saia F. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. J Heart Lung Transplant 2020; 39 :1353 \u0002 1362. 618. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, Stark MA, von Bardeleben RS, Cremer PC, Jaber WA, Celermajer DS, Kaye DM, Sievert H. The REDUCE FMR trial: a randomized sham-controlled study of percutane- ous mitral annuloplasty in functional mitral regurgitation.  JACC Heart Fail 2019; 7 :945 \u0002 955. 619. Geyer M, Keller K, Sotiriou E, Tamm AR, Ruf TF, Kreidel F, Beiras-Fernandez A, Gori T, Schulz E, Munzel T, von Bardeleben RS. Association of transcatheter direct mitral annuloplasty with acute anatomic, haemodynamic, and clinical out- comes in severe mitral valve regurgitation.  ESC Heart Fail  2020; 7 :3336 \u0002 3344. 620. Giallauria F, Di Lorenzo A, Parlato A, Testa C, Bobbio E, Vigorito C, Coats AJS. Individual patient data meta-analysis of the effects of the CARILLON V R  mitral contour system.  ESC Heart Fail  2020; 7 :3383 \u0002 3391. 621. Lipiecki J, Fahrat H, Monzy S, Caillot N, Siminiak T, Johnson T, Vogt S, Stark MA, Goldberg SL. Long-term prognosis of patients treated by coronary sinus- based percutaneous annuloplasty: single centre experience.  ESC Heart Fail 2020; 7 :3329 \u0002 3335. 622. Ruf TF, Kreidel F, Tamm AR, Geyer M, Hahad O, Zirbs JC, Schwidtal BL, Beiras-Fernandez A, Witte KK, Munzel T, von Bardeleben RS. Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secon- dary mitral regurgitation.  ESC Heart Fail  2020; 7 :1400 \u0002 1408. 623. Sorajja P, Moat N, Badhwar V, Walters D, Paone G, Bethea B, Bae R, Dahle G, Mumtaz M, Grayburn P, Kapadia S, Babaliaros V, Guerrero M, Satler L, Thourani V, Bedogni F, Rizik D, Denti P, Dumonteil N, Modine T, Sinhal A, Chuang ML, Popma JJ, Blanke P, Leipsic J, Muller D. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients.  J Am Coll Cardiol 2019; 73 :1250 \u0002 1260. 624. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, Miller VM, Nishimura RA. National trends and outcomes in isolated tricuspid valve surgery.  J Am Coll Cardiol  2017; 70 :2953 \u0002 2960. 625. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickening G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodes-Cabau J, Schafer U, Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation.  J Am Coll Cardiol  2019; 74 :2998 \u0002 3008. 626. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people.  Lancet  2014; 383 :1899 \u0002 1911. 627. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympa- thetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).  Eur J Heart Fail  2003; 5 :659 \u0002 667. 628. Kato S, Onishi K, Yamanaka T, Takamura T, Dohi K, Yamada N, Wada H, Nobori T, Ito M. Exaggerated hypertensive response to exercise in patients with diastolic heart failure.  Hypertens Res  2008; 31 :679 \u0002 684. 629. Uijl A, Savarese G, Vaartjes I, Dahlstrom U, Brugts JJ, Linssen GCM, van Empel V, Brunner-La Rocca HP, Asselbergs FW, Lund LH, Hoes AW, Koudstaal S. Identification of distinct phenotypic clusters in heart failure with preserved ejec- tion fraction.  Eur J Heart Fail  2021; 23 :973 \u0002 982. 630. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis.  J Hypertens  2018; 36 :1637 \u0002 1647. 631. Vaduganathan M, Pareek M, Kristensen AMD, Biering-Sorensen T, Byrne C, Almarzooq Z, Olesen TB, Olsen MH, Bhatt DL. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spec- trum of kidney function and albuminuria: a SPRINT substudy.  Eur J Heart Fail 2021; 23 :384 \u0002 392.\n",
      "keywords": [
        "early",
        "sambola",
        "long",
        "term",
        "antihypertensive",
        "influence",
        "permanyer",
        "blood pressure",
        "outcome",
        "heart failure",
        "tornos",
        "gomez",
        "surge",
        "adherence",
        "diastolic",
        "regurgitation",
        "mitral regurgitation",
        "toward",
        "older",
        "aortic",
        "tricuspid",
        "treated",
        "guideline",
        "soler",
        "miralda",
        "surgically",
        "evangelista",
        "age",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "120",
      "title": "632. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension  2009; 54 :1084 \u0002 1091. ",
      "start_page": 116,
      "end_page": 119,
      "content": "ESC Guidelines 3715\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ GMC. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart fail- ure.  Eur J Heart Fail  2020; 22 :196 \u0002 213. 648. Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo- Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial.  Circulation 2020; 142 :2205 \u0002 2215. 649. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.  JAMA Cardiol 2021; 6 :148 \u0002 158. 650. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2019; 21 :1169 \u0002 1186. 651. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of obser- vational studies involving 34,000 patients.  Circ Heart Fail  2013; 6 :395 \u0002 402. 652. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, Gislason GH. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia  2010; 53 :2546 \u0002 2553. 653. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369 :1317 \u0002 1326. 654. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.  Lancet  2015; 385 :2067 \u0002 2076. 655. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med  2015; 373 :232 \u0002 242. 656. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovas- cular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial.  JAMA  2019; 321 :69 \u0002 79. 657. McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H, VIVIDD Trial Committees and Investigators. Effects of vil- dagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 2018; 6 :8 \u0002 17. 658. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.  Diabetes Res Clin Pract 2019; 150 :8 \u0002 16. 659. Savarese G, D’Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 dia- betes mellitus: a meta-analysis.  Int J Cardiol  2016; 220 :595 \u0002 601. 660. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.  Lancet Diabetes Endocrinol 2019; 7 :776 \u0002 785. 661. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, Nilsson B, Moller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic\nheart failure patients with and without diabetes (LIVE)-a multicentre, double- blind, randomised, placebo-controlled trial.  Eur J Heart Fail  2017; 19 :69 \u0002 77. 662. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.  JAMA 2016; 316 :500 \u0002 508. 663. Gerstein HC, Jung H, Ryden L, Diaz R, Gilbert RE, Yusuf S, ORIGIN Investigators. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (Outcome Reduction With Initial Glargine Intervention).  Circulation  2018; 137 :88 \u0002 90. 664. Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Kober L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.  Eur J Heart Fail  2018; 20 :888 \u0002 895. 665. Shen L, Rorth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Kober L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.  Eur J Heart Fail  2019; 21 :974 \u0002 984. 666. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ  2009; 339 :b4731. 667. Roumie CL, Min JY, D’Agostino McGowan L, Presley C, Grijalva CG, Hackstadt AJ, Hung AM, Greevy RA, Elasy T, Griffin MR. Comparative safety of sulfony- lurea and metformin monotherapy on the risk of heart failure: a cohort study.  J Am Heart Assoc  2017; 6 . 668. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.  Lancet  2007; 370 :1129 \u0002 1136. 669. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid dysfunction and heart fail- ure: mechanisms and associations.  Curr Heart Fail Rep  2017; 14 :48 \u0002 58. 670. Kannan L, Shaw PA, Morley MP, Brandimarto J, Fang JC, Sweitzer NK, Cappola TP, Cappola AR. Thyroid dysfunction in heart failure and cardiovascular out- comes.  Circ Heart Fail  2018; 11 :e005266. 671. Sato Y, Yoshihisa A, Kimishima Y, Kiko T, Kanno Y, Yokokawa T, Abe S, Misaka T, Sato T, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Takeishi Y. Low T3 syndrome is associated with high mortality in hospitalized patients with heart failure.  J Card Fail  2019; 25 :195 \u0002 203. 672. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne JP, Byrne S, Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow M, O’Flynn A, O’Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C, Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R, Gussekloo J, TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism.  N Engl J Med  2017; 376 :2534 \u0002 2544. 673. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, Ford I, Gussekloo J, Kearney PM, Mooijaart S, Quinn T, Stott D, Westendorp R, Rodondi N, Dekkers OM. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis.  JAMA  2018; 320 :1349 \u0002 1359. 674. Peeters RP. Subclinical hypothyroidism.  N Engl J Med  2017; 376 :2556 \u0002 2565. 675. Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure and a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease.  Eur J Heart Fail  2020; 22 :1551 \u0002 1567. 676. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence sup- porting the existence of a distinct obese phenotype of heart failure with pre- served ejection fraction.  Circulation  2017; 136 :6 \u0002 19. 677. Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. Eur J Heart Fail 2020; 22 :1540 \u0002 1550. 678. Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox.  Mayo Clin Proc  2017; 92 :266 \u0002 279. 679. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure.  Prog Cardiovasc Dis  2018; 61 :151 \u0002 156. 680. Adamopoulos C, Meyer P, Desai RV, Karatzidou K, Ovalle F, White M, Aban I, Love TE, Deedwania P, Anker SD, Ahmed A. Absence of obesity paradox in\n3716 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ patients with chronic heart failure and diabetes mellitus: a propensity-matched study.  Eur J Heart Fail  2011; 13 :200 \u0002 206. 681. Zamora E, Lupon J, Enjuanes C, Pascual-Figal D, de Antonio M, Domingo M, Comin-Colet J, Vila J, Penafiel J, Farre N, Alonso N, Santesmases J, Troya M, Bayes-Genis A. No benefit from the obesity paradox for diabetic patients with heart failure.  Eur J Heart Fail  2016; 18 :851 \u0002 858. 682. Piepoli MF, Corra U, Veglia F, Bonomi A, Salvioni E, Cattadori G, Metra M, Lombardi C, Sinagra G, Limongelli G, Raimondo R, Re F, Magri D, Belardinelli R, Parati G, Mina C, Scardovi AB, Guazzi M, Cicoira M, Scrutinio D, Di Lenarda A, Bussotti M, Frigerio M, Correale M, Villani GQ, Paolillo S, Passino C, Agostoni P, MECKI Score Research Group. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group.  Eur J Heart Fail  2016; 18 :545 \u0002 553. 683. Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC. Waist-to- hip ratio and mortality in heart failure.  Eur J Heart Fail  2018; 20 :1269 \u0002 1277. 684. Carbone S, Elagizi A, Lavie CJ. Obesity and mortality risk in heart failure: when adipose tissue distribution matters.  Eur J Heart Fail  2018; 20 :1278 \u0002 1280. 685. Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrilla- tion, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment.  Eur J Heart Fail  2020; 22 :214 \u0002 227. 686. Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, Lainscak M, Jaarsma T, Ponikowski P, Rosano GMC, Seferovic P, Coats AJ. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure.  Eur J Heart Fail  2019; 21 :1299 \u0002 1305. 687. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prev- alence of frailty in heart failure: a systematic review and meta-analysis.  Int J Cardiol  2017; 236 :283 \u0002 289. 688. Bielecka-Dabrowa A, Ebner N, Dos Santos MR, Ishida J, Hasenfuss G, von Haehling S. Cachexia, muscle wasting, and frailty in cardiovascular disease.  Eur J Heart Fail  2020; 22 :2314 \u0002 2326. 689. Khan H, Kalogeropoulos AP, Georgiopoulou VV, Newman AB, Harris TB, Rodondi N, Bauer DC, Kritchevsky SB, Butler J. Frailty and risk for heart failure in older adults: the health, aging, and body composition study.  Am Heart J 2013; 166 :887 \u0002 894. 690. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB, Women’s Health Initiative. Frailty: emergence and consequences in women aged 65 and older in the Women’s Health Initiative Observational Study.  J Am Geriatr Soc  2005; 53 :1321 \u0002 1330. 691. Vidan MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Rexach JA, Bueno H. Prevalence and prognostic impact of frailty and its components in non- dependent elderly patients with heart failure. Eur J Heart Fail 2016; 18 :869 \u0002 875. 692. Dewan P, Jackson A, Jhund PS, Shen L, Ferreira JP, Petrie MC, Abraham WT, Desai AS, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV. The prevalence and importance of frailty in heart fail- ure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE.  Eur J Heart Fail  2020; 22 :2123 \u0002 2133. 693. Sanders NA, Supiano MA, Lewis EF, Liu J, Claggett B, Pfeffer MA, Desai AS, Sweitzer NK, Solomon SD, Fang JC. The frailty syndrome and outcomes in the TOPCAT trial.  Eur J Heart Fail  2018; 20 :1570 \u0002 1577. 694. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition.  Clin Nutr 2008; 27 :793 \u0002 799. 695. Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc.  J Cachexia Sarcopenia Muscle  2016; 7 :246 \u0002 260. 696. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview.  Pharmacol Ther  2009; 121 :227 \u0002 252. 697. Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, Morley JE, Strasser F, Landmesser U, Coats AJS, Anker SD. Orphan disease sta- tus of cancer cachexia in the USA and in the European Union: a systematic review.  J Cachexia Sarcopenia Muscle  2019; 10 :22 \u0002 34. 698. Bauer J, Morley JE, Schols A, Ferrucci L, Cruz-Jentoft AJ, Dent E, Baracos VE, Crawford JA, Doehner W, Heymsfield SB, Jatoi A, Kalantar-Zadeh K, Lainscak M, Landi F, Laviano A, Mancuso M, Muscaritoli M, Prado CM, Strasser F, von Haehling S, Coats AJS, Anker SD. Sarcopenia: a time for action. An SCWD position paper.  J Cachexia Sarcopenia Muscle  2019; 10 :956 \u0002 961. 699. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, Farmakis D, Lopez-Fernandez T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG, Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart\nfailure: epidemiology, clinical implications and gaps in knowledge.  Eur J Heart Fail 2018; 20 :879 \u0002 887. 700. Fonseca G, Dos Santos MR, de Souza FR, Takayama L, Rodrigues Pereira RM, Negrao CE, Alves MNN. Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index.  ESC Heart Fail 2020; 7 :84 \u0002 91. 701. Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, Loncar G, Springer J, Doehner W, Lainscak M, Hasenfuss G, Anker SD, von Haehling S. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).  Eur J Heart Fail  2018; 20 :1580 \u0002 1587. 702. Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W, Anker SD, von Haehling S. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA- HF).  Eur Heart J  2013; 34 :512 \u0002 519. 703. Springer J, Springer JI, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond: update 2017.  ESC Heart Fail  2017; 4 :492 \u0002 498. 704. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies.  Nat Rev Cardiol 2017; 14 :323 \u0002 341. 705. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double- blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54 :919 \u0002 927. 706. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies.  Circulation  2018; 138 :80 \u0002 98. 707. Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, Di Nora C, Cioffi G, Tarantini L, Gavazzi A, Sinagra G, Di Lenarda A. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.  Eur J Heart Fail 2018; 20 :1257 \u0002 1266. 708. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to ane- mia, exercise capacity, and survival.  J Am Coll Cardiol  2011; 58 :1241 \u0002 1251. 709. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, Cohen-Solal A, Kindermann I, Manito N, Pfister O, Pohjantahti-Maaroos H, Taylor J, Comin-Colet J. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice.  Eur J Heart Fail  2018; 20 :1664 \u0002 1672. 710. Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM, IRON CORE Group. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management.  Am J Hematol  2017; 92 :1068 \u0002 1078. 711. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet  2016; 387 :907 \u0002 916. 712. Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A, Rozentryt P, van der Meer P, Comin-Colet J, von Haehling S, Kosmala W, Przewlocka-Kosmala M, Banasiak W, Nowak J, Voors AA, Anker SD, Cleland JGF, Ponikowski P, Jankowska EA. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mor- tality.  Eur J Heart Fail  2020 Oct 27. doi: 10.1002/ejhf.2036 [Epub ahead of print]. 713. Rocha BML, Cunha GJL, Falcao Menezes LF. The burden of iron deficiency in heart failure: therapeutic approach.  J Am Coll Cardiol  2018; 71 :782 \u0002 793. 714. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis.  Am Heart J  2013; 165 :575 \u0002 582.e3. 715. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with sys- tolic chronic heart failure.  Eur Heart J  2010; 31 :1872 \u0002 1880. 716. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease.  Nat Rev Cardiol  2015; 12 :659 \u0002 669. 717. Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail 2016; 18 :762 \u0002 773. 718. Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJ, Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with chronic heart failure.  Eur Heart J 2013; 34 :827 \u0002 834. 719. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van\nESC Guidelines 3717\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ Veldhuisen DJ, RED-HF Committees, RED-HF Investigators. Treatment of ane- mia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368 :1210 \u0002 1219. 720. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron defi- ciency.  N Engl J Med  2009; 361 :2436 \u0002 2448. 721. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, Mori C, Willenheimer R, Ponikowski P, Anker SD. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.  Eur Heart J 2013; 34 :30 \u0002 38. 722. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.  Eur Heart J 2015; 36 :657 \u0002 668. 723. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136 :1374 \u0002 1383. 724. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials.  Eur J Heart Fail  2016; 18 :786 \u0002 795. 725. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mor- tality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.  Eur J Heart Fail  2018; 20 :125 \u0002 133. 726. Filippatos G, Farmakis D, Colet JC, Dickstein K, Luscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.  Eur J Heart Fail  2013; 15 :1267 \u0002 1276. 727. von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview.  JACC Heart Fail  2019; 7 :36 \u0002 46. 728. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial.  JAMA 2017; 317 :1958 \u0002 1966. 729. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail  2020; 22 :584 \u0002 603. 730. Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.  Eur J Heart Fail  2016; 18 :588 \u0002 598. 731. van der Pol A, van Gilst WH, Voors AA, van der Meer P. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail 2019; 21 :425 \u0002 435. 732. Lofman I, Szummer K, Dahlstrom U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.  Eur J Heart Fail  2017; 19 :1606 \u0002 1614. 733. Lofman I, Szummer K, Evans M, Carrero JJ, Lund LH, Jernberg T. Incidence of, associations with and prognostic impact of worsening renal function in heart failure with different ejection fraction categories. Am J Cardiol 2019; 124 :1575 \u0002 1583. 734. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management.  Nat Rev Nephrol  2016; 12 :610 \u0002 623. 735. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis.  Eur Heart J  2014; 35 :455 \u0002 469. 736. Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis  2019; 62 :298 \u0002 302.\n",
      "keywords": [
        "elderly",
        "antihypertensive",
        "heart failure",
        "wouters",
        "metformin",
        "insulin",
        "glp-1",
        "meta",
        "glucose",
        "hypertension",
        "diabetic",
        "left",
        "studies",
        "treatment",
        "obesity",
        "regression",
        "older",
        "comparative",
        "mass",
        "ventricular",
        "sex",
        "ejection fraction",
        "systolic",
        "diabetes",
        "analysis",
        "sglt2",
        "male",
        "randomized",
        "fagard",
        "celis"
      ],
      "tables": []
    },
    {
      "number": "121",
      "title": "737. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and kidney benefits of empagliflozin in heart",
      "start_page": 119,
      "end_page": 120,
      "content": "3718 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ patients with severe heart failure treated with a mineralocorticoid receptor antagonist.  Circ Heart Fail  2014; 7 :573 \u0002 579. 754. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).  Circ Heart Fail  2014; 7 :51 \u0002 58. 755. Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, Minana G, Santas E, Chorro FJ, Mollar A, Carratala A, Navarro J, Gorriz JL, Lupon J, Husser O, Metra M, Sanchis J. Long-term potassium monitoring and dynamics in heart failure and risk of mortality.  Circulation  2018; 137 :1320 \u0002 1330. 756. Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.  ESC Heart Fail 2019; 6 :280 \u0002 290. 757. Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, Dahlstrom U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH. Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.  Eur J Heart Fail  2020; 22 :1390 \u0002 1398. 758. Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH, Heart Failure Long-Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC- HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020; 22 :1378 \u0002 1389. 759. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure.  Eur Heart J  2007; 28 :1334 \u0002 1343. 760. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.  Eur Heart J Cardiovasc Pharmacother  2018; 4 :180 \u0002 188. 761. Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, Rossignol P, Zannad F, Packer M, Solomon SD, McMurray JJV. Serum potassium in the PARADIGM-HF trial.  Eur J Heart Fail  2020; 22 :2056 \u0002 2064. 762. Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, van Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.  Eur J Heart Fail  2020; 22 :1402 \u0002 1411. 763. Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O’Meara E, Shah SJ, Sweitzer NK, Solomon S, Pitt B. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with pre- served ejection fraction: analysis of the TOPCAT trial. J Card Fail 2018; 24 :313 \u0002 320. 764. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management.  Curr Heart Fail Rep  2009; 6 :272 \u0002 280. 765. Savarese G, Xu H, Trevisan M, Dahlstrom U, Rossignol P, Pitt B, Lund LH, Carrero JJ. Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction.  JACC Heart Fail  2019; 7 :65 \u0002 76. 766. Rosano GMC, Spoletini I, Agewall S. Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate.  Eur Heart J Suppl 2019; 21 :A28 \u0002 A33. 767. Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P. Maintenance of serum potassium with sodium zirconium cyclosili- cate (ZS-9) in heart failure patients: results from a phase 3 randomized, double- blind, placebo-controlled trial.  Eur J Heart Fail  2015; 17 :1050 \u0002 1056. 768. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.  Eur J Heart Fail  2015; 17 :1057 \u0002 1065. 769. Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, Barany P, Jernberg T, Lund LH, Carrero JJ. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.  Eur J Heart Fail  2018; 20 :1217 \u0002 1226.\n",
      "keywords": [
        "anker",
        "cardiovascular risk",
        "heart failure",
        "schnee",
        "pfarr",
        "zannad",
        "benefits",
        "butler",
        "kidney",
        "ferreira",
        "zeller",
        "heart",
        "packer",
        "wanner",
        "filippatos",
        "empagliflozin",
        "brueckmann",
        "pocock",
        "hauske",
        "ejection fraction",
        "cardiac"
      ],
      "tables": []
    },
    {
      "number": "122",
      "title": "770. Ferreira JP, Rossello X, Pocock SJ, Rossignol P, Claggett BL, Rouleau JL, Solomon SD, Pitt B, Pfeffer MA, Zannad F. Spironolactone dose in heart failure with preserved ejection fraction: findings",
      "start_page": 120,
      "end_page": 123,
      "content": "ESC Guidelines 3719\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 788. Griffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P, D’Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M, Tang WHW, Turner J, Mullens W, Wilson FP, Testani JM. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. cen- ter’s experience.  JACC Heart Fail  2020; 8 :199 \u0002 208. 789. Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, Clark AL. Low serum chloride in patients with chronic heart failure: clinical associations and prognos- tic significance.  Eur J Heart Fail  2018; 20 :1426 \u0002 1435. 790. Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP, Bellumkonda L, Jacoby D, Tang WH, Parikh CR. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart fail- ure.  Eur J Heart Fail  2016; 18 :660 \u0002 668. 791. Marchenko R, Sigal A, Wasser TE, Reyer J, Green J, Mercogliano C, Khan MS, Donato AA. Hypochloraemia and 30 day readmission rate in patients with acute decompensated heart failure.  ESC Heart Fail  2020; 7 :903 \u0002 907. 792. Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M, Starling RC, Testani JM, Tang WH. Prognostic role of serum chloride levels in acute decom- pensated heart failure.  J Am Coll Cardiol  2015; 66 :659 \u0002 666. 793. Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, Grodin JL, Assefa M, Samuel Broughton J, Planavsky NJ, Ahmad T, Bellumkonda L, Tang WH, Parikh CR, Testani JM. Hypochloremia and diuretic resistance in heart fail- ure: mechanistic insights.  Circ Heart Fail  2016; 9 . 794. Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogne W, Mullens W. Acetazolamide to increase natriuresis in con- gestive heart failure at high risk for diuretic resistance.  Eur J Heart Fail 2019; 21 :1415 \u0002 1422. 795. Axson EL, Ragutheeswaran K, Sundaram V, Bloom CI, Bottle A, Cowie MR, Quint JK. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis.  Respir Res  2020; 21 :54. 796. Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Pinilla JMG, Nyolczas N, Temporelli PL, Mebazaa A, Lainscak M, Laroche C, Maggioni AP, Piepoli MF, Coats AJS, Ferrari R, Tavazzi L, ESC-HFA Heart Failure Long-Term Registry Investigators. Characteristics, treatments and 1-year prognosis of hos- pitalized and ambulatory heart failure patients with chronic obstructive pulmo- nary disease in the European Society of Cardiology Heart Failure Long-Term Registry.  Eur J Heart Fail  2018; 20 :100 \u0002 110. 797. Uijl A, Koudstaal S, Direk K, Denaxas S, Groenwold RHH, Banerjee A, Hoes AW, Hemingway H, Asselbergs FW. Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records.  Eur J Heart Fail  2019; 21 :1197 \u0002 1206. 798. Caravita S, Vachiery JL. Obstructive ventilatory disorder in heart failure–caused by the heart or the lung?  Curr Heart Fail Rep  2016; 13 :310 \u0002 318. 799. Magnussen H, Canepa M, Zambito PE, Brusasco V, Meinertz T, Rosenkranz S. What can we learn from pulmonary function testing in heart failure?  Eur J Heart Fail  2017; 19 :1222 \u0002 1229. 800. Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, Rosenkranz S. Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. JACC Heart Fail 2019; 7 :823 \u0002 833. 801. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary dis- ease. 2020 report. https://goldcopd.org/wp-content/uploads/2019/12/GOLD- 2020-FINAL-ver1.2-03Dec19_WMV.pdf (31 May 2020). 802. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. www.ginasthma.org (28 May 2021). 803. Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE, SUMMIT Investigators. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.  Heart  2017; 103 :1536 \u0002 1542. 804. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE, SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardio- vascular risk (SUMMIT): a double-blind randomised controlled trial.  Lancet 2016; 387 :1817 \u0002 1826. 805. Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single- centre trial.  Lancet Respir Med  2018; 6 :368 \u0002 378. 806. Pearse SG, Cowie MR. Sleep-disordered breathing in heart failure.  Eur J Heart Fail  2016; 18 :353 \u0002 361. 807. Cowie MR, Gallagher AM. Sleep disordered breathing and heart failure: what does the future hold?  JACC Heart Fail  2017; 5 :715 \u0002 723. 808. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive servo-\nventilation for central sleep apnea in systolic heart failure.  N Engl J Med 2015; 373 :1095 \u0002 1105. 809. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, Abraham WT, remede´ System Pivotal Trial Study Group. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial.  Lancet  2016; 388 :974 \u0002 982. 810. Costanzo MR, Ponikowski P, Coats A, Javaheri S, Augostini R, Goldberg LR, Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, McKane S, Abraham WT, remede´ System Pivotal Trial Study Group. Phrenic nerve stimu- lation to treat patients with central sleep apnoea and heart failure.  Eur J Heart Fail  2018; 20 :1746 \u0002 1754. 811. Kjekshus J, Apetrei E, Barrios V, Bo¨hm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J \u0003 anosi A, Kamensk \u0003 y G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group. Rosuvastatin in older patients with systolic heart failure.  N Engl J Med  2007; 357 :2248 \u0002 2261. 812. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double- blind, placebo-controlled trial.  Lancet  2008; 372 :1231 \u0002 1239. 813. Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejec- tion fraction: a meta-analysis of randomized controlled trials.  PLoS One 2017; 12 :e0171168. 814. Rogers JK, Jhund PS, Perez AC, Bohm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).  JACC Heart Fail 2014; 2 :289 \u0002 297. 815. Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, Kjekshus J, Tavazzi L, McMurray J, Lloyd-Jones DM. Do statins reduce the risk of myocar- dial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF.  Eur J Heart Fail  2015; 17 :434 \u0002 441. 816. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes.  Arch Intern Med  2010; 170 :1358 \u0002 1364. 817. Borghi C, Palazzuoli A, Landolfo M, Cosentino E. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.  Heart Fail Rev 2020; 25 :43 \u0002 51. 818. Doehner W, Springer J, Landmesser U, Struthers AD, Anker SD. Uric acid in chronic heart failure–current pathophysiological concepts.  Eur J Heart Fail 2008; 10 :1269 \u0002 1270. 819. Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, Jing X, Chen J, Wang J. Uric acid and risk of heart failure: a systematic review and meta-analysis.  Eur J Heart Fail 2014; 16 :15 \u0002 24. 820. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378 :1200 \u0002 1210. 821. Hare JM, Mangal B, Brown J, Fisher C, Jr., Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP, OPT-CHF Investigators. Impact of oxypuri- nol in patients with symptomatic heart failure. Results of the OPT-CHF study.  J Am Coll Cardiol  2008; 51 :2301 \u0002 2309. 822. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-con- trolled crossover preliminary study.  Circ Heart Fail  2010; 3 :73 \u0002 81. 823. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF, NHLBI Heart Failure Clinical Research Network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) study. Circulation 2015; 131 :1763 \u0002 1771. 824. Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials.  BMC Cardiovasc Disord  2015; 15 :96. 825. Frommeyer G, Krawczyk J, Dechering DG, Kochhauser S, Leitz P, Fehr M, Eckardt L. Colchicine increases ventricular vulnerability in an experimental whole-heart model.  Basic Clin Pharmacol Toxicol  2017; 120 :505 \u0002 508. 826. Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, Safety of Non-steroidal Anti-inflammatory Drugs Project Consortium. Non-\n3720 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.  BMJ  2016; 354 :i4857. 827. Khalid Y, Dasu N, Shah A, Brown K, Kaell A, Levine A, Dasu K, Raminfard A. Incidence of congestive heart failure in rheumatoid arthritis: a review of litera- ture and meta-regression analysis.  ESC Heart Fail  2020; 7 :3745 \u0002 3753. 828. Mantel A, Holmqvist M, Andersson DC, Lund LH, Askling J. Association between rheumatoid arthritis and risk of ischemic and nonischemic heart fail- ure.  J Am Coll Cardiol  2017; 69 :1275 \u0002 1285. 829. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, pla- cebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.  Circulation  2003; 107 :3133 \u0002 3140. 830. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).  Circulation 2004; 109 :1594 \u0002 1602. 831. Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure?  Int J Mol Sci  2018; 19 :1739. 832. Baumhakel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Bohm M. Cardiovascular risk, drugs and erectile function–a systematic analysis.  Int J Clin Pract  2011; 65 :289 \u0002 298. 833. Jaarsma T. Sexual function of patients with heart failure: facts and numbers.  ESC Heart Fail  2017; 4 :3 \u0002 7. 834. Levine AB, Punihaole D, Levine TB. Characterization of the role of nitric oxide and its clinical applications.  Cardiology  2012; 122 :55 \u0002 68. 835. Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall’Armi V, Badagliacca R, Barbagallo F, Lenzi A, Isidori AM. Is chronic inhibition of phosphodiesterase type 5 cardio- protective and safe? A meta-analysis of randomized controlled trials.  BMC Med 2014; 12 :185. 836. Angermann CE, Ertl G. Depression, anxiety, and cognitive impairment: comor- bid mental health disorders in heart failure. Curr Heart Fail Rep 2018; 15 :398 \u0002 410. 837. Sbolli M, Fiuzat M, Cani D, O’Connor CM. Depression and heart failure: the lonely comorbidity.  Eur J Heart Fail  2020; 22 :2007 \u0002 2017. 838. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC state- of-the-art review.  J Am Coll Cardiol  2019; 73 :1827 \u0002 1845. 839. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N, Enhancing Recovery in Coronary Heart Disease Patients Investigators. Effects of treating depression and low per- ceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) random- ized trial.  JAMA  2003; 289 :3106 \u0002 3116. 840. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R, SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56 :692 \u0002 699. 841. Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Bohm M, Faller H, Deckert J, Ertl G, MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mor- tality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial.  JAMA  2016; 315 :2683 \u0002 2693. 842. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations.  Eur J Heart Fail  2019; 21 :1515 \u0002 1525. 843. Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyop- athy: secrets and lies.  Eur J Heart Fail  2018; 20 :907 \u0002 909. 844. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Baron-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol C, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Authors/Task Force Members, ESC Committee for Practice Guidelines, Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task\nForce for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).  Eur J Heart Fail  2017; 19 :9 \u0002 42. 845. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, Lopez-Fernandez T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G. The cancer patient and cardiology. Eur J Heart Fail 2020; 22 :2290 \u0002 2309. 846. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, Lopez-Fernandez T, Plummer C, Lenihan D. Baseline cardiovascular risk assess- ment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail  2020; 22 :1945 \u0002 1960. 847. Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Mousavi N, Park JH, Perales MA, Ryan TD, Scherrer-Crosbie M, Steingart RM, Yang EH, Zaha V, Barac A, Liu JE. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. J Am Coll Cardiol 2019; 74 :3153 \u0002 3163. 848. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment.  Circ Res  2016; 118 :1008 \u0002 1020. 849. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibi- tors and cardiovascular toxicity.  Lancet Oncol  2018; 19 :e447 \u0002 e458. 850. Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS, Gietema JA, Hooning MJ, Seynaeve CM, Maas A, Darby SC, Aleman BMP, Taylor CW, van Leeuwen FE. Heart failure after treatment for breast cancer. Eur J Heart Fail  2020; 22 :366 \u0002 374. 851. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrilla- tion in cancer.  J Am Coll Cardiol  2014; 63 :945 \u0002 953. 852. Tromp J, Boerman LM, Sama IE, Maass S, Maduro JH, Hummel YM, Berger MY, de Bock GH, Gietema JA, Berendsen AJ, van der Meer P. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro- inflammatory biomarker profile compared to matched controls.  Eur J Heart Fail 2020; 22 :1239 \u0002 1246. 853. Hasin T, Gerber Y, Weston SA, Jiang R, Killian JM, Manemann SM, Cerhan JR, Roger VL. Heart failure after myocardial infarction is associated with increased risk of cancer.  J Am Coll Cardiol  2016; 68 :265 \u0002 271. 854. Banke A, Schou M, Videbaek L, Moller JE, Torp-Pedersen C, Gustafsson F, Dahl JS, Kober L, Hildebrandt PR, Gislason GH. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail 2016; 18 :260 \u0002 266. 855. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res  2019; 115 :844 \u0002 853. 856. de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, Bauersachs J, Bertero E, Coats AJS, Celutkiene J, Chioncel O, Dodion P, Eschenhagen T, Farmakis D, Bayes-Genis A, Jager D, Jankowska EA, Kitsis RN, Konety SH, Larkin J, Lehmann L, Lenihan DJ, Maack C, Moslehi JJ, Muller OJ, Nowak-Sliwinska P, Piepoli MF, Ponikowski P, Pudil R, Rainer PP, Ruschitzka F, Sawyer D, Seferovic PM, Suter T, Thum T, van der Meer P, Van Laake LW, von Haehling S, Heymans S, Lyon AR, Backs J. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).  Eur J Heart Fail  2020; 22 :2272 \u0002 2289. 857. Selvaraj S, Bhatt DL, Claggett B, Djousse L, Shah SJ, Chen J, Imran TF, Qazi S, Sesso HD, Gaziano JM, Schrag D. Lack of association between heart failure and incident cancer.  J Am Coll Cardiol  2018; 71 :1501 \u0002 1510. 858. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Sillje HHW, de Boer RA. Heart failure stimu- lates tumor growth by circulating factors.  Circulation  2018; 138 :678 \u0002 691. 859. Lancellotti P, Suter TM, Lopez-Fernandez T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R. Cardio-oncology services: rationale, organization, and imple- mentation.  Eur Heart J  2019; 40 :1756 \u0002 1763. 860. Farmakis D, Keramida K, Filippatos G. How to build a cardio-oncology service? Eur J Heart Fail  2018; 20 :1732 \u0002 1734. 861. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced\nESC Guidelines 3721\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. .......................................................................................................................................................................... cardiomyopathy: clinical relevance and response to pharmacologic therapy.  J Am Coll Cardiol  2010; 55 :213 \u0002 220. 862. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.  Circulation  2015; 131 :1981 \u0002 1988. 863. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J  2016; 37 :1671 \u0002 1680. 864. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity.  J Clin Oncol  2017; 35 :870 \u0002 877. 865. Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S, Barberis V, Flachskampf FA, Ceponiene I, Haegler-Laube E, Suter T, Lapinskas T, Prasad S, de Boer RA, Wechalekar K, Anker MS, Iakobishvili Z, Bucciarelli- Ducci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS, Galderisi M, Lancellotti P, Bax J, Marwick TH, Chioncel O, Jaarsma T, Mullens W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F, Zamorano JL, Rosano G, Coats AJS, Asteggiano R, Seferovic P, Edvardsen T, Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).  Eur J Heart Fail  2020; 22 :1504 \u0002 1524. 866. Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, Ramachandran K, Tzavara C, Charalampopoulos G, Filippiadis D, Kouris N, Nihoyannopoulos P. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.  Eur J Heart Fail 2019; 21 :529 \u0002 535. 867. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, Aakhus S, Miyazaki S, Shirazi M, Galderisi M, Marwick TH, SUCCOUR Investigators. Strain-guided management of potentially cardiotoxic cancer ther- apy.  J Am Coll Cardiol  2021; 77 :392 \u0002 401. 868. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, Totzeck M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.  Eur J Heart Fail  2020; 22 :350 \u0002 361. 869. Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Sterba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hagler-Laube ES, Asteggiano R, Fernandez TL, de Boer RA, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.  Eur J Heart Fail  2020; 22 :1966 \u0002 1983. 870. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors.  Cardiovasc Res  2019; 115 :854 \u0002 868. 871. Banke A, Fosbol EL, Moller JE, Gislason GH, Andersen M, Bernsdorf M, Jensen MB, Schou M, Ejlertsen B. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.  Eur J Heart Fail  2018; 20 :1447 \u0002 1453. 872. Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, McMurray JJ. Prevalence and prognostic importance of precipitat- ing factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.  Eur J Heart Fail  2018; 20 :295 \u0002 303. 873. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, Metra M. COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.  Eur J Heart Fail 2020; 22 :957 \u0002 966; 23 :512 \u0002 526. 874. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease.  JAMA  2015; 313 :264 \u0002 274. 875. Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, Nozzoli C, Venditti M, Chirinos JA, Corrales-Medina VF, SIXTUS Study Group. Cardiovascular complications and short-term mortality risk in community- acquired pneumonia.  Clin Infect Dis  2017; 64 :1486 \u0002 1493.\n",
      "keywords": [
        "findings",
        "cardiovascular risk",
        "heart failure",
        "rossello",
        "zannad",
        "ferreira",
        "failure",
        "rossignol",
        "heart",
        "claggett",
        "rouleau",
        "dose",
        "solomon",
        "preserved",
        "spironolactone",
        "older",
        "pocock",
        "pfeffer",
        "pitt",
        "sex",
        "biomarker",
        "systolic",
        "diuretic",
        "ejection",
        "age",
        "fraction",
        "cardiomyopathy",
        "sudden cardiac death"
      ],
      "tables": []
    },
    {
      "number": "123",
      "title": "876. Rey JR, Caro-Codon J, Rosillo SO, Iniesta AM, Castrejon-Castrejon S, Marco- Clement I, Martin-Polo L, Merino-Argos C, Rodriguez-Sotelo L, Garcia-Veas JM, Martinez-Marin LA, Martinez-Cossiani M, B",
      "start_page": 123,
      "end_page": 127,
      "content": "3722 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 891. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray J, Yamac H, Labidi S, Struman I, Hilfiker-Kleiner D. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of- concept pilot study.  Circulation  2010; 121 :1465 \u0002 1473. 892. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J. The MOGE(S) classification for a phenotype- genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation.  J Am Coll Cardiol  2013; 62 :2046 \u0002 2072. 893. Hazebroek MR, Kemna MJ, Schalla S, Sanders-van Wijk S, Gerretsen SC, Dennert R, Merken J, Kuznetsova T, Staessen JA, Brunner-La Rocca HP, van Paassen P, Cohen Tervaert JW, Heymans S. Prevalence and prognostic rele- vance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granu- lomatosis with polyangiitis and granulomatosis with polyangiitis.  Int J Cardiol 2015; 199 :170 \u0002 179. 894. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, Duboc D, Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio AL, Charron P. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its impli- cations for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases.  Eur Heart J  2016; 37 :1850 \u0002 1858. 895. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimovic R, Milicic D, Milinkovic I, Noutsias M, Oto A, Oto O, Pavlovic SU, Piepoli MF, Ristic AD, Rosano GMC, Seggewiss H, Asanin M, Seferovic JP, Ruschitzka F, Celutkiene J, Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJS, Tschope C. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.  Eur J Heart Fail 2019; 21 :553 \u0002 576. 896. members Authors/Task Force, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diag- nosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).  Eur Heart J  2014; 35 :2733 \u0002 2779. 897. Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M, Hamdani N, Hilfiker-Kleiner D, Meder B, Leite-Moreira AF, Thum T, Tocchetti CG, Varricchi G, Van der Velden J, Walsh R, Heymans S. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res  2018; 114 :1287 \u0002 1303. 898. Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM. Genetic evaluation of cardiomyop- athy–a Heart Failure Society of America practice guideline.  J Card Fail 2018; 24 :281 \u0002 302. 899. Merlo M, Cannata A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving con- cepts in dilated cardiomyopathy.  Eur J Heart Fail  2018; 20 :228 \u0002 239. 900. Linschoten M, Teske AJ, Baas AF, Vink A, Dooijes D, Baars HF, Asselbergs FW. Truncating titin (TTN) variants in chemotherapy-induced cardiomyopathy.  J Card Fail  2017; 23 :476 \u0002 479. 901. Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, Jongbloed JD, Postma A, Gietema JA, van Tintelen JP, van den Berg MP. Potential genetic pre- disposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.  Open Heart  2014; 1 :e000116. 902. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchia J, Garcia-Pinilla JM, Pascual-Figal DA, Nunez J, Guzzo-Merello G, Gonzalez- Vioque E, Bardaji A, Manito N, Lopez-Garrido MA, Padron-Barthe L, Edwards E, Whiffin N, Walsh R, Buchan RJ, Midwinter W, Wilk A, Prasad S, Pantazis A, Baski J, O’Regan DP, Alonso-Pulpon L, Cook SA, Lara-Pezzi E, Barton PJ, Garcia-Pavia P. Genetic etiology for alcohol-induced cardiac toxicity.  J Am Coll Cardiol  2018; 71 :2293 \u0002 2302. 903. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker- Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J, 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z, IPAC Investigators, Imac. Shared genetic predisposition in peripartum and dilated cardiomyopathies.  N Engl J Med  2016; 374 :233 \u0002 241. 904. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D, Bollen IA, Sliwa K, Alders M, Almomani R, van Langen IM, van der Meer P, Sinke RJ, van der Velden J, Van Veldhuisen DJ, van Tintelen JP, Jongbloed JD.\nTitin gene mutations are common in families with both peripartum cardiomyop- athy and dilated cardiomyopathy.  Eur Heart J  2014; 35 :2165 \u0002 2173. 905. Choi SH, Weng LC, Roselli C, Lin H, Haggerty CM, Shoemaker MB, Barnard J, Arking DE, Chasman DI, Albert CM, Chaffin M, Tucker NR, Smith JD, Gupta N, Gabriel S, Margolin L, Shea MA, Shaffer CM, Yoneda ZT, Boerwinkle E, Smith NL, Silverman EK, Redline S, Vasan RS, Burchard EG, Gogarten SM, Laurie C, Blackwell TW, Abecasis G, Carey DJ, Fornwalt BK, Smelser DT, Baras A, Dewey FE, Jaquish CE, Papanicolaou GJ, Sotoodehnia N, Van Wagoner DR, Psaty BM, Kathiresan S, Darbar D, Alonso A, Heckbert SR, Chung MK, Roden DM, Benjamin EJ, Murray MF, Lunetta KL, Lubitz SA, Ellinor PT, DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Association between titin loss-of-function variants and early-onset atrial fibrillation.  JAMA  2018; 320 :2354 \u0002 2364. 906. Hazebroek MR, Krapels I, Verdonschot J, van den Wijngaard A, Vanhoutte E, Hoos M, Snijders L, van Montfort L, Witjens M, Dennert R, Crijns H, Brunner- La Rocca HP, Brunner HG, Heymans S. Prevalence of pathogenic gene muta- tions and prognosis do not differ in isolated left ventricular dysfunction com- pared with dilated cardiomyopathy.  Circ Heart Fail  2018; 11 :e004682. 907. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, Bruneval P, Burke M, Butany J, Calabrese F, d’Amati G, Edwards WD, Fallon JT, Fishbein MC, Gallagher PJ, Halushka MK, McManus B, Pucci A, Rodriguez ER, Saffitz JE, Sheppard MN, Steenbergen C, Stone JR, Tan C, Thiene G, van der Wal AC, Winters GL. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology.  Cardiovasc Pathol  2012; 21 :245 \u0002 274. 908. Halliday BP, Owen R, Gregson J, Vassiliou VS, Chen X, Wage R, Lota AS, Khalique Z, Tayal U, Hammersley DJ, Jones RE, Baksi AJ, Cowie MR, Cleland JGF, Pennell DJ, Prasad SK. Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF.  Eur J Heart Fail  2021; 23 :293 \u0002 301. 909. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D, EXPLORER-HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomy- opathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.  Lancet  2020; 396 :759 \u0002 769. 910. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, Bourfiss M, Fortier A, Lie OH, Saguner AM, Svensson A, Andorin A, Tichnell C, Murray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn AD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge DP, Yap SC, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins H, Te Riele A, James CA. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.  Eur Heart J  2019; 40 :1850 \u0002 1858. 911. Leren IS, Saberniak J, Haland TF, Edvardsen T, Haugaa KH. Combination of ECG and echocardiography for identification of arrhythmic events in early ARVC.  JACC Cardiovasc Imaging  2017; 10 :503 \u0002 513. 912. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, Daubert JP, de Chillou C, DePasquale EC, Desai MY, Estes NAM, 3rd, Hua W, Indik JH, Ingles J, James CA, John RM, Judge DP, Keegan R, Krahn AD, Link MS, Marcus FI, McLeod CJ, Mestroni L, Priori SG, Saffitz JE, Sanatani S, Shimizu W, van Tintelen JP, Wilde AAM, Zareba W. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomy- opathy.  Heart Rhythm  2019; 16 :e301 \u0002 e372. 913. Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbaek L, Bruun NE, Eiskjaer H, Wiggers H, Brandes A, Thogersen AM, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Signorovitch J, Kober L, Thune JJ. Risk models for prediction of implantable cardioverter-defibrillator benefit: insights from the DANISH trial.  JACC Heart Fail  2019; 7 :717 \u0002 724. 914. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C, Pelliccia A, Duru F, Protonotarios N, Estes NA, 3rd, McKenna WJ, Thiene G, Marcus FI, Calkins H. Treatment of arrhythmogenic right ventricular cardiomy- opathy/dysplasia: an international task force consensus statement.  Eur Heart J 2015; 36 :3227 \u0002 3237. 915. Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, Calkins H, Corrado D, Duru F, Green KJ, Judge DP, Kelsell D, Lambiase PD, McKenna WJ, Pilichou K, Protonotarios A, Saffitz JE, Syrris P, Tandri H, Te Riele A, Thiene G, Tsatsopoulou A, Tintelen JP. Definition and treatment of arrhythmogenic cardi- omyopathy: an updated expert panel report.  Eur J Heart Fail  2019; 21 :955 \u0002 964. 916. Mazzarotto F, Tayal U, Buchan RJ, Midwinter W, Wilk A, Whiffin N, Govind R, Mazaika E, de Marvao A, Dawes TJW, Felkin LE, Ahmad M, Theotokis PI, Edwards E, Ing AY, Thomson KL, Chan LLH, Sim D, Baksi AJ, Pantazis A, Roberts AM, Watkins H, Funke B, O’Regan DP, Olivotto I, Barton PJR, Prasad\nESC Guidelines 3723\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ SK, Cook SA, Ware JS, Walsh R. Reevaluating the genetic contribution of mon- ogenic dilated cardiomyopathy.  Circulation  2020; 141 :387 \u0002 398. 917. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position state- ment of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.  Eur Heart J  2013; 34 :2636-2648, 2648a-2648d. 918. Heymans S, Eriksson U, Lehtonen J, Cooper LT, Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy.  J Am Coll Cardiol 2016; 68 :2348 \u0002 2364. 919. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hubner N, Kelle S, Klingel K, Maatz H, Parwani AS, Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van Linthout S. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.  Nat Rev Cardiol  2021; 18 :169 \u0002 193. 920. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, Stalens C, Sacher F, Babuty D, Trochu JN, Moubarak G, Savvatis K, Porcher R, Laforet P, Fayssoil A, Marijon E, Stojkovic T, Behin A, Leonard-Louis S, Sole G, Labombarda F, Richard P, Metay C, Quijano-Roy S, Dabaj I, Klug D, Vantyghem MC, Chevalier P, Ambrosi P, Salort E, Sadoul N, Waintraub X, Chikhaoui K, Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J, Androulakis AFA, Zeppenfeld K, Thompson T, Barnerias C, Becane HM, Bieth E, Boccara F, Bonnet D, Bouhour F, Boule S, Brehin AC, Chapon F, Cintas P, Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I, Dieterich K, Durigneux J, Echaniz-Laguna A, Eschalier R, Ferreiro A, Ferrer X, Francannet C, Fradin M, Gaborit B, Gay A, Hagege A, Isapof A, Jeru I, Juntas Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F, Levy N, Magot A, Manel V, Martins R, Mayer M, Mercier S, Meune C, Michaud M, Minot-Myhie MC, Muchir A, Nadaj-Pakleza A, Pereon Y, Petiot P, Petit F, Praline J, Rollin A, Sabouraud P, Sarret C, Schaeffer S, Taithe F, Tard C, Tiffreau V, Toutain A, Vatier C, Walther-Louvier U, Eymard B, Charron P, Vigouroux C, Bonne G, Kumar S, Elliott P, Duboc D. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in lamino- pathies.  Circulation  2019; 140 :293 \u0002 302. 921. Echeverria LE, Marcus R, Novick G, Sosa-Estani S, Ralston K, Zaidel EJ, Forsyth C, ALP RI, Mendoza I, Falconi ML, Mitelman J, Morillo CA, Pereiro AC, Pinazo MJ, Salvatella R, Martinez F, Perel P, Liprandi AS, Pineiro DJ, Molina GR. WHF IASC roadmap on Chagas disease.  Glob Heart  2020; 15 :26. 922. Martinez F, Perna E, Perrone SV, Liprandi AS. Chagas disease and heart failure: an expanding issue worldwide.  Eur Cardiol  2019; 14 :82 \u0002 88. 923. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardio- myopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.  Circulation  2020; 142 :e533 \u0002 e557. 924. Walsh R, Mazzarotto F, Whiffin N, Buchan R, Midwinter W, Wilk A, Li N, Felkin L, Ingold N, Govind R, Ahmad M, Mazaika E, Allouba M, Zhang X, de Marvao A, Day SM, Ashley E, Colan SD, Michels M, Pereira AC, Jacoby D, Ho CY, Thomson KL, Watkins H, Barton PJR, Olivotto I, Cook SA, Ware JS. Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyop- athy.  Genome Med  2019; 11 :5. 925. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dougherty K, Harrison SM, McGlaughon J, Milko LV, Morales A, Seifert BA, Strande N, Thomson K, Peter van Tintelen J, Wallace K, Walsh R, Wells Q, Whiffin N, Witkowski L, Semsarian C, Ware JS, Hershberger RE, Funke B. Evaluating the clinical validity of hypertrophic cardiomyopathy genes.  Circ Genom Precis Med 2019; 12 :e002460. 926. Thomson KL, Ormondroyd E, Harper AR, Dent T, McGuire K, Baksi J, Blair E, Brennan P, Buchan R, Bueser T, Campbell C, Carr-White G, Cook S, Daniels M, Deevi SVV, Goodship J, Hayesmoore JBG, Henderson A, Lamb T, Prasad S, Rayner-Matthews P, Robert L, Sneddon L, Stark H, Walsh R, Ware JS, Farrall M, Watkins HC, NIHR BioResource - Rare Diseases Consortium. Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield.  Genet Med 2019; 21 :1576 \u0002 1584. 927. Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyop- athy: the future of treatment.  Eur J Heart Fail  2020; 22 :228 \u0002 240. 928. O’Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, Michels M, Magri D, Autore C, Fernandez A, Ochoa JP, Leong KMW, Varnava AM, Monserrat L, Anastasakis A, Garcia-Pavia P, Rapezzi C, Biagini E, Gimeno\nJR, Limongelli G, Omar RZ, Elliott PM. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardio- myopathy: a systematic review and meta-analysis.  Heart  2019; 105 :623 \u0002 631. 929. O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, Cecchi F, Olivotto I, Kitaoka H, Gotsman I, Carr-White G, Mogensen J, Antoniades L, Mohiddin SA, Maurer MS, Tang HC, Geske JB, Siontis KC, Mahmoud KD, Vermeer A, Wilde A, Favalli V, Guttmann OP, Gallego-Delgado M, Dominguez F, Tanini I, Kubo T, Keren A, Bueser T, Waters S, Issa IF, Malcolmson J, Burns T, Sekhri N, Hoeger CW, Omar RZ, Elliott PM. International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).  Circulation  2018; 137 :1015 \u0002 1023. 930. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM, Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).  Eur Heart J  2014; 35 :2010 \u0002 2020. 931. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG, ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope.  Eur Heart J  2018; 39 :1883 \u0002 1948. 932. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmo- genic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.  Circulation  2010; 121 :1533 \u0002 1541. 933. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A, Basso C, Bauce B, Brunckhorst C, Bucciarelli-Ducci C, Duru F, Elliott P, Hamilton RM, Haugaa KH, James CA, Judge D, Link MS, Marchlinski FE, Mazzanti A, Mestroni L, Pantazis A, Pelliccia A, Marra MP, Pilichou K, Platonov PGA, Protonotarios A, Rampazzo A, Saffitz JE, Saguner AM, Schmied C, Sharma S, Tandri H, Te Riele A, Thiene G, Tsatsopoulou A, Zareba W, Zorzi A, Wichter T, Marcus FI, Calkins H, International Experts. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and dif- ferential diagnosis.  Eur Heart J  2020; 41 :1414 \u0002 1429. 934. Reichl K, Kreykes SE, Martin CM, Shenoy C. Desmoplakin variant-associated arrhythmogenic cardiomyopathy presenting as acute myocarditis.  Circ Genom Precis Med  2018; 11 :e002373. 935. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, Sanchez-Munoz JJ, Oliva-Sandoval MJ, Gimeno JR. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia.  Heart Rhythm  2015; 12 :766 \u0002 773. 936. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, La Gerche A, Niebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F, Borjesson M, Carre F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I, Corrado D, Sinagra G, Sharma S. Recommendations for participation in com- petitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019; 40 :19 \u0002 33. 937. Sedaghat-Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, Liss M, Lai A, Frese K, Pribe-Wolferts R, Amr A, Li DT, Samani OS, Carstensen A, Bordalo DM, Muller M, Fischer C, Shao J, Wang J, Nie M, Yuan L, Hassfeld S, Schwartz C, Zhou M, Zhou Z, Shu Y, Wang M, Huang K, Zeng Q, Cheng L, Fehlmann T, Ehlermann P, Keller A, Dieterich C, Streckfuss-Bomeke K, Liao Y, Gotthardt M, Katus HA, Meder B. Clinical genetics and outcome of left ventricular non- compaction cardiomyopathy.  Eur Heart J  2017; 38 :3449 \u0002 3460. 938. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyop- athy.  Lancet  2015; 386 :813 \u0002 825. 939. Towbin JA, Jefferies JL. Cardiomyopathies due to left ventricular noncompac- tion, mitochondrial and storage diseases, and inborn errors of metabolism.  Circ Res  2017; 121 :838 \u0002 854. 940. Shen MJ, Arora R, Jalife J. Atrial myopathy. JACC Basic Transl Sci 2019; 4 :640 \u0002 654. 941. Reddy YNV, Borlaug BA. Left atrial myopathy in heart failure with preserved ejection fraction.  Eur J Heart Fail  2020; 22 :486 \u0002 488. 942. Reddy YNV, Obokata M, Gersh BJ, Borlaug BA. High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea.  Circulation  2018; 137 :534 \u0002 535. 943. Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrilla- tion and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy.  Circulation  2020; 141 :4 \u0002 6. 944. To AC, Flamm SD, Marwick TH, Klein AL. Clinical utility of multimodality LA imaging: assessment of size, function, and structure.  JACC Cardiovasc Imaging 2011; 4 :788 \u0002 798.\n3724 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ............................................................................................................................................................................ 945. Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population.  Eur Heart J 2020; 41 :4050 \u0002 4056. 946. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol 2017; 14 :472 \u0002 483. 947. Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA. Comparing biomarker profiles of patients with heart failure: atrial fibrilla- tion vs. sinus rhythm and reduced vs. preserved ejection fraction.  Eur Heart J 2018; 39 :3867 \u0002 3875. 948. Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Clopton P, Filippatos GS, Anand I, Ng L, Daniels LB, Neath SX, Shah K, Christenson R, Hartmann O, Anker SD, Maisel A. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail  2013; 1 :192 \u0002 199. 949. Kamel H, Longstreth WT, Jr., Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinzer C, Dillon C, Ewing I, Spilker JA, Di Tullio MR, Hod EA, Soliman EZ, Chaturvedi S, Moy CS, Janis S, Elkind MS. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods.  Int J Stroke  2019; 14 :207 \u0002 214. 950. Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapa- gliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial.  Circulation  2020; 141 :1227 \u0002 1234. 951. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.  Lancet  2015; 386 :743 \u0002 800. 952. Cooper LT Jr, Keren A, Sliwa K, Matsumori A, Mensah GA. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study.  Glob Heart  2014; 9 :121 \u0002 129. 953. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, Abdul Hamid M, Seiler M, Kolb J, Hoermann P, Ensinger C, Brunner-La Rocca HP, Poelzl G, Heymans S. Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy.  Circ Heart Fail  2018; 11 :e004228. 954. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tschope C, Cooper LT, Jr., Camici PG. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document.  Circ Heart Fail  2020; 13 :e007405. 955. Grigoratos C, Di Bella G, Aquaro GD. Diagnostic and prognostic role of car- diac magnetic resonance in acute myocarditis.  Heart Fail Rev  2019; 24 :81 \u0002 90. 956. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recom- mendations.  J Am Coll Cardiol  2018; 72 :3158 \u0002 3176. 957. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis.  J Am Coll Cardiol 2016; 68 :411 \u0002 421. 958. Bang V, Ganatra S, Shah SP, Dani SS, Neilan TG, Thavendiranathan P, Resnic FS, Piemonte TC, Barac A, Patel R, Sharma A, Parikh R, Chaudhry GM, Vesely M, Hayek SS, Leja M, Venesy D, Patten R, Lenihan D, Nohria A, Cooper LT. Management of patients with giant cell myocarditis: JACC review topic of the week.  J Am Coll Cardiol  2021; 77 :1122 \u0002 1134. 959. Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, Merlo M. Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.  Eur J Heart Fail  2021; 23 :211 \u0002 216. 960. Gannon MP, Schaub E, Grines CL, Saba SG. State of the art: evaluation and prognostication of myocarditis using cardiac MRI.  J Magn Reson Imaging 2019; 49 :e122 \u0002 e131. 961. Maisch B, Hufnagel G, Kolsch S, Funck R, Richter A, Rupp H, Herzum M, Pankuweit S. Treatment of inflammatory dilated cardiomyopathy and (peri)myocar- ditis with immunosuppression and i.v. immunoglobulins.  Herz  2004; 29 :624 \u0002 636. 962. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O, American Heart Association Heart Failure Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.  Circulation  2020; 141 :e69 \u0002 e92. 963. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin\nsubstitution in dilated cardiomyopathy: three-month results from a randomized study.  J Am Coll Cardiol  2000; 35 :1590 \u0002 1598. 964. Bajaj NS, Gupta K, Gharpure N, Pate M, Chopra L, Kalra R, Prabhu SD. Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature.  ESC Heart Fail  2020; 7 :1319 \u0002 1330. 965. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis.  Clin Med (Lond)  2018; 18 :s30 \u0002 s35. 966. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019; 73 :2872 \u0002 2891. 967. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso- Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.  Eur Heart J  2015; 36 :2585 \u0002 2594. 968. Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR, Mereuta OM, Theis JD, Dogan A, Edwards WD. Impact of incidental amyloido- sis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction.  Am J Cardiol 2014; 114 :1396 \u0002 1399. 969. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement.  Circ Cardiovasc Imaging  2016; 9 . 970. Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, Soman P, Forman DE, Schindler JT, Gleason TG, Lee JS, Schelbert EB. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.  J Cardiovasc Magn Reson  2017; 19 :98. 971. Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its pre- dictors among elderly patients with severe aortic stenosis undergoing transcath- eter aortic valve replacement.  Eur Heart J  2017; 38 :2879 \u0002 2887. 972. Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, Binder C, Koschutnik M, Stiftinger J, Goliasch G, Siller-Matula J, Winter MP, Anvari-Pirsch A, Andreas M, Geppert A, Beitzke D, Loewe C, Hacker M, Agis H, Kain R, Lang I, Bonderman D, Hengstenberg C, Mascherbauer J. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome.  Eur J Heart Fail  2020; 22 :1852 \u0002 1862. 973. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.  Eur J Heart Fail  2021; 23 :512 \u0002 526. 974. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, Aimo A, Baggiano A, Martinez-Naharro A, Whelan C, Quarta C, Passino C, Castiglione V, Chubuchnyi V, Spini V, Taddei C, Vergaro G, Petrie A, Ruiz-Guerrero L, Monivas V, Mingo-Santos S, Mirelis JG, Dominguez F, Gonzalez-Lopez E, Perlini S, Pontone G, Gillmore J, Hawkins PN, Garcia-Pavia P, Emdin M, Fontana M. Multiparametric echocardiography scores for the diag- nosis of cardiac amyloidosis.  JACC Cardiovasc Imaging  2020; 13 :909 \u0002 920. 975. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133 :2404 \u0002 2412. 976. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic reso- nance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis.  BMC Cardiovasc Disord  2016; 16 :129. 977. Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, Maurer MS. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).  Circ Heart Fail  2011; 4 :121 \u0002 128. 978. Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment.  Can J Cardiol 2020; 36 :416 \u0002 423. 979. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington- Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.  N Engl J Med 2018; 379 :1007 \u0002 1016.\nESC Guidelines 3725\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n. ................................................................................................... 980. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 2021; 23 :277 \u0002 285. 981. Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis.  Circulation  2019; 139 :431 \u0002 443. 982. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, Adams D. Efficacy and safety of patisiran for familial amyloidotic polyneurop- athy: a phase II multi-dose study.  Orphanet J Rare Dis  2015; 10 :109. 983. Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis.  Circ Heart Fail  2018; 11 :e004769. 984. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation  2011; 124 :2253 \u0002 2263. 985. Farmakis D, Triposkiadis F, Lekakis J, Parissis J. Heart failure in haemoglobinopa- thies: pathophysiology, clinical phenotypes, and management.  Eur J Heart Fail 2017; 19 :479 \u0002 489. 986. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalasse- mia major and thalassemia intermedia.  Chest  2005; 127 :1523 \u0002 1530. 987. Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobi- nopathies: prevalent but overlooked.  Circulation  2011; 123 :1227 \u0002 1232. 988. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos- Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K, ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congeni- tal heart disease.  Eur Heart J  2021; 42 :563 \u0002 645. 989. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, Babu- Narayan S, Wort SJ, Dimopoulos K, Gatzoulis MA. Survival prospects and cir- cumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre.  Circulation  2015; 132 :2118 \u0002 2125. 990. Budts W, Roos-Hesselink J, Radle-Hurst T, Eicken A, McDonagh TA, Lambrinou E, Crespo-Leiro MG, Walker F, Frogoudaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.  Eur Heart J  2016; 37 :1419 \u0002 1427. 991. Lluri G, Lin J, Reardon L, Miner P, Whalen K, Aboulhosn J. Early experience with sacubitril/valsartan in adult patients with congenital heart disease.  World J Pediatr Congenit Heart Surg  2019; 10 :292 \u0002 295.\n",
      "keywords": [
        "aortic stenosis",
        "cardiovascular risk",
        "elderly",
        "mri",
        "rosillo",
        "heart failure",
        "cossiani",
        "pulmonary hypertension",
        "ecg",
        "codon",
        "scd",
        "echocardiography",
        "hypertension",
        "hereditary",
        "caro",
        "syncope",
        "marco",
        "rodriguez",
        "marin",
        "castrejon",
        "iniesta",
        "alcohol",
        "aortic",
        "older",
        "polo",
        "argos",
        "garcia",
        "martinez",
        "genetic",
        "atrial fibrillation"
      ],
      "tables": []
    },
    {
      "number": "124",
      "title": "992. Appadurai V, Thoreau J, Malpas T, Nicolae M. Sacubitril/valsartan in adult con- genital heart disease patients with chronic heart failure – a single centre case series and call for an internation",
      "start_page": 127,
      "end_page": 127,
      "content": "3726 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 14 January 2026\n",
      "keywords": [
        "thoreau",
        "genital",
        "centre",
        "adult",
        "call",
        "disease",
        "failure",
        "malpas",
        "single",
        "heart",
        "case",
        "internation",
        "valsartan",
        "patients",
        "sacubitril",
        "series",
        "chronic",
        "appadurai",
        "nicolae"
      ],
      "tables": []
    }
  ]
}